FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Reis, MNG
   Guimaraes, ML
   Bello, G
   Stefani, MMA
AF Reis, Monica N. G.
   Guimaraes, Monick L.
   Bello, Gonzalo
   Stefani, Mariane M. A.
TI Identification of New HIV-1 Circulating Recombinant Forms CRF81_cpx and
   CRF99_BF1 in Central Western Brazil and of Unique BF1 Recombinant Forms
SO FRONTIERS IN MICROBIOLOGY
LA English
DT Article
DE HIV-1; CRFs; URFs; molecular epidemiology; Central Western; Brazil
ID TRANSMITTED DRUG-RESISTANCE; TYPE-1 SUBTYPE C; GENETIC DIVERSITY;
   PREGNANT-WOMEN; SAO-PAULO; MOLECULAR EPIDEMIOLOGY; MODERATE PREVALENCE;
   MATO-GROSSO; STATE; INFECTION
AB Intersubtype recombinants classified as circulating recombinant forms (CRFs) or unique recombinant forms (URFs) have been shown to play an important role in the complex and dynamic Brazilian HIV/AIDS epidemic. Previous pol region studies (2003-2013) in 828 patients from six states from Central Western, Northern and Northeastern Brazil reported variable rates of BF1, F1CB, BC, and CF1 mosaics. In this study HIV-1 subtype diversity BF1, F1CB, BC, and CF1 recombinants in pol were analyzed. Full/near-full/partial genome sequences were generated from F1CB and BF1 recombinants. Genomic DNA extracted from whole blood was used in nested-PCR to amplify four overlapping fragments encompassing the full HIV-1 genome. Phylogenetic trees were generated using the neighbor-joining/NJ method (MEGA 6.0). The time of the most recent common ancestor (TMRCA) of F1CB and BF1 clades was estimated using a Bayesian Markov Chain Monte Carlo approach (BEAST v1.8; BEAGLE). Bootscanning was used for recombination analyses (Simplot v3.5.1); separate NJ phylogenetic analysis of fragments confirmed subtypes. The phylogenetic analyses of protease/reverse-transcriptase sequences in 828 patients revealed 76% subtype B (n = 629), 6.4% subtype C (n = 53), 4.2% subtype F1 (n = 35), 13.4% intersubtype recombinants: 10.5% BF1 (n = 87), 2.3% BC (n = 19), 0.4% F1CB (n = 3), and 0.2% CF1 (n = 2). Two full and one partial BF1C genomes allowed the characterization of the CRF81_cpx that has 9 breakpoints dividing the genome into 10 subregions. Basic Local Alignment Search Tool searches (Los Alamos HIV Sequence Database) identified six other sequences with the same recombination profile in pol, five from Brazil, and one from Italy. The estimated median TMRCA of CRF81_cpx was 1999 (1992-2003). CRF60_BC-like sequences, originally described in Italy, were also found. Two full and one near full-length BF1 genomes led to the characterization of the new CRF99_BF1 that has six recombination breakpoints dividing the genome into seven subregions. Two new URFs BF1, with six recombination breakpoints and seven subregions were also characterized. The description of the first Brazilian BF1C CRF81_cpx and of the new CRF99_BF1 corroborate the important role of CRFs in the HIV/AIDS epidemic throughout Brazil. Our data also highlight the value of HIV-1 full-genome sequence studies in order to fully reveal the complexity of the epidemic in a huge country as Brazil.
C1 [Reis, Monica N. G.; Stefani, Mariane M. A.] Univ Fed Goias, Inst Patol Trop & Saude Publ, Lab Imunol Aids & Hanseniase, Goiania, Go, Brazil.
   [Guimaraes, Monick L.; Bello, Gonzalo] Fundacao Oswaldo Cruz, Inst Oswald Cruz, Lab Aids & Imunol Mol, Rio De Janeiro, Brazil.
RP Stefani, MMA (corresponding author), Univ Fed Goias, Inst Patol Trop & Saude Publ, Lab Imunol Aids & Hanseniase, Goiania, Go, Brazil.
EM mmastefani@gmail.com
RI Bello, Gonzalo/E-6842-2013
FU Programa de Apoio a Nucleos de Excelencia/PRONEX; Fundacao de Amparo a
   Pesquisa do Estado de Goias/FAPEG; Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico/CNPqNational Council for Scientific and
   Technological Development (CNPq) [201210267000801, 481208/2012-7]; FAPEG
   [201410267000598]; CNPqNational Council for Scientific and Technological
   Development (CNPq) [308381/2015-7, 307972/20014-3]
FX This work was supported by the "Programa de Apoio a Nucleos de
   Excelencia/PRONEX; Fundacao de Amparo a Pesquisa do Estado de
   Goias/FAPEG; Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico/CNPq (Grant Number: 201210267000801 to MS) and by the
   "Conselho Nacional de Desenvolvimento Cientifico e Tecnologico/CNPq
   Universal (Grant Number: 481208/2012-7 to MS). MR was supported by a
   scholarship from FAPEG (Grant Number: 201410267000598). MS and MG are
   recipients of fellowships from CNPq (Grant Number 308381/2015-7 to MS
   and Grant Number 307972/20014-3 to MG).
CR Alcantara KC, 2012, J CLIN VIROL, V54, P15, DOI 10.1016/j.jcv.2012.01.011
   Barreto CC, 2006, JAIDS-J ACQ IMM DEF, V41, P338
   Passaes CPB, 2009, AIDS RES HUM RETROV, V25, P1339, DOI 10.1089/aid.2009.0167
   Carvalho BC, 2011, AIDS RES HUM RETROV, V27, P1081, DOI [10.1089/aid.2010.0334, 10.1089/AID.2010.0334]
   da Costa ZB, 2013, AIDS PATIENT CARE ST, V27, P439, DOI 10.1089/apc.2012.0448
   Reis MND, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178578
   da Silveira AA, 2012, AIDS RES HUM RETROV, V28, P304, DOI 10.1089/aid.2011.0128
   Delatorre E, 2017, AIDS RES HUM RETROV, V33, P639, DOI [10.1089/aid.2017.0045, 10.1089/AID.2017.0045]
   Drummond AJ, 2002, GENETICS, V161, P1307
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   Faria NR, 2014, SCIENCE, V346, P56, DOI 10.1126/science.1256739
   Ferreira AS, 2011, J MED VIROL, V83, P1301, DOI 10.1002/jmv.22128
   Gaspareto KV, 2012, REV INST MED TROP SP, V54, P207, DOI 10.1590/S0036-46652012000400005
   Graf T, 2013, VIROLOGY, V435, P170, DOI 10.1016/j.virol.2012.08.048
   Graf T, 2016, J VIROL, V90, P8160, DOI 10.1128/JVI.00363-16
   Guimaraes ML, 2008, AIDS, V22, P433, DOI 10.1097/QAD.0b013e3282f47ad0
   Guimaraes ML, 2010, INFECT GENET EVOL, V10, P1094, DOI 10.1016/j.meegid.2010.07.001
   Jetzt AE, 2000, J VIROL, V74, P1234, DOI 10.1128/JVI.74.3.1234-1240.2000
   KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581
   Kumar S, 2002, MOL PHYLOGENETICS EV
   Lai A, 2010, HIV MED, V11, P593, DOI 10.1111/j.1468-1293.2010.00832.x
   Lai A, 2014, J MED VIROL, V86, P186, DOI 10.1002/jmv.23783
   Marques BCL, 2018, MEM I OSWALDO CRUZ, V113, DOI 10.1590/0074-02760170483
   Lima K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155854
   Lole KS, 1999, J VIROL, V73, P152, DOI 10.1128/JVI.73.1.152-160.1999
   Monno L, 2012, J CLIN VIROL, V55, P370, DOI 10.1016/j.jcv.2012.08.014
   Pessoa R., 2014, PLOS ONE, V17, DOI [10.1371/journal.pone.011, DOI 10.1371/JOURNAL.PONE.011]
   Pessoa R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152499
   Pessoa R, 2014, MICROBIOL RESOUR ANN, V2, DOI 10.1128/genomeA.00386-14
   Posada D, 2008, MOL BIOL EVOL, V25, P1253, DOI 10.1093/molbev/msn083
   Rambaut A, 2007, TRACER V1 6
   Lima YAR, 2016, J MED VIROL, V88, P1936, DOI 10.1002/jmv.24540
   Cavalcanti AMS, 2012, BRAZ J INFECT DIS, V16, P157, DOI [10.1590/S1413-86702012000200009, 10.1016/S1413-8670(12)70298-2]
   Sanabani S, 2006, INFECT GENET EVOL, V6, P368, DOI 10.1016/j.meegid.2006.01.003
   Sanabani SS, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-74
   Santos AF, 2006, AIDS, V20, P2011
   Silveira J, 2012, J CLIN VIROL, V54, P36, DOI 10.1016/j.jcv.2012.01.017
   Simonetti FR, 2014, INFECT GENET EVOL, V23, P176, DOI 10.1016/j.meegid.2014.02.007
   Soares EAJM, 2005, AIDS, V19, pS81, DOI 10.1097/01.aids.0000191497.00928.e4
   Moura MES, 2015, J MED VIROL, V87, P798, DOI 10.1002/jmv.24087
   Moura MES, 2015, AIDS RES HUM RETROV, V31, P250, DOI 10.1089/aid.2014.0261
   Suchard MA, 2009, BIOINFORMATICS, V25, P1370, DOI 10.1093/bioinformatics/btp244
   Tamura K, 2013, MOL BIOL EVOL, V30, P2725, DOI [10.1093/molbev/mst197, 10.1093/molbev/msr121]
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Cardoso LPV, 2011, AIDS RES HUM RETROV, V27, P1349, DOI 10.1089/aid.2011.0153
   Cardoso LPV, 2010, J MED VIROL, V82, P351, DOI 10.1002/jmv.21722
   Cardoso LPV, 2009, AIDS RES HUM RETROV, V25, P943, DOI 10.1089/aid.2009.0060
   Cardoso LPV, 2009, J CLIN VIROL, V46, P134, DOI 10.1016/j.jcv.2009.07.009
   Worobey M, 1999, J GEN VIROL, V80, P2535, DOI 10.1099/0022-1317-80-10-2535
   Xia X, 2001, J HERED, V92, P371, DOI 10.1093/jhered/92.4.371
NR 51
TC 4
Z9 4
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-302X
J9 FRONT MICROBIOL
JI Front. Microbiol.
PD FEB 11
PY 2019
VL 10
AR 97
DI 10.3389/fmicb.2019.00097
PG 13
WC Microbiology
SC Microbiology
GA HK8JF
UT WOS:000458235000001
PM 30804902
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Delatorre, E
   Fernandez, J
   Bello, G
AF Delatorre, Edson
   Fernandez, Jorge
   Bello, Gonzalo
TI Investigating the Role of Easter Island in Migration of Zika Virus from
   South Pacific to AmericasNNN
SO EMERGING INFECTIOUS DISEASES
LA English
DT Letter
ID OUTBREAK; BRAZIL
AB The role of Easter Island in the dissemination of Zika virus from the Pacific islands into the Americas remains unclear. We analyzed new Zika virus sequences from Eastern Island and found that Zika virus was independently disseminated from French Polynesia into the Americas and Easter Island at around the same time.
C1 [Delatorre, Edson; Bello, Gonzalo] Fiocruz MS, Inst Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Fernandez, Jorge] Publ Hlth Inst Chile, Santiago, Chile.
RP Delatorre, E (corresponding author), Fiocruz MS, Lab AIDS & Imunol Mol, Inst Oswaldo Cruz, Av Brasil 4365, BR-21040360 Rio De Janeiro, RJ, Brazil.
EM delatorre.ioc@gmail.com
RI Bello, Gonzalo/E-6842-2013; Delatorre, Edson/J-8330-2015
OI Delatorre, Edson/0000-0002-5746-0820
FU Programa Nacional de Pos-Doutorado (PNPD)/CAPES in Brazil
FX E.D. is funded by a postdoctoral fellowship from the Programa Nacional
   de Pos-Doutorado (PNPD)/CAPES in Brazil.
CR Aubry M, 2015, EMERG INFECT DIS, V21, P724, DOI 10.3201/eid2104.141741
   Campos GS, 2015, EMERG INFECT DIS, V21, P1885, DOI 10.3201/eid2110.150847
   Cao-Lormeau VM, 2014, EMERG INFECT DIS, V20, P1034, DOI 10.3201/eid2006.131413
   Dupont-Rouzeyrol M, 2017, EMERG MICROBES INFEC, V6, DOI 10.1038/emi.2017.102
   Faria NR, 2017, NATURE, V546, P406, DOI 10.1038/nature22401
   Faria NR, 2016, SCIENCE, V352, P345, DOI 10.1126/science.aaf5036
   Lednicky J, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004687
   Metsky HC, 2017, NATURE, V546, P411, DOI 10.1038/nature22402
   Petersen LR, 2016, NEW ENGL J MED, V374, P1552, DOI 10.1056/NEJMra1602113
   Tognarelli J, 2016, ARCH VIROL, V161, P665, DOI 10.1007/s00705-015-2695-5
NR 10
TC 3
Z9 3
U1 0
U2 4
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD NOV
PY 2018
VL 24
IS 11
BP 2119
EP 2121
DI 10.3201/eid2411.180586
PG 3
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA GX4UO
UT WOS:000447732600033
PM 30334729
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Mendoza, Y
   Garcia-Morales, C
   Bello, G
   Garrido-Rodriguez, D
   Tapia-Trejo, D
   Pascale, JM
   Giron-Callejas, AC
   Mendizabal-Burastero, R
   Escobar-Urias, IY
   Garcia-Gonzalez, BL
   Navas-Castillo, JS
   Quintana-Galindo, MC
   Pinzon-Meza, R
   Mejia-Villatoro, CR
   Avila-Rios, S
   Reyes-Teran, G
AF Mendoza, Yaxelis
   Garcia-Morales, Claudia
   Bello, Gonzalo
   Garrido-Rodriguez, Daniela
   Tapia-Trejo, Daniela
   Miguel Pascale, Juan
   Carolina Giron-Callejas, Amalia
   Mendizabal-Burastero, Ricardo
   Yessenia Escobar-Urias, Ingrid
   Leticia Garcia-Gonzalez, Blanca
   Sabrina Navas-Castillo, Jessenia
   Cristina Quintana-Galindo, Maria
   Pinzon-Meza, Rodolfo
   Rodolfo Mejia-Villatoro, Carlos
   Avila-Rios, Santiago
   Reyes-Teran, Gustavo
TI Evolutionary history and spatiotemporal dynamics of the HIV-1 subtype B
   epidemic in Guatemala
SO PLOS ONE
LA English
DT Article
ID POPULATION-DYNAMICS; MAXIMUM-LIKELIHOOD; CENTRAL-AMERICA; LATIN-AMERICA;
   SEQUENCES; INFERENCE; HIV/AIDS; ACCURATE; CLADES
AB Different explanations exist on how HIV-1 subtype B spread in Central America, but the role of Guatemala, the Central American country with the highest number of people living with the virus, in this scenario is unknown. We investigated the evolutionary history and spatiotemporal dynamics of HIV-1 subtype B in Guatemala. A total of 1,047 HIV-1 subtype B pol sequences, from newly diagnosed ART-naive, HIV-infected Guatemalan subjects enrolled between 2011 and 2013 were combined with published subtype B sequences from other Central American countries (n = 2,101) and with reference sequences representative of the B-PANDEMIC and B-CAR lineages from the United States (n = 465), France (n = 344) and the Caribbean (n = 238). Estimates of evolutionary, demographic, and phylogeographic parameters were obtained from sequence data using maximum likelihood and Bayesian coalescent-based methods. The majority of Guatemalan sequences (98.9%) belonged to the B-PANDEMIC clade, and 75.2% of these sequences branched within 10 monophyletic clades: four also included sequences from other Central American countries (BCAM-I to BCAM-IV) and six were mostly (>99%) composed by Guatemalan sequences (B-GU clades). Most clades mainly comprised sequences from heterosexual individuals. Bayesian coalescent-based analyses suggested that B-GU clades originated during the 1990s and 2000s, whereas B-CAM clades originated between the late 1970s and mid 1980s. The major hub of dissemination of all B-GU, and of BCAM-II, and BCAM-IV clades was traced to the Department of Guatemala, while the root location of BCAM-I and BCAM-III was traced to Honduras. Most Guatemalan clades experienced initial phases of exponential growth (0.23 and 3.6 year(-1)), followed by recent growth declines. Our observations suggest that the Guatemalan HIV-1 subtype B epidemic is driven by dissemination of multiple B-PANDEMIC founder viral strains, some restricted to Guatemala and others widely disseminated in the Central American region, with Guatemala City identified as a major hub of viral dissemination. Our results also suggest the existence of different sub-epidemics within Guatemala for which different targeted prevention efforts might be needed.
C1 [Mendoza, Yaxelis; Miguel Pascale, Juan] Gorgas Mem Inst Hlth Studies, Panama City, Panama.
   [Mendoza, Yaxelis] Univ Panama, Dept Genet & Mol Biol, Panama City, Panama.
   [Garcia-Morales, Claudia; Garrido-Rodriguez, Daniela; Tapia-Trejo, Daniela; Avila-Rios, Santiago; Reyes-Teran, Gustavo] Natl Inst Resp Dis, Ctr Res Infect Dis, Mexico City, DF, Mexico.
   [Bello, Gonzalo] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, Rio De Janeiro, Brazil.
   [Carolina Giron-Callejas, Amalia; Mendizabal-Burastero, Ricardo] Univ Valle Guatemala, Guatemala City, Guatemala.
   [Yessenia Escobar-Urias, Ingrid; Leticia Garcia-Gonzalez, Blanca; Sabrina Navas-Castillo, Jessenia; Cristina Quintana-Galindo, Maria; Pinzon-Meza, Rodolfo; Rodolfo Mejia-Villatoro, Carlos] Roosevelt Hosp, Infect Dis Clin, Guatemala City, Guatemala.
RP Avila-Rios, S; Reyes-Teran, G (corresponding author), Natl Inst Resp Dis, Ctr Res Infect Dis, Mexico City, DF, Mexico.
EM santiago.avila@cieni.org.mx; gustavo.reyesteran@gmail.com
RI Giron-Callejas, Amalia Carolina/F-7328-2017; Bello, Gonzalo/E-6842-2013;
   Avila-Rios, Santiago/AAB-4383-2020
OI Giron-Callejas, Amalia Carolina/0000-0001-8242-0436; 
FU Mexican Government (Comision de Equidad y Genero de las Legislaturas
   LX-LXI); Mexican Government (Comision de Igualdad de Genero de la
   Legislatura LXII de la H. Camara de Diputados de la Republica Mexicana);
   Consejo Nacional de Ciencia y Tecnologia (CONACyT)Consejo Nacional de
   Ciencia y Tecnologia (CONACyT) [SALUD-2013-01-202475]
FX This work was supported by grants from the Mexican Government (Comision
   de Equidad y Genero de las Legislaturas LX-LXI y Comision de Igualdad de
   Genero de la Legislatura LXII de la H. Camara de Diputados de la
   Republica Mexicana), received by GRT, and Consejo Nacional de Ciencia y
   Tecnologia (CONACyT SALUD-2013-01-202475; http://www.conacyt.mx),
   received by SAR. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Aguilera G., 1997, ENOCA CONT 1945 ACTU, VVI, P135
   Anisimova M, 2006, SYST BIOL, V55, P539, DOI 10.1080/10635150600755453
   [Anonymous], 2015, GUATEMALA EVALUACION
   [Anonymous], 2014, MINISTERIO DE SALUD
   Arias J., 1997, ENOCA CONT 1945 ACTU, VVI, P195
   Avila-Rios S, 2015, AIDS RES HUM RETROV, V31, P401, DOI 10.1089/aid.2014.0057
   Baele G, 2012, MOL BIOL EVOL, V29, P2157, DOI 10.1093/molbev/mss084
   Bielejec F, 2011, BIOINFORMATICS, V27, P2910, DOI 10.1093/bioinformatics/btr481
   Caballeros Alvaro, 2013, PERFIL MIGRATORIO GU
   Cabello M, 2015, AIDS, V29, P483, DOI 10.1097/QAD.0000000000000552
   Cabello M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106045
   Crabtree-Ramirez B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020272
   de Oliveira T, 2005, BIOINFORMATICS, V21, P3797, DOI 10.1093/bioinformatics/bti607
   Delatorre E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072448
   Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/msi103
   Drummond AJ, 2002, GENETICS, V161, P1307
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   Garcia J., 2017, VIGILANCIA EPIDEMIOL
   Gilbert MTP, 2007, P NATL ACAD SCI USA, V104, P18566, DOI 10.1073/pnas.0705329104
   Giron-Callejas AC, 2011, ANALISIS VIGILANCIA
   Guindon S, 2005, NUCLEIC ACIDS RES, V33, pW557, DOI 10.1093/nar/gki352
   Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520
   Hue S, 2005, P NATL ACAD SCI USA, V102, P4425, DOI 10.1073/pnas.0407534102
   Garcia JI, 2015, AIDS RES TREAT, V2015, DOI 10.1155/2015/372816
   Junqueira DM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027489
   Lemey P, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000520
   Leyva-Flores R, 2014, REV PANAM SALUD PUBL, V36, P143
   LI YC, 2011, PLOS ONE, V6
   Mendoza Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095360
   Mir D, 2015, AIDS, V29, P1863, DOI 10.1097/QAD.0000000000000770
   Montejo V., 1997, PORANEA 1945 ACTUALI, VVI, P367
   Morales-Miranda S, 2013, ENCUESTA VIGILANCIA
   MSPAS, 2017, INF NAC CASC CONT AT
   Murillo W, 2013, J VIROL, V87, P7463, DOI 10.1128/JVI.01602-12
   Nadai Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004814
   Pagan I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069218
   Paraskevis D, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-49
   Posada D, 2008, MOL BIOL EVOL, V25, P1253, DOI 10.1093/molbev/msn083
   Rambaut A, TRACER V1 6
   Rambaut A, TREE FIGURE DRAWING
   Schroten H., 1987, MIGRACION INTERNA GU
   Suchard MA, 2009, BIOINFORMATICS, V25, P1370, DOI 10.1093/bioinformatics/btp244
   Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   UNAIDS, 2015, AIDS CHANG EV MDG6 1
   World Health Organization, 2016, CONS GUID US ANT DRU
   Zehender G, 2010, JAIDS-J ACQ IMM DEF, V55, P156, DOI 10.1097/QAI.0b013e3181eb3002
NR 48
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 13
PY 2018
VL 13
IS 9
AR e0203916
DI 10.1371/journal.pone.0203916
PG 21
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GT5KH
UT WOS:000444545800100
PM 30212548
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Caetano, DG
   Cortes, FH
   Bello, G
   Teixeira, SLM
   Hoagland, B
   Grinsztejn, B
   Veloso, VG
   Guimaraes, ML
   Morgado, MG
AF Caetano, Diogo Gama
   Cortes, Fernanda Heloise
   Bello, Gonzalo
   Maia Teixeira, Sylvia Lopes
   Hoagland, Brenda
   Grinsztejn, Beatriz
   Veloso, Valdilea Goncalves
   Guimaraes, Monick Lindenmeyer
   Morgado, Mariza Goncalves
TI Next-generation sequencing analyses of the emergence and maintenance of
   mutations in CTL epitopes in HIV controllers with differential viremia
   control
SO RETROVIROLOGY
LA English
DT Article
DE HIV-1; HIV controller; CTL epitope; Single-nucleotide polymorphism;
   Escape mutant; Next-generation sequencing
ID HUMAN-IMMUNODEFICIENCY-VIRUS; LYMPHOCYTE ESCAPE MUTATIONS; VIRAL
   REPLICATION CAPACITY; LONG-TERM NONPROGRESSORS; LOW-LEVEL VIREMIA;
   T-CELL RESPONSES; ELITE SUPPRESSORS; POPULATION-LEVEL; GAG; EVOLUTION
AB Background: Despite the low level of viral replication in HIV controllers (HICs), studies have reported viral mutations related to escape from cytotoxic T-lymphocyte (CTL) response in HIV-1 plasma sequences. Thus, evaluating the dynamics of the emergence of CTL-escape mutants in HICs reservoirs is important for understanding viremia control. To analyze the HIV-1 mutational profile and dynamics of CTL-escape mutants in HICs, we selected 11 long-term non-progressor individuals and divided them into the following groups: (1) viremic controllers (VCs; n = 5) and (2) elite controllers (ECs; n = 6). For each individual, we used HIV-1 proviral DNA from PBMCs related to earliest (V-E) and latest (V-L) visits to obtain gag and nef sequences using the Illumina HiSeq system. The consensus of each mapped gene was used to assess viral divergence, and next-generation sequencing data were employed to identify SNPs and variations within and flanking CTL epitopes.
   Results: Divergence analysis showed higher values for nef compared to gag among the HICs. EC and VC groups showed similar divergence rates for both genes. Analysis of the number of SNPs showed that VCs present more variability in both genes. Synonymous/non-synonymous mutation ratios were < 1 for gag among ECs and for nef among ECs and VCs, exhibiting a predominance of non-synonymous mutations. Such mutations were observed in regions encoding CTL-restricted epitopes in all individuals. All ECs presented non-synonymous mutations in CTL epitopes but generally at low frequency (< 1%); all VCs showed a high number of mutations, with significant frequency changes between V-E and V-L visits. A higher frequency of internal mutations was observed for gag epitopes, with significant changes across visits compared to Nef epitopes, indicating a pattern associated with differential genetic pressure.
   Conclusions: The high genetic conservation of HIV-1 gag and nef among ECs indicates that the higher level of viremia control restricts the evolution of both genes. Although viral replication levels in HICs are low or undetectable, all individuals exhibited CTL epitope mutations in proviral gag and nef variants, indicating that potential CTL escape mutants are present in HIC reservoirs and that situations leading to a disequilibrium of the host-virus relationship can result in the spread of CTL-escape variants.
C1 [Caetano, Diogo Gama; Cortes, Fernanda Heloise; Bello, Gonzalo; Maia Teixeira, Sylvia Lopes; Guimaraes, Monick Lindenmeyer; Morgado, Mariza Goncalves] Fiocruz MS, Inst Oswaldo Cruz, Lab Aids & Imunol Mol, Ave Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
   [Hoagland, Brenda; Grinsztejn, Beatriz; Veloso, Valdilea Goncalves] Fiocruz MS, Inst Nacl Infectol Evandro Chagas INI, Lab Pesquisa Clin DST & Aids, Rio De Janeiro, Brazil.
RP Morgado, MG (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab Aids & Imunol Mol, Ave Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
EM mmorgado@ioc.fiocruz.br
RI Cortes, Fernanda/AAF-9254-2020; Bello, Gonzalo/E-6842-2013
FU Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro - FAPERJCarlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ); Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico - CNPqNational Council for Scientific and Technological
   Development (CNPq); Fiocruz; NATIONAL EYE INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Eye Institute (NEI) [R01EY026103, R01EY026103,
   R01EY026103, R01EY026103] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476,
   UM1AI069476, UM1AI069476, UM1AI069476] Funding Source: NIH RePORTER
FX This work was supported by the Fundacao de Amparo a Pesquisa do Estado
   do Rio de Janeiro - FAPERJ and the Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico - CNPq and Fiocruz.
CR Dilernia DA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003429
   Altfeld M, 2003, AIDS, V17, P2581, DOI 10.1097/00002030-200312050-00005
   [Anonymous], 2015, FASTQC QUAL CONTR TO
   Assone T, 2016, VIRUSES-BASEL, V8, DOI [10.1016/J.VIROL.2012.09.028, 10.3390/v8020038]
   Bailey JR, 2007, J INFECT DIS, V196, P50, DOI 10.1086/518515
   Bailey JR, 2006, J EXP MED, V203, P1357, DOI 10.1084/jem.20052319
   Bailey JR, 2009, J VIROL, V83, P88, DOI 10.1128/JVI.01958-08
   Bello G, 2005, J GEN VIROL, V86, P355, DOI 10.1099/vir.0.80410-0
   Bello G, 2007, AIDS RES HUM RETROV, V23, P1242, DOI 10.1089/aid.2007.0074
   Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170
   Boutwell CL, 2009, J VIROL, V83, P2460, DOI 10.1128/JVI.01970-08
   Brumme ZL, 2008, J VIROL, V82, P9216, DOI 10.1128/JVI.01041-08
   Cale EM, 2011, J VIROL, V85, P3746, DOI 10.1128/JVI.02420-10
   Carlson JM, 2008, MICROBES INFECT, V10, P455, DOI 10.1016/j.micinf.2008.01.013
   Carlson JM, 2015, TRENDS MICROBIOL, V23, P212, DOI 10.1016/j.tim.2014.12.008
   Carlson JM, 2012, J VIROL, V86, P13202, DOI 10.1128/JVI.01998-12
   Casadella M, 2015, AIDS, V29, P1493, DOI 10.1097/QAD.0000000000000748
   Chen RX, 2004, CURR PHARM DESIGN, V10, P4065, DOI 10.2174/1381612043382404
   Cortes FH, 2015, JAIDS-J ACQ IMM DEF, V68, P377, DOI 10.1097/QAI.0000000000000500
   Cortes FH, 2013, VACCINE, V31, P1106, DOI 10.1016/j.vaccine.2012.12.023
   Cozzi-Lepri A, 2015, J ANTIMICROB CHEMOTH, V70, P930, DOI 10.1093/jac/dku426
   Dalmau J, 2014, AIDS, V28, P1261, DOI 10.1097/QAD.0000000000000293
   Darriba D, 2012, NAT METHODS, V9, P772, DOI 10.1038/nmeth.2109
   de Azevedo SSD, 2017, RETROVIROLOGY, V14, DOI 10.1186/s12977-017-0354-5
   Deng K, 2015, NATURE, V517, P381, DOI 10.1038/nature14053
   Erdmann N, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005111
   Feeney ME, 2004, J VIROL, V78, P8927, DOI 10.1128/JVI.78.16.8927-8930.2004
   Fischer W, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012303
   Fryer HR, 2012, J VIROL, V86, P8568, DOI 10.1128/JVI.07020-11
   Gaardbo JC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063744
   Gijsbers EF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081235
   Goulder PJR, 2004, NAT REV IMMUNOL, V4, P630, DOI 10.1038/nri1417
   Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212
   Gounder K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119886
   Hatano H, 2009, J VIROL, V83, P329, DOI 10.1128/JVI.01763-08
   Hayat T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179576
   Henn MR, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002529
   Hughes AL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047818
   Immonen TT, 2014, RETROVIROLOGY, V11, DOI 10.1186/s12977-014-0081-0
   Joshi N.A., 2011, SICKLE SLIDING WINDO
   Juarez-Molina CI, 2014, J VIROL, V88, P10392, DOI 10.1128/JVI.01162-14
   Kearse M, 2012, BIOINFORMATICS, V28, P1647, DOI 10.1093/bioinformatics/bts199
   KOENIG S, 1995, NAT MED, V1, P330, DOI 10.1038/nm0495-330
   Torres AJL, 2013, REV INST MED TROP SP, V55, P323, DOI 10.1590/S0036-46652013000500005
   Leslie AJ, 2004, NAT MED, V10, P282, DOI 10.1038/nm992
   Lewis GK, 2017, IMMUNOL REV, V275, P271, DOI 10.1111/imr.12510
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Los Alamos National Laboratory, 2015, LOS AL IMM DAT
   Martin E, 2014, RETROVIROLOGY, V11, DOI 10.1186/s12977-014-0064-1
   Mens H, 2010, J VIROL, V84, P12971, DOI 10.1128/JVI.00387-10
   Metzner KJ, 2014, AIDS, V28, P2231, DOI 10.1097/QAD.0000000000000397
   Migueles SA, 2003, J VIROL, V77, P6889, DOI 10.1128/JVI.77.12.6889-6898.2003
   Miura T, 2009, J VIROL, V83, P2743, DOI 10.1128/JVI.02265-08
   Mothe B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029717
   Mudd PA, 2012, J IMMUNOL, V188, P3364, DOI 10.4049/jimmunol.1102470
   O'Connell KA, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-63
   O'Connell KA, 2010, J VIROL, V84, P7018, DOI 10.1128/JVI.00548-10
   Okulicz JF, 2012, J AIDS CLIN RES, VS8, P005
   Ouyang YB, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05594-5
   Pantaleo G, 1996, ANNU REV MICROBIOL, V50, P825, DOI 10.1146/annurev.micro.50.1.825
   Pereyra F, 2009, J INFECT DIS, V200, P984, DOI 10.1086/605446
   Perreau M, 2013, CURR OPIN HIV AIDS, V8, P333, DOI 10.1097/COH.0b013e328361faf4
   Pohlmeyer CW, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-152
   Radebe M, 2015, AIDS, V29, P23, DOI 10.1097/QAD.0000000000000508
   Roberts HE, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1004914
   Saez-Cirion A, 2007, P NATL ACAD SCI USA, V104, P6776, DOI 10.1073/pnas.0611244104
   Saez-Cirion A, 2013, IMMUNOL REV, V254, P281, DOI 10.1111/imr.12076
   Saez-Cirion A, 2009, J IMMUNOL, V182, P7828, DOI 10.4049/jimmunol.0803928
   Salgado M, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-94
   Setiawan LC, 2015, J GEN VIROL, V96, P2372, DOI 10.1099/vir.0.000148
   Shankarappa R, 1999, J VIROL, V73, P10489, DOI 10.1128/JVI.73.12.10489-10502.1999
   Sharkey M, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001303
   STARCICH BR, 1986, CELL, V45, P637, DOI 10.1016/0092-8674(86)90778-6
   Sun JP, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004429
   Sunshine JE, 2015, J VIROL, V89, P10303, DOI 10.1128/JVI.01876-15
   Swenson LC, 2012, CURR OPIN HIV AIDS, V7, P478, DOI 10.1097/COH.0b013e328356e9da
   Teixeira SLM, 2014, GENES IMMUN, V15, P256, DOI 10.1038/gene.2014.14
   TERSMETTE M, 1989, J VIROL, V63, P2118, DOI 10.1128/JVI.63.5.2118-2125.1989
   Yebra G, 2015, 22 HIV DYN EVOL WORK
   Zaunders J, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00095
NR 80
TC 3
Z9 3
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PD SEP 10
PY 2018
VL 15
AR 62
DI 10.1186/s12977-018-0444-z
PG 13
WC Virology
SC Virology
GA GT5CG
UT WOS:000444522900001
PM 30201008
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Bello, G
   Nacher, M
   Divino, F
   Darcissac, E
   Mir, D
   Lacoste, V
AF Bello, Gonzalo
   Nacher, Mathieu
   Divino, Flavia
   Darcissac, Edith
   Mir, Daiana
   Lacoste, Vincent
TI The HIV-1 Subtype B Epidemic in French Guiana and Suriname Is Driven by
   Ongoing Transmissions of Pandemic and Non-pandemic Lineages
SO FRONTIERS IN MICROBIOLOGY
LA English
DT Article
DE HIV-1; subtype B; pandemic; non-pandemic; phylodynamics; French Guiana;
   Suriname
ID NAIVE ADULT PATIENTS; RESISTANCE MUTATIONS; POPULATION-DYNAMICS; GENETIC
   DIVERSITY; ALGORITHMS; HISTORY; GENOMES; CLADES
AB The HIV-1 subtype B epidemic in French Guiana and Suriname is characterized by the co-circulation of the globally disseminated "B-PANDEMIC" lineage and of non pandemic subtype B lineages of Caribbean origin (B-CAR). To reconstruct the spatiotemporal pattern of spread of those viral lineages circulating in these two countries, a total of 361 HIV-1 subtype B pol sequences recovered from treatment-naive adult patients from French Guiana and Suriname between 2006 and 2012 were combined with B-PANDEMIC and B-CAR reference sequences. Major Guianese/Surinamese B-PANDEMIC and B-CAR lineages were identified by Maximum Likelihood phylogenetic analysis and the spatiotemporal and demographic parameters estimated using a Bayesian coalescent-based method. We detected four B-CAR and three B-PANDEMIC transmission chains of large size that together comprise most pandemic and non-pandemic subtype B sequences from French Guiana (>= 52%) and Suriname (>= 70%) here analyzed. These major lineages were probably introduced into French Guiana and Suriname from the Caribbean (B-CAR) and North/South America (B-PANDEMIC) between the middle 1970s and the late 1980s and spread among populations from both countries with roughly comparable demographic growth rates. We detected a significant trend for higher viral loads and higher proportion of homosexual/bisexual men among subjects infected with B-PANDEMIC relative to B-CAR strains in French Guiana. These results show that the HIV subtype B epidemic in French Guiana and Suriname has been driven by multiple active B-CAR and B-PANDEMIC transmission chains that arose since the middle 1970s onward and operate in both countries simultaneously. Although no significant differences in the epidemic potential of major B-CAR and B-PANDEMIC lineages were observed, relevant associations between the infecting subtype B lineage and epidemiological and clinical characteristics were detected in French Guiana.
C1 [Bello, Gonzalo; Divino, Flavia; Mir, Daiana] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, Rio De Janeiro, Brazil.
   [Nacher, Mathieu] Ctr Hosp Cayenne Andree Rosemon, Coordinat Reg Lutte VIH COREVIH, Cayenne, French Guiana.
   [Nacher, Mathieu] Ctr Hosp Cayenne Andree Rosemon, Ctr Invest Clin CIC INSERM 1424, Cayenne, French Guiana.
   [Darcissac, Edith; Lacoste, Vincent] Inst Pasteur, Lab Interact Virus Hotes, Cayenne, French Guiana.
RP Lacoste, V (corresponding author), Inst Pasteur, Lab Interact Virus Hotes, Cayenne, French Guiana.
EM vlacoste@pasteur-cayenne.fr
RI Bello, Gonzalo/E-6842-2013; LACOSTE, Vincent/V-2321-2019
OI LACOSTE, Vincent/0000-0002-3173-4053; nacher,
   mathieu/0000-0001-9397-3204
FU European CommissionEuropean CommissionEuropean Commission Joint Research
   Centre [REGPOT-CT-2011-285837-STRonGer]; Agence Nationale de la
   Recherche (CEBA)French National Research Agency (ANR)
   [ANR-10-LABX-25-01]; Agencia Nacional de Investigacion e Innovacion
   (ANII-Uruguay); Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior (CAPES-Brazil)CAPES
FX This study has benefited from a European Commission
   "REGPOT-CT-2011-285837-STRonGer" grant within the FP7 and an
   "Investissement d'Avenir" grant managed by the Agence Nationale de la
   Recherche (CEBA, Ref. ANR-10-LABX-25-01). DM was funded by fellowships
   from "Agencia Nacional de Investigacion e Innovacion (ANII-Uruguay)" and
   "Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES-Brazil)".
CR Anisimova M, 2006, SYST BIOL, V55, P539, DOI 10.1080/10635150600755453
   Baele G, 2012, MOL BIOL EVOL, V29, P2157, DOI 10.1093/molbev/mss084
   Bertels F, 2018, MOL BIOL EVOL, V35, P27, DOI 10.1093/molbev/msx246
   Bonhoeffer S, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004634
   Borland R, 2004, HIV AIDS MOBILE POPU
   Bourdier F, 2005, HOMMES MIGR, V1256, P116, DOI [10.3406/homig.2005.4376, DOI 10.3406/HOMIG.2005.4376]
   Cabello M, 2016, SCI REP-UK, V6, DOI 10.1038/srep33971
   Cabello M, 2015, AIDS, V29, P483, DOI 10.1097/QAD.0000000000000552
   Cabello M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106045
   Collomb G., 2016, MOBILITES ETHNICITES
   Corbin H.P, 2007, BRAZILIAN MIGRATION
   Cordova Alcaraz R, 2012, MIGRATORY ROUTES DYN
   Darcissac E, 2016, AIDS RES HUM RETROV, V32, P801, DOI [10.1089/aid.2016.0048, 10.1089/AID.2016.0048]
   de Oliveira T, 2005, BIOINFORMATICS, V21, P3797, DOI 10.1093/bioinformatics/bti607
   Delatorre E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072448
   Divino F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162112
   Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/msi103
   Drummond AJ, 2002, GENETICS, V161, P1307
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   Ferreira MAR, 2008, CAN J STAT, V36, P355, DOI 10.1002/cjs.5550360302
   Guindon S, 2005, NUCLEIC ACIDS RES, V33, pW557, DOI 10.1093/nar/gki352
   Guindon S, 2010, SYST BIOL, V59, P307, DOI 10.1093/sysbio/syq010
   Hue S, 2005, P NATL ACAD SCI USA, V102, P4425, DOI 10.1073/pnas.0407534102
   Hyles Joshua R., 2014, GUIANA SHADOWS EMPIR
   Jaries R, 2017, AIDS CARE, V29, P1448, DOI 10.1080/09540121.2017.1291899
   Junqueira DM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156712
   Kazanji M, 2001, AIDS RES HUM RETROV, V17, P857, DOI 10.1089/088922201750252052
   Kramer MA, 2011, AIDS RES HUM RETROV, V27, P123, DOI 10.1089/aid.2010.0115
   Lemey P, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000520
   Li YC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018954
   Lole KS, 1999, J VIROL, V73, P152, DOI 10.1128/JVI.73.1.152-160.1999
   Magiorkinis G, 2016, INFECT GENET EVOL, V46, P169, DOI 10.1016/j.meegid.2016.05.041
   Mendoza Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095360
   Mir D, 2015, AIDS, V29, P1863, DOI 10.1097/QAD.0000000000000770
   Nacher M, 2010, INT J STD AIDS, V21, P359, DOI 10.1258/ijsa.2010.009570
   Paraskevis D, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-49
   Parriault MC, 2015, CAD SAUDE PUBLICA, V31, P1615, DOI 10.1590/0102-311X00138514
   Pereira Mariana Cunha, 2006, Estud. av., V20, P209, DOI 10.1590/S0103-40142006000200016
   Posada D, 2008, MOL BIOL EVOL, V25, P1253, DOI 10.1093/molbev/msn083
   Rambaut A, 2007, TRACER V1 6
   Rambaut A, 2009, FIGTREE V1 4 TREE FI
   Rambaut A, 2016, VIRUS EVOL, V2, DOI 10.1093/ve/vew007
   Ronsard L, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01467
   Ronsard L, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00706
   Soares CL, 2011, PRACS REV HUMANIDADE, V4, P129
   Suchard MA, 2009, BIOINFORMATICS, V25, P1370, DOI 10.1093/bioinformatics/btp244
   Tamura K, 2013, MOL BIOL EVOL, V30, P2725, DOI [10.1093/molbev/mst197, 10.1093/molbev/msr121]
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   UNAIDS, 2013, REP GLOB AIDS EP
   Wahid FA, 2016, AIDS RES HUM RETROV, V32, P1223, DOI 10.1089/aid.2016.0161
   Worobey M, 2016, NATURE, V539, P98, DOI 10.1038/nature19827
   Zehender G, 2010, JAIDS-J ACQ IMM DEF, V55, P156, DOI 10.1097/QAI.0b013e3181eb3002
NR 53
TC 7
Z9 7
U1 0
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-302X
J9 FRONT MICROBIOL
JI Front. Microbiol.
PD JUL 31
PY 2018
VL 9
AR 1738
DI 10.3389/fmicb.2018.01738
PG 12
WC Microbiology
SC Microbiology
GA GO8CH
UT WOS:000440310500001
PM 30108576
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Cortes, FH
   de Paula, HHS
   Bello, G
   Ribeiro-Alves, M
   de Azevedo, SSD
   Caetano, DG
   Teixeira, SLM
   Hoagland, B
   Grinsztejn, B
   Veloso, VG
   Guimaraes, ML
   Morgado, MG
AF Cortes, Fernanda H.
   de Paula, Hury H. S.
   Bello, Gonzalo
   Ribeiro-Alves, Marcelo
   de Azevedo, Suwellen S. D.
   Caetano, Diogo G.
   Teixeira, Sylvia L. M.
   Hoagland, Brenda
   Grinsztejn, Beatriz
   Veloso, Valdilea G.
   Guimaraes, Monick L.
   Morgado, Mariza G.
TI Plasmatic Levels of IL-18, IP-10, and Activated CD8(+) T Cells Are
   Potential Biomarkers to Identify HIV-1 Elite Controllers With a True
   Functional Cure Profile
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE HIV-1; inflammation; immune activation; elite controller; IP-10; IL-18
ID HUMAN-IMMUNODEFICIENCY-VIRUS; IMMUNE ACTIVATION; CD4/CD8 RATIO;
   INDIVIDUALS; ABSENCE; INFECTION; LONG; HETEROGENEITY; SUPPRESSION;
   DEPLETION
AB Elite controllers (ECs) are rare individuals able to naturally control HIV-1 replication below the detection limit of viral load (VL) commercial assays. It is unclear, however, whether ECs might be considered a natural model of a functional cure because some studies have noted CD4(+) T cell depletion and disease progression associated with abnormally high levels of immune activation and/or inflammation in this group. Here, we propose the use of immunological parameters to identify HIV-1 ECs that could represent the best model of a functional cure. We compared plasma levels of six inflammatory biomarkers (IP-10, IL-18, sCD163, sCD14, CRP, and IL-6) and percentages of activated CD8(+) T cells (CD38(+)HLA-DR+) between 15 ECs [8 with persistent undetectable viremia (persistent elite controllers) and 7 with occasional viral blips (ebbing elite controllers)], 13 viremic controllers (VCs-plasma VL between 51 and 2,000 RNA copies/mL), and 18 HIV-1 infected patients in combined antiretroviral therapy, with suppressed viremia, and 18 HIV-uninfected controls (HIV-neg). The two groups of ECs presented inflammation and activation profiles similar to HIV-neg individuals, and there was no evidence of CD4(+) T cell decline over time. VCs, by contrast, had higher levels of IL-18, IP-10, and CRP and a lower CD4/CD8 ratio than that of HIV-neg (P < 0.05). Plasma levels of IL-18 and IP-10 correlated positively with CD8(+) T cell activation and negatively with both CD4/CD8 and CD4% in HIV-1 controllers. These results suggest that most ECs, defined using stringent criteria in relation to the cutoff level of viremia (<= 50 copies/mL) and a minimum follow-up time of >5 years, show no evidence of persistent inflammation or immune activation. This study further suggests that plasmatic levels of IL-18/IP-10 combined with the frequency of CD8(+) CD38(+) HLA-DR+T cells can be important biomarkers to identify models of a functional cure among HIV-1 ECs.
C1 [Cortes, Fernanda H.; de Paula, Hury H. S.; Bello, Gonzalo; de Azevedo, Suwellen S. D.; Caetano, Diogo G.; Teixeira, Sylvia L. M.; Guimaraes, Monick L.; Morgado, Mariza G.] Fiocruz MS, Inst Oswaldo Cruz, Lab Aids & Imunol Mol, Rio De Janeiro, Brazil.
   [Ribeiro-Alves, Marcelo; Hoagland, Brenda; Grinsztejn, Beatriz; Veloso, Valdilea G.] Fiocruz MS, Inst Nacl Infectol Evandro Chagas, Lab Pesquisa Clin DST Aids, Rio De Janeiro, Brazil.
RP Cortes, FH (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab Aids & Imunol Mol, Rio De Janeiro, Brazil.
EM fheloise@ioc.fiocruz.br
RI Cortes, Fernanda/AAF-9254-2020; Bello, Gonzalo/E-6842-2013; de Azevedo,
   Suwellen/P-7199-2017
OI de Azevedo, Suwellen/0000-0001-6681-0987; Ribeiro-Alves,
   Marcelo/0000-0002-8663-3364
FU Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro - FAPERJCarlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ); Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico - CNPqNational Council for Scientific and Technological
   Development (CNPq); Fiocruz; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [UM1AI069476, UM1AI069476,
   UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476,
   UM1AI069476, UM1AI069476] Funding Source: NIH RePORTER
FX This work was supported by the Fundacao de Amparo a Pesquisa do Estado
   do Rio de Janeiro - FAPERJ; the Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico - CNPq; and Fiocruz.
CR Ahmad R, 2002, J VIROL, V76, P12448, DOI 10.1128/JVI.76.24.12448-12456.2002
   Andrade A, 2008, CLIN INFECT DIS, V46, pE78, DOI 10.1086/529387
   Autran B, 2011, CURR OPIN HIV AIDS, V6, P181, DOI 10.1097/COH.0b013e328345a328
   Bansal A, 2015, AIDS, V29, P2245, DOI 10.1097/QAD.0000000000000860
   Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01
   Bello G, 2009, J MED VIROL, V81, P1681, DOI 10.1002/jmv.21565
   BOX GEP, 1964, J ROY STAT SOC B, V26, P211, DOI 10.1111/j.2517-6161.1964.tb00553.x
   Canoui E, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx064
   Castley A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115226
   Chereau F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173893
   Chun TW, 2013, J INFECT DIS, V208, P1443, DOI 10.1093/infdis/jit306
   Cortes FH, 2015, JAIDS-J ACQ IMM DEF, V68, P377, DOI 10.1097/QAI.0000000000000500
   de Azevedo SSD, 2017, RETROVIROLOGY, V14, DOI 10.1186/s12977-017-0354-5
   Deeks SG, 2004, BLOOD, V104, P942, DOI 10.1182/blood-2003-09-3333
   Deeks SG, 2007, IMMUNITY, V27, P406, DOI 10.1016/j.immuni.2007.08.010
   Giorgi JV, 2002, J ACQ IMMUN DEF SYND, V29, P346, DOI 10.1097/00126334-200204010-00004
   Gurdasani D, 2014, AIDS, V28, P149, DOI 10.1097/QAD.0000000000000049
   Hatano H, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003691
   Hatano H, 2009, J VIROL, V83, P329, DOI 10.1128/JVI.01763-08
   Helleberg M, 2015, J INFECT DIS, V211, P1726, DOI 10.1093/infdis/jiu669
   HOLM S, 1979, SCAND J STAT, V6, P65
   Hua S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101920
   Hunt PW, 2008, J INFECT DIS, V197, P126, DOI 10.1086/524143
   Iannello A, 2017, CYTOKINE, V90, P96, DOI 10.1016/j.cyto.2016.10.018
   Kamya P, 2011, AIDS RES THER, V8, DOI 10.1186/1742-6405-8-20
   Lambotte O, 2009, AIDS, V23, P897, DOI 10.1097/QAD.0b013e328329f97d
   Leon A, 2016, AIDS, V30, P1209, DOI 10.1097/QAD.0000000000001050
   Margolick JB, 2006, JAIDS-J ACQ IMM DEF, V42, P620, DOI 10.1097/01.qai.0000223028.55080.9d
   Noel N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131922
   Noel N, 2014, AIDS, V28, P467, DOI 10.1097/QAD.0000000000000174
   Pastor L, 2017, CLIN INFECT DIS, V65, P1670, DOI 10.1093/cid/cix600
   Pereyra F, 2008, J INFECT DIS, V197, P563, DOI 10.1086/526786
   Pereyra F, 2009, J INFECT DIS, V200, P984, DOI 10.1086/605446
   Pirzada Yasmin, 2006, AIDS Res Ther, V3, P20, DOI 10.1186/1742-6405-3-20
   Saez-Cirion A, 2007, P NATL ACAD SCI USA, V104, P6776, DOI 10.1073/pnas.0611244104
   Saez-Cirion A, 2009, J IMMUNOL, V182, P7828, DOI 10.4049/jimmunol.0803928
   SATTERTHWAITE FE, 1946, BIOMETRICS BULL, V2, P110, DOI 10.2307/3002019
   Sedaghat AR, 2009, CLIN INFECT DIS, V49, P1763, DOI 10.1086/648081
   Serrano-Villar S, 2013, J INFECTION, V66, P57, DOI 10.1016/j.jinf.2012.09.013
   Sousa AE, 2002, J IMMUNOL, V169, P3400, DOI 10.4049/jimmunol.169.6.3400
   Veenhuis RT, 2017, CLIN INFECT DIS, V64, P589, DOI 10.1093/cid/ciw771
   Wada NI, 2015, AIDS, V29, P463, DOI 10.1097/QAD.0000000000000545
   Walker-Sperling VE, 2017, EBIOMEDICINE, V16, P141, DOI 10.1016/j.ebiom.2017.01.034
   Wiercinska-Drapalo A, 2004, MICROBES INFECT, V6, P1273, DOI 10.1016/j.micinf.2004.07.009
   Yandell BS, 1997, CHAPMAN HALL CRC TEX
NR 45
TC 10
Z9 10
U1 0
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JUL 11
PY 2018
VL 9
AR 1576
DI 10.3389/fimmu.2018.01576
PG 11
WC Immunology
SC Immunology
GA GM6TK
UT WOS:000438306900001
PM 30050532
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Temerozo, JR
   de Azevedo, SSD
   Insuela, DBR
   Vieira, RC
   Ferreira, PLC
   Carvalho, VF
   Bello, G
   Bou-Habib, DC
AF Temerozo, Jairo R.
   de Azevedo, Suwellen S. D.
   Insuela, Daniella B. R.
   Vieira, Rhaissa C.
   Ferreira, Pedro L. C.
   Carvalho, Vinicius F.
   Bello, Gonzalo
   Bou-Habib, Dumith Chequer
TI The neuropeptides Vasoactive Intestinal Peptide and Pituitary Adenylate
   Cyclase-Activating Polypeptide Control HIV-1 Infection in Macrophages
   Through Activation of Protein Kinases A and C
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE HIV-1; vasoactive intestinal peptide; pituitary adenylate
   cyclase-activating polypeptide; neuropeptides; macrophages; protein
   kinase C; protein kinase A
ID NF-KAPPA-B; HUMAN-IMMUNODEFICIENCY-VIRUS; ELEMENT-BINDING PROTEIN;
   NECROSIS-FACTOR-ALPHA; SIGNALING PATHWAY; COUPLED RECEPTORS;
   TRANSCRIPTIONAL ACTIVITY; NEUROENDOCRINE RECEPTOR; MOLECULAR-MECHANISMS;
   DEPENDENT PATHWAY
AB Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) are highly similar neuropeptides present in several tissues, endowed with immunoregulatory functions and other systemic effects. We previously reported that both neuropeptides reduce viral production in HIV-1-infected primary macrophages, with the participation of beta-chemokines and IL-10, and now we describe molecular mechanisms engaged in this activity. Macrophages exposed to VIP or PACAP before HIV-1 infection showed resistance to viral replication, comparable to that observed when the cells were treated after infection. Also, multiple treatments with a suboptimal dose of VIP or PACAP after macrophage infection resulted in a decline of virus production similar to the inhibition promoted by a single exposure to the optimal inhibitory concentration. Cellular signaling pathways involving cAMP production and activation of protein kinases A and C were critical components of the VIP and PACAP anti-HIV-1 effects. Analysis of the transcription factors and the transcriptional/cell cycle regulators showed that VIP and PACAP induced cAMP response element-binding protein activation, inhibited NF-kappa B, and reduced Cyclin D1 levels in HIV-1-infected cells. Remarkably, VIP and PACAP promoted G-to-A mutations in the HIV-1 provirus, matching those derived from the activity of the APOBEC family of viral restriction factors, and reduced viral infectivity. In conclusion, our findings strengthen the antiretroviral potential of VIP and PACAP and point to new therapeutic approaches to control the progression of HIV-1 infection.
C1 [Temerozo, Jairo R.; Vieira, Rhaissa C.; Ferreira, Pedro L. C.; Bou-Habib, Dumith Chequer] Fiocruz MS, Lab Thymus Res, Oswaldo Cruz Inst, Rio De Janeiro, Brazil.
   [Temerozo, Jairo R.; Carvalho, Vinicius F.; Bou-Habib, Dumith Chequer] Fiocruz MS, Natl Inst Sci & Technol Neuroimmunomodulat, Oswaldo Cruz Inst, Rio De Janeiro, Brazil.
   [de Azevedo, Suwellen S. D.; Bello, Gonzalo] Fiocruz MS, Lab AIDS & Mol Immunol, Oswaldo Cruz Inst, Rio De Janeiro, Brazil.
   [Insuela, Daniella B. R.; Carvalho, Vinicius F.] Fiocruz MS, Lab Inflammat, Oswaldo Cruz Inst, Rio De Janeiro, Brazil.
RP Temerozo, JR; Bou-Habib, DC (corresponding author), Fiocruz MS, Lab Thymus Res, Oswaldo Cruz Inst, Rio De Janeiro, Brazil.; Temerozo, JR; Bou-Habib, DC (corresponding author), Fiocruz MS, Natl Inst Sci & Technol Neuroimmunomodulat, Oswaldo Cruz Inst, Rio De Janeiro, Brazil.
EM jairojrt@gmail.com; dumith@ioc.fiocruz.br
RI Carvalho, Vinicius F/M-4762-2016; Temerozo, Jairo Ramos/K-4894-2012;
   Bello, Gonzalo/E-6842-2013; de Azevedo, Suwellen/P-7199-2017
OI Temerozo, Jairo Ramos/0000-0002-8092-2149; de Azevedo,
   Suwellen/0000-0001-6681-0987
FU Brazilian National Research Council (CNPq)National Council for
   Scientific and Technological Development (CNPq); Carlos Chagas Filho Rio
   de Janeiro Research Foundation (Faperj); Mercosur Fund for Structural
   Convergence (FOCEM, Mercosur) [03/11]; CNPqNational Council for
   Scientific and Technological Development (CNPq); FAPERJCarlos Chagas
   Filho Foundation for Research Support of the State of Rio de Janeiro
   (FAPERJ)
FX This study was supported by the Brazilian research funding agencies
   Brazilian National Research Council (CNPq) and Carlos Chagas Filho Rio
   de Janeiro Research Foundation (Faperj), and also by the Mercosur Fund
   for Structural Convergence (FOCEM, Mercosur, grant number 03/11). JT and
   SA were supported by fellowships from CNPq and FAPERJ, and DI, RV, and
   PF from CNPq. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Anderson P, 2010, MOL CELL BIOL, V30, P2537, DOI 10.1128/MCB.01282-09
   Arainga M, 2017, RETROVIROLOGY, V14, DOI 10.1186/s12977-017-0344-7
   Arsenijevic T, 2006, CELL CYCLE, V5, P1217, DOI 10.4161/cc.5.11.2802
   Asamitsu K, 2017, CURR PHARM DESIGN, V23, P4091, DOI 10.2174/1381612823666170710164148
   Bokaei PB, 2007, VIROLOGY, V362, P38, DOI 10.1016/j.virol.2006.12.012
   Branch DR, 2002, AIDS, V16, P309, DOI 10.1097/00002030-200202150-00001
   Carey RG, 2002, J NEUROSCI, V22, P1583, DOI 10.1523/JNEUROSCI.22-05-01583.2002
   Cary DC, 2016, J CLIN INVEST, V126, P448, DOI 10.1172/JCI80565
   Chen H, 2017, MOLECULES, V22, DOI 10.3390/molecules22091498
   Chen PQ, 1997, J BIOL CHEM, V272, P22385, DOI 10.1074/jbc.272.36.22385
   Chik CL, 1996, FASEB J, V10, P1310
   Choe W, 2002, J VIROL, V76, P5274, DOI 10.1128/JVI.76.10.5274-5277.2002
   De Vita F, 2012, CELL CYCLE, V11, P1583, DOI 10.4161/cc.20003
   Delgado M, 2000, EUR J IMMUNOL, V30, P3236, DOI 10.1002/1521-4141(200011)30:11<3236::AID-IMMU3236>3.0.CO;2-L
   Delgado M, 2001, J BIOL CHEM, V276, P369, DOI 10.1074/jbc.M006923200
   Delgado M, 2001, J IMMUNOL, V167, P966, DOI 10.4049/jimmunol.167.2.966
   Delgado M, 2003, BIOCHEM BIOPH RES CO, V302, P275, DOI 10.1016/S0006-291X(03)00149-9
   Delgado M, 2013, AMINO ACIDS, V45, P25, DOI 10.1007/s00726-011-1184-8
   Delghandi MP, 2005, CELL SIGNAL, V17, P1343, DOI 10.1016/j.cellsig.2005.02.003
   DeLuca C, 1996, J VIROL, V70, P5183, DOI 10.1128/JVI.70.8.5183-5193.1996
   Dey A, 2000, BBA-MOL CELL RES, V1497, P135, DOI 10.1016/S0167-4889(00)00053-7
   Dickson L, 2009, PHARMACOL THERAPEUT, V121, P294, DOI 10.1016/j.pharmthera.2008.11.006
   Ding WH, 2007, J INVEST DERMATOL, V127, P2357, DOI 10.1038/sj.jid.5700858
   Emery AC, 2012, FASEB J, V26, P3199, DOI 10.1096/fj.11-203042
   Georg B, 2016, NEUROPEPTIDES, V60, P83, DOI 10.1016/j.npep.2016.09.004
   Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90
   Gonzalez-Rey E, 2007, CURR PHARM DESIGN, V13, P1113, DOI 10.2174/138161207780618966
   Grumolato L, 2003, EUR J NEUROSCI, V17, P71, DOI 10.1046/j.1460-9568.2003.02426.x
   Guan LJ, 2007, J BIOL CHEM, V282, P14213, DOI 10.1074/jbc.M610513200
   Guo CM, 2012, ENDOCRINOLOGY, V153, P4938, DOI 10.1210/en.2012-1441
   Herskovitz J, 2019, J NEUROIMMUNE PHARM, V14, P52, DOI 10.1007/s11481-018-9785-6
   Hiscott J, 2001, J CLIN INVEST, V107, P143, DOI 10.1172/JCI11918
   Holtz CM, 2013, NUCLEIC ACIDS RES, V41, P6139, DOI 10.1093/nar/gkt246
   Hu QX, 2006, J INFECT DIS, V194, P1547, DOI 10.1086/508898
   Jimenez VC, 2012, SCI REP-UK, V2, DOI 10.1038/srep00763
   Juhasz T, 2015, PEPTIDES, V66, P51, DOI 10.1016/j.peptides.2015.02.001
   Kanasaki H, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101635
   Kumar S, 2008, BRIEF BIOINFORM, V9, P299, DOI 10.1093/bib/bbn017
   Kyei GB, 2015, CELL HOST MICROBE, V17, P98, DOI 10.1016/j.chom.2014.11.009
   Laburthe M, 2007, PEPTIDES, V28, P1631, DOI 10.1016/j.peptides.2007.04.026
   Leceta J, 2000, ANN NY ACAD SCI, V921, P92
   Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910
   Lima RG, 2002, J INFECT DIS, V185, P1561, DOI 10.1086/340412
   Liu Y, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0523-z
   Martin F, 2011, BRIT J PHARMACOL, V163, P857, DOI 10.1111/j.1476-5381.2011.01287.x
   Matt T, 2002, ACTA MED AUST, V29, P77, DOI 10.1046/j.1563-2571.2002.02010.x
   May V, 2014, AM J PHYSIOL-CELL PH, V306, pC1068, DOI 10.1152/ajpcell.00001.2014
   Meltzer B, 2018, VIROLOGY, V518, P241, DOI 10.1016/j.virol.2018.03.006
   Minguet S, 2005, EUR J IMMUNOL, V35, P31, DOI 10.1002/eji.200425524
   Monajemi M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093428
   Mut M, 2010, TURK NEUROSURG, V20, P277, DOI 10.5137/1019-5149.JTN.3008-10.1
   Nekhai S, 2006, FUTURE MICROBIOL, V1, P417, DOI 10.2217/17460913.1.4.417
   Nelson PJ, 2002, BMC MICROBIOL, V2, DOI 10.1186/1471-2180-2-26
   Niewiadomski P, 2013, CELL SIGNAL, V25, P2222, DOI 10.1016/j.cellsig.2013.07.012
   Njaine B, 2010, EUR J NEUROSCI, V32, P311, DOI 10.1111/j.1460-9568.2010.07286.x
   Page K, 2002, AM J RESP CELL MOL, V27, P204, DOI 10.1165/ajrcmb.27.2.20010016oc
   Romanchikova N, 2003, IMMUNOBIOLOGY, V208, P361, DOI 10.1078/0171-2985-00283
   Romani B, 2009, ARCH VIROL, V154, P1579, DOI 10.1007/s00705-009-0481-y
   Rose KM, 2004, J BIOL CHEM, V279, P41744, DOI 10.1074/jbc.M406760200
   Ruiz A, 2015, CELL CYCLE, V14, P1657, DOI 10.1080/15384101.2015.1030558
   Sattentau QJ, 2016, CELL HOST MICROBE, V19, P304, DOI 10.1016/j.chom.2016.02.013
   Schomerus C, 1996, CELL TISSUE RES, V286, P305
   SEWING A, 1994, ONCOGENE, V9, P2733
   Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821
   Shenkar R, 2001, AM J PHYSIOL-LUNG C, V281, pL418
   Shirakawa K, 2008, NAT STRUCT MOL BIOL, V15, P1184, DOI 10.1038/nsmb.1497
   Souza TML, 2011, BLOOD, V117, P2944, DOI 10.1182/blood-2010-05-287193
   Strebel K, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-48
   Takahashi N, 2002, EUR J BIOCHEM, V269, P4559, DOI 10.1046/j.1432-1033.2002.03157.x
   Tan YV, 2011, ASN NEURO, V3, P195, DOI 10.1042/AN20110024
   Temerozo JR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067701
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   van Oirschot BA, 2001, J BIOL CHEM, V276, P33854, DOI 10.1074/jbc.M104395200
   Vaudry D, 2009, PHARMACOL REV, V61, P283, DOI 10.1124/pr.109.001370
   Victoria S, 2013, IMMUNOBIOLOGY, V218, P1529, DOI 10.1016/j.imbio.2013.06.006
   WESTENDORP MO, 1995, EMBO J, V14, P546, DOI 10.1002/j.1460-2075.1995.tb07030.x
   Xia JH, 2012, J NUTR BIOCHEM, V23, P1668, DOI 10.1016/j.jnutbio.2011.11.010
   Xu FB, 2016, BIOL TRACE ELEM RES, V170, P424, DOI 10.1007/s12011-015-0461-x
   Yu L, 2017, BLOOD REV, V31, P77, DOI 10.1016/j.blre.2016.10.001
   Zanassi P, 2001, J BIOL CHEM, V276, P11487, DOI 10.1074/jbc.M007631200
NR 80
TC 4
Z9 4
U1 0
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JUN 12
PY 2018
VL 9
AR 1336
DI 10.3389/fimmu.2018.01336
PG 16
WC Immunology
SC Immunology
GA GJ0WZ
UT WOS:000434976500001
PM 29951068
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Mir, D
   Graf, T
   Almeida, SED
   Pinto, AR
   Delatorre, E
   Bello, G
AF Mir, Daiana
   Graef, Tiago
   de Matos Almeida, Sabrina Esteves
   Pinto, Aguinaldo Roberto
   Delatorre, Edson
   Bello, Gonzalo
TI Inferring population dynamics of HIV-1 subtype C epidemics in Eastern
   Africa and Southern Brazil applying different Bayesian phylodynamics
   approaches
SO SCIENTIFIC REPORTS
LA English
DT Article
ID III INFECTION; SEQUENCE DATA; VIRUS; AIDS; COALESCENT; MODEL;
   PREVALENCE; INFERENCE; BEHAVIOR; HISTORY
AB The subtype C Eastern Africa clade (CEA), a particularly successful HIV-1 subtype C lineage, has seeded several sub-epidemics in Eastern African countries and Southern Brazil during the 1960s and 1970s. Here, we characterized the past population dynamics of the major CEA sub-epidemics in Eastern Africa and Brazil by using Bayesian phylodynamic approaches based on coalescent and birth-death models. All phylodynamic models support similar epidemic dynamics and exponential growth rates until roughly the mid-1980s for all the CEA sub-epidemics. Divergent growth patterns, however, were supported afterwards. The Bayesian skygrid coalescent model (BSKG) and the birth-death skyline model (BDSKY) supported longer exponential growth phases than the Bayesian skyline coalescent model (BSKL). The BDSKY model uncovers patterns of a recent decline for the CEA sub-epidemics in Burundi/Rwanda and Tanzania (R-e < 1) and a recent growth for Southern Brazil (R-e > 1); whereas coalescent models infer an epidemic stabilization. To the contrary, the BSKG model captured a decline of Ethiopian CEA subepidemic between the mid-1990s and mid-2000s that was not uncovered by the BDSKY model. These results underscore that the joint use of different phylodynamic approaches may yield complementary insights into the past HIV population dynamics.
C1 [Mir, Daiana; Delatorre, Edson; Bello, Gonzalo] Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, FIOCRUZ, Rio De Janeiro, Brazil.
   [Graef, Tiago] Univ Fed Rio de Janeiro, Inst Biol, Dept Genet, Rio De Janeiro, Brazil.
   [Graef, Tiago] Univ KwaZulu Natal, Coll Hlth Sci, KwaZulu Natal Res Innovat & Sequencing Platform K, Durban, South Africa.
   [de Matos Almeida, Sabrina Esteves] Fundacao Estadual Prod & Pesquisa Saude, Ctr Desenvolvimento Cient & Tecnol, Porto Alegre, RS, Brazil.
   [de Matos Almeida, Sabrina Esteves] Univ Fed Rio Grande do Sul, Programa Posgrad Genet & Biol Mol, Porto Alegre, RS, Brazil.
   [de Matos Almeida, Sabrina Esteves] Univ Feevale, Inst Ciencias Saude, Novo Hamburgo, Brazil.
   [Pinto, Aguinaldo Roberto] Univ Fed Santa Catarina, Dept Microbiol Imunol & Parasitol, Lab Imunol Aplicada, Florianopolis, SC, Brazil.
RP Mir, D (corresponding author), Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, FIOCRUZ, Rio De Janeiro, Brazil.
EM daianamir@gmail.com
RI , daiana/J-5515-2019; Graf, Tiago/S-8535-2019; Delatorre,
   Edson/J-8330-2015; Bello, Gonzalo/E-6842-2013; Pinto, Aguinaldo
   Roberto/R-6625-2016
OI , daiana/0000-0002-3172-4867; Graf, Tiago/0000-0003-4921-7975;
   Delatorre, Edson/0000-0002-5746-0820; Pinto, Aguinaldo
   Roberto/0000-0002-0991-8876
FU Agencia Nacional de Investigacion e Innovacion (ANII-Uruguay);
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES-Brazil)CAPES; Programa Nacional de Pos-Doutorado (CAPES-Brazil);
   VIROGENESIS Project as part of the European Union's Horizon 2020
   Research and Innovation Programme [634650]; Medical Research Council
   (MRC) of the Republic of South AfricaMedical Research Council UK (MRC)
   [MRC-RFA-FSP-01-2013/UKZN HIVEPI]
FX D.M. was funded by fellowships from "Agencia Nacional de Investigacion e
   Innovacion (ANII-Uruguay)" and "Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES-Brazil)". E.D. was funded by a
   fellowship from "Programa Nacional de Pos-Doutorado (CAPES-Brazil)". TG
   in 2016-2017/2 was supported by the VIROGENESIS Project as part of the
   European Union's Horizon 2020 Research and Innovation Programme under
   grant agreement 634650 and from a Flagship grant from the Medical
   Research Council (MRC) of the Republic of South Africa
   (MRC-RFA-FSP-01-2013/UKZN HIVEPI).
CR [Anonymous], 2011, 3 5 COUNTR INF
   Baele G, 2012, MOL BIOL EVOL, V29, P2157, DOI 10.1093/molbev/mss084
   BAYLEY AC, 1985, LANCET, V1, P359
   Bello G, 2008, AIDS, V22, P1993, DOI 10.1097/QAD.0b013e328315e0aa
   Bello G, 2009, AIDS RES HUM RETROV, V25, P1065, DOI 10.1089/aid.2009.0106
   Berkman A, 2005, AM J PUBLIC HEALTH, V95, P1162, DOI 10.2105/AJPH.2004.054593
   Bezemer D, 2008, AIDS, V22, P1071, DOI 10.1097/QAD.0b013e3282fd167c
   Boskova V, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003913
   Bouckaert R, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003537
   Brazilian Ministry of Health, 2017, SYPH EP B
   Brazilian Ministry of Health, 2016, AIDS EP B
   Buve A, 2002, LANCET, V359, P2011, DOI 10.1016/S0140-6736(02)08823-2
   Veras NMC, 2011, J GEN VIROL, V92, P1698, DOI 10.1099/vir.0.028951-0
   de Oliveira T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009311
   de Silva E, 2012, J R SOC INTERFACE, V9, P1797, DOI 10.1098/rsif.2011.0850
   Delatorre E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074072
   Delatorre EO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041904
   DIEKMANN O, 1990, J MATH BIOL, V28, P365
   Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/msi103
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   Faria NR, 2014, SCIENCE, V346, P56, DOI 10.1126/science.1256739
   Fontella R, 2008, AIDS, V22, P2001, DOI 10.1097/QAD.0b013e3283108f69
   Fu YX, 2006, THEOR POPUL BIOL, V69, P385, DOI 10.1016/j.tpb.2005.11.005
   Gill MS, 2016, SYST BIOL, V65, P1041, DOI 10.1093/sysbio/syw050
   Gill MS, 2013, MOL BIOL EVOL, V30, P713, DOI 10.1093/molbev/mss265
   Graef T, 2015, J VIROL, V89, P12341, DOI 10.1128/JVI.01681-15
   Graf T, 2013, VIROLOGY, V435, P170, DOI 10.1016/j.virol.2012.08.048
   Graf T, 2011, J CLIN VIROL, V51, P186, DOI 10.1016/j.jcv.2011.04.011
   Graf T, 2016, J VIROL, V90, P8160, DOI 10.1128/JVI.00363-16
   Guindon S, 2005, NUCLEIC ACIDS RES, V33, pW557, DOI 10.1093/nar/gki352
   Guindon S, 2010, SYST BIOL, V59, P307, DOI 10.1093/sysbio/syq010
   Hearst N, 2004, STUD FAMILY PLANN, V35, P39, DOI 10.1111/j.1728-4465.2004.00004.x
   Hemelaar J, 2011, AIDS, V25, P679, DOI 10.1097/QAD.0b013e328342ff93
   Iliffe J., 2006, AFRICAN AIDS EPIDEMI
   JONCKHEER T, 1985, LANCET, V1, P400
   Le Vu S, 2010, LANCET INFECT DIS, V10, P682, DOI 10.1016/S1473-3099(10)70167-5
   Levi GC, 2002, AIDS, V16, P2373, DOI 10.1097/00002030-200212060-00001
   Lole KS, 1999, J VIROL, V73, P152, DOI 10.1128/JVI.73.1.152-160.1999
   Lugalla J, 2004, SOC SCI MED, V59, P185, DOI 10.1016/j.socscimed.2003.10.033
   Macintyre K, 2001, AIDS EDUC PREV, V13, P160, DOI 10.1521/aeap.13.2.160.19736
   MELBYE M, 1986, BRIT MED J, V292, P5, DOI 10.1136/bmj.292.6512.5
   Mhalu F. S, 1988, AIDS ASS CANC AFRICA, DOI [10.1159/000415521, DOI 10.1159/000415521]
   Ngweshemi JZL, 1996, AIDS, V10, P1415, DOI 10.1097/00002030-199610000-00015
   Nyindo M, 2005, East Afr Med J, V82, P40
   Omare D, 2011, J PUBLIC HEALTH AFR, V2, P34, DOI 10.4081/jphia.2011.e9
   Pollakis G, 2003, AIDS RES HUM RETROV, V19, P999, DOI 10.1089/088922203322588350
   Posada D, 2008, MOL BIOL EVOL, V25, P1253, DOI 10.1093/molbev/msn083
   Pybus OG, 2001, SCIENCE, V292, P2323, DOI 10.1126/science.1058321
   Rambaut A., 2013, TRACER V1 6
   Rambaut A, 2016, VIRUS EVOL, V2, DOI 10.1093/ve/vew007
   Ramjee G, 2013, AIDS RES THER, V10, DOI 10.1186/1742-6405-10-30
   Rasmussen DA, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002136
   Richardson ET, 2014, J INT AIDS SOC, V17, DOI 10.7448/IAS.17.1.19035
   SERWADDA D, 1985, LANCET, V2, P849, DOI 10.1016/S0140-6736(85)90122-9
   Soares MA, 2003, AIDS, V17, P11, DOI 10.1097/00002030-200301030-00004
   Spiegel PB, 2004, DISASTERS, V28, P322, DOI 10.1111/j.0361-3666.2004.00261.x
   Stadler T, 2013, P NATL ACAD SCI USA, V110, P228, DOI 10.1073/pnas.1207965110
   Stadler T, 2012, MOL BIOL EVOL, V29, P347, DOI 10.1093/molbev/msr217
   Stoneburner R, 1998, AIDS, V12, P226
   Terminski Bogumil, 2013, DEVELOPMENT, V10, P101
   The Kirby Institute/Sydney University of New South Wales, 2011, HIV VIR HEP SEX TRAN
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Thomson MM, 2011, VIROLOGY, V415, P30, DOI 10.1016/j.virol.2011.03.021
   UNAIDS, 2003, HIV AIDS CONFL
   Volz EM, 2018, SYST BIOL, V67, P719, DOI 10.1093/sysbio/syy007
   White PJ, 2006, AIDS, V20, P1898, DOI 10.1097/01.aids.0000244213.23574.fa
   Williams B. G., 2014, 14066912 ARXIV, P1
   Williams B. G, 2014, 13043720 ARXIV
   World Health Organization, 2005, CHALL OB WHO EUR REG, P1
NR 70
TC 5
Z9 5
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUN 8
PY 2018
VL 8
AR 8778
DI 10.1038/s41598-018-26824-4
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GI6VL
UT WOS:000434641100008
PM 29884822
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Gomez, MM
   de Abreu, FVS
   dos Santos, AAC
   de Mello, IS
   Santos, MP
   Ribeiro, IP
   Ferreira-de-Brito, A
   de Miranda, RM
   de Castro, MG
   Ribeiro, MS
   Laterriere, RD
   Aguiar, SF
   Meira, GLS
   Antunes, D
   Torres, PHM
   Mir, D
   Vicente, ACP
   Guimaraes, ACR
   Caffarena, ER
   Bello, G
   Lourenco-de-Oliveira, R
   Bonaldo, MC
AF Gomez, Mariela Martinez
   Santos de Abreu, Filipe Vieira
   Cunha dos Santos, Alexandre Araujo
   de Mello, Iasmim Silva
   Santos, Marta Pereira
   Ribeiro, Ieda Pereira
   Ferreira-de-Brito, Anielly
   de Miranda, Rafaella Moraes
   de Castro, Marcia Goncalves
   Ribeiro, Mario Sergio
   Laterriere Junior, Roberto da Costa
   Aguiar, Shirlei Ferreira
   Silva Meira, Guilherme Louzada
   Antunes, Deborah
   Monteiro Torres, Pedro Henrique
   Mir, Daiana
   Paulo Vicente, Ana Carolina
   Ramos Guimaraes, Ana Carolina
   Caffarena, Ernesto Raul
   Bello, Gonzalo
   Lourenco-de-Oliveira, Ricardo
   Bonaldo, Myrna Cristina
TI Genomic and structural features of the yellow fever virus from the
   2016-2017 Brazilian outbreak
SO JOURNAL OF GENERAL VIROLOGY
LA English
DT Article
DE yellow fever virus; 2016-2017 Brazilian outbreak; amino acid changes;
   genetic diversity; evolution
ID NS2B-NS3 PROTEASE; MOSAIC STRUCTURE; ZIKA VIRUS; NS3; RECOMBINATION;
   EMERGENCE; PROTEINS; ELECTROSTATICS; EVOLUTIONARY; PROTECTION
AB Southeastern Brazil has been suffering a rapid expansion of a severe sylvatic yellow fever virus (YFV) outbreak since late 2016, which has reached one of the most populated zones in Brazil and South America, heretofore a yellow fever-free zone for more than 70 years. In the current study, we describe the complete genome of 12 YFV samples from mosquitoes, humans and non-human primates from the Brazilian 2017 epidemic. All of the YFV sequences belong to the modern lineage (sub-lineage 1E) of South American genotype I, having been circulating for several months prior to the December 2016 detection. Our data confirm that viral strains associated with the most severe YF epidemic in South America in the last 70 years display unique amino acid substitutions that are mainly located in highly conserved positions in non-structural proteins. Our data also corroborate that YFV has spread southward into Rio de Janeiro state following two main sylvatic dispersion routes that converged at the border of the great metropolitan area comprising nearly 12 million unvaccinated inhabitants. Our original results can help public health authorities to guide the surveillance, prophylaxis and control measures required to face such a severe epidemiological problem. Finally, it will also inspire other workers to further investigate the epidemiological and biological significance of the amino acid polymorphisms detected in the Brazilian 2017 YFV strains.
C1 [Gomez, Mariela Martinez; Cunha dos Santos, Alexandre Araujo; de Mello, Iasmim Silva; Santos, Marta Pereira; Ribeiro, Ieda Pereira; Bonaldo, Myrna Cristina] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Biol Mol Flavivirus, Rio De Janeiro, Brazil.
   [Santos de Abreu, Filipe Vieira; Ferreira-de-Brito, Anielly; de Miranda, Rafaella Moraes; de Castro, Marcia Goncalves; Lourenco-de-Oliveira, Ricardo] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Mosquitos Transmissores Hematozoarios, Rio De Janeiro, Brazil.
   [Santos de Abreu, Filipe Vieira] Inst Fed Norte Minas Gerais, Salinas, MG, Brazil.
   [Ribeiro, Mario Sergio] Secretaria Estadual Saude, Superintendencia Vigilancia Epidemiol & Ambiental, Rio De Janeiro, Brazil.
   [Laterriere Junior, Roberto da Costa] Secretaria Estadual Saude Espirito Santo, Nucleo Especial Vigilancia Ambiental, Vitoria, Brazil.
   [Aguiar, Shirlei Ferreira; Silva Meira, Guilherme Louzada] Lab Cent Saude Publ Noel Nutels LACEN RJ, Rio De Janeiro, Brazil.
   [Antunes, Deborah; Monteiro Torres, Pedro Henrique; Caffarena, Ernesto Raul] Fundacao Oswaldo Cruz, Programa Computacao Cient PROCC, Rio De Janeiro, Brazil.
   [Mir, Daiana; Bello, Gonzalo] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab AIDS Imunol Mol, Rio De Janeiro, Brazil.
   [Paulo Vicente, Ana Carolina] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Genet Mol Microorganismos, Rio De Janeiro, Brazil.
   [Ramos Guimaraes, Ana Carolina] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Genom Func & Bioinformat, Rio De Janeiro, Brazil.
RP Bonaldo, MC (corresponding author), Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Biol Mol Flavivirus, Rio De Janeiro, Brazil.; Lourenco-de-Oliveira, R (corresponding author), Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Mosquitos Transmissores Hematozoarios, Rio De Janeiro, Brazil.
EM lourenco@ioc.fiocruz; mbonaldo@ioc.fiocruz.br
RI , daiana/J-5515-2019; Caffarena, Ernesto R/G-4467-2011; Torres, Pedro
   Henrique Monteiro/C-7657-2015; Guimaraes, Ana Carolina
   Ramos/P-7914-2018; Antunes, Deborah/O-2505-2019; Antunes,
   Deborah/P-5615-2018; Caffarena, Ernesto/O-5920-2019; Bello,
   Gonzalo/E-6842-2013
OI , daiana/0000-0002-3172-4867; Caffarena, Ernesto R/0000-0002-8353-3034;
   Torres, Pedro Henrique Monteiro/0000-0002-0945-1495; Guimaraes, Ana
   Carolina Ramos/0000-0003-1260-543X; Antunes,
   Deborah/0000-0002-2927-0800; Antunes, Deborah/0000-0002-2927-0800;
   Caffarena, Ernesto/0000-0002-8353-3034; Ribeiro, Ivonizete
   Pires/0000-0003-0737-5430
FU Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de
   Janeiro [E-26/102.351/2013, E-26/201.335/2016]; Conselho Nacional
   Desenvolvimento Cientifico e TecnologicoNational Council for Scientific
   and Technological Development (CNPq) [309577/2013-6, 440865/2016-6];
   Coordenacao de Aperfeicoamento de Pessoal de Nivel SuperiorCAPES
   [88881130684/2016-00]; Institut Pasteur, Transversal Research Program
   (PTR) [528]
FX This work was funded by Fundacao Carlos Chagas Filho de Amparo a
   Pesquisa do Estado do Rio de Janeiro (grants nos E-26/102.351/2013 and
   E-26/201.335/2016 to R.L.O.), Conselho Nacional Desenvolvimento
   Cientifico e Tecnologico [grants nos 309577/2013-6 (to R.L.O.) and
   440865/2016-6 (to M.C.B.)], Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior (grant no. 88881130684/2016-00 to M.C.B.) and the
   Institut Pasteur, Transversal Research Program (PTR grant no. 528 to
   R.L.O.). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Baele G, 2012, MOL BIOL EVOL, V29, P2157, DOI 10.1093/molbev/mss084
   Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398
   Barnett ED, 2007, CLIN INFECT DIS, V44, P850, DOI 10.1086/511869
   Beasley DWC, 2015, ANTIVIR RES, V115, P48, DOI 10.1016/j.antiviral.2014.12.010
   Benkert P, 2009, NUCLEIC ACIDS RES, V37, pW510, DOI 10.1093/nar/gkp322
   Bonaldo MC, 2017, MEM I OSWALDO CRUZ, V112, P447, DOI 10.1590/0074-02760170134
   Bond CS, 2009, ACTA CRYSTALLOGR D, V65, P510, DOI 10.1107/S0907444909007835
   Boni MF, 2007, GENETICS, V176, P1035, DOI 10.1534/genetics.106.068874
   Bryant JE, 2007, PLOS PATHOG, V3, P668, DOI 10.1371/journal.ppat.0030075
   Carpp LN, 2011, MICROBES INFECT, V13, P85, DOI 10.1016/j.micinf.2010.10.010
   Carrington CVF, 2013, INFECT GENET EVOL, V13, P198, DOI 10.1016/j.meegid.2012.08.015
   CAUSEY OR, 1950, AM J TROP MED, V30, P301
   Coffey LL, 2013, FUTURE MICROBIOL, V8, P155, DOI [10.2217/FMB.12.139, 10.2217/fmb.12.139]
   Consoli RAGB, 1994, PRINCIPAIS MOSQUITOS
   Couto-Lima D, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05186-3
   Cumberworth SL, 2017, CELL MICROBIOL, V19, DOI 10.1111/cmi.12737
   de Souza RP, 2010, J MED VIROL, V82, P175, DOI 10.1002/jmv.21606
   Tommaso P, 2011, NUCLEIC ACIDS RES, V39, pW13, DOI 10.1093/nar/gkr245
   Dolinsky TJ, 2004, NUCLEIC ACIDS RES, V32, pW665, DOI 10.1093/nar/gkh381
   Dorigatti I, 2017, EUROSURVEILLANCE, V22, P10, DOI 10.2807/1560-7917.ES.2017.22.28.30572
   Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/msi103
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   Drummond AJ, 2012, MOL BIOL EVOL, V29, P1969, DOI 10.1093/molbev/mss075
   Environment BMot, 2017, MON BIOM
   FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x
   Ferreira-de-Brito A, 2016, MEM I OSWALDO CRUZ, V111, P655, DOI 10.1590/0074-02760160332
   Fioravanti C., 2018, REV PESQUISA FAPESP
   Gibbs MJ, 2000, BIOINFORMATICS, V16, P573, DOI 10.1093/bioinformatics/16.7.573
   Health BMo, 2017, EM EP FEBR AM NO BRA
   (IBGE) BIoGaS, 2017, MAPAS
   Jung L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129789
   KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581
   Kong GH, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005139
   Le Breton M, 2011, BMC MICROBIOL, V11, DOI 10.1186/1471-2180-11-234
   Lemey P, 2010, MOL BIOL EVOL, V27, P1877, DOI 10.1093/molbev/msq067
   Lim SP, 2013, J BIOL CHEM, V288, P31105, DOI 10.1074/jbc.M113.508606
   Lindorff-Larsen K, 2010, PROTEINS, V78, P1950, DOI 10.1002/prot.22711
   Lu GL, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003549
   Luo DH, 2015, ANTIVIR RES, V118, P148, DOI 10.1016/j.antiviral.2015.03.014
   Martin D, 2000, BIOINFORMATICS, V16, P562, DOI 10.1093/bioinformatics/16.6.562
   Martin DP, 2015, VIRUS EVOL, V1, DOI 10.1093/ve/vev003
   Martin DP, 2005, AIDS RES HUM RETROV, V21, P98, DOI 10.1089/aid.2005.21.98
   Romano APM, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002740
   Mathew A, 2014, FUTURE MICROBIOL, V9, P411, DOI 10.2217/fmb.13.171
   Mir D, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07873-7
   Monath TP, 2015, J CLIN VIROL, V64, P160, DOI 10.1016/j.jcv.2014.08.030
   Mutebi JP, 2001, J VIROL, V75, P6999, DOI 10.1128/JVI.75.15.6999-7008.2001
   Nunes MRT, 2012, J VIROL, V86, P13263, DOI 10.1128/JVI.00565-12
   Padidam M, 1999, VIROLOGY, V265, P218, DOI 10.1006/viro.1999.0056
   Pan American Health Organization, 2017, EP UPD YELL FEV
   Patkar CG, 2008, J VIROL, V82, P3342, DOI 10.1128/JVI.02447-07
   Phoo WW, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13410
   Posada D, 2001, P NATL ACAD SCI USA, V98, P13757, DOI 10.1073/pnas.241370698
   SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454
   SCHLESINGER JJ, 1993, VIROLOGY, V192, P132, DOI 10.1006/viro.1993.1015
   SMITH JM, 1992, J MOL EVOL, V34, P126
   Staples JE, 2008, JAMA-J AM MED ASSOC, V300, P960, DOI 10.1001/jama.300.8.960
   Suchard MA, 2009, BIOINFORMATICS, V25, P1370, DOI 10.1093/bioinformatics/btp244
   Teramoto T, 2017, J BIOL CHEM, V292, P9465, DOI [10.1074/jbc.M117.775643, 10.1074/jbc.m117.775643]
   Tsetsarkin KA, 2011, P NATL ACAD SCI USA, V108, P7872, DOI 10.1073/pnas.1018344108
   Vasconcelos PFC, 2016, VECTOR-BORNE ZOONOT, V16, P566, DOI 10.1089/vbz.2016.2031
   Vasconcelos PFC, 2004, EMERG INFECT DIS, V10, P1578, DOI 10.3201/eid1009.040197
   Weaver SC, 2010, ANTIVIR RES, V85, P328, DOI 10.1016/j.antiviral.2009.10.008
   Webb B, 2014, METHODS MOL BIOL, V1137, P1, DOI 10.1007/978-1-4939-0366-5_1
   Wu JH, 2005, J VIROL, V79, P10268, DOI 10.1128/JVI.79.16.10268-10277.2005
   Wu RH, 2017, J VIROL, V91, DOI [10.1128/JVI.01836-16, 10.1128/jvi.01836-16]
   Zou J, 2015, J VIROL, V89, P3471, DOI 10.1128/JVI.03454-14
NR 69
TC 17
Z9 17
U1 0
U2 3
PU MICROBIOLOGY SOC
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER ST, LONDON WC1N 2JU, ERKS, ENGLAND
SN 0022-1317
EI 1465-2099
J9 J GEN VIROL
JI J. Gen. Virol.
PD APR
PY 2018
VL 99
IS 4
BP 536
EP 548
DI 10.1099/jgv.0.001033
PG 13
WC Biotechnology & Applied Microbiology; Virology
SC Biotechnology & Applied Microbiology; Virology
GA GE2CH
UT WOS:000431022600011
PM 29469689
OA Bronze
DA 2020-12-01
ER

PT J
AU Delatorre, E
   Mir, D
   Bello, G
AF Delatorre, Edson
   Mir, Daiana
   Bello, Gonzalo
TI Tracing the origin of the NS1 A188V substitution responsible for recent
   enhancement of Zika virus Asian genotype infectivity
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE Zika Virus; NS1; infectivity; evolution
ID CD-HIT; AMERICA; SEQUENCES
AB A recent study showed that infectivity of Zika virus (ZIKV) Asian genotype was enhanced by an alanine-to-valine amino acid substitution at residue 188 of the NS1 protein, but the precise time and location of origin of this mutation were not formally estimated. Here, we applied a Bayesian coalescent-based framework to estimate the age and location of the ancestral viral strain carrying the A188V substitution. Our results support that the ancestral ZIKV strain carrying the A188V substitution arose in Southeastern Asia at the early 2000s and circulated in that region for some time (5-10 years) before being disseminated to Southern Pacific islands and the Americas.
C1 [Delatorre, Edson; Mir, Daiana; Bello, Gonzalo] Fundacao Oswaldo Cruz, FIOCRUZ, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, Rio De Janeiro, RJ, Brazil.
RP Bello, G (corresponding author), Fundacao Oswaldo Cruz, FIOCRUZ, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, Rio De Janeiro, RJ, Brazil.
EM gbellobr@gmail.com
RI Delatorre, Edson/J-8330-2015; Bentancor, Gonzalo Jose Bello/N-7377-2019;
   Bello, Gonzalo/E-6842-2013; , daiana/J-5515-2019
OI Delatorre, Edson/0000-0002-5746-0820; Bentancor, Gonzalo Jose
   Bello/0000-0002-2724-2793; , daiana/0000-0002-3172-4867
FU FIOCRUZ; PNPD/CAPESCAPES; ANII-Uruguay; CAPES-BrazilCAPES
FX FIOCRUZ; ED is a fellowship from PNPD/CAPES; DM is funded by fellowships
   from ANII-Uruguay and CAPES-Brazil.
CR de Melo Freire CCIA, 2015, BIORXIV
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/msi103
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   Faria NR, 2017, NATURE, V546, P406, DOI 10.1038/nature22401
   Faria NR, 2016, SCIENCE, V352, P345, DOI 10.1126/science.aaf5036
   Gatherer D, 2016, J GEN VIROL, V97, P269, DOI 10.1099/jgv.0.000381
   Guindon S, 2010, SYST BIOL, V59, P307, DOI 10.1093/sysbio/syq010
   Hayes EB, 2009, EMERG INFECT DIS, V15, P1347, DOI 10.3201/eid1509.090442
   Huang Y, 2010, BIOINFORMATICS, V26, P680, DOI 10.1093/bioinformatics/btq003
   Lemey P, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000520
   Li WZ, 2006, BIOINFORMATICS, V22, P1658, DOI 10.1093/bioinformatics/btl158
   Liu Y, 2017, NATURE, V545, P482, DOI 10.1038/nature22365
   Metsky HC, 2017, NATURE, V546, P411, DOI 10.1038/nature22402
   Pettersson JHO, 2016, MBIO, V7, DOI [10.1128/mBio.01239-16, 10.1128/mbio.01239-16]
   Posada D, 2008, MOL BIOL EVOL, V25, P1253, DOI 10.1093/molbev/msn083
   Rambaut A, 2016, VIRUS EVOL, V2, DOI 10.1093/ve/vew007
NR 18
TC 9
Z9 9
U1 0
U2 3
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD NOV
PY 2017
VL 112
IS 11
BP 793
EP 795
DI 10.1590/0074-02760170299
PG 3
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA FL2CW
UT WOS:000414023000011
PM 28876359
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Mir, D
   Delatorre, E
   Bonaldo, M
   Lourenco-de-Oliveira, R
   Vicente, AC
   Bello, G
AF Mir, Daiana
   Delatorre, Edson
   Bonaldo, Myrna
   Lourenco-de-Oliveira, Ricardo
   Vicente, Ana Carolina
   Bello, Gonzalo
TI Phylodynamics of Yellow Fever Virus in the Americas: new insights into
   the origin of the 2017 Brazilian outbreak
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ENZOOTIC TRANSMISSION; MOSAIC STRUCTURE; RECOMBINATION; EVOLUTIONARY;
   ALGORITHMS; SEQUENCES; DISPERSAL; EMERGENCE
AB Yellow fever virus (YFV) strains circulating in the Americas belong to two distinct genotypes (I and II) that have diversified into several concurrent enzootic lineages. Since 1999, YFV genotype I has spread outside endemic regions and its recent (2017) reemergence in non-endemic Southeastern Brazilian states fuels one of the largest epizootic of jungle Yellow Fever registered in the country. To better understand this phenomenon, we reconstructed the phylodynamics of YFV American genotypes using sequences from nine countries sampled along 60 years, including strains from Brazilian 2017 outbreak. Our analyses reveals that YFV genotypes I and II follow roughly similar evolutionary and demographic dynamics until the early 1990s, when a dramatic change in the diversification process of the genotype I occurred associated with the emergence and dissemination of a new lineage (here called modern). Trinidad and Tobago was the most likely source of the YFV modern-lineage that spread to Brazil and Venezuela around the late 1980s, where it replaced all lineages previously circulating. The modern-lineage caused all major YFV outbreaks detected in non-endemic South American regions since 2000, including the 2017 Brazilian outbreak, and its dissemination was coupled to the accumulation of several amino acid substitutions particularly within non-structural viral proteins.
C1 [Mir, Daiana; Delatorre, Edson; Bello, Gonzalo] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, Rio De Janeiro, Brazil.
   [Bonaldo, Myrna] Fiocruz MS, Inst Oswaldo Cruz, Lab Biol Mol Flavivirus, Rio De Janeiro, Brazil.
   [Lourenco-de-Oliveira, Ricardo] Fiocruz MS, Inst Oswaldo Cruz, Lab Mosquitos Transmissores Hematozoarios, Rio De Janeiro, Brazil.
   [Vicente, Ana Carolina] Fiocruz MS, Inst Oswaldo Cruz, Lab Genet Mol Microrganismos, Rio De Janeiro, Brazil.
RP Mir, D; Delatorre, E (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, Rio De Janeiro, Brazil.
EM daianamir@gmail.com; delatorre.ioc@gmail.com
RI , daiana/J-5515-2019; Bello, Gonzalo/E-6842-2013; Delatorre,
   Edson/J-8330-2015; Bentancor, Gonzalo Jose Bello/N-7377-2019
OI , daiana/0000-0002-3172-4867; Delatorre, Edson/0000-0002-5746-0820;
   Bentancor, Gonzalo Jose Bello/0000-0002-2724-2793
FU Agencia Nacional de Investigacion e Innovacion (ANII-Uruguay);
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES-Brazil)CAPES; Programa Nacional de Pos-Doutorado (CAPES-Brazil)
FX D.M. was funded by fellowships from "Agencia Nacional de Investigacion e
   Innovacion (ANII-Uruguay)" and "Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES-Brazil)". E.D. is funded by a
   fellowship from "Programa Nacional de Pos-Doutorado (CAPES-Brazil)".
CR Almeida MAB, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002741
   Anisimova M, 2006, SYST BIOL, V55, P539, DOI 10.1080/10635150600755453
   Auguste AJ, 2015, EMERG INFECT DIS, V21, P99, DOI 10.3201/eid2101.140814
   Auguste AJ, 2010, J VIROL, V84, P9967, DOI 10.1128/JVI.00588-10
   Baele G, 2012, MOL BIOL EVOL, V29, P2157, DOI 10.1093/molbev/mss084
   Baronti C, 2011, VECTOR-BORNE ZOONOT, V11, P277, DOI 10.1089/vbz.2010.0017
   Beck A, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0001910
   Bonaldo M. C., 2017, MEM I O CRUZ, P1
   Boni MF, 2007, GENETICS, V176, P1035, DOI 10.1534/genetics.106.068874
   Brasil M. da S, 2017, COES FEBR AM NO 36 2
   Bryant J, 2003, EMERG INFECT DIS, V9, P926
   Bryant JE, 2007, PLOS PATHOG, V3, P668, DOI 10.1371/journal.ppat.0030075
   Byk LA, 2016, ANNU REV VIROL, V3, P263, DOI 10.1146/annurev-virology-110615-042334
   Carrington CVF, 2013, INFECT GENET EVOL, V13, P198, DOI 10.1016/j.meegid.2012.08.015
   Charif D., 2007, STRUCTURAL APPROACHE
   Chikhi L, 2010, GENETICS, V186, P983, DOI 10.1534/genetics.110.118661
   Costa ZGA, 2010, REV PAN AMAZ SAUDE, V2, P11
   Vasconcelos PFD, 2010, REV SAUDE PUBL, V44, P1144, DOI 10.1590/S0034-89102010005000046
   Darriba D, 2012, NAT METHODS, V9, P772, DOI 10.1038/nmeth.2109
   de Souza RP, 2010, J MED VIROL, V82, P175, DOI 10.1002/jmv.21606
   Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/msi103
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   Drummond AJ, 2012, MOL BIOL EVOL, V29, P1969, DOI 10.1093/molbev/mss075
   Ferreira MAR, 2008, CAN J STAT, V36, P355, DOI 10.1002/cjs.5550360302
   Gibbs MJ, 2000, BIOINFORMATICS, V16, P573, DOI 10.1093/bioinformatics/16.7.573
   Guindon S, 2010, SYST BIOL, V59, P307, DOI 10.1093/sysbio/syq010
   Heller R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062992
   Lee CM, 2015, J VIROL, V89, P6171, DOI 10.1128/JVI.00546-15
   Lemey P, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000520
   Liu Y, 2017, NATURE, V545, P482, DOI 10.1038/nature22365
   Martin D, 2000, BIOINFORMATICS, V16, P562, DOI 10.1093/bioinformatics/16.6.562
   Martin DP, 2015, VIRUS EVOL, V1, DOI 10.1093/ve/vev003
   Martin DP, 2005, AIDS RES HUM RETROV, V21, P98, DOI 10.1089/aid.2005.21.98
   Romano APM, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002740
   Ministerio da Saude B, 2015, B EPIDEMIOLOGICO, V46
   Monath TP, 2015, J CLIN VIROL, V64, P160, DOI 10.1016/j.jcv.2014.08.030
   Mutebi JP, 2001, J VIROL, V75, P6999, DOI 10.1128/JVI.75.15.6999-7008.2001
   Nunes MRT, 2012, J VIROL, V86, P13263, DOI 10.1128/JVI.00565-12
   Padidam M, 1999, VIROLOGY, V265, P218, DOI 10.1006/viro.1999.0056
   Patkar CG, 2007, J VIROL, V81, P6471, DOI 10.1128/JVI.02120-06
   Posada D, 2001, P NATL ACAD SCI USA, V98, P13757, DOI 10.1073/pnas.241370698
   Rambaut A, 2016, VIRUS EVOL, V2, DOI 10.1093/ve/vew007
   Sall AA, 2010, J VIROL, V84, P765, DOI 10.1128/JVI.01738-09
   Sironi M., 2016, PLOS NEGLECT TROP D, V10, P1
   SMITH JM, 1992, J MOL EVOL, V34, P126
   Suchard MA, 2009, BIOINFORMATICS, V25, P1370, DOI 10.1093/bioinformatics/btp244
   Vasconcelos PFC, 2004, EMERG INFECT DIS, V10, P1578, DOI 10.3201/eid1009.040197
   Wang Q, 2012, BBA-GENE REGUL MECH, V1819, P411, DOI 10.1016/j.bbagrm.2012.01.003
NR 49
TC 38
Z9 38
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 7
PY 2017
VL 7
AR 7385
DI 10.1038/s41598-017-07873-7
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FC8GP
UT WOS:000407080100015
PM 28785067
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Delatorre, E
   Couto-Fernandez, JC
   Bello, G
AF Delatorre, Edson
   Couto-Fernandez, Jose Carlos
   Bello, Gonzalo
TI HIV-1 Genetic Diversity in Northeastern Brazil: High Prevalence of Non-B
   Subtypes
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
DE HIV; subtypes; Northeastern region; Brazil
ID TRANSMITTED DRUG-RESISTANCE; RIO-DE-JANEIRO; CIRCULATING RECOMBINANT
   FORMS; SAO-PAULO; ANTIRETROVIRAL TREATMENT; MOLECULAR EPIDEMIOLOGY;
   SOUTHERN BRAZIL; BLOOD-DONORS; STATE; IDENTIFICATION
AB The Northeastern Brazilian region has experienced a constant increase in the number of newly reported AIDS cases over the last decade, but the genetic diversity of HIV-1 strains currently disseminated in this region remains poorly explored. HIV-1 pol sequences were obtained from 140 patients followed at outpatient clinics from four Northeastern Brazilian states (Alagoas, Bahia, Ceara, and Piaui) between 2014 and 2015. Subtype B was the most prevalent HIV-1 clade (72%) detected in the Northeastern region, followed by subtypes F1 (6%), C (5%), and D (1%). The remaining strains (16%) displayed a recombinant structure and were classified as follows: BF1 (11%), BC (4%), BCF1 (1%), and CRF02_AG like (1%). The 20 HIV-1 BF1 and BC recombinant sequences detected were distributed among 11 lineages classified as follows: CRF28/29_BF like (n=5), CRF39_BF like (n=1), URF_BF (n=9), and URF_BC (n=5). Non-B subtypes were detected in all Northeastern Brazilian states, but with variable prevalence, ranging from 16% in Ceara to 55% in Alagoas. Phylogenetic analyses support that subtype D and CRF02_AG strains detected in the Northeastern region resulted from the expansion of autochthonous transmission networks, rather than from exogenous introductions from other countries. These results reveal that HIV-1 epidemic spreading in the Northeastern Brazilian region comprised by multiple subtypes and recombinant strains and the molecular epidemiologic pattern in this Brazilian region is much more complex than originally estimated.
C1 [Delatorre, Edson; Couto-Fernandez, Jose Carlos; Bello, Gonzalo] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, Av Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
RP Delatorre, E (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, Av Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM edsonod@ioc.fiocruz.br
RI Delatorre, Edson/J-8330-2015; Bello, Gonzalo/E-6842-2013; Bentancor,
   Gonzalo Jose Bello/N-7377-2019
OI Delatorre, Edson/0000-0002-5746-0820; Bentancor, Gonzalo Jose
   Bello/0000-0002-2724-2793; Couto-Fernandez, Jose
   Carlos/0000-0001-7091-9774
FU Programa Nacional de Pos-Doutorado (CAPES-Brazil)
FX The authors thank the Department of AIDS, STD and Viral Hepatitis,
   Ministry of Health, and Oswaldo Cruz Institute-IOC/FIOCRUZ. E.D. is
   funded by a fellowship from "Programa Nacional de Pos-Doutorado
   (CAPES-Brazil).''
CR Alcantara KC, 2013, J MED VIROL, V85, P396, DOI 10.1002/jmv.23474
   Alencar CS, 2013, JAIDS-J ACQ IMM DEF, V63, P387, DOI 10.1097/QAI.0b013e31828ff979
   Araujo AF, 2010, AIDS RES HUM RETROV, V26, P1249, DOI 10.1089/aid.2010.0068
   Arruda E, 2011, AIDS RES HUM RETROV, V27, P153, DOI 10.1089/aid.2010.0028
   Barreto CC, 2006, JAIDS-J ACQ IMM DEF, V41, P338
   Bermudez-Aza EH, 2011, JAIDS-J ACQ IMM DEF, V57, pS186, DOI 10.1097/QAI.0b013e31821e9c36
   Brazilian, 2015, AIDS EP B
   Brennan CA, 2007, AIDS RES HUM RETROV, V23, P1434, DOI 10.1089/aid.2007.0121
   Brigido LFM, 2011, AIDS RES HUM RETROV, V27, P339, DOI 10.1089/aid.2010.0157
   Cabello M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106045
   Couto-Fernandez JC, 2006, AIDS RES HUM RETROV, V22, P207, DOI 10.1089/aid.2006.22.207
   da Costa CM, 2016, AIDS RES HUM RETROV, V32, P918, DOI [10.1089/AID.2016.0044, 10.1089/aid.2016.0044]
   Soares CMPD, 2014, J INT AIDS SOC, V17, DOI 10.7448/IAS.17.1.19042
   de Oliveira T, 2005, BIOINFORMATICS, V21, P3797, DOI 10.1093/bioinformatics/bti607
   De Sa DJ, 2006, AIDS RES HUM RETROV, V22, P1
   Delatorre E, 2017, AIDS RES HUM RETROV, V33, P68, DOI [10.1089/aid.2016.0159, 10.1089/AID.2016.0159]
   Delatorre E, 2015, AIDS RES HUM RETROV, V31, P1230, DOI 10.1089/aid.2015.0183
   Delatorre EO, 2012, AIDS RES HUM RETROV, V28, P1369, DOI 10.1089/aid.2011.0381
   Divino F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162112
   Eyer-Silva WA, 2007, MEM I OSWALDO CRUZ, V102, P809, DOI 10.1590/S0074-02762007005000112
   Ferreira AS, 2011, J MED VIROL, V83, P1301, DOI 10.1002/jmv.22128
   Gifford RJ, 2007, J VIROL, V81, P13050, DOI 10.1128/JVI.00889-07
   Graef T, 2015, J VIROL, V89, P12341, DOI 10.1128/JVI.01681-15
   Graf T, 2013, VIROLOGY, V435, P170, DOI 10.1016/j.virol.2012.08.048
   Guimaraes ML, 2008, AIDS, V22, P433, DOI 10.1097/QAD.0b013e3282f47ad0
   Guindon S, 2010, SYST BIOL, V59, P307, DOI 10.1093/sysbio/syq010
   Lima K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155854
   Machado LFA, 2009, AIDS RES HUM RETROV, V25, P961, DOI 10.1089/aid.2009.0027
   Mendoza Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095360
   Monteiro-Cunha JP, 2011, AIDS RES HUM RETROV, V27, P623, DOI [10.1089/AID.2010.0126, 10.1089/aid.2010.0126]
   Morgado MG, 1998, J ACQ IMMUN DEF SYND, V18, P488, DOI 10.1097/00042560-199808150-00011
   Leite TCNF, 2017, AIDS RES HUM RETROV, V33, P41, DOI [10.1089/aid.2016.0126, 10.1089/AID.2016.0126]
   Ferreira JLP, 2013, ADV VIROL, V2013, DOI 10.1155/2013/878237
   Pessoa R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152499
   Pessoa R, 2014, MICROBIOL RESOUR ANN, V2, DOI 10.1128/genomeA.00586-14
   Pires IL, 2004, J CLIN MICROBIOL, V42, P426, DOI 10.1128/JCM.42.1.426-430.2004
   Posada D, 2008, MOL BIOL EVOL, V25, P1253, DOI 10.1093/molbev/msn083
   Rajaram ML, 2007, PROCEEDINGS OF THE 7TH IEEE INTERNATIONAL SYMPOSIUM ON BIOINFORMATICS AND BIOENGINEERING, VOLS I AND II, P707
   Ray S., SIMPLOT V2 5 0
   Salustiano Cavalcanti AM, 2007, MEM I OSWALDO CRUZ, V102, P785
   Sanabani SS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025869
   Santos LA, 2011, J MED VIROL, V83, P2066, DOI 10.1002/jmv.22170
   Silva LD, 2016, AIDS RES HUM RETROV, V32, P373, DOI [10.1089/aid.2015.0280, 10.1089/AID.2015.0280]
   Moura MES, 2015, J MED VIROL, V87, P798, DOI 10.1002/jmv.24087
   Moura MES, 2015, AIDS RES HUM RETROV, V31, P250, DOI 10.1089/aid.2014.0261
   Velasco-de-Castro CA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087622
NR 46
TC 3
Z9 3
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD JUL
PY 2017
VL 33
IS 7
BP 639
EP 647
DI 10.1089/aid.2017.0045
PG 9
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA EZ8RT
UT WOS:000404995300003
PM 28325060
DA 2020-12-01
ER

PT J
AU Andrade, JSR
   Fumian, TM
   Leite, JPG
   de Assis, MR
   Bello, G
   Mir, D
   Miagostovich, MP
AF Andrade, Juliana S. R.
   Fumian, Tulio M.
   Leite, Jose Paulo G.
   de Assis, Matheus R.
   Bello, Gonzalo
   Mir, Daiana
   Miagostovich, Marize P.
TI Detection and molecular characterization of emergent GII.P17/GII.17
   Norovirus in Brazil, 2015
SO INFECTION GENETICS AND EVOLUTION
LA English
DT Article
DE Norovirus; GII.17 variant; Molecular characterization; Phylogenetic
   analysis; Brazil
ID GII.17 NOROVIRUS; CHILDREN; STRAINS
AB A newly GII.17 Kawazaki_2014 variant strain was detected recently in Brazil. Phylogenetic analysis reveals at least four independent introduction events of this lineage into this country that took place throughout 2014, coinciding with FIFA World Cup in Brazil, 2014, and Hong Kong has been identified as the most likely source of introduction. This variant emerged in Asia causing outbreaks and replacing prevalent GII.4. Emergence of GII.P17/GII.17 variant emphasizes the need for active laboratory surveillance for NoV including molecular epidemiology and studies on virus evolution. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Andrade, Juliana S. R.; Fumian, Tulio M.; Leite, Jose Paulo G.; Bello, Gonzalo; Mir, Daiana; Miagostovich, Marize P.] Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
   [de Assis, Matheus R.] Univ Estado Rio De Janeiro, Rio De Janeiro, Brazil.
RP Andrade, JSR (corresponding author), Fiocruz MS, Oswaldo Cruz Inst, Ave Brasil 4365, Rio De Janeiro, RJ, Brazil.
EM juliana@ioc.fiocruz.br
RI LEITE, JOSE PAULO GAGLIARDI/AAY-1230-2020; Bello, Gonzalo/E-6842-2013;
   Bentancor, Gonzalo Jose Bello/N-7377-2019; , daiana/J-5515-2019
OI Bentancor, Gonzalo Jose Bello/0000-0002-2724-2793; ,
   daiana/0000-0002-3172-4867
FU Oswaldo Cruz Institute/Fiocruz; Brazilian National Council for
   Scientific and Technological Development (CNPq)National Council for
   Scientific and Technological Development (CNPq); Carlos Chagas Filho
   Foundation for Research Support in the State of Rio de Janeiro (Faperj);
   Coordination of Personal Improvement of Higher Education (CAPES);
   National Agency for Research and Innovation
FX This work was supported by Oswaldo Cruz Institute/Fiocruz, Brazilian
   National Council for Scientific and Technological Development (CNPq) and
   Carlos Chagas Filho Foundation for Research Support in the State of Rio
   de Janeiro (Faperj). DM was funded by a fellowship from Coordination of
   Personal Improvement of Higher Education (CAPES) and National Agency for
   Research and Innovation (A.N.I.I.).
CR Beuret C, 2002, APPL ENVIRON MICROB, V68, P1925, DOI 10.1128/AEM.68.4.1925-1931.2002
   Bull RA, 2011, TRENDS MICROBIOL, V19, P233, DOI 10.1016/j.tim.2011.01.002
   Chan MCW, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10061
   da Silva LD, 2017, INFECT GENET EVOL, V48, P1, DOI 10.1016/j.meegid.2016.11.027
   Degiuseppe JI, 2017, INFECT GENET EVOL, V47, P121, DOI 10.1016/j.meegid.2016.11.026
   Dinu S, 2016, EUROSURVEILLANCE, V21, P2, DOI 10.2807/1560-7917.ES.2016.21.7.30141
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Fumian TM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0145391
   Galeano ME, 2013, J CLIN VIROL, V58, P378, DOI 10.1016/j.jcv.2013.07.008
   Thanh HD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154284
   Kageyama T, 2003, J CLIN MICROBIOL, V41, P1548, DOI 10.1128/JCM.41.4.1548-1557.2003
   Khamrin P, 2016, INFECT GENET EVOL, V44, P330, DOI 10.1016/j.meegid.2016.07.031
   Knipe DM, 2013, FIELDS VIROLOGY, V1, P582
   Kojima S, 2002, J VIROL METHODS, V100, P107, DOI 10.1016/S0166-0934(01)00404-9
   Kroneman A, 2013, ARCH VIROL, V158, P2059, DOI 10.1007/s00705-013-1708-5
   Lartillot N, 2006, SYST BIOL, V55, P195, DOI 10.1080/10635150500433722
   LeBlanc JJ, 2016, CAN J INFECT DIS MED, V2016, DOI 10.1155/2016/1280247
   Lu J, 2015, EMERG INFECT DIS, V21, P1240, DOI 10.3201/eid2107.150226
   Matsushima Y, 2015, EUROSURVEILLANCE, V20, P2, DOI 10.2807/1560-7917.ES2015.20.26.21173
   Parra GI, 2015, EMERG INFECT DIS, V21, P1477, DOI 10.3201/eid2108.150652
   Patel MM, 2008, EMERG INFECT DIS, V14, P1224, DOI 10.3201/eid1408.071114
   Tamura K., 2013, MOL BIOL EVOL
   van Beek J, 2013, EUROSURVEILLANCE, V18, P8
   White PA, 2014, CLIN MICROBIOL INFEC, V20, P741, DOI 10.1111/1469-0691.12746
   Xie WG, 2011, SYST BIOL, V60, P150, DOI 10.1093/sysbio/syq085
   Xue L, 2016, J APPL MICROBIOL, V120, P1130, DOI 10.1111/jam.13052
   Zheng DP, 2006, VIROLOGY, V346, P312, DOI 10.1016/j.virol.2005.11.015
NR 27
TC 12
Z9 13
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567-1348
EI 1567-7257
J9 INFECT GENET EVOL
JI Infect. Genet. Evol.
PD JUL
PY 2017
VL 51
BP 28
EP 32
DI 10.1016/j.meegid.2017.03.011
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA EW4AJ
UT WOS:000402444100006
PM 28300648
DA 2020-12-01
ER

PT J
AU Reis, MND
   Bello, G
   Guimaraes, ML
   Stefani, MMA
AF da Guarda Reis, Monica Nogueira
   Bello, Gonzalo
   Guimaraes, Monick Lindenmeyer
   Araujo Stefani, Mariane Martins
TI Characterization of HIV-1 CRF90_BF1 and putative novel CRFs_BF1 in
   Central West, North and Northeast Brazilian regions
SO PLOS ONE
LA English
DT Article
ID TRANSMITTED DRUG-RESISTANCE; CIRCULATING RECOMBINANT FORMS; TYPE-1
   SUBTYPE C; GENETIC DIVERSITY; PREGNANT-WOMEN; MOLECULAR EPIDEMIOLOGY;
   MODERATE PREVALENCE; STATE; IDENTIFICATION; SURVEILLANCE
AB The Brazilian AIDS epidemic has been characterized by an increasing rate of BF1 recombinants and so far eight circulating recombinant forms/CRFs_BF1 have been described countrywide. In this study, pol sequences (protease/PR, reverse transcriptase/RT) of 87 BF1 mosaic isolates identified among 828 patients living in six Brazilian States from three geographic regions (Central West, North, Northeast) were analyzed. Phylogenetic and boot-scan analyses were performed to investigate the evolutionary relationship and mosaic structure of BF1 isolates. Those analyses showed that 20.7% of mosaics (18 out of 87) were CRFs-like isolates, mostly represented by CRF28/CRF29_BF-like viruses (14 out of 18). We also identified five highly supported clusters that together comprise 42 out of 87 (48.3%) BF1 sequences, each cluster containing at least five sequences sharing a similar mosaic structure, suggesting possible new unidentified CRFs_BF1. The divergence time of these five potential new CRFs_BF1 clusters was estimated using a Bayesian approach and indicate that they probably originated between the middle 1980s and the middle 1990s. DNA was extracted from whole blood and four overlapping fragments were amplified by PCR providing full/near full length genomes (FLG/NFLG) and partial genomes. Eleven HIV-1 isolates from Cluster # 5 identified in epidemiologically unlinked individuals living in Central West and North regions provided FLG/NFLG/partial genome sequences with identical mosaic structure. These viruses differ from any known CRF_BF1 reported to date and were named CRF90_BF1 by the Los Alamos National Laboratory. This is the 9th CRF_BF1 described in Brazil and the first one identified in Central West and North regions. Our results highlight the importance of continued molecular screening and surveillance studies, especially of full genome sequences to understand the evolutionary dynamics of the HIV-1 epidemic in a country of continental dimensions as Brazil.
C1 [da Guarda Reis, Monica Nogueira; Araujo Stefani, Mariane Martins] Univ Fed Goias, Inst Patol Trop & Saude Publ, Lab Imunol AIDS & Hanseniase, Goiania, Go, Brazil.
   [Bello, Gonzalo; Guimaraes, Monick Lindenmeyer] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, Rio De Janeiro, Brazil.
RP Stefani, MMA (corresponding author), Univ Fed Goias, Inst Patol Trop & Saude Publ, Lab Imunol AIDS & Hanseniase, Goiania, Go, Brazil.
EM mmastefani@gmail.com
RI Bello, Gonzalo/E-6842-2013; Bentancor, Gonzalo Jose Bello/N-7377-2019
OI Bentancor, Gonzalo Jose Bello/0000-0002-2724-2793
FU Programa de Apoio a Nucleos de Excelencia/PRONEX; Fundacao de Amparo a
   Pesquisa do Estado de Goias/FAPEG; Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico/ CNPqNational Council for Scientific and
   Technological Development (CNPq) [201210267000801]; Conselho Nacional de
   DesenvolvimentoCientifico e Tecnologico/CNPq UniversalNational Council
   for Scientific and Technological Development (CNPq) [481208/2012-7];
   FAPEG [201410267000598]; fellowship from CNPqNational Council for
   Scientific and Technological Development (CNPq) [308381/2015-7]
FX This work was supported by the "Programa de Apoio a Nucleos de
   Excelencia/PRONEX; Fundacao de Amparo a Pesquisa do Estado de
   Goias/FAPEG; Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico/ CNPq (grant number:201210267000801 to MMAS) and by the
   "Conselho Nacional de DesenvolvimentoCientifico e Tecnologico/CNPq
   Universal grant number: 481208/2012-7 to MMAS). MNGR was supported by a
   scholarship from FAPEG (grant number:201410267000598). MMAS is a
   recipient of a fellowship from CNPq (grant number 308381/2015-7). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Alcantara KC, 2012, J CLIN VIROL, V54, P15, DOI 10.1016/j.jcv.2012.01.011
   Alencar CS, 2013, JAIDS-J ACQ IMM DEF, V63, P387, DOI 10.1097/QAI.0b013e31828ff979
   Barreto CC, 2006, JAIDS-J ACQ IMM DEF, V41, P338
   Bello G, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-22
   Passaes CPB, 2009, INFECT GENET EVOL, V9, P474, DOI 10.1016/j.meegid.2009.01.008
   Brindeiro RM, 2003, AIDS, V17, P1063, DOI 10.1097/00002030-200305020-00016
   Carr JK, 2001, AIDS, V15, pF41, DOI 10.1097/00002030-200110190-00002
   Carvalho BC, 2011, AIDS RES HUM RETROV, V27, P1081, DOI [10.1089/aid.2010.0334, 10.1089/AID.2010.0334]
   da Costa CM, 2016, AIDS RES HUM RETROV, V32, P918, DOI [10.1089/AID.2016.0044, 10.1089/aid.2016.0044]
   da Costa ZB, 2013, AIDS PATIENT CARE ST, V27, P439, DOI 10.1089/apc.2012.0448
   De Sa DJ, 2006, AIDS RES HUM RETROV, V22, P1
   de Sa DJ, 2009, AIDS RES HUM RETROV, V25, P925, DOI 10.1089/aid.2009.0073
   DELWART EL, 1993, SCIENCE, V262, P1257, DOI 10.1126/science.8235655
   Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/msi103
   Drummond AJ, 2002, GENETICS, V161, P1307
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   Ferreira AS, 2011, J MED VIROL, V83, P1301, DOI 10.1002/jmv.22128
   Gao F, 1996, J VIROL, V70, P7013, DOI 10.1128/JVI.70.10.7013-7029.1996
   Guimaraes ML, 2008, AIDS, V22, P433, DOI 10.1097/QAD.0b013e3282f47ad0
   Guimaraes ML, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141372
   Guimaraes ML, 2010, INFECT GENET EVOL, V10, P1094, DOI 10.1016/j.meegid.2010.07.001
   Hemelaar J, 2011, AIDS, V25, P679, DOI 10.1097/QAD.0b013e328342ff93
   Inocencio LA, 2009, J INT AIDS SOC, V12, DOI 10.1186/1758-2652-12-20
   KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581
   Lole KS, 1999, J VIROL, V73, P152, DOI 10.1128/JVI.73.1.152-160.1999
   Monteiro-Cunha JP, 2011, AIDS RES HUM RETROV, V27, P623, DOI [10.1089/AID.2010.0126, 10.1089/aid.2010.0126]
   Najera R, 2002, GENETIC RECOMBINATIO, V4, pS3
   Nei M, 2002, MOL PHYLOGENET EVOL, V3, P567
   Pessoa R, 2014, GENOME ANNOUNC, V2
   Pessoa R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152499
   Pessoa R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112674
   Prellwitz IM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069033
   Ramos A, 1999, EMERG INFECT DIS, V5, P65, DOI 10.3201/eid0501.990108
   Lima YAR, 2016, J MED VIROL, V88, P1936, DOI 10.1002/jmv.24540
   Ristic N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017485
   Robertson DL, 2000, SCIENCE, V288, P55, DOI 10.1126/science.288.5463.55d
   ROBERTSON DL, 1995, J MOL EVOL, V40, P249, DOI 10.1007/BF00163230
   SABINO EC, 1994, J VIROL, V68, P6340, DOI 10.1128/JVI.68.10.6340-6346.1994
   Sanabani SS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062552
   Sanabani SS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025869
   Sanabani SS, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-74
   Santos LA, 2011, J MED VIROL, V83, P2066, DOI 10.1002/jmv.22170
   Sierra Maria, 2005, Infection Genetics and Evolution, V5, P209, DOI 10.1016/j.meegid.2004.07.010
   Silveira AA, 2012, RES HUM RETROVIRUSES, V28, P304
   Silveira J, 2012, J CLIN VIROL, V54, P36, DOI 10.1016/j.jcv.2012.01.017
   Moura MES, 2015, J MED VIROL, V87, P798, DOI 10.1002/jmv.24087
   Moura MES, 2015, AIDS RES HUM RETROV, V31, P250, DOI 10.1089/aid.2014.0261
   Suchard MA, 2009, BIOINFORMATICS, V25, P1370, DOI 10.1093/bioinformatics/btp244
   Tamura K, 2013, MOL BIOL EVOL, V30, P2725, DOI [10.1093/molbev/mst197, 10.1093/molbev/msr121]
   Tebit DM, 2011, LANCET INFECT DIS, V11, P45, DOI 10.1016/S1473-3099(10)70186-9
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Thomson MM, 2005, AIDS REV, V7, P210
   Thomson MM, 2002, LANCET INFECT DIS, V2, P461, DOI 10.1016/S1473-3099(02)00343-2
   Cardoso LPV, 2011, AIDS RES HUM RETROV, V27, P1349, DOI 10.1089/aid.2011.0153
   Cardoso LPV, 2010, J MED VIROL, V82, P351, DOI 10.1002/jmv.21722
   Cardoso LPV, 2009, AIDS RES HUM RETROV, V25, P943, DOI 10.1089/aid.2009.0060
   Cardoso LPV, 2009, J CLIN VIROL, V46, P134, DOI 10.1016/j.jcv.2009.07.009
   Xia X, 2001, J HERED, V92, P371, DOI 10.1093/jhered/92.4.371
NR 59
TC 10
Z9 10
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 19
PY 2017
VL 12
IS 6
AR e0178578
DI 10.1371/journal.pone.0178578
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EY5TN
UT WOS:000404043100005
PM 28628667
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU de Azevedo, SSD
   Caetano, DG
   Cortes, FH
   Teixeira, SLM
   Silva, KD
   Hoagland, B
   Grinsztejn, B
   Veloso, VG
   Morgado, MG
   Bello, G
AF de Azevedo, Suwellen S. D.
   Caetano, Diogo Gama
   Cortes, Fernanda H.
   Teixeira, Sylvia L. M.
   Silva, Karina dos Santos
   Hoagland, Brenda
   Grinsztejn, Beatriz
   Veloso, Valdilea G.
   Morgado, Mariza G.
   Bello, Gonzalo
TI Highly divergent patterns of genetic diversity and evolution in proviral
   quasispecies from HIV controllers
SO RETROVIROLOGY
LA English
DT Article
DE HIV-1; Elite controllers; Viremic controllers; Reservoir; Diversity;
   Evolution; Reseeding
ID IMMUNODEFICIENCY-VIRUS TYPE-1; LONG-TERM NONPROGRESSORS; ELITE
   SUPPRESSORS; ANTIRETROVIRAL THERAPY; NATURAL CONTROL; SEX-DIFFERENCES;
   PLASMA VIRUS; INFECTION; SEQUENCES; REPLICATION
AB Background: Ongoing intra-host HIV-1 evolution has been shown in individuals that naturally suppress the viremia to low levels (HIV controllers) by the analysis of the RNA in plasma compartment. Detection of evolution at the DNA proviral compartment in HIV controllers, however, has been more challenging and the precise correlation between the systemic viral suppression level and rate of reservoir's reseeding in those individuals is not fully understood. In this sense, we examined the proviral DNA quasispecies by single genome amplification of the env gene in a cohort of 23 HIV controllers from Brazil, divided in three groups, according to the level of systemic viral suppression: (1) elite controllers with persistent undetectable viral load (PEC, n = 6); (2) elite controllers with occasional episodes of transient (51-400 copies/mL) viremia (EEC, n = 7); and (3) viremic controllers with persistent low-level (80-2000 copies/mL) viremia (VC, n = 10).
   Results: The HIV-1 diversity of the PBMC-associated proviral quasispecies in EC was significantly (P < 0.01) lower than in VC, but not significantly different between PEC and EEC groups. We detected a considerable variation in the average pairwise nucleotide distance and proportion of unique sequences in the HIV-1 proviral quasispecies of PEC and EEC. Some PEC and EEC displayed highly homogenous proviral populations with large clusters of identical sequences, while others exhibited relatively diverse proviral populations with a high proportion of unique sequences comparable to VC subjects. The long-term (10-15 years) follow-up of the HIV-1 proviral populations revealed a complete evolutionary stasis in one PEC and measurable divergence rates in one EEC [3.1 (1.2-5.6) x 10(-3) substitutions/site/year and one VC [2.9 (0.7-5.1) x 10(-3) substitutions/site/year].
   Conclusions: There is no simple relationship between systemic viral suppression and intra-host proviral diversity or rate of reservoir's reseeding in chronically infected HIV controllers. Our results demonstrate that very divergent patterns of intra-host viral diversity and divergence could be detected in the setting of natural suppression of HIV-1 replication and that ongoing evolution and reseeding of the PBMC proviral reservoir occurs in some elite controllers.
C1 [de Azevedo, Suwellen S. D.; Caetano, Diogo Gama; Cortes, Fernanda H.; Teixeira, Sylvia L. M.; Silva, Karina dos Santos; Morgado, Mariza G.; Bello, Gonzalo] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, Av Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
   [Hoagland, Brenda; Grinsztejn, Beatriz; Veloso, Valdilea G.] Fiocruz MS, Inst Nacl Infectol Evandro Chagas, Av Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
RP Bello, G (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, Av Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
EM gbello@ioc.fiocruz.br
RI Cortes, Fernanda/AAF-9254-2020; Bentancor, Gonzalo Jose
   Bello/N-7377-2019; Bello, Gonzalo/E-6842-2013; de Azevedo,
   Suwellen/P-7199-2017
OI Bentancor, Gonzalo Jose Bello/0000-0002-2724-2793; de Azevedo,
   Suwellen/0000-0001-6681-0987
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Fundacao de Amparo a Pesquisa do Estado do Rio de
   Janeiro-FAPERJCarlos Chagas Filho Foundation for Research Support of the
   State of Rio de Janeiro (FAPERJ) [E-26/110.123/2014]; NATIONAL INSTITUTE
   OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [UM1AI069476,
   UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476,
   UM1AI069476, UM1AI069476, UM1AI069476] Funding Source: NIH RePORTER
FX SSDA is supported by funding from the Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq). This work was supported
   by Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro-FAPERJ
   (Grant Number E-26/110.123/2014).
CR Abrahams MR, 2009, J VIROL, V83, P3556, DOI 10.1128/JVI.02132-08
   Anisimova M, 2006, SYST BIOL, V55, P539, DOI 10.1080/10635150600755453
   Avila-Rios S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158560
   Bagnarelli P, 1999, J VIROL, V73, P3764, DOI 10.1128/JVI.73.5.3764-3777.1999
   Bailey JR, 2006, J EXP MED, V203, P1357, DOI 10.1084/jem.20052319
   Bailey JR, 2006, J VIROL, V80, P4758, DOI 10.1128/JVI.80.10.4758-4770.2006
   Bar KJ, 2010, J VIROL, V84, P6241, DOI 10.1128/JVI.00077-10
   Bello G, 2005, J GEN VIROL, V86, P355, DOI 10.1099/vir.0.80410-0
   Bello G, 2004, J GEN VIROL, V85, P399, DOI 10.1099/vir.0.19365-0
   Bello G, 2007, AIDS RES HUM RETROV, V23, P1242, DOI 10.1089/aid.2007.0074
   Bello G, 2007, VIROLOGY, V362, P294, DOI 10.1016/j.virol.2006.11.039
   Boritz EA, 2016, CELL, V166, P1004, DOI 10.1016/j.cell.2016.06.039
   Buchbinder S, 1999, MICROBES INFECT, V1, P1113, DOI 10.1016/S1286-4579(99)00204-X
   Cortes FH, 2015, JAIDS-J ACQ IMM DEF, V68, P377, DOI 10.1097/QAI.0000000000000500
   Darriba D, 2012, NAT METHODS, V9, P772, DOI 10.1038/nmeth.2109
   Deeks SG, 2007, IMMUNITY, V27, P406, DOI 10.1016/j.immuni.2007.08.010
   Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/msi103
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   Drummond AJ, 2012, MOL BIOL EVOL, V29, P1969, DOI 10.1093/molbev/mss075
   Ferreira MAR, 2008, CAN J STAT, V36, P355, DOI 10.1002/cjs.5550360302
   Gottlieb GS, 2008, J INFECT DIS, V197, P1011, DOI 10.1086/529206
   Gregori J, 2016, VIROLOGY, V493, P227, DOI 10.1016/j.virol.2016.03.017
   Grenfell BT, 2004, SCIENCE, V303, P327, DOI 10.1126/science.1090727
   Grinsztejn B, 2011, ANTIVIR THER, V16, P1057, DOI 10.3851/IMP1872
   Guindon S, 2005, NUCLEIC ACIDS RES, V33, pW557, DOI 10.1093/nar/gki352
   Kearney M, 2009, J VIROL, V83, P2715, DOI 10.1128/JVI.01960-08
   Kumar S, 2016, MOL BIOL EVOL, V33, P1870, DOI [10.1093/molbev/msw054, 10.1093/molbev/msv279]
   Lengauer T, 2007, NAT BIOTECHNOL, V25, P1407, DOI 10.1038/nbt1371
   Li HC, 2010, J NANOMATER, V2010, DOI 10.1155/2010/962718
   Mens H, 2010, J VIROL, V84, P12971, DOI 10.1128/JVI.00387-10
   Miura T, 2009, J VIROL, V83, P3407, DOI 10.1128/JVI.02459-08
   Miura T, 2009, J VIROL, V83, P2743, DOI 10.1128/JVI.02265-08
   Novitsky V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016714
   O'Connell KA, 2011, P NATL ACAD SCI USA, V108, pE689, DOI 10.1073/pnas.1108866108
   O'Connell KA, 2010, J VIROL, V84, P7018, DOI 10.1128/JVI.00548-10
   Oksanen J., 2017, VEGAN COMMUNITY ECOL
   Okulicz JF, 2009, J INFECT DIS, V200, P1714, DOI 10.1086/646609
   Pereyra F, 2009, J INFECT DIS, V200, P984, DOI 10.1086/605446
   Pernas M, 2013, JAIDS-J ACQ IMM DEF, V64, P225, DOI 10.1097/QAI.0b013e31829bdc85
   Pimentel VF, 2013, AIDS RES HUM RETROV, V29, P1553, DOI [10.1089/aid.2013.0050, 10.1089/AID.2013.0050]
   Pinheiro Rejane Sobrino, 2002, Ciênc. saúde coletiva, V7, P687
   Rambaut A, 2016, VIRUS EVOL, V2, DOI 10.1093/ve/vew007
   Rodrigo AG, 1997, AIDS RES HUM RETROV, V13, P737, DOI 10.1089/aid.1997.13.737
   Rose PP, 2000, BIOINFORMATICS, V16, P400, DOI 10.1093/bioinformatics/16.4.400
   Ruel TD, 2011, CLIN INFECT DIS, V53, P592, DOI 10.1093/cid/cir484
   Sagar M, 2006, AIDS RES HUM RETROV, V22, P430, DOI 10.1089/aid.2006.22.430
   Sagar M, 2004, J VIROL, V78, P7279, DOI 10.1128/JVI.78.13.7279-7283.2004
   Salgado M, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-94
   Sandonis V, 2009, VIROLOGY, V391, P73, DOI 10.1016/j.virol.2009.05.022
   Shankarappa R, 1999, J VIROL, V73, P10489, DOI 10.1128/JVI.73.12.10489-10502.1999
   Sharkey M, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001303
   Sterling TR, 1999, J INFECT DIS, V180, P666, DOI 10.1086/314967
   Wang B, 2003, VIROLOGY, V312, P135, DOI 10.1016/S0042-6822(03)00159-4
   Wang B, 2000, AIDS, V14, P213, DOI 10.1097/00002030-200002180-00002
NR 54
TC 15
Z9 15
U1 0
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PD MAY 2
PY 2017
VL 14
AR 29
DI 10.1186/s12977-017-0354-5
PG 13
WC Virology
SC Virology
GA EU0MA
UT WOS:000400704600001
PM 28464889
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Corado, ADG
   Bello, G
   Leao, RAC
   Granja, F
   Naveca, FG
AF Guerra Corado, Andre de Lima
   Bello, Gonzalo
   Carvalho Leao, Renato Augusto
   Granja, Fabiana
   Naveca, Felipe Gomes
TI HIV-1 genetic diversity and antiretroviral drug resistance among
   individuals from Roraima state, northern Brazil
SO PLOS ONE
LA English
DT Article
ID SUBTYPE-C; TREATMENT-NAIVE; MUTATIONS; PREVALENCE; SURVEILLANCE;
   AMAZONAS; THERAPY; NETWORK
AB The HIV-1 epidemic in Brazil has spread towards the Northern country region, but little is known about HIV-1 subtypes and prevalence of HIV strains with resistance mutations to antiretrovirals in some of the Northern states. HIV-1 protease (PR) and reverse transcriptase (RT) sequences were obtained from 73 treatment-naive and -experienced subjects followed between 2013 and 2014 at a public health reference unit from Roraima, the northernmost Brazilian state. The most prevalent HIV-1 clade observed in the study population was the subtype B (91%), followed by subtype C (9%). Among 12 HIV-1 strains from treatment-naive patients, only one had a transmitted drug resistance mutation for NNRTI. Among 59 treatment-experienced patients, 12 (20%) harbored HIV-1 strains with acquired drug resistance mutations (ADRM) that reduce the susceptibility to two classes of antiretroviral drugs (NRTI and NNRTI or NRTI and PI), and five (8%) harbored HIV-1 strains with ADRM that reduced susceptibility to only one class of antiretroviral drugs (NNRTI or PI). No patients harboring HIV strains with reduced susceptibility to all three classes of antiretroviral drugs were detected. A substantial fraction of treatment-experienced patients with (63%) and without (70%) ADRM had undetectable plasma viral loads (<40 copies/ml) at the time of sampling. Among treatment-experienced with plasma viral loads above 2,000 copies/ml, 44% displayed no ADRM. This data showed that the HIV-1 epidemic in Roraima displayed a much lower level of genetic diversity and a lower prevalence of ADRM than that described in other Brazilian states.
C1 [Guerra Corado, Andre de Lima; Naveca, Felipe Gomes] Fiocruz MS, Inst Leonidas Maria Deane, Manaus, Amazonas, Brazil.
   [Bello, Gonzalo] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS Imunol Mol, Rio De Janeiro, Brazil.
   [Carvalho Leao, Renato Augusto] LACEN RR, Lab Cent Saude Publ Roraima, Roraima, Brazil.
   [Granja, Fabiana] Univ Fed Roraima UFRR, Lab Biol Mol, Roraima, Brazil.
RP Corado, ADG; Naveca, FG (corresponding author), Fiocruz MS, Inst Leonidas Maria Deane, Manaus, Amazonas, Brazil.
EM andrecorado@gmail.com; felipe.naveca@fiocruz.br
RI Naveca, Felipe/H-1130-2012; Bentancor, Gonzalo Jose Bello/N-7377-2019;
   Bello, Gonzalo/E-6842-2013
OI Naveca, Felipe/0000-0002-2888-1060; Bentancor, Gonzalo Jose
   Bello/0000-0002-2724-2793; 
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) -
   Fundacao Oswaldo Cruz/ILMD - POM
FX ALGC was supported by Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior (CAPES) (www.capes.gov.br), financial supported was provided by
   Fundacao Oswaldo Cruz/ILMD (www.amazonia.fiocruz.br) - POM 2014-15. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Alencar CS, 2013, JAIDS-J ACQ IMM DEF, V63, P387, DOI 10.1097/QAI.0b013e31828ff979
   Anisimova M, 2006, SYST BIOL, V55, P539, DOI 10.1080/10635150600755453
   Bahia Fabianna, 2004, Braz J Infect Dis, V8, P281, DOI 10.1590/S1413-86702004000400003
   Bello G, 2008, AIDS, V22, P1993, DOI 10.1097/QAD.0b013e328315e0aa
   Brazilian, 2015, AIDS EP B
   Brindeiro RM, 2003, AIDS, V17, P1063, DOI 10.1097/00002030-200305020-00016
   Carvalho BC, 2011, AIDS RES HUM RETROV, V27, P1081, DOI [10.1089/aid.2010.0334, 10.1089/AID.2010.0334]
   Couto-Fernandez JC, 2005, MEM I OSWALDO CRUZ, V100, P73, DOI 10.1590/S0074-02762005000100014
   Cunha LKH, 2012, BRAZ J MED BIOL RES, V45, P104, DOI 10.1590/S0100-879X2012007500003
   da Costa CM, 2016, AIDS RES HUM RETROV, V32, P918, DOI [10.1089/AID.2016.0044, 10.1089/aid.2016.0044]
   Soares CMPD, 2014, J INT AIDS SOC, V17, DOI 10.7448/IAS.17.1.19042
   de Oliveira T, 2005, BIOINFORMATICS, V21, P3797, DOI 10.1093/bioinformatics/bti607
   Delgado E, 2001, AIDS RES HUM RETROV, V17, P753, DOI 10.1089/088922201750237022
   Diaz RS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139677
   Diniz AMA, 2005, CAD GEOGR, V15, P23
   Divino F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162112
   Gifford RJ, 2009, BIOINFORMATICS, V25, P1197, DOI 10.1093/bioinformatics/btp134
   Guindon S, 2005, NUCLEIC ACIDS RES, V33, pW557, DOI 10.1093/nar/gki352
   Guindon S, 2010, SYST BIOL, V59, P307, DOI 10.1093/sysbio/syq010
   Hacker MA, 2007, CAD SAUDE PUBLICA, V23, pS345, DOI 10.1590/S0102-311X2007001500003
   Inocencio LA, 2009, J INT AIDS SOC, V12, DOI 10.1186/1758-2652-12-20
   Liu TF, 2006, CLIN INFECT DIS, V42, P1608, DOI 10.1086/503914
   Lopes CAF, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/738528
   MACEDO O, 2012, REV PAN-AMAZ SAUDE, V3, P11, DOI DOI 10.5123/S2176-62232012000200002
   Machado LFA, 2009, AIDS RES HUM RETROV, V25, P961, DOI 10.1089/aid.2009.0027
   Toledo PV, 2010, BRAZ J INFECT DIS, V14, P360, DOI 10.1590/S1413-86702010000400009
   Pessoa R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152499
   Rangel HR, 2009, MEM I OSWALDO CRUZ, V104, P522, DOI 10.1590/S0074-02762009000300020
   Saad FF, 2010, INT J MOL MED, V26, P585, DOI 10.3892/ijmm_00000503
   Salustiano Cavalcanti AM, 2007, MEM I OSWALDO CRUZ, V102, P785
   Silva LD, 2016, AIDS RES HUM RETROV, V32, P373, DOI [10.1089/aid.2015.0280, 10.1089/AID.2015.0280]
   Sprinz E, 2009, AIDS RES HUM RETROV, V25, P861, DOI 10.1089/aid.2009.0012
   Stefani MMA, 2007, J CLIN VIROL, V39, P205, DOI 10.1016/j.jcv.2007.04.012
   Tanuri A, 2002, J CLIN VIROL, V25, P39, DOI 10.1016/S1386-6532(01)00249-9
   Cardoso LPV, 2009, AIDS RES HUM RETROV, V25, P943, DOI 10.1089/aid.2009.0060
NR 35
TC 6
Z9 6
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 16
PY 2017
VL 12
IS 3
AR e0173894
DI 10.1371/journal.pone.0173894
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EN9KE
UT WOS:000396318300090
PM 28301548
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Mir, D
   Jung, M
   Delatorre, E
   Vidal, N
   Peeters, M
   Bello, G
AF Mir, Daiana
   Jung, Matthieu
   Delatorre, Edson
   Vidal, Nicole
   Peeters, Martine
   Bello, Gonzalo
TI Phylodynamics of the major HIV-1 CRF02_AG African lineages and its
   global dissemination
SO INFECTION GENETICS AND EVOLUTION
LA English
DT Article
DE HIV-1; CRF02_AG; Africa; Worldwide; Phylodynamics
ID NON-B SUBTYPES; GENETIC-CHARACTERIZATION; TYPE-1 CRF02-AG; TRANSMISSION;
   DIVERSITY; RECOMBINANT; ALGORITHMS; SYSTEM; CLADE
AB The HIV-1 CRF02_AG clade is the most prevalent HIV variant in West and West-Central Africa and its detection outside Africa is increasingly common. Little is known, however, about the number and phylodynamics of major CRF02_AG lineages circulating worldwide. To this end, a total of 3170 HIV-1 CRF02_AG-like pol sequences isolated around the world, over a period of 25 years (1989 to 2013), were analyzed using Maximum Likelihood and Bayesian coalescent-based methods. Our results suggest that most of the current CRF02_AG diversity comes from the dissemination of a few founder strains out of Central Africa into West Africa and Cameroon between the late 1960s and the middle 1980s. The CRF02_AG strain introduced into West Africa established a large regional epidemic with low phylogeographic structure. This strain was also successfully disseminated out of the West African region and originated at least three large secondary outbreaks in Cameroon at around the late 1970s, in the former Soviet Union (FSU) countries at around the late 1990s, and in Bulgaria/Germany at around the early 2000s. The CRF02_AG African lineages introduced into Cameroon remained mostly restricted to this country and its neighbors. Demographic reconstructions indicate that major CRF02_AG clades circulating in Africa exhibited a decline in growth rate since the middle 1980s/1990s, whereas CRF02_AG clades in Europe and the FSU countries continue to grow exponentially until the middle to late 2000s. Substantial differences in the median estimated growth rate of the same CRF02_AG clade circulating in different regions (0.63-2.00 year(-1)), and of different CRF02_AG clades circulating in the same country (0.41-0.75 year(-1)) were observed. Thus, the cause of the epidemic outcome of the different HIV-1 CRF02_AG lineages is probably multifactorial. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Mir, Daiana; Delatorre, Edson; Bello, Gonzalo] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, Av Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
   [Jung, Matthieu; Vidal, Nicole; Peeters, Martine] INSERM, U1175, Inst Rech Dev, Unite Mixte Int 233, Montpellier, France.
   [Jung, Matthieu; Vidal, Nicole; Peeters, Martine] Univ Montpellier, Montpellier, France.
   [Jung, Matthieu; Peeters, Martine] Univ Montpellier, UMR CNRS 5506, Inst Biol Computat, LIRMM, Montpellier, France.
   [Jung, Matthieu] Univ Strasbourg, IGBMC, INSERM, U596,CNRS,UMR7104, Illkirch Graffenstaden, France.
RP Bello, G (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, Av Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
EM gbellobr@gmail.com
RI Bentancor, Gonzalo Jose Bello/N-7377-2019; Delatorre, Edson/J-8330-2015;
   Vidal, Nicole/L-4130-2017; , daiana/J-5515-2019; Bello,
   Gonzalo/E-6842-2013
OI Bentancor, Gonzalo Jose Bello/0000-0002-2724-2793; Delatorre,
   Edson/0000-0002-5746-0820; Vidal, Nicole/0000-0001-7022-2643; ,
   daiana/0000-0002-3172-4867; 
FU Agencia Nacional de Investigacion e Innovacion (ANII-Uruguay);
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES-Brazil)CAPES; Programa Nacional de Pos-Doutorado (CAPES-Brazil)
FX D.M. was funded by fellowships from "Agencia Nacional de Investigacion e
   Innovacion (ANII-Uruguay)" and "Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES-Brazil)". E.D. was funded by a
   fellowship from "Programa Nacional de Pos-Doutorado (CAPES-Brazil)".
CR Abecasis AB, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-7
   Abecasis AB, 2009, J VIROL, V83, P12917, DOI 10.1128/JVI.01022-09
   Anisimova M, 2006, SYST BIOL, V55, P539, DOI 10.1080/10635150600755453
   Baele G, 2012, MOL BIOL EVOL, V29, P2157, DOI 10.1093/molbev/mss084
   Baryshev PB, 2012, ARCH VIROL, V157, P2335, DOI 10.1007/s00705-012-1442-4
   Brand D, 2014, J CLIN MICROBIOL, V52, P4010, DOI 10.1128/JCM.01141-14
   Carr JK, 2005, JAIDS-J ACQ IMM DEF, V39, P570
   Charrierre F., 2008, W AFRICA MIGRATION P
   Veras NMC, 2011, AIDS RES HUM RETROV, V27, P1173, DOI [10.1089/aid.2010.0333, 10.1089/AID.2010.0333]
   Dauwe K, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1217-0
   de Oliveira T, 2005, BIOINFORMATICS, V21, P3797, DOI 10.1093/bioinformatics/bti607
   Delatorre E, 2015, AIDS RES HUM RETROV, V31, P1230, DOI 10.1089/aid.2015.0183
   Delatorre E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098908
   Delatorre EO, 2012, AIDS RES HUM RETROV, V28, P1369, DOI 10.1089/aid.2011.0381
   Diez-Fuertes F, 2015, INFECT GENET EVOL, V33, P197, DOI 10.1016/j.meegid.2015.05.003
   Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/msi103
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   Esbjornsson J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017025
   European Centre for Disease Prevention and Control (ECDC), 2014, TECHNICAL REPORT
   Eyer-Silva WA, 2007, MEM I OSWALDO CRUZ, V102, P809, DOI 10.1590/S0074-02762007005000112
   Eyzaguirre LM, 2007, JAIDS-J ACQ IMM DEF, V46, P19, DOI 10.1097/01.qai.0000286598.00313.a6
   Faria NR, 2014, SCIENCE, V346, P56, DOI 10.1126/science.1256739
   Faria NR, 2012, INFECT GENET EVOL, V12, P453, DOI 10.1016/j.meegid.2011.04.028
   Gashnikova NM, 2015, AIDS RES HUM RETROV, V31, P456, DOI [10.1089/aid.2014.0375, 10.1089/AID.2014.0375]
   Gnisci D., 2009, W AFRICAN STUDIES RE
   Guindon S, 2010, SYST BIOL, V59, P307, DOI 10.1093/sysbio/syq010
   Hemelaar J, 2011, AIDS, V25, P679, DOI 10.1097/QAD.0b013e328342ff93
   Hernando V, 2015, JAIDS-J ACQ IMM DEF, V70, P204, DOI 10.1097/QAI.0000000000000717
   Ivanov IA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059666
   Kazennova E., 2014, AIDS RES HUM RETROVI, V30
   Laga V, 2015, J HIV AIDS, V1
   Lapovok I, 2014, AIDS RES HUM RETROV, V30, P769, DOI [10.1089/aid.2013.0291, 10.1089/AID.2013.0291]
   Lihana RW, 2012, AIDS REV, V14, P83
   Lole KS, 1999, J VIROL, V73, P152, DOI 10.1128/JVI.73.1.152-160.1999
   Peeters M, 2003, AIDS, V17, P2547, DOI 10.1097/00002030-200312050-00002
   Posada D, 2001, MOL BIOL EVOL, V18, P897, DOI 10.1093/oxfordjournals.molbev.a003890
   Pyne MT, 2013, J CLIN MICROBIOL, V51, P2662, DOI 10.1128/JCM.00880-13
   Shcherbakova NS, 2014, AIDS RES HUM RETROV, V30, P912, DOI [10.1089/aid.2014.0075, 10.1089/AID.2014.0075]
   Struck D, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku739
   Suchard MA, 2009, BIOINFORMATICS, V25, P1370, DOI 10.1093/bioinformatics/btp244
   Tamalet C., 2015, J MED VIROL, V87
   Tatem A. J., 2012, SPATIAL ACCESSIBILIT, P1
   *UNODC, 2008, ILL DRUG TRENDS CENT
   von Wyl V, 2011, J INFECT DIS, V204, P1095, DOI 10.1093/infdis/jir491
NR 45
TC 11
Z9 12
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567-1348
EI 1567-7257
J9 INFECT GENET EVOL
JI Infect. Genet. Evol.
PD DEC
PY 2016
VL 46
BP 190
EP 199
DI 10.1016/j.meegid.2016.05.017
PG 10
WC Infectious Diseases
SC Infectious Diseases
GA EF6QP
UT WOS:000390456000027
PM 27180893
DA 2020-12-01
ER

PT J
AU Delatorre, E
   Bello, G
AF Delatorre, Edson
   Bello, Gonzalo
TI Time-scale of minor HIV-1 complex circulating recombinant forms from
   Central and West Africa
SO BMC EVOLUTIONARY BIOLOGY
LA English
DT Article
DE HIV-1; Complex CRFs; Africa; Phylodynamics; Phylogeography
ID IMMUNODEFICIENCY-VIRUS TYPE-1; SUBTYPE-A; MOLECULAR EPIDEMIOLOGY;
   ANTIRETROVIRAL RESISTANCE; DEMOGRAPHIC HISTORY; GENETIC-ANALYSIS;
   DRUG-RESISTANCE; COMMON ANCESTOR; HIGH PREVALENCE; IDENTIFICATION
AB Background: Several HIV-1 circulating recombinant forms with a complex mosaic structure (CRFs_cpx) circulate in central and western African regions. Here we reconstruct the evolutionary history of some of these complex CRFs (09_cpx, 11_cpx, 13_cpx and 45_cpx) and further investigate the dissemination dynamic of the CRF11_cpx clade by using a Bayesian coalescent-based method.
   Results: The analysis of two HIV-1 datasets comprising 181 pol (36 CRF09_cpx, 116 CRF11_cpx, 20 CRF13_cpx and 9 CRF45_cpx) and 125 env (12 CRF09_cpx, 67 CRF11_cpx, 17 CRF13_cpx and 29 CRF45_cpx) sequences pointed to quite consistent onset dates for CRF09_cpx (similar to 1966: 1958-1979), CRF11_cpx (similar to 1957: 1950-1966) and CRF13_cpx (similar to 1965: 1958-1973) clades; while some divergence was found for the estimated date of origin of CRF45_cpx clade [pol = 1970 (1964-1976); env = 1960 (1952-1969)]. Phylogeographic reconstructions indicate that the HIV-1 CRF11_cpx clade most probably emerged in Cameroon and from there it was first disseminated to the Central Africa Republic and Chad in the early 1970s and to other central and western African countries from the early 1980s onwards. Demographic reconstructions suggest that the CRF11_cpx epidemic grew between 1960 and 1990 with a median exponential growth rate of 0.27 year(-1), and stabilized after.
   Conclusions: These results reveal that HIV-1 CRFs_cpx clades have been circulating in Central Africa for a period comparable to other much more prevalent HIV-1 group M lineages. Cameroon was probably the epicenter of dissemination of the CRF11_cpx clade that seems to have experienced a long epidemic growth phase before stabilization. The epidemic growth of the CRF11_cpx clade was roughly comparable to other HIV-1 group M lineages circulating in Central Africa.
C1 [Delatorre, Edson; Bello, Gonzalo] Inst Oswaldo Cruz FIOCRUZ, Lab AIDS & Imunol Mol, Av Brasil 4365, BR-21040360 Rio De Janeiro, RJ, Brazil.
RP Delatorre, E (corresponding author), Inst Oswaldo Cruz FIOCRUZ, Lab AIDS & Imunol Mol, Av Brasil 4365, BR-21040360 Rio De Janeiro, RJ, Brazil.
EM edsonod@ioc.fiocruz.br
RI Delatorre, Edson/J-8330-2015; Bello, Gonzalo/E-6842-2013; Bentancor,
   Gonzalo Jose Bello/N-7377-2019
OI Delatorre, Edson/0000-0002-5746-0820; Bentancor, Gonzalo Jose
   Bello/0000-0002-2724-2793
FU "Programa Nacional de Pos-Doutorado" (CAPES-Brazil)
FX E.D. is funded by a fellowship from "Programa Nacional de Pos-Doutorado"
   (CAPES-Brazil).
CR Abecasis AB, 2009, J VIROL, V83, P12917, DOI 10.1128/JVI.01022-09
   Afonso JM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042996
   An MH, 2012, J VIROL, V86, P12402, DOI 10.1128/JVI.00262-12
   Castelbranco EPAF, 2010, AIDS RES HUM RETROV, V26, P1313, DOI 10.1089/aid.2010.0111
   Anisimova M, 2006, SYST BIOL, V55, P539, DOI 10.1080/10635150600755453
   Antoniadou ZA, 2014, AIDS RES HUM RETROV, V30, P225, DOI [10.1089/aid.2013.0166, 10.1089/AID.2013.0166]
   Baele G, 2012, MOL BIOL EVOL, V29, P2157, DOI 10.1093/molbev/mss084
   Bello G, 2007, INFECT GENET EVOL, V7, P263, DOI 10.1016/j.meegid.2006.11.002
   Bello G, 2009, AIDS RES HUM RETROV, V25, P1065, DOI 10.1089/aid.2009.0106
   Bielejec F, 2011, BIOINFORMATICS, V27, P2910, DOI 10.1093/bioinformatics/btr481
   Charpentier C, 2011, ANTIVIR THER, V16, P429, DOI 10.3851/IMP1754
   d'Aquin TT, 2007, AIDS RES HUM RETROV, V23, P1155
   de Silva TI, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-82
   Delatorre E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098908
   Delatorre E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072448
   Delatorre E, 2013, AIDS, V27, P1313, DOI 10.1097/QAD.0b013e32835f1df4
   Delgado E, 2008, JAIDS-J ACQ IMM DEF, V48, P599, DOI 10.1097/QAI.0b013e3181806c0e
   Djoko CF, 2011, AIDS RES HUM RETROV, V27, P323, DOI 10.1089/aid.2010.0201
   Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/msi103
   Drummond AJ, 2002, GENETICS, V161, P1307
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   Drummond AJ, 2012, MOL BIOL EVOL, V29, P1969, DOI 10.1093/molbev/mss075
   Faria NR, 2014, SCIENCE, V346, P56, DOI 10.1126/science.1256739
   Faria NR, 2012, INFECT GENET EVOL, V12, P453, DOI 10.1016/j.meegid.2011.04.028
   Ferreira MAR, 2008, CAN J STAT, V36, P355, DOI 10.1002/cjs.5550360302
   Gao F, 1998, J VIROL, V72, P10234, DOI 10.1128/JVI.72.12.10234-10241.1998
   Graf T, 2016, J VIROL, V90, P8160, DOI 10.1128/JVI.00363-16
   Guimaraes ML, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-39
   Guindon S, 2005, NUCLEIC ACIDS RES, V33, pW557, DOI 10.1093/nar/gki352
   Guindon S, 2010, SYST BIOL, V59, P307, DOI 10.1093/sysbio/syq010
   Hemelaar J, 2011, AIDS, V25, P679, DOI 10.1097/QAD.0b013e328342ff93
   Hue S, 2005, P NATL ACAD SCI USA, V102, P4425, DOI 10.1073/pnas.0407534102
   Kalish ML, 2004, EMERG INFECT DIS, V10, P1227
   Kousiappa I, 2009, AIDS RES HUM RETROV, V25, P727, DOI 10.1089/aid.2008.0239
   Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404
   Lemey P, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000520
   Lole KS, 1999, J VIROL, V73, P152, DOI 10.1128/JVI.73.1.152-160.1999
   Luk KC, 2008, AIDS RES HUM RETROV, V24, P1309, DOI 10.1089/aid.2008.0124
   Marechal V, 2006, AIDS RES HUM RETROV, V22, P1036, DOI 10.1089/aid.2006.22.1036
   McCutchan FE, 2004, AIDS RES HUM RETROV, V20, P819, DOI 10.1089/0889222041725163
   Mehta SR, 2011, INFECT GENET EVOL, V11, P975, DOI 10.1016/j.meegid.2011.03.009
   Mir D, 2016, INFECT GENET EVOL
   Montavon C, 2002, AIDS RES HUM RETROV, V18, P231, DOI 10.1089/08892220252781301
   Montavon C, 2002, J ACQ IMMUN DEF SYND, V29, P522, DOI 10.1097/00126334-200204150-00014
   Niama FR, 2009, AIDS RES HUM RETROV, V25, P1345, DOI 10.1089/aid.2009.0169
   Pineda-Pena AC, 2013, INFECT GENET EVOL, V19, P337, DOI 10.1016/j.meegid.2013.04.032
   Pircher M, 2012, AIDS RES HUM RETROV, V28, P1798, DOI [10.1089/aid.2012.0083, 10.1089/AID.2012.0083]
   Powell RLR, 2007, AIDS RES HUM RETROV, V23, P923, DOI 10.1089/aid.2007.0040
   Rambaut A, 2014, FIGTREE V1 4
   Robertson DL, 2000, SCIENCE, V288, P55, DOI 10.1126/science.288.5463.55d
   Rome M, 2010, J ACQUIR INMUNE DEFI, V55, P156
   Rousseau CM, 2007, J VIROL, V81, P4492, DOI 10.1128/JVI.02050-06
   Struck D, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku739
   Suchard MA, 2009, BIOINFORMATICS, V25, P1370, DOI 10.1093/bioinformatics/btp244
   Tatem AJ, 2012, AIDS, V26, P2351, DOI 10.1097/QAD.0b013e328359a904
   Tebit DM, 2009, J MED VIROL, V81, P1691, DOI 10.1002/jmv.21600
   Thomson MA, 2005, AIDS, V19, P1155, DOI 10.1097/01.aids.0000176215.95119.1d
   Tongo M, 2015, J VIROL, V90
   Travers SAA, 2004, J VIROL, V78, P10501, DOI 10.1128/JVI.78.19.10501-10506.2004
   Vidal N, 2008, AIDS RES HUM RETROV, V24, P315, DOI 10.1089/aid.2007.0241
   Walker Polly R., 2005, Infection Genetics and Evolution, V5, P199, DOI 10.1016/j.meegid.2004.06.011
   Wilbe K, 2002, AIDS RES HUM RETROV, V18, P849, DOI 10.1089/08892220260190326
   Worobey M, 2008, NATURE, V455, P661, DOI 10.1038/nature07390
   Zeng HY, 2014, INFECT GENET EVOL, V26, P139, DOI 10.1016/j.meegid.2014.05.006
NR 64
TC 4
Z9 5
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2148
J9 BMC EVOL BIOL
JI BMC Evol. Biol.
PD NOV 16
PY 2016
VL 16
AR 249
DI 10.1186/s12862-016-0824-8
PG 11
WC Evolutionary Biology; Genetics & Heredity
SC Evolutionary Biology; Genetics & Heredity
GA EC3JX
UT WOS:000388023500001
PM 27852214
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU de Bruycker-Nogueira, F
   Mir, D
   dos Santos, FB
   Bello, G
AF de Bruycker-Nogueira, Fernanda
   Mir, Daiana
   dos Santos, Flavia Barreto
   Bello, Gonzalo
TI Evolutionary history and spatiotemporal dynamics of DENV-1 genotype V in
   the Americas
SO INFECTION GENETICS AND EVOLUTION
LA English
DT Article
DE DENV-1; Genotype V; Lineages; Phylogeny; Evolution; Americas
ID DENGUE HEMORRHAGIC-FEVER; POPULATION-DYNAMICS; LINEAGE REPLACEMENT;
   CO-CIRCULATION; KEY-WEST; VIRUS; TYPE-1; BRAZIL; REVEALS; PHYLOGEOGRAPHY
AB The genotype V has been the most prevalent dengue virus type 1 (DENV-1) clade circulating in the Americas over the last 40 years. In this study, we investigate the spatiotemporal pattern of emergence and dissemination of DENV-1 lineages in the continent. We applied phylogenetic and phylogeographic approaches to a comprehensive data set of 836 DENV-1 E gene sequences of the genotype V isolated from 46 different countries around the world over a period of 50 years (1962 to 2014). Our study reveals that genetic diversity of DENV-1 genotype V in the Americas resulted from two independent introductions of this genotype from India. The first genotype V strain was most probably introduced into the Lesser Antilles at around the early 1970s and this Caribbean region becomes the source population of several DENV-1 lineages that spread in the Americas during the 1970s and 1980s. Most of those lineages appear to become extinct during the 1990s, except one that persisted in Venezuela and later spread to other American countries, dominating the DENV-1 epidemics in the region from the early 2000s onwards. The second genotype V strain of Indian origin was also most probably introduced into the Lesser Antilles at around the early 1980s. This lineage remained almost undetected for nearly 15 years, until it was introduced in Northern Brazil around the middle 1990s and later spread to other country regions. These results demonstrate that different geographic regions have played a role in maintaining and spreading the DENV-1 genotype V in the Americas over time. DENV-1 genotype V lineages have originated, spread and died out in the Americas with very different dynamics and the phenomenon of lineage replacement across successive DENV-1 epidemic outbreaks was a common characteristic in most American countries. (C) 2016 Elsevier B.V. All rights reserved.
C1 [de Bruycker-Nogueira, Fernanda; dos Santos, Flavia Barreto] Fiocruz MS, Oswaldo Cruz Inst, Lab Viral Immunol, Av Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
   [Mir, Daiana; Bello, Gonzalo] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Mol Immunol, Av Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
RP dos Santos, FB (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab Viral Immunol, Av Brasil 4365, BR-21045360 Rio De Janeiro, RJ, Brazil.
EM flaviab@ioc.fiocruz.br
RI , daiana/J-5515-2019; Bentancor, Gonzalo Jose Bello/N-7377-2019; Bello,
   Gonzalo/E-6842-2013
OI , daiana/0000-0002-3172-4867; Bentancor, Gonzalo Jose
   Bello/0000-0002-2724-2793; 
FU Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico/CNPqNational Council for Scientific and Technological
   Development (CNPq) [303822/2015-5]; Programa Estrategico de Pesquisa em
   Saude/PAPES VI-FIOCRUZ [407690/2012-3]; "Agencia Nacional de
   Investigacion e Innovacion (ANII-Uruguay)"; "Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES)"CAPES
FX To Postgraduate in Parasitary Biology at Oswaldo Cruz Institute/FIOCRUZ
   and Third International Bioinformatics Workshop on Molecular Biology and
   Evolution of Viruses for complementary training of FBN. This work was
   supported by Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico/CNPq [grant number 303822/2015-5] and Programa Estrategico
   de Pesquisa em Saude/PAPES VI-FIOCRUZ [grant number 407690/2012-3]. DM
   is funded by a fellowship from "Agencia Nacional de Investigacion e
   Innovacion (ANII-Uruguay)". FBN and DM have fellowships from the
   "Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)".
CR Allicock OM, 2012, MOL BIOL EVOL, V29, P1533, DOI 10.1093/molbev/msr320
   Anez G, 2012, AM J TROP MED HYG, V87, P548, DOI 10.4269/ajtmh.2012.12-0091
   Anisimova M, 2006, SYST BIOL, V55, P539, DOI 10.1080/10635150600755453
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Carneiro AR, 2012, MEM I OSWALDO CRUZ, V107, P805, DOI 10.1590/S0074-02762012000600016
   Carrillo-Valenzo E, 2010, ARCH VIROL, V155, P1401, DOI 10.1007/s00705-010-0721-1
   Cunha MD, 2016, INFECT GENET EVOL, V43, P130, DOI 10.1016/j.meegid.2016.05.021
   de Bruycker-Nogueira F, 2015, INFECT GENET EVOL, V34, P126, DOI 10.1016/j.meegid.2015.07.007
   dos Santos FB, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-387
   Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/msi103
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   Drumond BP, 2012, ARCH VIROL, V157, P2061, DOI 10.1007/s00705-012-1393-9
   Gubler DJ, 1998, CLIN MICROBIOL REV, V11, P480, DOI 10.1128/CMR.11.3.480
   Gubler DJ, 2014, DENGUE AND DENGUE HEMORRHAGIC FEVER, 2ND EDITION, P1, DOI 10.1079/9781845939649.0001
   Gubler Duane J, 2011, Trop Med Health, V39, P3, DOI 10.2149/tmh.2011-S05
   Guindon S, 2010, SYST BIOL, V59, P307, DOI 10.1093/sysbio/syq010
   Guzman MG, 2003, J CLIN VIROL, V27, P1, DOI 10.1016/S1386-6532(03)00010-6
   Katoh K, 2002, NUCLEIC ACIDS RES, V30, P3059, DOI 10.1093/nar/gkf436
   Lemey P, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000520
   Li WZ, 2006, BIOINFORMATICS, V22, P1658, DOI 10.1093/bioinformatics/btl158
   San Martin JL, 2010, AM J TROP MED HYG, V82, P128, DOI 10.4269/ajtmh.2010.09-0346
   Mendez JA, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-226
   Mir D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098519
   Munoz-Jordan JL, 2013, EMERG INFECT DIS, V19, P652, DOI 10.3201/eid1904.121295
   Pierson T.C., 2013, FIELDS VIROLOGY, V6, P747
   Posada D, 2008, MOL BIOL EVOL, V25, P1253, DOI 10.1093/molbev/msn083
   Rambaut A., 2012, FIGTREE 1 4 0
   Suchard MA, 2009, BIOINFORMATICS, V25, P1370, DOI 10.1093/bioinformatics/btp244
   Tittarelli E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111017
   Villabona-Arenas CJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062649
   Villabona-Arenas CJ, 2011, INFECT GENET EVOL, V11, P878, DOI 10.1016/j.meegid.2011.02.007
   Walimbe AM, 2014, INFECT GENET EVOL, V22, P30, DOI 10.1016/j.meegid.2014.01.001
   Weaver SC, 2009, INFECT GENET EVOL, V9, P523, DOI 10.1016/j.meegid.2009.02.003
   World Health Organization, 2012, GLOB STRAT DENG PREV
NR 35
TC 12
Z9 12
U1 0
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567-1348
EI 1567-7257
J9 INFECT GENET EVOL
JI Infect. Genet. Evol.
PD NOV
PY 2016
VL 45
BP 454
EP 460
DI 10.1016/j.meegid.2016.09.025
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA ED0ZY
UT WOS:000388574400060
PM 27713055
OA Bronze
DA 2020-12-01
ER

PT J
AU Cabello, M
   Romero, H
   Bello, G
AF Cabello, Marina
   Romero, Hector
   Bello, Gonzalo
TI Multiple introductions and onward transmission of non-pandemic HIV-1
   subtype B strains in North America and Europe
SO SCIENTIFIC REPORTS
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; GENETIC-ANALYSIS REVEALS;
   MAXIMUM-LIKELIHOOD; POPULATION-DYNAMICS; WEB SERVER; DIVERSITY;
   INFERENCE; SPREAD; PHYLOGENETICS; PERFORMANCE
AB Most HIV-1 subtype B infections in North America and Europe seem to have resulted from the expansion of a single pandemic lineage (BPANDEMIC) disseminated from the United States (US). Some non-pandemic subtype B strains of Caribbean origin (BCAR) may have also reached North America and Europe, but their epidemiological relevance in those regions remains largely unknown. Here we analyze a total of 20,045 HIV-1 subtype B pol sequences from the US, Canada, and Europe, to estimate the prevalence and to reconstruct the spatiotemporal dynamics of dissemination of HIV-1 BCAR strains in those regions. We find that BCAR strains were probably disseminated from the Caribbean into North America and Europe at multiple times since the early 1970s onwards. The BCAR strains reached the US, Canada and at least 16 different European countries, where they account for a very low fraction (<5%) of subtype B infections, with exception of the Czech Republic (7.7%). We also find evidence of the onward transmission of BCAR clades in the US, Canada, the Czech Republic, Germany, Italy, Spain and the UK, as well as short-distance spreading of BCAR lineages between neighboring European countries from Central and Western Europe, and long-distance dissemination between the US and Europe.
C1 [Cabello, Marina; Bello, Gonzalo] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, Rio De Janeiro, Brazil.
   [Romero, Hector] Univ Republica, Fac Ciencias CURE, Dept Ecol & Evoluc, Lab Org & Evoluc Genoma, Montevideo, Uruguay.
RP Bello, G (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, Rio De Janeiro, Brazil.
EM gbello@ioc.fiocruz.br
RI Bello, Gonzalo/E-6842-2013; Bentancor, Gonzalo Jose Bello/N-7377-2019
OI Bentancor, Gonzalo Jose Bello/0000-0002-2724-2793
FU Public Health Service from the CNPq (Brazil) - MEC (Uruguay)
   [490378/2013-7]
FX This work was supported by Public Health Service grant 490378/2013-7
   from the CNPq (Brazil) - MEC (Uruguay).
CR Abecasis AB, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-7
   Anisimova M, 2006, SYST BIOL, V55, P539, DOI 10.1080/10635150600755453
   Anisimova M, 2011, SYST BIOL, V60, P685, DOI 10.1093/sysbio/syr041
   Beloukas A., 2016, INFECT GENE IN PRESS
   Berger SA, 2011, SYST BIOL, V60, P291, DOI 10.1093/sysbio/syr010
   Bielejec F, 2011, BIOINFORMATICS, V27, P2910, DOI 10.1093/bioinformatics/btr481
   Borland R, 2004, HIV AIDS MOBILE POPU
   Cabello M, 2015, AIDS, V29, P483, DOI 10.1097/QAD.0000000000000552
   Cabello M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106045
   Caribbean Tourism Organization (CTO), CAR TOUR REV 2014
   Centers for Disease Control and Prevention, 2014, HIV SURV REP
   Chen JHK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025286
   Cordova Alcaraz R, 2012, MIGRATORY ROUTES DYN
   de Oliveira T, 2005, BIOINFORMATICS, V21, P3797, DOI 10.1093/bioinformatics/bti607
   Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/msi103
   Drummond AJ, 2002, GENETICS, V161, P1307
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   Faria NR, 2014, SCIENCE, V346, P56, DOI 10.1126/science.1256739
   Faria NR, 2012, J GEN VIROL, V93, P889, DOI 10.1099/vir.0.038638-0
   Ferreira MAR, 2008, CAN J STAT, V36, P355, DOI 10.1002/cjs.5550360302
   Frentz D, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-36
   Gilbert MTP, 2007, P NATL ACAD SCI USA, V104, P18566, DOI 10.1073/pnas.0705329104
   Guindon S, 2005, NUCLEIC ACIDS RES, V33, pW557, DOI 10.1093/nar/gki352
   Guindon S, 2010, SYST BIOL, V59, P307, DOI 10.1093/sysbio/syq010
   Hemelaar J, 2011, AIDS, V25, P679, DOI 10.1097/QAD.0b013e328342ff93
   Hue S, 2005, P NATL ACAD SCI USA, V102, P4425, DOI 10.1073/pnas.0407534102
   Huelsenbeck JP, 2002, SYST BIOL, V51, P673, DOI 10.1080/10635150290102366
   Junqueira DM, 2016, VIROLOGY, V495, P173, DOI 10.1016/j.virol.2016.05.003
   Junqueira DM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027489
   Kramer MA, 2008, SEX TRANSM INFECT, V84, P554, DOI 10.1136/sti.2008.032094
   Kramer MA, 2011, AIDS RES HUM RETROV, V27, P123, DOI 10.1089/aid.2010.0115
   Kuiken C, 2000, AM J EPIDEMIOL, V152, P814, DOI 10.1093/aje/152.9.814
   Lemey P, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000520
   Lukashov VV, 1996, AIDS RES HUM RETROV, V12, P1179, DOI 10.1089/aid.1996.12.1179
   Mendoza Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095360
   Nurse K, 2004, MIGRATION DEV CARIBB
   Paraskevis D, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-49
   Pharris A., 2015, EURO SURVEILLANCE EU, V20
   Posada D, 2008, MOL BIOL EVOL, V25, P1253, DOI 10.1093/molbev/msn083
   Public Health Agency of Canada, 2014, SUMM EST HIV INC PRE
   Pyne MT, 2013, J CLIN MICROBIOL, V51, P2662, DOI 10.1128/JCM.00880-13
   Rambaut A, TRACER V1 6
   Rambaut A, FIGTREE V1 4 TREE FI
   Rambaut A, 2016, VIRUS EVOL, V2, DOI 10.1093/ve/vew007
   Siemieniuk RAC, 2013, CAN J INFECT DIS MED, V24, P69, DOI 10.1155/2013/230380
   Stamatakis A, 2014, BIOINFORMATICS, V30, P1312, DOI 10.1093/bioinformatics/btu033
   Stanojevic M, 2012, AIDS REV, V14, P28
   Suchard MA, 2009, BIOINFORMATICS, V25, P1370, DOI 10.1093/bioinformatics/btp244
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Thomson MM, 2007, J INFECT DIS, V196, P1120, DOI 10.1086/521683
   UNAIDS, 2013, REP GLOB AIDS EP
   Zehender G, 2010, JAIDS-J ACQ IMM DEF, V55, P156, DOI 10.1097/QAI.0b013e3181eb3002
NR 53
TC 5
Z9 5
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD SEP 22
PY 2016
VL 6
AR 33971
DI 10.1038/srep33971
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DW5OY
UT WOS:000383696900001
PM 27653834
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Divino, F
   Corado, ADG
   Naveca, FG
   Stefani, MMA
   Bello, G
AF Divino, Flavia
   Guerra Corado, Andre de Lima
   Naveca, Felipe Gomes
   Stefani, Mariane M. A.
   Bello, Gonzalo
TI High Prevalence and Onward Transmission of Non-Pandemic HIV-1 Subtype B
   Clades in Northern and Northeastern Brazilian Regions
SO PLOS ONE
LA English
DT Article
ID POPULATION-DYNAMICS; GENETIC DIVERSITY; DRUG-RESISTANCE; ALGORITHMS
AB The Human immunodeficiency virus type-1 (HIV-1) epidemic in Brazil is mainly driven by the subtype B pandemic lineage (B-PANDEMIC), while Caribbean non-pandemic subtype B clades (B-CAR) seem to account for a very low fraction of HIV-infections in this country. The molecular characteristics of the HIV-1 subtype B strains disseminated in the Northern and Northeastern Brazilian regions, however, have not been explored so far. In this study, we estimate the prevalence of the HIV-1 B-PANDEMIC and B-CAR clades across different Brazilian regions and we reconstruct the spatiotemporal dynamics of dissemination of the major Brazilian B-CAR clades. A total of 2,682 HIV-1 subtype B pol sequences collected from 21 different Brazilian states from the five country regions between 1998 and 2013 were analyzed. Maximum Likelihood phylogenetic analyses revealed that the B-CAR strains reached 16 out 21 Brazilian states here analyzed. The B-CAR clades comprise a low fraction (< 10%) of subtype B infections in most Brazilian states analyzed, with exception of Roraima (41%), Amazonas (14%) and Maranhao (14%). Bayesian phylogeographic analyses indicate that B-CAR strains originally from the Hispaniola and Trinidad and Tobago were introduced at multiple times into different states from all Brazilian regions and a few of those strains, probably introduced into Roraima, Maranhao and Sao Paulo between the late 1970s and the early 1980s, established secondary outbreaks in the Brazilian population. These results support that the HIV-1 subtype B epidemics in some Brazilian states from the Northern and Northeastern regions display a unique molecular pattern characterized by the high prevalence of B-CAR lineages, which probably reflects a strong epidemiological link with the HIV-1 epidemics in the Caribbean region.
C1 [Divino, Flavia; Bello, Gonzalo] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, Rio De Janeiro, RJ, Brazil.
   [Guerra Corado, Andre de Lima; Naveca, Felipe Gomes] Fundacao Oswaldo Cruz, Inst Leonidas & Maria Deane, Manaus, Amazonas, Brazil.
   [Stefani, Mariane M. A.] Univ Fed Goias, Trop Pathol & Publ Hlth Inst, Goiania, Go, Brazil.
RP Bello, G (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, Rio De Janeiro, RJ, Brazil.
EM gbellobr@gmail.com
RI Bello, Gonzalo/E-6842-2013; Bentancor, Gonzalo Jose Bello/N-7377-2019;
   Naveca, Felipe/H-1130-2012
OI Bentancor, Gonzalo Jose Bello/0000-0002-2724-2793; Naveca,
   Felipe/0000-0002-2888-1060
FU Public Health Service from the "Fundacao Carlos Chagas Filho de Amparo a
   Pesquisa do Estado do Rio de Janeiro" (FAPERJ) [E-26/110.439/2014];
   "Conselho Nacional de Desenvolvimento Cientifico e Tecnologico"
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [472896/2012-1]; Instituto Oswaldo Cruz-FIOCRUZ
FX GB was supported by Public Health Service grants E-26/110.439/2014 from
   the "Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio
   de Janeiro" (FAPERJ) and 472896/2012-1 from the "Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico" (CNPq). FD was funded by a
   fellowship from Instituto Oswaldo Cruz- FIOCRUZ. The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Amaral EF, 2005, ONLINE J MIGRATION P
   Anisimova M, 2006, SYST BIOL, V55, P539, DOI 10.1080/10635150600755453
   Arouck R, 2000, LUSOTOPIE, P67
   Bielejec F, 2011, BIOINFORMATICS, V27, P2910, DOI 10.1093/bioinformatics/btr481
   Brazilian (2015) Ministry of Health, 2015, AIDS EP B
   Brindeiro RM, 2003, AIDS, V17, P1063, DOI 10.1097/00002030-200305020-00016
   Cabello M, 2015, AIDS, V29, P483, DOI 10.1097/QAD.0000000000000552
   Cabello M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106045
   Chen J.J., 2011, MODEL SIMUL ENG, V2011, P1, DOI DOI 10.1371/J0URNAL.P0NE.0025286
   Corbin H.P, 2007, BRAZILIAN MIGRATION
   da Costa CM, 2016, AIDS RES HUM RETROVI
   Soares CMPD, 2014, J INT AIDS SOC, V17, DOI 10.7448/IAS.17.1.19042
   de Oliveira T, 2005, BIOINFORMATICS, V21, P3797, DOI 10.1093/bioinformatics/bti607
   De Theije Marjo, 2009, EUR REV LATIN AM CAR, V87, P5
   Diniz AMA, 2005, CAD GEOGR, V15, P23
   Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/msi103
   Drummond AJ, 2002, GENETICS, V161, P1307
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   Ferreira MAR, 2008, CAN J STAT, V36, P355, DOI 10.1002/cjs.5550360302
   Gilbert MTP, 2007, P NATL ACAD SCI USA, V104, P18566, DOI 10.1073/pnas.0705329104
   Guimaraes ML, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141372
   Guindon S, 2005, NUCLEIC ACIDS RES, V33, pW557, DOI 10.1093/nar/gki352
   Guindon S, 2010, SYST BIOL, V59, P307, DOI 10.1093/sysbio/syq010
   Heemskerk M, 2014, SURINAME MIGRATION P
   Hue S, 2005, P NATL ACAD SCI USA, V102, P4425, DOI 10.1073/pnas.0407534102
   Lemey P, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000520
   Leonardi V., 2000, FRONTEIRAS AMAZONICA
   Martins CC, 2011, AN 3 S POS GRAD REL
   Mendoza Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095360
   Pereira Mariana Cunha, 2006, Estud. av., V20, P209, DOI 10.1590/S0103-40142006000200016
   Pessoa R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152499
   Posada D, 2008, MOL BIOL EVOL, V25, P1253, DOI 10.1093/molbev/msn083
   Rambaut A, 2007, TRACER V1 6
   Rambaut A, 2009, FIGTREE V1 4 TREE FI
   Silva LD, 2016, AIDS RES HUM RETROV, V32, P373, DOI [10.1089/aid.2015.0280, 10.1089/AID.2015.0280]
   Soares CL, 2011, PRACS REV HUMANIDADE, V4, P129
   Stefani MMA, 2007, J CLIN VIROL, V39, P205, DOI 10.1016/j.jcv.2007.04.012
   Suchard MA, 2009, BIOINFORMATICS, V25, P1370, DOI 10.1093/bioinformatics/btp244
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Vale Ana Lia Farias, 2006, Estud. av., V20, P255, DOI 10.1590/S0103-40142006000200019
   Zehender G, 2010, JAIDS-J ACQ IMM DEF, V55, P156, DOI 10.1097/QAI.0b013e3181eb3002
NR 42
TC 8
Z9 8
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 7
PY 2016
VL 11
IS 9
AR e0162112
DI 10.1371/journal.pone.0162112
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DV9IX
UT WOS:000383255200042
PM 27603317
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU da Costa, CM
   de Oliveira, CMC
   de Melo, YFC
   Delatorre, E
   Bello, G
   Couto-Fernandez, JC
AF da Costa, Carolina Marinho
   Costa de Oliveira, Cintia Mara
   Chehuan de Melo, Yonne Francis
   Delatorre, Edson
   Bello, Gonzalo
   Couto-Fernandez, Jose Carlos
TI High HIV-1 Genetic Diversity in Patients from Northern Brazil
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID DRUG-RESISTANCE SURVEILLANCE; TYPE-1 SUBTYPE-C; MODERATE PREVALENCE; POL
   RECOMBINANTS; MATO-GROSSO; STATE; AMAZONAS; NETWORK
AB The HIV-1 epidemic in Brazil is driven by subtypes B, F1, and C and recombinants forms among those subtypes. The distribution of HIV-1 subtypes, however, may vary across different Brazilian regions and the molecular epidemiologic profile in Northern Brazil remains poorly explored. HIV-1 pol sequences were obtained from 305 patients failing antiretroviral therapy followed at outpatient clinics from five Northern Brazilian states. The most prevalent HIV-1 clade observed in the Northern Brazilian region was subtype B (81%), followed by BF1 recombinants (10%), subtype F1 (4%), subtype C (3%), BC recombinants (2%), and BU recombinants (1%). Although HIV-1 subtype B was the predominant HIV-1 clade in Northern Brazil, its prevalence greatly varies among different states, ranging from 63% in Rondonia to 92% in Acre. Among the 37 HIV-1 recombinant sequences detected in the Northern Brazilian region, nine (24%) displayed a unique recombinant form structure, five (14%) a CRF28/29_BF-like structure, and four (11%) a CRF31_BC-like structure. Two other BF1 recombinant patterns were identified in 16 (43%) and three (8%) samples that may correspond to two potentially new CRFs_BF characteristic of the Northern region. This study reveals that despite the low spatial connectivity with other Brazilian regions, the genetic complexity of the HIV-1 epidemic in Northern Brazil is very high and that the molecular epidemiologic pattern may vary across different northern states, reflecting a complex epidemic with multiple independent viral introductions into this Brazilian region.
C1 [da Costa, Carolina Marinho; Costa de Oliveira, Cintia Mara; Chehuan de Melo, Yonne Francis] Governo Estado Amazonas, Secretaria Estado Saude, Fundacao Med Trop Dr Heitor Vieira Dourado, Lab Genotipagem HIV, Manaus, Amazonas, Brazil.
   [da Costa, Carolina Marinho] Univ Estado Amazonas, Manaus, Amazonas, Brazil.
   [Delatorre, Edson; Bello, Gonzalo; Couto-Fernandez, Jose Carlos] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, Room 413,Ave Brasil 4365 Manguinhos, BR-21045900 Rio De Janeiro, Brazil.
RP Bello, G (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, Room 413,Ave Brasil 4365 Manguinhos, BR-21045900 Rio De Janeiro, Brazil.
EM gbello@ioc.fiocruz.br
RI Bentancor, Gonzalo Jose Bello/N-7377-2019; Bello, Gonzalo/E-6842-2013;
   Delatorre, Edson/J-8330-2015
OI Bentancor, Gonzalo Jose Bello/0000-0002-2724-2793; Delatorre,
   Edson/0000-0002-5746-0820; Couto-Fernandez, Jose
   Carlos/0000-0001-7091-9774
FU Programa Nacional de Pos-Doutorado (CAPES-Brazil)
FX E.D. is funded by a fellowship from "Programa Nacional de Pos-Doutorado
   (CAPES-Brazil).''
CR Alcantara KC, 2013, J MED VIROL, V85, P396, DOI 10.1002/jmv.23474
   Alencar CS, 2013, JAIDS-J ACQ IMM DEF, V63, P387, DOI 10.1097/QAI.0b013e31828ff979
   Passaes CPB, 2009, INFECT GENET EVOL, V9, P474, DOI 10.1016/j.meegid.2009.01.008
   Brazilian, 2015, AIDS EP B
   Brigido LFM, 2007, AIDS RES HUM RETROV, V23, P1579, DOI 10.1089/aid.2007.0102
   Brindeiro RM, 2003, AIDS, V17, P1063, DOI 10.1097/00002030-200305020-00016
   Carvalho BC, 2011, AIDS RES HUM RETROV, V27, P1081, DOI [10.1089/aid.2010.0334, 10.1089/AID.2010.0334]
   Cunha LKH, 2012, BRAZ J MED BIOL RES, V45, P104, DOI 10.1590/S0100-879X2012007500003
   da Silveira AA, 2012, AIDS RES HUM RETROV, V28, P304, DOI 10.1089/aid.2011.0128
   de Medeiros RM, 2011, J MED VIROL, V83, P1682, DOI 10.1002/jmv.22188
   Soares CMPD, 2014, J INT AIDS SOC, V17, DOI 10.7448/IAS.17.1.19042
   de Oliveira T, 2005, BIOINFORMATICS, V21, P3797, DOI 10.1093/bioinformatics/bti607
   De Sa DJ, 2006, AIDS RES HUM RETROV, V22, P1
   de Sa DJ, 2008, AIDS RES HUM RETROV, V24, P347, DOI 10.1089/aid.2007.0203
   Ferreira AS, 2011, J MED VIROL, V83, P1301, DOI 10.1002/jmv.22128
   Graf T, 2013, VIROLOGY, V435, P170, DOI 10.1016/j.virol.2012.08.048
   Guindon S, 2010, SYST BIOL, V59, P307, DOI 10.1093/sysbio/syq010
   Inocencio LA, 2009, J INT AIDS SOC, V12, DOI 10.1186/1758-2652-12-20
   Lopes CAF, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/738528
   MACEDO O, 2012, REV PAN-AMAZ SAUDE, V3, P11, DOI DOI 10.5123/S2176-62232012000200002
   Machado LFA, 2009, AIDS RES HUM RETROV, V25, P961, DOI 10.1089/aid.2009.0027
   de Souza ACMF, 2008, AIDS RES HUM RETROV, V24, P1521, DOI 10.1089/aid.2008.0089
   Monteiro JP, 2009, J MED VIROL, V81, P391, DOI 10.1002/jmv.21414
   Posada D, 2008, MOL BIOL EVOL, V25, P1253, DOI 10.1093/molbev/msn083
   Ray S., SIMPLOT V2 5 0
   Santos AF, 2007, JAIDS-J ACQ IMM DEF, V45, P328
   Santos AF, 2006, AIDS, V20, P2011
   Santos LA, 2011, J MED VIROL, V83, P2066, DOI 10.1002/jmv.22170
   Silva LD, 2016, AIDS RES HUM RETROV, V32, P373, DOI [10.1089/aid.2015.0280, 10.1089/AID.2015.0280]
   Sprinz E, 2009, AIDS RES HUM RETROV, V25, P861, DOI 10.1089/aid.2009.0012
   Vicente ACP, 2000, J ACQ IMMUN DEF SYND, V23, P327
NR 31
TC 7
Z9 7
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD SEP
PY 2016
VL 32
IS 9
BP 918
EP 922
DI 10.1089/aid.2016.0044
PG 5
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA DV9SY
UT WOS:000383283400015
PM 27091699
DA 2020-12-01
ER

PT J
AU Mirazo, S
   Mir, D
   Bello, G
   Ramos, N
   Musto, H
   Arbiza, J
AF Mirazo, Santiago
   Mir, Daiana
   Bello, Gonzalo
   Ramos, Natalia
   Musto, Hector
   Arbiza, Juan
TI New insights into the hepatitis E virus genotype 3 phylodynamics and
   evolutionary history
SO INFECTION GENETICS AND EVOLUTION
LA English
DT Article
DE Hepatitis E virus genotype 3 phylodynamics; South America; Evolutionary
   history
ID GENETIC-HETEROGENEITY; JAPAN; INFECTION; SEQUENCES; PHYLOGEOGRAPHY;
   EPIDEMIOLOGY; TRANSMISSION; DIVERSITY; SUBTYPES; URUGUAY
AB Hepatitis E virus (HEV) is an emergent hepatotropic virus endemic mainly in Asia and other developing areas. However, in the last decade it has been increasingly reported in high-income countries. Human infecting HEV strains are currently classified into four genotypes (1-4). Genotype 3 (HEV-3) is the prevalent virus genotype and the mostly associated with autochthonous and sporadic cases of HEV in developed areas. The evolutionary history of HEV worldwide remains largely unknown. In this study we reconstructed the spatiotemporal and population dynamics of HEV-3 at global scale, but with particular emphasis in South America, where case reports have increased dramatically in the last years. To achieve this, we applied a Bayesian coalescent-based approach to a comprehensive data set comprising 97 GenBank HEV-3 sequences for which the location and sampling date was documented. Our phylogenetic analyses suggest that the worldwide genetic diversity of HEV-3 can be grouped into two main Clades (I and II) with a T-mrca dated in approximately 320 years ago (95% HPD: 420236 years) and that a unique independent introduction of HEV-3 seems to have occurred in Uruguay, where most of the human HEV cases in South America have been described. The phylodynamic inference indicates that the population size of this virus suffered substantial temporal variations after the second half of the 20th century. In this sense and conversely to what is postulated to date, we suggest that the worldwide effective population size of HEV-3 is not decreasing and that frequently sources of error in its estimates stem from assumptions that the analyzed sequences are derived from a single panmictic population.
   Novel insights on the global population dynamics of HEV are given. Additionally, this work constitutes an attempt to further describe in a Bayesian coalescent framework, the phylodynamics and evolutionary history of HEV-3 in the South American region. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Mirazo, Santiago; Ramos, Natalia; Arbiza, Juan] Univ Republica, Fac Ciencias, Secc Virol, Igua 4225, Montevideo 11400, Uruguay.
   [Mir, Daiana; Bello, Gonzalo] Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, Av Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
   [Musto, Hector] Univ Republica, Fac Ciencias, Lab Org & Evoluc Genoma, Igua 4225, Montevideo 11400, Uruguay.
RP Arbiza, J (corresponding author), Univ Republica, Fac Ciencias, Secc Virol, Igua 4225, Montevideo 11400, Uruguay.
EM jarbiza@fcien.edu.uy
RI Bello, Gonzalo/E-6842-2013; , daiana/J-5515-2019; Bentancor, Gonzalo
   Jose Bello/N-7377-2019
OI , daiana/0000-0002-3172-4867; Bentancor, Gonzalo Jose
   Bello/0000-0002-2724-2793
CR Anisimova M, 2006, SYST BIOL, V55, P539, DOI 10.1080/10635150600755453
   Chikhi L, 2010, GENETICS, V186, P983, DOI 10.1534/genetics.110.118661
   Cruells M R, 1997, Gastroenterol Hepatol, V20, P295
   DAWSON GJ, 1992, LANCET, V340, P426, DOI 10.1016/0140-6736(92)91507-5
   Donati MC, 1997, VIRAL HEPATITIS LIVE, P313
   Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/msi103
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   Drummond AJ, 2012, MOL BIOL EVOL, V29, P1969, DOI 10.1093/molbev/mss075
   Echevarria JM, 2013, J MED VIROL, V85, P1037, DOI 10.1002/jmv.23526
   Faria NR, 2012, J GEN VIROL, V93, P889, DOI 10.1099/vir.0.038638-0
   Garcia G, 2011, GENET MOL BIOL, V34, P329, DOI 10.1590/S1415-47572011005000015
   Hakze-van der Honing RW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022673
   Heller R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062992
   Holla RP, 2013, SEMIN LIVER DIS, V33, P3, DOI 10.1055/s-0033-1338110
   Katoh K, 2002, NUCLEIC ACIDS RES, V30, P3059, DOI 10.1093/nar/gkf436
   Kumar S, 2013, INT J INFECT DIS, V17, pE228, DOI 10.1016/j.ijid.2012.11.026
   Lartillot N, 2006, SYST BIOL, V55, P195, DOI 10.1080/10635150500433722
   Li WZ, 2006, BIOINFORMATICS, V22, P1658, DOI 10.1093/bioinformatics/btl158
   Lu L, 2006, REV MED VIROL, V16, P5, DOI 10.1002/rmv.482
   Meng XJ, 2013, SEMIN LIVER DIS, V33, P41, DOI 10.1055/s-0033-1338113
   Meng XJ, 2011, VIRUS RES, V161, P23, DOI 10.1016/j.virusres.2011.01.016
   Mirazo S, 2013, VIRUS RES, V173, P364, DOI 10.1016/j.virusres.2013.01.005
   Nakano T., 2015, LIVER INT
   Nakano T, 2012, INFECT GENET EVOL, V12, P1524, DOI 10.1016/j.meegid.2012.06.002
   Nakano T, 2012, LIVER INT, V32, P675, DOI 10.1111/j.1478-3231.2011.02728.x
   Nishizawa T, 2003, J GEN VIROL, V84, P1245, DOI 10.1099/vir.0.19052-0
   Oddone J. A., 1966, EMIGRACION EUROPEA R
   Okamoto H, 2001, BIOCHEM BIOPH RES CO, V289, P929, DOI 10.1006/bbrc.2001.6088
   Okamoto H, 2007, VIRUS RES, V127, P216, DOI 10.1016/j.virusres.2007.02.002
   Pischke S, 2014, DTSCH ARZTEBL INT, V111, P577, DOI 10.3238/arztebl.2014.0577
   Purcell R.H., 2001, ILAR J, V42, P1
   Purdy MA, 2012, EMERG INFECT DIS, V18, P339, DOI 10.3201/eid1802.111453
   Purdy MA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014376
   Saito C., 2011, REV UFG, V12, P57
   Sans Mónica, 2009, Runa, V30, P163
   Sato Y, 2011, ARCH VIROL, V156, P1345, DOI 10.1007/s00705-011-0988-x
   Schlauder GG, 2001, J MED VIROL, V65, P282, DOI 10.1002/jmv.2031
   Smith DB, 2016, J GEN VIROL, V97, P537, DOI 10.1099/jgv.0.000393
   Sonoda H, 2004, J CLIN MICROBIOL, V42, P5371, DOI 10.1128/JCM.42.11.5371-5374.2004
   Tanaka Y, 2006, J GEN VIROL, V87, P949, DOI 10.1099/vir.0.81661-0
   Tei S, 2003, LANCET, V362, P371, DOI 10.1016/S0140-6736(03)14025-1
   Teo CG, 2010, CLIN MICROBIOL INFEC, V16, P24, DOI 10.1111/j.1469-0691.2009.03111.x
   Tesse S, 2012, J CLIN VIROL, V54, P197, DOI 10.1016/j.jcv.2012.02.007
   Wichmann Ole, 2008, J Infect Dis, V198, P1732, DOI 10.1086/593211
   Xie WG, 2011, SYST BIOL, V60, P150, DOI 10.1093/sysbio/syq085
   Zehender G, 2014, INFECT GENET EVOL, V25, P138, DOI 10.1016/j.meegid.2014.04.016
NR 47
TC 11
Z9 11
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567-1348
EI 1567-7257
J9 INFECT GENET EVOL
JI Infect. Genet. Evol.
PD SEP
PY 2016
VL 43
BP 267
EP 273
DI 10.1016/j.meegid.2016.06.003
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA DR1YP
UT WOS:000379701100036
PM 27264728
DA 2020-12-01
ER

PT J
AU Born, PS
   Siqueira, MM
   Faria, NR
   Resende, PC
   Motta, FC
   Bello, G
AF Born, Priscila Silva
   Siqueira, Marilda Mendonca
   Faria, Nuno Rodrigues
   Resende, Paola Cristina
   Motta, Fernando Couto
   Bello, Gonzalo
TI Phylodynamics of influenza A(H3N2) in South America, 1999-2012
SO INFECTION GENETICS AND EVOLUTION
LA English
DT Article
DE Influenza A; H3N2; Viral evolution; Phylogeography; South America
ID PHYLOGENETIC INFERENCE; EVOLUTIONARY DYNAMICS; GLOBAL CIRCULATION;
   MAXIMUM-LIKELIHOOD; WEB SERVER; CD-HIT; VIRUS; SEASONALITY; SEQUENCES;
   TROPICS
AB The limited influenza A(H3N2) genetic data available from the Southern Hemisphere (particularly from Africa and Latin America), constrains the accurate reconstruction of viral dissemination dynamics within those regions. Our objective was to describe the spatial dissemination dynamics of influenza A(H3N2) within South America. A total of 469 sequences of the HA1 portion of the hemagglutinin gene (HA) from influenza A(H3N2) viruses sampled in temperate and tropical South American countries between 1999 and 2012 were combined with available contemporary sequences from Australia, Hong Kong, United Kingdom and the United States. Phylogenetic analyses revealed that influenza A(H3N2) sequences from South America were highly intermixed with sequences from other geographical regions, although a clear geographic virus population structure was detected globally. We identified 14 clades mostly (>= 80%) composed of influenza sequences from South American countries. Bayesian phylogeographic analyses of those clades support a significant role of both temperate and tropical regions in the introduction and dissemination of new influenza A(H3N2) strains within South America and identify an intensive bidirectional viral exchange between different geographical areas. These findings indicate that seasonal influenza A(H3N2) epidemics in South America are seeded by both the continuous importation of viral variants from other geographic regions and the short-term persistence of local lineages. This study also supports a complex metapopulation model of influenza A(H3N2) dissemination in South America, with no preferential direction in viral movement between temperate and tropical regions. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Born, Priscila Silva; Siqueira, Marilda Mendonca; Resende, Paola Cristina; Motta, Fernando Couto] Fiocruz MS, Inst Oswaldo Cruz, Resp Viruses & Measles Lab, Av Brasil 4365, BR-21040360 Rio De Janeiro, RJ, Brazil.
   [Faria, Nuno Rodrigues] Univ Oxford, Dept Zool, S Parks Rd, Oxford OX1 3PS, England.
   [Bello, Gonzalo] Fiocruz MS, Inst Oswaldo Cruz, AIDS & Mol Immunol Lab, Av Brasil 4365, BR-21040360 Rio De Janeiro, RJ, Brazil.
RP Born, PS (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Resp Viruses & Measles Lab, Av Brasil 4365, BR-21040360 Rio De Janeiro, RJ, Brazil.
EM psborn@ioc.fiocruz.br
RI Bello, Gonzalo/E-6842-2013; Bentancor, Gonzalo Jose Bello/N-7377-2019;
   Faria, Nuno R/I-2975-2012; Resende, Paola Cristina/P-5002-2015
OI Bentancor, Gonzalo Jose Bello/0000-0002-2724-2793; Faria, Nuno
   R/0000-0001-8839-2798; Resende, Paola Cristina/0000-0002-2884-3662
FU CNPqNational Council for Scientific and Technological Development (CNPq)
   [400150/2011-5]; FAPERJCarlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ) [112.654/2012];
   Decit/SCTIE/MS [TC 1812009]
FX We thank Dr. David Brown for critical review of the manuscript. We also
   gratefully acknowledge the authors, originating and submitting
   laboratories of the sequences from GISAID's EpiFlu Database, which we
   used for this research. All submitters of data may be contacted directly
   via the GISAID website www.gisaid.org. This work was supported by the
   CNPq (grant 400150/2011-5), FAPERJ (grant 112.654/2012) and
   Decit/SCTIE/MS (grant TC 1812009).
CR ACI, 2012, AIRP COUNC INT ACI W
   Alonso WJ, 2007, AM J EPIDEMIOL, V165, P1434, DOI 10.1093/aje/kwm012
   Ann J, 2012, J CLIN VIROL, V53, P88, DOI 10.1016/j.jcv.2011.09.016
   Bahl J, 2011, P NATL ACAD SCI USA, V108, P19359, DOI 10.1073/pnas.1109314108
   Bedford T, 2015, NATURE, V523, P217, DOI 10.1038/nature14460
   Bedford T, 2014, ELIFE, V3, DOI 10.7554/eLife.01914
   Bedford T, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000918
   Bielejec F, 2011, BIOINFORMATICS, V27, P2910, DOI 10.1093/bioinformatics/btr481
   Bogner P, 2006, NATURE, V442, P981, DOI 10.1038/442981a
   Chan J, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1001005
   Chew FT, 1998, EPIDEMIOL INFECT, V121, P121, DOI 10.1017/S0950268898008905
   de Mello WA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005095
   Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/msi103
   Drummond AJ, 2002, GENETICS, V161, P1307
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   Faria NR, 2012, J GEN VIROL, V93, P889, DOI 10.1099/vir.0.038638-0
   Ferreira MAR, 2008, CAN J STAT, V36, P355, DOI 10.1002/cjs.5550360302
   FITCH WM, 1991, P NATL ACAD SCI USA, V88, P4270, DOI 10.1073/pnas.88.10.4270
   Fitch WM, 1997, P NATL ACAD SCI USA, V94, P7712, DOI 10.1073/pnas.94.15.7712
   Galiano M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033166
   Ghedin E, 2005, NATURE, V437, P1162, DOI 10.1038/nature04239
   Grenfell BT, 2004, SCIENCE, V303, P327, DOI 10.1126/science.1090727
   Guindon S, 2005, NUCLEIC ACIDS RES, V33, pW557, DOI 10.1093/nar/gki352
   Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520
   Huang Y, 2010, BIOINFORMATICS, V26, P680, DOI 10.1093/bioinformatics/btq003
   KULLBACK S, 1951, ANN MATH STAT, V22, P79, DOI 10.1214/aoms/1177729694
   Lemey P, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003932
   Lemey P, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000520
   Li WZ, 2006, BIOINFORMATICS, V22, P1658, DOI 10.1093/bioinformatics/btl158
   Lindstrom S, 2012, EMERG INFECT DIS, V18, P834, DOI 10.3201/eid1805.111922
   Lofgren E, 2007, J VIROL, V81, P5429, DOI 10.1128/JVI.01680-06
   Minin VN, 2008, PHILOS T R SOC B, V363, P3985, DOI 10.1098/rstb.2008.0176
   Minin VN, 2008, J MATH BIOL, V56, P391, DOI 10.1007/s00285-007-0120-8
   Moura FEA, 2010, CURR OPIN INFECT DIS, V23, P415, DOI 10.1097/QCO.0b013e32833cc955
   Moura FEA, 2009, AM J TROP MED HYG, V81, P180, DOI 10.4269/ajtmh.2009.81.180
   Nelson MI, 2006, PLOS PATHOG, V2, P1144, DOI 10.1371/journal.ppat.0020125
   Palese P, 2007, FIELDS VIROLOGY, P1647
   Parker J, 2008, INFECT GENET EVOL, V8, P239, DOI 10.1016/j.meegid.2007.08.001
   Pollett S, 2015, EMERG INFECT DIS, V21, P1330, DOI 10.3201/eid2108.150084
   Posada D, 2008, MOL BIOL EVOL, V25, P1253, DOI 10.1093/molbev/msn083
   Rambaut A, 2009, FIGTREE V1 4 TREE FI
   Rambaut A., 2007, TRACER V1 5
   Rambaut A, 2008, NATURE, V453, P615, DOI 10.1038/nature06945
   Ronquist F, 2012, SYST BIOL, V61, P539, DOI 10.1093/sysbio/sys029
   Russell CA, 2008, SCIENCE, V320, P340, DOI 10.1126/science.1154137
   Suchard MA, 2009, BIOINFORMATICS, V25, P1370, DOI 10.1093/bioinformatics/btp244
   Talbi C, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001166
   Nunes MRT, 2012, EMERG INFECT DIS, V18, P1858, DOI 10.3201/eid1811.120217
   Wang TH, 2001, J VIROL, V75, P11686, DOI 10.1128/JVI.75.23.11686-11699.2001
NR 50
TC 1
Z9 1
U1 0
U2 13
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567-1348
EI 1567-7257
J9 INFECT GENET EVOL
JI Infect. Genet. Evol.
PD SEP
PY 2016
VL 43
BP 312
EP 320
DI 10.1016/j.meegid.2016.06.012
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA DR1YP
UT WOS:000379701100042
PM 27275847
DA 2020-12-01
ER

PT J
AU Santos, AF
   Bello, G
   Vidal, LL
   Souza, SL
   Mir, D
   Soares, MA
AF Santos, Andre F.
   Bello, Gonzalo
   Vidal, Luanna L.
   Souza, Suiane L.
   Mir, Daiana
   Soares, Marcelo A.
TI In-depth phylogenetic analysis of hepatitis C virus subtype 1a and
   occurrence of 80K and associated polymorphisms in the NS3 protease
SO SCIENTIFIC REPORTS
LA English
DT Article
ID HCV GENOTYPE 1; RESISTANCE; SIMEPREVIR; MUTATIONS
AB HCV genetic diversity is high and impacts disease progression, treatment and drug resistance. HCV subtype 1a is divided in two clades (I and II), and the 80 K natural polymorphism in the viral NS3 protease is prevalent in clade I. Paradoxically, countries dominated by this clade have contrasting frequencies of 80 K. Over 2,000 HCV 1a NS3 sequences were retrieved from public databases representing Europe, Oceania and the Americas. Sequences were aligned with HCV reference sequences and subjected to phylogenetic analysis to investigate the relative presence of different subtype 1a clades and NS3 protease mutations. HCV-1a sequences split into clades I and II. Clade I was further structured into three subclades, IA to C. Sub-clade IA prevailed in the U.S., while subclade IC was major in Brazil. The NS3 80 K polymorphism was associated with subclade IA, but nearly absent in subclades IB and IC, a pattern similarly seen for the 91S/T compensatory mutation. Three HCV-1a-I sub-clades have been identified, with different frequencies in distinct regions. The 80 K and 91A/S mutations were associated with subclade IA, which provide an explanation for the disparities seen in simeprevir resistance profiles of countries dominated by HCV 1a-I, like the U.S. and Brazil.
C1 [Santos, Andre F.; Vidal, Luanna L.; Souza, Suiane L.; Soares, Marcelo A.] Univ Fed Rio de Janeiro, Dept Genet, Rio De Janeiro, Brazil.
   [Bello, Gonzalo; Mir, Daiana] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, Rio De Janeiro, Brazil.
   [Soares, Marcelo A.] Inst Nacl Canc, Programa Oncovirol, Rio De Janeiro, Brazil.
RP Soares, MA (corresponding author), Univ Fed Rio de Janeiro, Dept Genet, Rio De Janeiro, Brazil.; Soares, MA (corresponding author), Inst Nacl Canc, Programa Oncovirol, Rio De Janeiro, Brazil.
EM masoares@inca.gov.br
RI Bentancor, Gonzalo Jose Bello/N-7377-2019; Santos, Andre FA/I-5734-2016;
   Soares, Marcelo A/G-5662-2010; , daiana/J-5515-2019; Bello,
   Gonzalo/E-6842-2013
OI Bentancor, Gonzalo Jose Bello/0000-0002-2724-2793; ,
   daiana/0000-0002-3172-4867; Lima de Souza, Suiane/0000-0003-1059-3041
FU Brazilian Ministry of Heath; United Nations Organization for Drugs and
   Crime [CA 114/2014]; Rio de Janeiro State Science Foundations - FAPERJ
   [E-26/112.647/2012]; Brazilian Ministry of Education - CAPESCAPES;
   "Agencia Nacional de Investigacion e Innovacion - ANII", Uruguay
FX This work has been funded by the Brazilian Ministry of Heath and the
   United Nations Organization for Drugs and Crime (CA 114/2014 to M.A.S.)
   and by Rio de Janeiro State Science Foundations - FAPERJ
   (E-26/112.647/2012 to M.A.S.). L.L.V. and D.M. are recipients of PhD
   fellowships from the Brazilian Ministry of Education - CAPES. D.M. is
   also funded by a PhD fellowship from "Agencia Nacional de Investigacion
   e Innovacion - ANII", Uruguay.
CR Alexopoulou A, 2015, ANN GASTROENTEROL, V28, P55
   De Luca A, 2015, OPEN FORUM INFECT DI, V2, DOI 10.1093/ofid/ofv043
   De Luca A, 2014, CURR OPIN PHARMACOL, V18, P9, DOI 10.1016/j.coph.2014.07.016
   European Medical Association, 2014, OL SIM
   Forns X, 2014, GASTROENTEROLOGY, V146, P1669, DOI 10.1053/j.gastro.2014.02.051
   Gower E, 2014, J HEPATOL, V61, pS45, DOI 10.1016/j.jhep.2014.07.027
   Guindon S, 2005, NUCLEIC ACIDS RES, V33, pW557, DOI 10.1093/nar/gki352
   Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520
   Lampe E, 2013, ANTIVIR THER, V18, P435, DOI 10.3851/IMP2606
   Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404
   Lenz O, 2010, ANTIMICROB AGENTS CH, V54, P1878, DOI 10.1128/AAC.01452-09
   Lisboa-Neto G, 2015, ANTIVIR THER, V20, P281, DOI 10.3851/IMP2873
   McCloskey RM, 2015, J INFECT DIS, V211, P1288, DOI 10.1093/infdis/jiu613
   Morel V, 2014, J CLIN VIROL, V61, P149, DOI 10.1016/j.jcv.2014.06.023
   Papastergiou V, 2015, WORLD J CLIN CASES, V3, P210, DOI 10.12998/wjcc.v3.i3.210
   Peres-da-Silva A, 2015, J ANTIMICROB CHEMOTH, V70, P726, DOI 10.1093/jac/dku462
   Peres-da-Silva A, 2012, MEM I OSWALDO CRUZ, V107, P254, DOI 10.1590/S0074-02762012000200016
   Pickett BE, 2011, J VIRAL HEPATITIS, V18, P608, DOI 10.1111/j.1365-2893.2010.01342.x
   Posada D, 2008, MOL BIOL EVOL, V25, P1253, DOI 10.1093/molbev/msn083
   Smith DB, 2014, HEPATOLOGY, V59, P318, DOI 10.1002/hep.26744
   United States Food and Drug Administration, 2014, OL SIM TREATM CHRON
   Vicenti I, 2012, J ANTIMICROB CHEMOTH, V67, P984, DOI 10.1093/jac/dkr581
   Vidal LL, 2015, J ANTIMICROB CHEMOTH, V70, P2024, DOI 10.1093/jac/dkv081
   Wyles DL, 2014, J VIRAL HEPATITIS, V21, P229, DOI 10.1111/jvh.12230
NR 24
TC 9
Z9 9
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 17
PY 2016
VL 6
AR 31780
DI 10.1038/srep31780
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DT4XE
UT WOS:000381483900001
PM 27531254
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Mendoza, Y
   Mewa, JC
   Martinez, AA
   Zaldivar, Y
   Sosa, N
   Arteaga, G
   Armien, B
   Bautista, CT
   Garcia-Morales, C
   Tapia-Trejo, D
   Avila-Rios, S
   Reyes-Teran, G
   Bello, G
   Pascale, JM
AF Mendoza, Yaxelis
   Mewa, Juan Castillo
   Martinez, Alexander A.
   Zaldivar, Yamitzel
   Sosa, Nestor
   Arteaga, Griselda
   Armien, Blas
   Bautista, Christian T.
   Garcia-Morales, Claudia
   Tapia-Trejo, Daniela
   Avila-Rios, Santiago
   Reyes-Teran, Gustavo
   Bello, Gonzalo
   Pascale, Juan M.
TI HIV-1 Antiretroviral Drug Resistance Mutations in Treatment Naive and
   Experienced Panamanian Subjects: Impact on National Use of EFV-Based
   Schemes
SO PLOS ONE
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; REVERSE-TRANSCRIPTASE INHIBITORS; SUBTYPE
   B; VIROLOGICAL FAILURE; SURVEILLANCE; EPIDEMIC; INDIVIDUALS; MECHANISM;
   INFECTION; PATTERNS
AB The use of antiretroviral therapy in HIV infected subjects prevents AIDS-related illness and delayed occurrence of death. In Panama, rollout of ART started in 1999 and national coverage has reached 62.8% since then. The objective of this study was to determine the level and patterns of acquired drug resistance mutations of clinical relevance (ADR-CRM) and surveillance drug resistance mutations (SDRMs) from 717 HIV-1 pol gene sequences obtained from 467 ARV drug-experienced and 250 ARV drug-naive HIV-1 subtypes B infected subjects during 2007-2013, respectively. The overall prevalence of SDRM and of ADR-CRM during the study period was 9.2% and 87.6%, respectively. The majority of subjects with ADR-CRM had a pattern of mutations that confer resistance to at least two classes of ARV inhibitors. The non-nucleoside reverse transcriptase inhibitor (NNRTI) mutations K103N and P225H were more prevalent in both ARV drug-naive and ARV drug-experienced subjects. The nucleoside reverse transcriptase inhibitor (NRTI) mutation M184V was more frequent in ARV drug-experienced individuals, while T215YFrev and M41L were more frequent in ARV drug-naive subjects. Prevalence of mutations associated to protease inhibitors (PI) was lower than 4.1% in both types of subjects. Therefore, there is a high level of resistance (>73%) to Efavirenz/Nevirapine, Lamivudine and Azidothymidine in ARV drug-experienced subjects, and an intermediate to high level of resistance (5-10%) to Efavirenz/Nevirapine in ARV drug-naive subjects. During the study period, we observed an increasing trend in the prevalence of ADR-CRM in subjects under first-line schemes, but not significant changes in the prevalence of SDRM. These results reinforce the paramount importance of a national surveillance system of ADR-CRM and SDRM for national management policies of subjects living with HIV.
C1 [Mendoza, Yaxelis; Mewa, Juan Castillo; Martinez, Alexander A.; Zaldivar, Yamitzel; Sosa, Nestor; Armien, Blas; Bautista, Christian T.; Pascale, Juan M.] Gorgas Mem Inst Hlth Studies, Direct Res & Technol Dev, Panama City, Panama.
   [Mendoza, Yaxelis; Martinez, Alexander A.] Acharya Nagarjuna Univ, Dept Biotechnol, Guntur City, India.
   [Mendoza, Yaxelis] Univ Panama, Sch Biol, Dept Genet & Mol Biol, Panama City, Panama.
   [Mendoza, Yaxelis; Martinez, Alexander A.] Inst Sci Res & High Technol Serv Panama, Panama City, Panama.
   [Arteaga, Griselda; Pascale, Juan M.] Univ Panama, Sch Med, Dept Microbiol, Panama City, Panama.
   [Armien, Blas] Univ Interamer Panama, Fac Ciencias Salud, Panama City, Panama.
   [Garcia-Morales, Claudia; Tapia-Trejo, Daniela; Avila-Rios, Santiago; Reyes-Teran, Gustavo] Natl Inst Resp Dis, Ctr Res Infect Dis, Mexico City, DF, Mexico.
   [Bello, Gonzalo] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, BR-21045900 Rio De Janeiro, Brazil.
RP Pascale, JM (corresponding author), Gorgas Mem Inst Hlth Studies, Direct Res & Technol Dev, Panama City, Panama.; Pascale, JM (corresponding author), Univ Panama, Sch Med, Dept Microbiol, Panama City, Panama.
EM jpascale@gorgas.gob.pa
RI Bello, Gonzalo/E-6842-2013; Bentancor, Gonzalo Jose Bello/N-7377-2019;
   Avila-Rios, Santiago/AAB-4383-2020
OI Bentancor, Gonzalo Jose Bello/0000-0002-2724-2793; Bautista,
   Christian/0000-0002-1228-0754
FU Department of Genomics and Proteomics (ICGES, Panama); Ministry of
   Health (Panama); International Atomic Energy Agency (IAEA,
   Austria)International Atomic Energy Agency [PAN-6011]; Secretaria de
   Ciencia y Tecnologia (SENACYT, Panama) [ECS11-012]; SENACYT; Instituto
   para la Formacion de Recursos Humanos (IFARHU)
FX This work was supported by the Department of Genomics and Proteomics
   (ICGES, Panama), the Ministry of Health (Panama), grants PAN-6011 from
   the International Atomic Energy Agency (IAEA, Austria) and grants
   ECS11-012 from Secretaria de Ciencia y Tecnologia (SENACYT, Panama). YM
   was funded by a fellowship from SENACYT and Instituto para la Formacion
   de Recursos Humanos (IFARHU). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Ahumada-Ruiz S, 2008, AIDS RES HUM RETROV, V24, P1461, DOI 10.1089/aid.2008.0153
   Ahumada-Ruiz S, 2009, INFECT GENET EVOL, V9, P933, DOI 10.1016/j.meegid.2009.06.013
   Altfeld M, 2012, HIV 2012 2013
   [Anonymous], 2011, B EST, P113
   [Anonymous], 1999, AIDS TREATMENT NEWS
   [Anonymous], 2011, NORM MAN TER PERS CO
   [Anonymous], 2006, NIV FLUJ REC COST EN
   [Anonymous], 2007, NORM MAN TER PERS CO
   [Anonymous], 2006, NORM AT INT PERS CON
   Avila-Rios S, 2015, AIDS RES HUM RETROV, V31, P401, DOI 10.1089/aid.2014.0057
   Avila-Rios S, 2011, REV PANAM SALUD PUBL, V30, P641, DOI 10.1590/S1020-49892011001200024
   Avila-Rios S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027812
   Bennett DE, 2008, ANTIVIR THER, V13, P25
   Bennett DE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004724
   Cabello M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106045
   Castillo J, 2011, REV PANAM SALUD PUBL, V30, P649, DOI 10.1590/S1020-49892011001200025
   Comision Nacional para la Prevencion y Control del VIH SIDA C, 2009, PLAN ESTR NAC MULT I, P1
   Delatorre E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072448
   DiazGranados CA, 2010, INT J INFECT DIS, V14, pE298, DOI 10.1016/j.ijid.2009.05.006
   ESNOUF R, 1995, NAT STRUCT BIOL, V2, P303, DOI 10.1038/nsb0495-303
   Gao HQ, 2000, J MOL BIOL, V300, P403, DOI 10.1006/jmbi.2000.3823
   Gilbert MTP, 2007, P NATL ACAD SCI USA, V104, P18566, DOI 10.1073/pnas.0705329104
   Hassan AS, 2014, AIDS RES THER, V11, DOI 10.1186/1742-6405-11-9
   Hirsch MS, 1998, JAMA-J AM MED ASSOC, V279, P1984, DOI 10.1001/jama.279.24.1984
   Holguin A, 2013, CLIN MICROBIOL INFEC, V17, P1469
   Inocencio LA, 2009, J INT AIDS SOC, V12, DOI 10.1186/1758-2652-12-20
   Ivetac A, 2009, J MOL BIOL, V388, P644, DOI 10.1016/j.jmb.2009.03.037
   Iyidogan P, 2014, VIRUSES-BASEL, V6, P4095, DOI 10.3390/v6104095
   Johnson Victoria A, 2013, Top Antivir Med, V21, P6
   Kawamoto A, 2008, INT J BIOCHEM CELL B, V40, P2410, DOI 10.1016/j.biocel.2008.04.007
   LARDER BA, 1991, J VIROL, V65, P5232, DOI 10.1128/JVI.65.10.5232-5236.1991
   Lessells RJ, 2012, CURR OPIN VIROL, V2, P636, DOI 10.1016/j.coviro.2012.08.006
   Li Y, 2010, VIROLOGY, V402, P223, DOI 10.1016/j.virol.2010.03.048
   Li Z, 2012, AIDS, V26, P877, DOI 10.1097/QAD.0b013e328351430d
   Li ZF, 2013, ANTIMICROB AGENTS CH, V57, P5500, DOI 10.1128/AAC.01195-13
   Marcelin AG, 2004, J MED VIROL, V72, P162, DOI 10.1002/jmv.10550
   Mendoza Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095360
   Mendoza Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085153
   Meresse M, 2014, HIV MED, V15, P478, DOI 10.1111/hiv.12140
   Montaner JSG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087872
   Murillo W, 2010, J CLIN VIROL, V49, P239, DOI 10.1016/j.jcv.2010.03.013
   Nadai Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004814
   Nunez A, 2014, INFROM NACL PROGR RE
   Posada D, 2008, MOL BIOL EVOL, V25, P1253, DOI 10.1093/molbev/msn083
   Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303
   Ren J, 2000, STRUCTURE, V8, P1089, DOI 10.1016/S0969-2126(00)00513-X
   Santoro MM, 2013, ISRN MICROBIOL, V2013, DOI DOI 10.1155/2013/481314
   Shubber Z, 2013, AIDS, V27, P1403, DOI 10.1097/QAD.0b013e32835f1db0
   Sui HS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091803
   UNAIDS, 2015, FACT SHEET GLOB HIV
   Vingerhoets J, 2009, ANTIVIR THER, V14, pA35
   Wheeler DA, 2001, JAMA-J AM MED ASSOC, V286, P853, DOI 10.1001/jama.286.7.853
   WHO, 2012, WHO GLOB STRAT SURV
NR 53
TC 14
Z9 14
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 27
PY 2016
VL 11
IS 4
AR e0154317
DI 10.1371/journal.pone.0154317
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DK5QZ
UT WOS:000374976200060
PM 27119150
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Faria, NR
   Azevedo, RDD
   Kraemer, MUG
   Souza, R
   Cunha, MS
   Hill, SC
   Theze, J
   Bonsall, MB
   Bowden, TA
   Rissanen, I
   Rocco, IM
   Nogueira, JS
   Maeda, AY
   Vasami, FGD
   Macedo, FLD
   Suzuki, A
   Rodrigues, SG
   Cruz, ACR
   Nunes, BT
   Medeiros, DBD
   Rodrigues, DSG
   Queiroz, ALN
   da Silva, EVP
   Henriques, DF
   da Rosa, EST
   de Oliveira, CS
   Martins, LC
   Vasconcelos, HB
   Casseb, LMN
   Simith, DD
   Messina, JP
   Abade, L
   Loureno, J
   Alcantara, LCJ
   de Lima, MM
   Giovanetti, M
   Hay, SI
   de Oliveira, RS
   Lemos, PD
   de Oliveira, LF
   de Lima, CPS
   da Silva, SP
   de Vasconcelos, JM
   Franco, L
   Cardoso, JF
   Vianez, JLDG
   Mir, D
   Bello, G
   Delatorre, E
   Khan, K
   Creatore, M
   Coelho, GE
   de Oliveira, WK
   Tesh, R
   Pybus, OG
   Nunes, MRT
   Vasconcelos, PFC
AF Faria, Nuno Rodrigues
   da Silva Azevedo, Raimunda do Socorro
   Kraemer, Moritz U. G.
   Souza, Renato
   Cunha, Mariana Sequetin
   Hill, Sarah C.
   Theze, Julien
   Bonsall, Michael B.
   Bowden, Thomas A.
   Rissanen, Ilona
   Rocco, Iray Maria
   Nogueira, Juliana Silva
   Maeda, Adriana Yurika
   da Silva Vasami, Fernanda Giseli
   de Lima Macedo, Fernando Luiz
   Suzuki, Akemi
   Rodrigues, Sueli Guerreiro
   Ribeiro Cruz, Ana Cecilia
   Nunes, Bruno Tardeli
   de Almeida Medeiros, Daniele Barbosa
   Guerreiro Rodrigues, Daniela Sueli
   Nunes Queiroz, Alice Louize
   Pinto da Silva, Eliana Vieira
   Henriques, Daniele Freitas
   Travassos da Rosa, Elisabeth Salbe
   de Oliveira, Consuelo Silva
   Martins, Livia Caricio
   Vasconcelos, Helena Baldez
   Neves Casseb, Livia Medeiros
   Simith, Darlene de Brito
   Messina, Jane P.
   Abade, Leandro
   Loureno, Jose
   Junior Alcantara, Luiz Carlos
   de Lima, Maricelia Maia
   Giovanetti, Marta
   Hay, Simon I.
   de Oliveira, Rodrigo Santos
   Lemos, Poliana da Silva
   de Oliveira, Layanna Freitas
   Silva de Lima, Clayton Pereira
   da Silva, Sandro Patroca
   de Vasconcelos, Janaina Mota
   Franco, Luciano
   Cardoso, Jedson Ferreira
   da Silva Gonalves Vianez-Junior, Joao Lidio
   Mir, Daiana
   Bello, Gonzalo
   Delatorre, Edson
   Khan, Kamran
   Creatore, Marisa
   Coelho, Giovanini Evelim
   de Oliveira, Wanderson Kleber
   Tesh, Robert
   Pybus, Oliver G.
   Nunes, Marcio R. T.
   Vasconcelos, Pedro F. C.
TI Zika virus in the Americas: Early epidemiological and genetic findings
SO SCIENCE
LA English
DT Article
ID FRENCH-POLYNESIA; TRANSMISSION; INFECTION; BRAZIL; OUTBREAK; EVOLUTION;
   ISLAND; TRAVEL; CHILD
AB Brazil has experienced an unprecedented epidemic of Zika virus (ZIKV), with similar to 30,000 cases reported to date. ZIKV was first detected in Brazil in May 2015, and cases of microcephaly potentially associated with ZIKV infection were identified in November 2015. We performed next-generation sequencing to generate seven Brazilian ZIKV genomes sampled from four self-limited cases, one blood donor, one fatal adult case, and one newborn with microcephaly and congenital malformations. Results of phylogenetic and molecular clock analyses show a single introduction of ZIKV into the Americas, which we estimated to have occurred between May and December 2013, more than 12 months before the detection of ZIKV in Brazil. The estimated date of origin coincides with an increase in air passengers to Brazil from ZIKV-endemic areas, as well as with reported outbreaks in the Pacific Islands. ZIKV genomes from Brazil are phylogenetically interspersed with those from other South American and Caribbean countries. Mapping mutations onto existing structural models revealed the context of viral amino acid changes present in the outbreak lineage; however, no shared amino acid changes were found among the three currently available virus genomes from microcephaly cases. Municipality-level incidence data indicate that reports of suspected microcephaly in Brazil best correlate with ZIKV incidence around week 17 of pregnancy, although this correlation does not demonstrate causation. Our genetic description and analysis of ZIKV isolates in Brazil provide a baseline for future studies of the evolution and molecular epidemiology of this emerging virus in the Americas.
C1 [Faria, Nuno Rodrigues; de Oliveira, Rodrigo Santos; Lemos, Poliana da Silva; de Oliveira, Layanna Freitas; Silva de Lima, Clayton Pereira; da Silva, Sandro Patroca; de Vasconcelos, Janaina Mota; Franco, Luciano; Cardoso, Jedson Ferreira; da Silva Gonalves Vianez-Junior, Joao Lidio; Nunes, Marcio R. T.] Minist Hlth, Evandro Chagas Inst, Ctr Technol Innovat, BR-67030000 Ananindeua, PA, Brazil.
   [Faria, Nuno Rodrigues; Kraemer, Moritz U. G.; Hill, Sarah C.; Theze, Julien; Bonsall, Michael B.; Messina, Jane P.; Abade, Leandro; Loureno, Jose; Pybus, Oliver G.] Univ Oxford, Dept Zool, S Parks Rd, Oxford OX1 3PS, England.
   [da Silva Azevedo, Raimunda do Socorro; Rodrigues, Sueli Guerreiro; Ribeiro Cruz, Ana Cecilia; Nunes, Bruno Tardeli; de Almeida Medeiros, Daniele Barbosa; Guerreiro Rodrigues, Daniela Sueli; Nunes Queiroz, Alice Louize; Pinto da Silva, Eliana Vieira; Henriques, Daniele Freitas; Travassos da Rosa, Elisabeth Salbe; de Oliveira, Consuelo Silva; Martins, Livia Caricio; Vasconcelos, Helena Baldez; Neves Casseb, Livia Medeiros; Simith, Darlene de Brito; Vasconcelos, Pedro F. C.] Minist Hlth, Dept Arbovirol & Hemorrhag Fevers, Evandro Chagas Inst, Ananindeua, Para, Brazil.
   [Souza, Renato; Cunha, Mariana Sequetin; Rocco, Iray Maria; Nogueira, Juliana Silva; Maeda, Adriana Yurika; da Silva Vasami, Fernanda Giseli; de Lima Macedo, Fernando Luiz; Suzuki, Akemi] Univ Sao Paulo, Inst Adolfo Lutz, Sao Paulo, Brazil.
   [Bowden, Thomas A.; Rissanen, Ilona; Hay, Simon I.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.
   [Messina, Jane P.; Pybus, Oliver G.] Metabiota, San Francisco, CA 94104 USA.
   [Junior Alcantara, Luiz Carlos; Giovanetti, Marta] Oswaldo Cruz Fdn FIOCRUZ, Salvador, BA, Brazil.
   [de Lima, Maricelia Maia] Univ Estadual Feira de Santana, Ctr Post Grad Collect Hlth, Dept Hlth, Feira De Santana, BA, Brazil.
   [Hay, Simon I.] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98121 USA.
   [Mir, Daiana; Bello, Gonzalo; Delatorre, Edson] Fiocruz MS, Lab AIDS & Imunol Mol, Inst Oswaldo Cruz, BR-21045900 Rio De Janeiro, Brazil.
   [Khan, Kamran] St Michaels Hosp, Li Ka Shing Knowledge Inst, 30 Bond St, Toronto, ON M5B 1W8, Canada.
   [Khan, Kamran] Univ Toronto, Dept Med, Div Infect Dis, Toronto, ON, Canada.
   [Creatore, Marisa] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada.
   [Coelho, Giovanini Evelim; de Oliveira, Wanderson Kleber] Brazilian Minist Hlth, Brasilia, DF, Brazil.
   [Tesh, Robert; Nunes, Marcio R. T.] Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA.
RP Nunes, MRT (corresponding author), Minist Hlth, Evandro Chagas Inst, Ctr Technol Innovat, BR-67030000 Ananindeua, PA, Brazil.; Pybus, OG (corresponding author), Univ Oxford, Dept Zool, S Parks Rd, Oxford OX1 3PS, England.; Vasconcelos, PFC (corresponding author), Minist Hlth, Dept Arbovirol & Hemorrhag Fevers, Evandro Chagas Inst, Ananindeua, Para, Brazil.; Pybus, OG (corresponding author), Metabiota, San Francisco, CA 94104 USA.; Nunes, MRT (corresponding author), Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA.
EM oliver.pybus@zoo.ox.ac.uk; marcionunesbrasil@yahoo.com.br;
   pedrovasconcelos@iec.pa.gov.br
RI Azevedo, Raimunda/T-4656-2019; Giovanetti, Marta/AAK-7408-2020;
   Delatorre, Edson/J-8330-2015; Bentancor, Gonzalo Jose Bello/N-7377-2019;
   Cruz, Ana Cecilia Ribeiro/V-9276-2019; Pybus, Oliver G/B-2640-2012; ,
   daiana/J-5515-2019; Hay, Simon I/F-8967-2015; Bello,
   Gonzalo/E-6842-2013; Faria, Nuno R/I-2975-2012; Vasconcelos,
   Pedro/AAH-3142-2019; Oliveira, Wanderson/AAF-5182-2019; Vianez Junior,
   Joao Lidio/I-9547-2016
OI Azevedo, Raimunda/0000-0003-1932-9976; Delatorre,
   Edson/0000-0002-5746-0820; Bentancor, Gonzalo Jose
   Bello/0000-0002-2724-2793; Pybus, Oliver G/0000-0002-8797-2667; ,
   daiana/0000-0002-3172-4867; Hay, Simon I/0000-0002-0611-7272; Faria,
   Nuno R/0000-0001-8839-2798; Oliveira, Wanderson/0000-0002-9662-1930;
   Pereira de Souza, Renato/0000-0003-1315-7085; Hill,
   Sarah/0000-0002-2995-2596; Bowden, Thomas/0000-0002-8066-8785;
   Giovanetti, Marta/0000-0002-5849-7326; de Lima Macedo, Fernando
   Luiz/0000-0003-2097-0429; Alcantara, Luiz/0000-0002-6769-9931; Vianez
   Junior, Joao Lidio/0000-0001-6226-9441; Lourenco,
   Jose/0000-0002-9318-2581; Theze, Julien/0000-0001-8188-9494; Rissanen,
   Ilona/0000-0003-4937-1825
FU European Research Council (ERC) under the European UnionEuropean
   Research Council (ERC) [614725-PATHPHYLODYN]; ERC under the European
   Union [268904-DIVERSITY]; Metabiota; American people through the United
   States Agency for International Development (USAID) Emerging Pandemic
   Threats Program-PREDICTUnited States Agency for International
   Development (USAID); Wellcome TrustWellcome Trust [095066, 102427,
   090532/Z/09/Z]; Bill and Melinda Gates FoundationBill & Melinda Gates
   Foundation [OPP1119467, OPP1093011, OPP1106023, OPP1132415]; Evandro
   Chagas Institute; Brazilian Ministry of Health; CNPq (Brazilian National
   Council for Scientific and Technological Development)National Council
   for Scientific and Technological Development (CNPq) [302032/2011-8,
   200024/2015-9]; National Institute of Science and Technology for Viral
   Hemorrhagic Fevers; U.S. NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R24 AT 120942]; UK
   Medical Research CouncilMedical Research Council UK (MRC)
   [MR/L009528/1]; CNPq-National Agency for Scientific and Technologic
   Development [573739/2008-0, 301641/2010-2, 457664/2013-4]; Medical
   Research CouncilMedical Research Council UK (MRC) [MR/L009528/1] Funding
   Source: researchfish; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R24AI120942, R24AI120942, R24AI120942,
   R24AI120942, R24AI120942, R24AI120942] Funding Source: NIH RePORTER
FX We thank X. de Lamballerie and J. Lednicky for permission to include
   their unpublished ZIKV genomes in our analysis. We thank the Death
   Verification Service (SVO); Central Laboratories of Public Health
   (LACEN); and health departments of the Ceara State and Maranhao State,
   Brazil, for collaboration. O.G.P. is supported by the European Research
   Council (ERC) under the European Union's Seventh Framework Programme
   (FP7/2007-2013)/ERC grant 614725-PATHPHYLODYN. J.L. is supported by the
   ERC under the European Union's Seventh Framework Programme
   (FP7/2007-2013)/ERC grant 268904-DIVERSITY. O.G.P. received consulting
   fees from Metabiota between 2015 and 2016. This study is made possible
   in part by the generous support of the American people through the
   United States Agency for International Development (USAID) Emerging
   Pandemic Threats Program-PREDICT. The contents are the responsibility of
   the authors and do not necessarily reflect the views of USAID or the
   U.S. government. S.I.H. is funded by a Senior Research Fellowship from
   the Wellcome Trust (095066) and grants from the Bill and Melinda Gates
   Foundation (OPP1119467, OPP1093011, OPP1106023, and OPP1132415).
   M.R.T.N. is funded as an associated researcher in public health by the
   Evandro Chagas Institute, Brazilian Ministry of Health, and as a
   researcher in scientific productivity by CNPq (Brazilian National
   Council for Scientific and Technological Development) grants
   302032/2011-8 and 200024/2015-9 and is also supported in part by the
   National Institute of Science and Technology for Viral Hemorrhagic
   Fevers. R.T. is funded by grant R24 AT 120942 from the U.S. NIH. S.C.H.
   is supported by a Wellcome Trust grant (102427). T.A.B. and I.R. are
   supported by grants from the UK Medical Research Council (MR/L009528/1)
   and the Wellcome Trust (090532/Z/09/Z). P.F.C.V. is supported by
   CNPq-National Agency for Scientific and Technologic Development (grants
   573739/2008-0, 301641/2010-2, and 457664/2013-4). All samples were
   obtained from persons visiting local clinics or hospitalized by the
   Brazilian Ministry of Health personnel as part of dengue, chikungunya,
   and Zika fever surveillance activities. In these cases, patient consent
   was oral and not recorded. The study was authorized by the Coordination
   of the National Program for Dengue, Chikungunya, and Zika Control
   coordinated by Brazil's Ministry of Health. The data are available at
   DRYAD (DOI: 10.5061/dryad.6kn23). The ZIKV genomes reported in this
   study are deposited in GenBank under accession numbers KU321639,
   KU365777 to KU365780, KU729217, and KU729218.
CR Besnard M, 2014, EUROSURVEILLANCE, V19, P13, DOI 10.2807/1560-7917.ES2014.19.13.20751
   Calvet G, 2016, LANCET INFECT DIS, V16, P653, DOI 10.1016/S1473-3099(16)00095-5
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   Cao-Lormeau VM, 2014, EMERG INFECT DIS, V20, P1085, DOI 10.3201/eid2006.140138
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   Dowd KA, 2011, VIROLOGY, V411, P306, DOI 10.1016/j.virol.2010.12.020
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Dupont-Rouzeyrol M, 2015, EMERG INFECT DIS, V21, P381, DOI 10.3201/eid2102.141553
   European Centre for Disease Prevention and Control, 2015, RAP RISK ASS MICR BR
   FAGBAMI A, 1988, AM J TROP MED HYG, V38, P205, DOI 10.4269/ajtmh.1988.38.205
   Faye O, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-311
   Foy BD, 2011, EMERG INFECT DIS, V17, P880, DOI 10.3201/eid1705.101939
   Gerardin P, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002996
   Haddow AD, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001477
   Hennessey M, 2016, MMWR-MORBID MORTAL W, V65, P55, DOI 10.15585/mmwr.mm6503e1
   Ioos S, 2014, MED MALADIES INFECT, V44, P302, DOI 10.1016/j.medmal.2014.04.008
   Lemey P, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003932
   Lindenbach BD, 2003, ADV VIRUS RES, V59, P23, DOI 10.1016/S0065-3527(03)59002-9
   Martines RB, 2016, MMWR-MORBID MORTAL W, V65, P159, DOI 10.15585/mmwr.mm6506e1
   Meyer AG, 2015, VIRUS EVOL, V1, DOI 10.1093/ve/vev006
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Musso D, 2014, EUROSURVEILLANCE, V19, P6, DOI 10.2807/1560-7917.ES2014.19.14.20761
   Musso D, 2015, EMERG INFECT DIS, V21, P1887, DOI 10.3201/eid2110.151125
   Musso D, 2015, EMERG INFECT DIS, V21, P359, DOI 10.3201/eid2102.141363
   Nunes MRT, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002769
   PAHO & WHO, 2015, EP AL NEUR SYNDR CON
   Park DJ, 2015, CELL, V161, P1516, DOI 10.1016/j.cell.2015.06.007
   Pybus OG, 2015, P ROY SOC B-BIOL SCI, V282, DOI 10.1098/rspb.2014.2878
   Pybus OG, 2012, P NATL ACAD SCI USA, V109, P15066, DOI 10.1073/pnas.1206598109
   Pyke Alyssa T, 2014, PLoS Curr, V6, DOI 10.1371/currents.outbreaks.4635a54dbffba2156fb2fd76dc49f65e
   Roehrig JT, 2003, ADV VIRUS RES, V59, P141, DOI 10.1016/S0065-3527(03)59005-4
   Schuler-Faccini L, 2016, MMWR-MORBID MORTAL W, V65, P59, DOI 10.15585/mmwr.mm6503e2
   Secretaria de Vigilancia em Saude, 2016, B EP MON CAS DENG FE, V47
   Silva MMO, 2016, EMERG INFECT DIS, V22, P336, DOI 10.3201/eid2202.150495
   Sorichetta A, 2015, SCI DATA, V2, DOI 10.1038/sdata.2015.45
   Tang HL, 2016, CELL STEM CELL, V18, P587, DOI 10.1016/j.stem.2016.02.016
   Nunes MRT, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0348-x
   Nunes MRT, 2012, EMERG INFECT DIS, V18, P1858, DOI 10.3201/eid1811.120217
   Tognarelli J, 2016, ARCH VIROL, V161, P665, DOI 10.1007/s00705-015-2695-5
   Ventura CV, 2016, ARQ BRAS OFTALMOL, V79, P1, DOI 10.5935/0004-2749.20160002
   Ventura CV, 2016, LANCET, V387, P228, DOI 10.1016/S0140-6736(16)00006-4
   Victora CG, 2016, LANCET, V387, P621, DOI 10.1016/S0140-6736(16)00273-7
   Waehre T, 2014, EMERG INFECT DIS, V20, P1412, DOI 10.3201/eid2008.140302
   World Health Organization, 2016, ASS INF MICR CONT ZI
   Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192
NR 45
TC 555
Z9 567
U1 3
U2 248
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD APR 15
PY 2016
VL 352
IS 6283
BP 345
EP 349
DI 10.1126/science.aaf5036
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DJ1UK
UT WOS:000373990100041
PM 27013429
OA Green Accepted, Bronze
DA 2020-12-01
ER

PT J
AU Silva, LD
   Divino, F
   Rego, MOD
   Lopes, IGL
   Costa, CMN
   Pereira, FCD
   de Filippis, I
   Bello, G
AF Silva, Lindomar dos Anjos
   Divino, Flavia
   da Silva Rego, Marlisson Octavio
   Lima Lopes, Ivina Geselle
   Nobrega Costa, Claudia Maria
   da Silva Pereira, Francis Christian
   de Filippis, Ivano
   Bello, Gonzalo
TI HIV-1 Genetic Diversity and Transmitted Drug Resistance in
   Antiretroviral Treatment-Naive Individuals from Amapa State, Northern
   Brazil
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID MODERATE PREVALENCE; SUBTYPE-C; SURVEILLANCE; NETWORK
AB The pattern of HIV-1 subtype distribution and prevalence of transmitted drug resistance mutations (TDRM) is heterogeneous across different Brazilian regions. Little information is available about the molecular epidemiologic profile in Northern Brazil. HIV-1 protease (PR) and reverse transcriptase (RT) sequences were obtained from 97 drug-naive HIV-1-infected individuals from Amapa, one of the most isolated Northern Brazilian states, for subtype determination and analysis of drug resistance mutations. The most prevalent HIV-1 clade observed in Amapa was subtype B (74%), followed by subtype F1 (14%), BF1 recombinants (8%), subtype C (1%), CRF31_BC (1%), and CRF02_AG (1%). Only one TDRM (K103N) was detected in a single patient from our study population. This study reveals that the HIV-1 epidemic in Amapa is characterized by a high level of genetic diversity comparable to that observed in major Brazilian cities, but a much lower rate of TDRM (1%).
C1 [Silva, Lindomar dos Anjos; da Silva Rego, Marlisson Octavio; Lima Lopes, Ivina Geselle; Nobrega Costa, Claudia Maria; da Silva Pereira, Francis Christian] Lab Cent Saude Publ Amapa LACEN AP, Macapa, Brazil.
   [Divino, Flavia; Bello, Gonzalo] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS, Av Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
   [de Filippis, Ivano; Bello, Gonzalo] Fiocruz MS, Inst Oswaldo Cruz, Imunol Mol, Av Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
   [de Filippis, Ivano] Fiocruz MS, Inst Nacl Controle Qualidade Saude, BR-21045900 Rio De Janeiro, Brazil.
RP Bello, G (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS, Av Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.; Bello, G (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Imunol Mol, Av Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
EM gbello@ioc.fiocruz.br
RI Bentancor, Gonzalo Jose Bello/N-7377-2019; Bello, Gonzalo/E-6842-2013;
   de Filippis, Ivano/X-8759-2019
OI Bentancor, Gonzalo Jose Bello/0000-0002-2724-2793; de Filippis,
   Ivano/0000-0003-0610-8648
FU Instituto Oswaldo Cruz-FIOCRUZ
FX F.D. was funded by a fellowship from Instituto Oswaldo Cruz-FIOCRUZ. The
   authors are grateful to the "Plataforma Genomica-Sequenciamento de DNA,
   RPT01A, PDTIS/FIOCRUZ.''
CR Alencar CS, 2013, JAIDS-J ACQ IMM DEF, V63, P387, DOI 10.1097/QAI.0b013e31828ff979
   Bello G, 2008, AIDS, V22, P1993, DOI 10.1097/QAD.0b013e328315e0aa
   Brazilian Ministry of Health, 2013, AIDS EP B
   Brindeiro RM, 2003, AIDS, V17, P1063, DOI 10.1097/00002030-200305020-00016
   Carvalho BC, 2011, AIDS RES HUM RETROV, V27, P1081, DOI [10.1089/aid.2010.0334, 10.1089/AID.2010.0334]
   de Oliveira T, 2005, BIOINFORMATICS, V21, P3797, DOI 10.1093/bioinformatics/bti607
   Ferreira AS, 2011, J MED VIROL, V83, P1301, DOI 10.1002/jmv.22128
   Gifford RJ, 2009, BIOINFORMATICS, V25, P1197, DOI 10.1093/bioinformatics/btp134
   Guindon S, 2010, SYST BIOL, V59, P307, DOI 10.1093/sysbio/syq010
   Inocencio LA, 2009, J INT AIDS SOC, V12, DOI 10.1186/1758-2652-12-20
   Machado LFA, 2009, AIDS RES HUM RETROV, V25, P961, DOI 10.1089/aid.2009.0027
   Ray S., SIMPLOT V2 5 0
   Moura MES, 2015, J MED VIROL, V87, P798, DOI 10.1002/jmv.24087
   Sprinz E, 2009, AIDS RES HUM RETROV, V25, P861, DOI 10.1089/aid.2009.0012
   Cardoso LPV, 2009, J CLIN VIROL, V46, P134, DOI 10.1016/j.jcv.2009.07.009
NR 15
TC 13
Z9 13
U1 0
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD APR 1
PY 2016
VL 32
IS 4
BP 373
EP 376
DI 10.1089/aid.2015.0280
PG 4
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA DI5JE
UT WOS:000373533900011
PM 26529282
DA 2020-12-01
ER

PT J
AU Delatorre, E
   Velasco-De-Castro, CA
   Pilotto, JH
   Couto-Fernandez, JC
   Bello, G
   Morgado, MG
AF Delatorre, Edson
   Velasco-De-Castro, Carlos A.
   Pilotto, Jose H.
   Couto-Fernandez, Jose Carlos
   Bello, Gonzalo
   Morgado, Mariza G.
TI Short Communication: Reassessing the Origin of the HIV-1 CRF02_AG
   Lineages Circulating in Brazil
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID RIO-DE-JANEIRO; TYPE-1 SUBTYPE C; NON-B SUBTYPES; DRUG-RESISTANCE;
   MAXIMUM-LIKELIHOOD; SAO-PAULO; HETEROSEXUAL TRANSMISSION; MOLECULAR
   EPIDEMIOLOGY; PHYLOGENETIC ANALYSIS; GENETIC DIVERSITY
AB HIV-1 CRF02_AG is responsible for at least 8% of the HIV-1 infections worldwide and is distributed mainly in West Africa. CRF02_AG has recently been reported in countries where it is not native, including Brazil. In a previous study including 10 CRF02_AG Brazilian samples, we found at least four independent introductions and two autochthonous transmission networks of this clade in Brazil. As more CRF02_AG samples have been identified in Brazil, we performed a new phylogeographic analysis using a larger dataset than before. A total of 20 Brazilian (18 from Rio de Janeiro and two from SAo Paulo) and 1,485 African HIV-1 CRF02_AG pol sequences were analyzed using maximum likelihood (ML). The ML tree showed that the Brazilian sequences were distributed in five different lineages. The Bayesian phylogeographic analysis of the Brazilian and their most closely related African sequences (n=212) placed the origin of all Brazilian lineages in West Africa, probably Ghana, Senegal, and Nigeria. Two monophyletic clades were identified, comprising only sequences from Rio de Janeiro, and their date of origin was estimated at around 1985 (95% highest posterior density: 1979-1992). These results support the existence of at least five independent introductions of the CRF02_AG lineage from West Africa into Brazil and further indicate that at least two of these lineages have been locally disseminated in the Rio de Janeiro state over the past 30 years.
C1 [Delatorre, Edson; Pilotto, Jose H.; Couto-Fernandez, Jose Carlos; Bello, Gonzalo; Morgado, Mariza G.] Inst Oswaldo Cruz, FIOCRUZ, Lab AIDS & Imunol Mol, BR-21045900 Rio De Janeiro, RJ, Brazil.
   [Velasco-De-Castro, Carlos A.] Inst Nacl Saude Mulher Crianca & Adolescente Fern, FIOCRUZ, Dept Patol Clin, Virol Lab, Rio De Janeiro, Brazil.
   [Pilotto, Jose H.] Hosp Geral Nova Iguacu, Rio De Janeiro, Brazil.
RP Delatorre, E (corresponding author), Inst Oswaldo Cruz, FIOCRUZ, Lab AIDS & Imunol Mol, Ave Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
EM edsonod@ioc.fiocruz.br
RI Bello, Gonzalo/E-6842-2013; Bentancor, Gonzalo Jose Bello/N-7377-2019;
   Pilotto, Jose Henrique/AAD-9773-2019; Delatorre, Edson/J-8330-2015
OI Bentancor, Gonzalo Jose Bello/0000-0002-2724-2793; Pilotto, Jose
   Henrique/0000-0003-0521-8597; Delatorre, Edson/0000-0002-5746-0820;
   Couto-Fernandez, Jose Carlos/0000-0001-7091-9774
FU Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)Carlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ)
FX E.D. is supported by Fundacao de Amparo a Pesquisa do Estado do Rio de
   Janeiro (FAPERJ). We thank Dr. Vera Bongertz for the English review of
   the manuscript.
CR Abecasis AB, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-7
   Afonso JM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042996
   Alcantara KC, 2013, J MED VIROL, V85, P396, DOI 10.1002/jmv.23474
   Alencar CS, 2013, JAIDS-J ACQ IMM DEF, V63, P387, DOI 10.1097/QAI.0b013e31828ff979
   Almeida SEM, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-306
   Anisimova M, 2006, SYST BIOL, V55, P539, DOI 10.1080/10635150600755453
   [Anonymous], 2015, UNHCR STAT ONL POP D
   Barreto CC, 2006, JAIDS-J ACQ IMM DEF, V41, P338
   Bello G, 2008, AIDS, V22, P1993, DOI 10.1097/QAD.0b013e328315e0aa
   Bello G, 2007, INFECT GENET EVOL, V7, P263, DOI 10.1016/j.meegid.2006.11.002
   Bello G, 2012, INFECT GENET EVOL, V12, P1079, DOI 10.1016/j.meegid.2012.03.014
   Black R, 2004, MIGRATION PROPOOR PO
   Brennan CA, 2010, TRANSFUSION, V50, P2707, DOI 10.1111/j.1537-2995.2010.02767.x
   Brigido LFM, 2011, AIDS RES HUM RETROV, V27, P339, DOI 10.1089/aid.2010.0157
   Caride E, 2000, VIROLOGY, V275, P107, DOI 10.1006/viro.2000.0487
   Carrion G, 2003, AIDS RES HUM RETROV, V19, P329, DOI 10.1089/088922203764969537
   Castro E, 2010, AIDS RES HUM RETROV, V26, P1233, DOI 10.1089/aid.2010.0083
   Chan PA, 2014, INFECT GENET EVOL, V28, P358, DOI 10.1016/j.meegid.2014.03.027
   Veras NMC, 2011, J GEN VIROL, V92, P1698, DOI 10.1099/vir.0.028951-0
   Couto-Fernandez JC, 2006, AIDS RES HUM RETROV, V22, P207, DOI 10.1089/aid.2006.22.207
   Couto-Fernandez JC, 2005, MEM I OSWALDO CRUZ, V100, P73, DOI 10.1590/S0074-02762005000100014
   de Felipe B, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-416
   de Oliveira T, 2005, BIOINFORMATICS, V21, P3797, DOI 10.1093/bioinformatics/bti607
   Delatorre E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074072
   Delatorre EO, 2012, AIDS RES HUM RETROV, V28, P1369, DOI 10.1089/aid.2011.0381
   Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/msi103
   Drummond AJ, 2002, GENETICS, V161, P1307
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   Eyer-Silva WA, 2007, MEM I OSWALDO CRUZ, V102, P809, DOI 10.1590/S0074-02762007005000112
   Faria NR, 2012, INFECT GENET EVOL, V12, P453, DOI 10.1016/j.meegid.2011.04.028
   Ferreira MAR, 2008, CAN J STAT, V36, P355, DOI 10.1002/cjs.5550360302
   Fontella R, 2008, AIDS, V22, P2001, DOI 10.1097/QAD.0b013e3283108f69
   Gaspareto KV, 2012, REV INST MED TROP SP, V54, P207, DOI 10.1590/S0036-46652012000400005
   Gnisci D, 2009, REGIONAL ATLAS W AFR, P67
   Graf T, 2011, J CLIN VIROL, V51, P186, DOI 10.1016/j.jcv.2011.04.011
   Guimaraes ML, 2001, J CLIN VIROL, V21, P143, DOI 10.1016/S1386-6532(01)00158-5
   Guindon S, 2005, NUCLEIC ACIDS RES, V33, pW557, DOI 10.1093/nar/gki352
   Guindon S, 2010, SYST BIOL, V59, P307, DOI 10.1093/sysbio/syq010
   Hemelaar J, 2012, TRENDS MOL MED, V18, P182, DOI 10.1016/j.molmed.2011.12.001
   Hemelaar J, 2011, AIDS, V25, P679, DOI 10.1097/QAD.0b013e328342ff93
   Huang Y, 2010, BIOINFORMATICS, V26, P680, DOI 10.1093/bioinformatics/btq003
   Inocencio LA, 2009, J INT AIDS SOC, V12, DOI 10.1186/1758-2652-12-20
   Lemey P, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000520
   Lole KS, 1999, J VIROL, V73, P152, DOI 10.1128/JVI.73.1.152-160.1999
   Machado LFA, 2009, AIDS RES HUM RETROV, V25, P961, DOI 10.1089/aid.2009.0027
   Ministerio da Saude, 2014, B EP AIDS DST
   Morgado MG, 1998, J ACQ IMMUN DEF SYND, V18, P488, DOI 10.1097/00042560-199808150-00011
   Ferreira JLP, 2013, ADV VIROL, V2013, DOI 10.1155/2013/878237
   Pimentel VF, 2013, AIDS RES HUM RETROV, V29, P1553, DOI [10.1089/aid.2013.0050, 10.1089/AID.2013.0050]
   Pires IL, 2004, J CLIN MICROBIOL, V42, P426, DOI 10.1128/JCM.42.1.426-430.2004
   Posada D, 2008, MOL BIOL EVOL, V25, P1253, DOI 10.1093/molbev/msn083
   Rambaut A, 2014, FIGTREE V1 4
   Rambaut A., 2013, TRACER V1 6
   Salustiano Cavalcanti AM, 2007, MEM I OSWALDO CRUZ, V102, P785
   Sanabani SS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025869
   Schmidt HA, 2002, BIOINFORMATICS, V18, P502, DOI 10.1093/bioinformatics/18.3.502
   Sharp PM, 2011, CSH PERSPECT MED, V1, DOI 10.1101/cshperspect.a006841
   Lopez-Lopes GIS, 2013, INTERVIROLOGY, V56, P217, DOI 10.1159/000348511
   Silveira J, 2012, J CLIN VIROL, V54, P36, DOI 10.1016/j.jcv.2012.01.017
   Strimmer K, 1997, P NATL ACAD SCI USA, V94, P6815, DOI 10.1073/pnas.94.13.6815
   Suchard MA, 2009, BIOINFORMATICS, V25, P1370, DOI 10.1093/bioinformatics/btp244
   Tamura K, 2013, MOL BIOL EVOL, V30, P2725, DOI [10.1093/molbev/mst197, 10.1093/molbev/msr121]
   Teixeira SLM, 2004, J CLIN VIROL, V31, P221, DOI 10.1016/j.jcv.2004.03.016
   Tramuto F, 2013, INFECT GENET EVOL, V16, P290, DOI 10.1016/j.meegid.2013.02.012
   UNAIDS O, 2013, GLOBAL REPORT UNAIDS
   Velasco-de-Castro CA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087622
   Xia XH, 2013, MOL BIOL EVOL, V30, P1720, DOI 10.1093/molbev/mst064
NR 68
TC 5
Z9 5
U1 0
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD DEC 1
PY 2015
VL 31
IS 12
BP 1230
EP 1237
DI 10.1089/aid.2015.0183
PG 8
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA CX3EH
UT WOS:000365578100007
PM 26353079
DA 2020-12-01
ER

PT J
AU Rangel, HR
   Bello, G
   Villalba, JA
   Sulbaran, YF
   Garzaro, D
   Maes, M
   Loureiro, CL
   de Waard, JH
   Pujol, FH
AF Rangel, Hector R.
   Bello, Gonzalo
   Villalba, Julian A.
   Sulbaran, Yoneira F.
   Garzaro, Domingo
   Maes, Mailis
   Loureiro, Carmen L.
   de Waard, Jacobus H.
   Pujol, Flor H.
TI The Evolving HIV-1 Epidemic in Warao Amerindians Is Dominated by an
   Extremely High Frequency of CXCR4-Utilizing Strains
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID SUBTYPE-B; TUBERCULOSIS; VENEZUELA; PHYLOGENETICS; PHYLODYNAMICS;
   TRANSMISSION
AB We previously reported a high prevalence of HIV-1 infection in Warao Amerindians from Venezuela due to the rapid spread of a single B subtype strain. In this study we evaluated the coreceptor use of the HIV-1 strains infecting this Amerindian community. Sequences of the HIV-1 V3 loop from 56 plasma samples were genotyped for coreceptor use. An extremely high frequency of CXCR4 strains was found among HIV-1-infecting Waraos (47/49, 96%), compared to HIV-1 strains infecting the non-Amerindian Venezuelan population (35/79, 44%, p<0.00001). Evolutionary analysis showed that a significant number of infections occurred between 1 and 12 months before collection and that a great proportion (50-70%) of HIV-1 transmissions occurred within the very early phase of infection (12 months). This is consistent with an initial infection dominated by an X4 strain or a very rapid selection of X4 variants after infection. This Amerindian population also exhibits the highest prevalence of tuberculosis in Venezuela, being synergistically bad prognostic factors for the evolution of morbidity and mortality in this vulnerable population.
C1 [Rangel, Hector R.; Sulbaran, Yoneira F.; Garzaro, Domingo; Loureiro, Carmen L.; Pujol, Flor H.] Inst Venezolano Invest Cient, Mol Virol Lab, Caracas 1020A, Venezuela.
   [Bello, Gonzalo] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Inmunol Mol, BR-21045900 Rio De Janeiro, Brazil.
   [Villalba, Julian A.; Maes, Mailis; de Waard, Jacobus H.] Inst Biomed, Lab TB, Caracas, Venezuela.
   [Villalba, Julian A.] Brigham & Womens Hosp, Div Pulm & Crit Care Med, Boston, MA 02115 USA.
   [Villalba, Julian A.] Harvard Univ, Sch Med, Boston, MA USA.
   [Maes, Mailis] Univ Cambridge, Dept Med, Cambridge CB2 2QQ, England.
RP Rangel, HR (corresponding author), Inst Venezolano Invest Cient, Ctr Microbiol & Biol Celular, Mol Virol Lab, Apartado 20632, Caracas 1020A, Venezuela.
EM hrangel2006@gmail.com
RI Bentancor, Gonzalo Jose Bello/N-7377-2019; Bello, Gonzalo/E-6842-2013;
   Villalba, Julian/AAK-4222-2020; Rangel, Hector/E-5575-2010; Pujol, Flor
   H/E-5687-2010
OI Bentancor, Gonzalo Jose Bello/0000-0002-2724-2793; Villalba,
   Julian/0000-0001-9230-8747; Loureiro Marino, Carmen
   Luisa/0000-0003-3665-1107; Rangel, Hector/0000-0001-5937-9690; Pujol,
   Flor H/0000-0001-6086-6883; de Waard, Jacobus H./0000-0003-4118-1015
FU PEI-FONACIT, Venezuela [G-2012000822]
FX This work was supported by grant G-2012000822 by PEI-FONACIT, Venezuela
CR Ball SC, 2003, J VIROL, V77, P1021, DOI 10.1128/JVI.77.2.1021-1038.2003
   Cardozo T, 2007, AIDS RES HUM RETROV, V23, P415, DOI 10.1089/aid.2006.0130
   Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/msi103
   Drummond AJ, 2002, GENETICS, V161, P1307
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   Hoshino Y, 2004, J IMMUNOL, V172, P6251, DOI 10.4049/jimmunol.172.10.6251
   Hughes GJ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000590
   Lewis F, 2008, PLOS MED, V5, P392, DOI 10.1371/journal.pmed.0050050
   Maes M, 2008, TUBERCULOSIS, V88, P490, DOI 10.1016/j.tube.2008.04.003
   Maes M, 2014, J INFECT DEV COUNTR, V8, P176, DOI 10.3855/jidc.3297
   Naif HM, 2013, INFECT DIS REP, V5, P26, DOI 10.4081/idr.2013.s1.e6
   Rambaut A, 2007, TRACER V1 6
   Rambaut A, 2009, FIGTREE V1 4 TREE FI
   Rangel HR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040626
   Rangel HR, 2009, AIDS RES HUM RETROV, V25, P347, DOI 10.1089/aid.2008.0241
   Sarrami-Forooshani R, 2014, RETROVIROLOGY, V11, DOI 10.1186/1742-4690-11-52
   Suchard MA, 2009, BIOINFORMATICS, V25, P1370, DOI 10.1093/bioinformatics/btp244
   UNAIDS Global statistics, 2014, FACT SHEET
   Verhagen LM, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-383
   Villalba JA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0085638
   Villalba JA, 2013, AIDS, V27, P1783, DOI 10.1097/QAD.0b013e3283601bdb
   WILEN CB, 2012, CSH PERSPECT MED, V2, DOI DOI 10.1101/CSHPERSPECT.A006866
   Zavaleta C, 2007, AM J TROP MED HYG, V76, P703, DOI 10.4269/ajtmh.2007.76.703
NR 24
TC 1
Z9 1
U1 0
U2 5
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD DEC 1
PY 2015
VL 31
IS 12
BP 1265
EP 1268
DI 10.1089/aid.2015.0155
PG 4
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA CX3EH
UT WOS:000365578100012
PM 26414846
DA 2020-12-01
ER

PT J
AU Castells, M
   Bello, G
   Ifran, S
   Pereyra, S
   Boschi, S
   Uriarte, R
   Cristina, J
   Colina, R
AF Castells, M.
   Bello, G.
   Ifran, S.
   Pereyra, S.
   Boschi, S.
   Uriarte, R.
   Cristina, J.
   Colina, R.
TI Epidemic history of major genotypes of hepatitis C virus in Uruguay
SO INFECTION GENETICS AND EVOLUTION
LA English
DT Article
DE Hepatitis C; History; Reconstruction; Clades; Evolution; Uruguay
ID GENETIC DIVERSITY; HEPATOCELLULAR-CARCINOMA; MOLECULAR EPIDEMIOLOGY;
   MAXIMUM-LIKELIHOOD; HCV; PHYLOGENIES; ACCURATE; ORIGIN; CLOCK
AB Worldwide, more than 170 million people are chronically infected with the hepatitis C virus (HCV) and every year die more than 350,000 people from HCV-related liver diseases. Recently, HCV was reclassified into,seven major genotypes and 67 subtypes. Some subtypes as 1a, 1b and 3a, have become epidemic as a result of the new parenteral transmission routes and are responsible for most HCV infections in Western countries. HCV 1a subtype have been sub-categorized into two separate sub clades. Recent studies based on the analysis of NS5B genome region, reveal that HCV epidemics in Argentina and Brazil are characterized by multiple introductions events of subtypes 1a, 1b and 3a, followed by subsequent local dispersion. There is no data about HCV genotypes circulating in Uruguay and their evolutionary and demographic history. To this end, a total of 153 HCV NS5B gene sequences were obtained from Uruguayan patients between 2005 and 2011. 86 (56%) sequences grouped with subtype 1a, 40 (26%) with subtype 3a and 27 (18%) with subtype 1b. Furthermore, subtype 1a sequences were distributed among both clades, 1 (n=62, 72%) and 2 (n=24, 28%). Four local HCV clades were found: UY-1a(I), UY-1a(III) and UY-3a; comprising a 39% of all HCV viruses analyzed in this study. HCV epidemic in Uruguay has been driving by multiple introductions of subtypes 1a, 1b and 3a and by local dissemination of a few country-specific strains. The evolutionary and demographic history of the major Uruguayan HCV clade UY-1a(I) was reconstructed under two different molecular clock rate models and displayed an epidemic history characterized by an initial phase of rapid expansion followed by a more recent reduction of growth rate since 2000-2005. This is the first comprehensive study about the molecular epidemiology and epidemic history of HCV in Uruguay. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Castells, M.; Colina, R.] Univ Republ, Lab Virol Mol, Reg Norte, Ctr Univ Reg Noroeste, Salto 50000, Uruguay.
   [Bello, G.] Inst Oswaldo Cruz FIOCRUZ, Lab AIDS & Inmunol Mol, Rio De Janeiro, Brazil.
   [Ifran, S.; Pereyra, S.; Boschi, S.; Uriarte, R.] Asociac Espanola Primera Socorros Mutuos, Mol Biol Lab, Montevideo, Uruguay.
   [Cristina, J.] Univ Republica, Fac Ciencias, Ctr Invest Nucl, Mol Virol Lab, Montevideo, Uruguay.
RP Colina, R (corresponding author), Univ Republ, Lab Virol Mol, Reg Norte, Gral Rivera 1350, Salto 50000, Uruguay.
EM rodneycolina1@gmail.com
RI Bentancor, Gonzalo Jose Bello/N-7377-2019; Bello, Gonzalo/E-6842-2013;
   Pereyra, Silvana/Q-5038-2019; Castells, Matias/J-7079-2016
OI Bentancor, Gonzalo Jose Bello/0000-0002-2724-2793; Pereyra,
   Silvana/0000-0002-8969-4138; Colina, Rodney/0000-0003-3731-5383;
   Castells, Matias/0000-0001-7533-218X
FU Program "Polo de Desarrollo Universitario" (PDU), Universidad de
   Republica (UdelaR), Uruguay; Sistema Nacional de Becas, Agencia Nacional
   de Investigacion e Innovacion (ANII), Uruguay
FX This work was supported by projects from: Program "Polo de Desarrollo
   Universitario" (PDU), Universidad de Republica (UdelaR), Uruguay.
   Project CSIC I + D 2010, Universidad de la Republica (UdelaR). ANII-ALI
   1603, from the Agencia Nacional de Investigacion e Innovacion (ANII),
   Uruguay.; M.C. acknowledges financial support for Master studies from
   the Sistema Nacional de Becas, Agencia Nacional de Investigacion e
   Innovacion (ANII), Uruguay.
CR AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705
   Alter MJ, 2007, WORLD J GASTROENTERO, V13, P2436, DOI 10.3748/wjg.v13.i17.2436
   Anisimova M, 2006, SYST BIOL, V55, P539, DOI 10.1080/10635150600755453
   Baldo V, 2008, CURR PHARM DESIGN, V14, P1646, DOI 10.2174/138161208784746770
   Caiaffa WT, 2011, ADDICTION, V106, P143, DOI 10.1111/j.1360-0443.2010.03118.x
   Cantaloube JF, 2005, J CLIN MICROBIOL, V43, P3624, DOI 10.1128/JCM.43.8.3624-3629.2005
   Culasso ACA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044757
   del Pino N, 2013, WORLD J GASTROENTERO, V19, P5813, DOI 10.3748/wjg.v19.i35.5813
   Departamento de laboratorio de salud publica (DLSP), 2002, B EPIDEMIOLOGICO
   di Filippo D, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-242
   Di Lello FA, 2009, J MED VIROL, V81, P1887, DOI 10.1002/jmv.21607
   Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/msi103
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   Drummond AJ, 2012, MOL BIOL EVOL, V29, P1969, DOI 10.1093/molbev/mss075
   El-Serag HB, 2002, J CLIN GASTROENTEROL, V35, pS72, DOI 10.1097/00004836-200211002-00002
   Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520
   Guindon S, 2010, SYST BIOL, V59, P307, DOI 10.1093/sysbio/syq010
   Heller R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062992
   Ho SYW, 2005, MOL BIOL EVOL, V22, P1355, DOI 10.1093/molbev/msi125
   Jaspe RC, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-214
   Kershenobich D, 2011, LIVER INT, V31, P18, DOI 10.1111/j.1478-3231.2011.02538.x
   Kuiken C, 2005, BIOINFORMATICS, V21, P379, DOI 10.1093/bioinformatics/bth485
   Kuiken C., 2008, NUCL ACIDS RES, V36
   Lampe E, 2013, ANTIVIR THER, V18, P435, DOI 10.3851/IMP2606
   Lampe E, 2010, INFECT GENET EVOL, V10, P886, DOI 10.1016/j.meegid.2010.05.010
   Lavanchy D, 2011, CLIN MICROBIOL INFEC, V17, P107, DOI 10.1111/j.1469-0691.2010.03432.x
   Lole KS, 1999, J VIROL, V73, P152, DOI 10.1128/JVI.73.1.152-160.1999
   Magiorkinis G, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000198
   Mendez-Sanchez N, 2010, ANN HEPATOL, V9, pS27, DOI 10.1016/S1665-2681(19)31719-3
   Osimani M.L., 2005, ADICCIONES, V17, P157
   Peres-da-Silva A, 2012, MEM I OSWALDO CRUZ, V107, P254, DOI 10.1590/S0074-02762012000200016
   Pickett BE, 2011, J VIRAL HEPATITIS, V18, P608, DOI 10.1111/j.1365-2893.2010.01342.x
   Posada D, 2008, MOL BIOL EVOL, V25, P1253, DOI 10.1093/molbev/msn083
   Poynard T, 1997, LANCET, V349, P825, DOI 10.1016/S0140-6736(96)07642-8
   Pybus OG, 2001, SCIENCE, V292, P2323, DOI 10.1126/science.1058321
   Re VE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019471
   Sanyal AJ, 2010, HEPATOLOGY, V51, P727, DOI 10.1002/hep.23583
   Shepard CW, 2005, LANCET INFECT DIS, V5, P558, DOI 10.1016/S1473-3099(05)70216-4
   Simmonds P, 2004, J GEN VIROL, V85, P3173, DOI 10.1099/vir.0.80401-0
   Simmonds P, 2013, CURR TOP MICROBIOL, V369, P1, DOI 10.1007/978-3-642-27340-7_1
   Smith DB, 2014, HEPATOLOGY, V59, P318, DOI 10.1002/hep.26744
   Swindell S R, 1997, Methods Mol Biol, V70, P75, DOI 10.1385/0-89603-358-9:75
   Szabo SM, 2012, ANN HEPATOL, V11, P623, DOI 10.1016/S1665-2681(19)31435-8
   Tamura K, 2013, MOL BIOL EVOL, V30, P2725, DOI [10.1093/molbev/mst197, 10.1093/molbev/msr121]
   Tanaka Y, 2002, P NATL ACAD SCI USA, V99, P15584, DOI 10.1073/pnas.242608099
NR 45
TC 2
Z9 3
U1 0
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567-1348
EI 1567-7257
J9 INFECT GENET EVOL
JI Infect. Genet. Evol.
PD JUN
PY 2015
VL 32
BP 231
EP 238
DI 10.1016/j.meegid.2015.03.021
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA CI8MV
UT WOS:000355027300030
PM 25801607
DA 2020-12-01
ER

PT J
AU de Pina-Araujo, IIM
   Delatorre, E
   Guimaraes, ML
   Morgado, MG
   Bello, G
AF de Pina-Araujo, Isabel Ines M.
   Delatorre, Edson
   Guimaraes, Monick L.
   Morgado, Mariza G.
   Bello, Gonzalo
TI Origin and Population Dynamics of a Novel HIV-1 Subtype G Clade
   Circulating in Cape Verde and Portugal
SO PLOS ONE
LA English
DT Article
ID NORTH-CENTRAL NIGERIA; NAIVE PREGNANT-WOMEN; DRUG-RESISTANCE; HIGH
   PREVALENCE; MOLECULAR EPIDEMIOLOGY; OYO-STATE; TYPE-1; SEQUENCES;
   THERAPY; STRAINS
AB The human immunodeficiency virus type 1 (HIV-1) subtype G is the most prevalent and second most prevalent HIV-1 clade in Cape Verde and Portugal, respectively; but there is no information about the origin and spatiotemporal dispersal pattern of this HIV-1 clade circulating in those countries. To this end, we used Maximum Likelihood and Bayesian coalescent-based methods to analyze a collection of 578 HIV-1 subtype G pol sequences sampled throughout Portugal, Cape Verde and 11 other countries from West and Central Africa over a period of 22 years (1992 to 2013). Our analyses indicate that most subtype G sequences from Cape Verde (80%) and Portugal (95%) branched together in a distinct monophyletic cluster (here called G(CV-PT)). The G(CV-PT) clade probably emerged after a single migration of the virus out of Central Africa into Cape Verde between the late 1970s and the middle 1980s, followed by a rapid dissemination to Portugal a couple of years later. Reconstruction of the demographic history of the G(CV-PT) clade circulating in Cape Verde and Portugal indicates that this viral clade displayed an initial phase of exponential growth during the 1980s and 1990s, followed by a decline in growth rate since the early 2000s. Our data also indicate that during the exponential growth phase the G(CV-PT) clade recombined with a preexisting subtype B viral strain circulating in Portugal, originating the CRF14_BG clade that was later disseminated to Spain and Cape Verde. Historical and recent human population movements between Angola, Cape Verde and Portugal probably played a key role in the origin and dispersal of the G(CV-PT) and CRF14_BG clades.
C1 [de Pina-Araujo, Isabel Ines M.] Univ Cabo Verde, Dept Ciencia & Tecnol, Praia, Santiago, Cape Verde.
   [Delatorre, Edson; Guimaraes, Monick L.; Morgado, Mariza G.; Bello, Gonzalo] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, BR-21045900 Rio De Janeiro, Brazil.
RP Bello, G (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, BR-21045900 Rio De Janeiro, Brazil.
EM gbellobr@gmail.com
RI Bello, Gonzalo/E-6842-2013; Delatorre, Edson/J-8330-2015; Bentancor,
   Gonzalo Jose Bello/N-7377-2019
OI Delatorre, Edson/0000-0002-5746-0820; Bentancor, Gonzalo Jose
   Bello/0000-0002-2724-2793; Monteiro de Pina Araujo, Isabel
   Ines/0000-0001-7766-1059
FU CAPES PEC-PG Program; FAPERJCarlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ); Public Health Service
   grant from CNPq [490468/2008-0, E-26/111.758/2012]
FX This work was sponsored by Public Health Service grants 490468/2008-0
   and E-26/111.758/2012 from the CNPq. IIMPA was supported by a fellowship
   from the CAPES PEC-PG Program. ED is supported by a fellowship from the
   FAPERJ. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Abecasis AB, 2011, AIDS RES HUM RETROV, V27, P803, DOI [10.1089/aid.2010.0312, 10.1089/AID.2010.0312]
   Afonso JM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042996
   Agwale SM, 2002, VACCINE, V20, P2131, DOI 10.1016/S0264-410X(02)00059-2
   Ajoge HO, 2012, AIDS RES HUM RETROV, V28, P115, DOI [10.1089/AID.2011.0115, 10.1089/aid.2011.0115]
   Anisimova M, 2006, SYST BIOL, V55, P539, DOI 10.1080/10635150600755453
   Archer J, 2007, AIDS, V21, P1693, DOI 10.1097/QAD.0b013e32825eabd0
   Bartolo I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113626
   Bartolo I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024130
   Bartolo I, 2009, INFECT GENET EVOL, V9, P672, DOI 10.1016/j.meegid.2008.05.003
   Bello G, 2012, INFECT GENET EVOL, V12, P1079, DOI 10.1016/j.meegid.2012.03.014
   Carling J., 2004, POPUL SPACE PLACE, V10, P113, DOI DOI 10.1002/PSP.322
   Chamberland A, 2012, SEX TRANSM INFECT, V88, P179, DOI 10.1136/sextrans-2011-050209
   Chaplin B, 2011, AIDS RES HUM RETROV, V27, P71, DOI 10.1089/aid.2010.0050
   Charpentier C, 2011, ANTIVIR THER, V16, P429, DOI 10.3851/IMP1754
   Dagnra AY, 2011, J INT AIDS SOC, V14, DOI 10.1186/1758-2652-14-30
   de Oliveira T, 2005, BIOINFORMATICS, V21, P3797, DOI 10.1093/bioinformatics/bti607
   de Pina-Araujo IIM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096201
   Delatorre E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098908
   Delatorre E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072448
   Delgado E, 2002, J ACQ IMMUN DEF SYND, V29, P536, DOI 10.1097/00126334-200204150-00016
   Dias P, 2014, RELATORIO IMIGRACAO
   Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/msi103
   Drummond AJ, 2002, GENETICS, V161, P1307
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   Esteves A, 2003, AIDS RES HUM RETROV, V19, P511, DOI 10.1089/088922203766774568
   Esteves A, 2002, AIDS RES HUM RETROV, V18, P313, DOI 10.1089/088922202753519089
   Faria NR, 2012, J GEN VIROL, V93, P889, DOI 10.1099/vir.0.038638-0
   Ferreira MAR, 2008, CAN J STAT, V36, P355, DOI 10.1002/cjs.5550360302
   Guindon S, 2005, NUCLEIC ACIDS RES, V33, pW557, DOI 10.1093/nar/gki352
   Guindon S, 2010, SYST BIOL, V59, P307, DOI 10.1093/sysbio/syq010
   Hamers RL, 2011, LANCET INFECT DIS, V11, P750, DOI 10.1016/S1473-3099(11)70149-9
   Hemelaar J, 2011, AIDS, V25, P679, DOI 10.1097/QAD.0b013e328342ff93
   Imade GE, 2014, AIDS RES HUM RETROV, V30, P127, DOI [10.1089/aid.2013.0074, 10.1089/AID.2013.0074]
   Lemey P, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000520
   Lole KS, 1999, J VIROL, V73, P152, DOI 10.1128/JVI.73.1.152-160.1999
   Mamadou S, 2002, AIDS RES HUM RETROV, V18, P723, DOI 10.1089/088922202760072357
   Neron B, 2009, BIOINFORMATICS, V25, P3005, DOI 10.1093/bioinformatics/btp493
   Ojesina AI, 2006, AIDS RES HUM RETROV, V22, P770, DOI 10.1089/aid.2006.22.770
   Oliveira V, 2012, AIDS RES HUM RETROV, V28, P510, DOI [10.1089/aid.2011.0174, 10.1089/AID.2011.0174]
   Palma AC, 2007, INFECT GENET EVOL, V7, P391, DOI 10.1016/j.meegid.2007.01.009
   Peeters M, 2000, AIDS RES HUM RETROV, V16, P315, DOI 10.1089/088922200309197
   Posada D, 2008, MOL BIOL EVOL, V25, P1253, DOI 10.1093/molbev/msn083
   Rambaut A, 2007, TRACER V1 6
   Rambaut A, 2009, FIGTREE V1 4 TREE FI
   Sankale JL, 2007, AIDS RES HUM RETROV, V23, P1020, DOI 10.1089/aid.2006.0304
   Schmidt HA, 2002, BIOINFORMATICS, V18, P502, DOI 10.1093/bioinformatics/18.3.502
   Strimmer K, 1997, P NATL ACAD SCI USA, V94, P6815, DOI 10.1073/pnas.94.13.6815
   Suchard MA, 2001, MOL BIOL EVOL, V18, P1001, DOI 10.1093/oxfordjournals.molbev.a003872
   Suchard MA, 2009, BIOINFORMATICS, V25, P1370, DOI 10.1093/bioinformatics/btp244
   Xia X, 2001, J HERED, V92, P371, DOI 10.1093/jhered/92.4.371
   Yaotse DA, 2009, INFECT GENET EVOL, V9, P646, DOI 10.1016/j.meegid.2009.04.002
NR 52
TC 2
Z9 2
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 20
PY 2015
VL 10
IS 5
AR e0127384
DI 10.1371/journal.pone.0127384
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CI7CV
UT WOS:000354921400111
PM 25993094
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Cortes, FH
   Passaes, CPB
   Bello, G
   Teixeira, SLM
   Vorsatz, C
   Babic, D
   Sharkey, M
   Grinsztejn, B
   Veloso, V
   Stevenson, M
   Morgado, MG
AF Cortes, Fernanda H.
   Passaes, Caroline P. B.
   Bello, Gonzalo
   Teixeira, Sylvia L. M.
   Vorsatz, Carla
   Babic, Dunja
   Sharkey, Mark
   Grinsztejn, Beatriz
   Veloso, Valdilea
   Stevenson, Mario
   Morgado, Mariza G.
TI HIV Controllers With Different Viral Load Cutoff Levels Have Distinct
   Virologic and Immunologic Profiles
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE HIV-1; elite controllers; viral load blips; ongoing replication; immune
   activation and microbial translocation; immune response
ID T-CELL RESPONSES; HUMAN-IMMUNODEFICIENCY-VIRUS; ELITE CONTROLLERS;
   IMMUNE ACTIVATION; RNA LEVELS; INFECTION; INDIVIDUALS; VIREMIA;
   REPLICATION; ASSOCIATION
AB Background: The mechanisms behind natural control of HIV replication are still unclear, and several studies pointed that elite controllers (ECs) are a heterogeneous group.
   Methods: We performed analyses of virologic, genetic, and immunologic parameters of HIV-1 controllers groups: (1) ECs (viral load, <80 copies/mL); (2) ebbing elite controllers (EECs; transient viremia/blips); and viremic controllers (VCs; detectable viremia, <5000 copies/mL). Untreated noncontrollers (NCs), patients under suppressive highly active antiretroviral therapy (HAART), and HIV-1-negative individuals were analyzed as controls.
   Results: Total and integrated HIV-1 DNA for EC were significantly lower than for NC and HAART groups. 2-LTR circles were detected in EEC (3/5) and VC (6/7) but not in EC. Although EC and EEC maintain normal T-cell counts over time, some VC displayed negative CD4(+) T-cell slopes. VC and EEC showed a higher percentage of activated CD8(+) T cells and microbial translocation than HIV-1-negative controls. EC displayed a weaker Gag/Nef IFN-gamma T-cell response and a significantly lower proportion of anti-HIV IgG antibodies than EEC, VC, and NC groups.
   Conclusion: Transient/persistent low-level viremia in HIV controllers may have an impact on immunologic and virologic profiles. Classified HIV controller patients taking into account their virologic profile may decrease the heterogeneity of HIV controllers cohorts, which may help to clarify the mechanisms associated to the elite control of HIV.
C1 [Cortes, Fernanda H.; Passaes, Caroline P. B.; Bello, Gonzalo; Teixeira, Sylvia L. M.; Morgado, Mariza G.] Inst Oswaldo Cruz FIOCRUZ, Lab AIDS & Imunol Mol, BR-21040900 Rio De Janeiro, Brazil.
   [Vorsatz, Carla; Grinsztejn, Beatriz; Veloso, Valdilea] Fiocruz MS, Inst Nacl Infectol Evandro Chagas INI, Lab Pesquisa Clin DST AIDS, BR-21045900 Rio De Janeiro, Brazil.
   [Babic, Dunja; Sharkey, Mark; Stevenson, Mario] Univ Miami, Miller Sch Med, Dept Med, Miami, FL 33136 USA.
RP Morgado, MG (corresponding author), Inst Oswaldo Cruz FIOCRUZ, Lab AIDS & Imunol Mol, Av Brasil 4365,Leonidas Deane Bldg,Room 413, BR-21040900 Rio De Janeiro, Brazil.
EM mmorgado@ioc.fiocruz.br
RI Bello, Gonzalo/E-6842-2013; Cortes, Fernanda/AAF-9254-2020; Passaes,
   Caroline/AAH-3392-2020; Bentancor, Gonzalo Jose Bello/N-7377-2019
OI Passaes, Caroline/0000-0002-0813-2521; Bentancor, Gonzalo Jose
   Bello/0000-0002-2724-2793
FU Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico-CNPqNational Council for Scientific and Technological
   Development (CNPq) [480875/2010-33]; Fundacao de Amparo a Pesquisa do
   Estado do Rio de Janeiro-FAPERJCarlos Chagas Filho Foundation for
   Research Support of the State of Rio de Janeiro (FAPERJ)
   [E-26/103.095/2011, E-26/100.299/2011]; National Institutes of Allergy
   and Infectious Diseases of the National Institutes of Health [U19
   AI096109]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [P30AI073961, P30AI073961, U19AI096109, U19AI096109,
   P30AI073961, U19AI096109, P30AI073961, P30AI073961, P30AI073961,
   U19AI096109, P30AI073961, P30AI073961, P30AI073961, P30AI073961,
   UM1AI069476, P30AI073961, P30AI073961, U19AI096109, P30AI073961,
   P30AI073961, U19AI096109, U19AI096109, P30AI073961, U19AI096109,
   P30AI073961, P30AI073961, P30AI073961, U19AI096109, UM1AI069476,
   P30AI073961, P30AI073961, P30AI073961, P30AI073961, U19AI096109,
   P30AI073961, UM1AI069476, P30AI073961, P30AI073961, P30AI073961,
   U19AI096109, P30AI073961, U19AI096109, P30AI073961, P30AI073961,
   P30AI073961, P30AI073961, P30AI073961, P30AI073961, P30AI073961,
   U19AI096109, U19AI096109, U19AI096109, U19AI096109, U19AI096109,
   U19AI096109, U19AI096109, P30AI073961, P30AI073961, U19AI096109,
   P30AI073961, U19AI096109, P30AI073961, U19AI096109, U19AI096109,
   U19AI096109, U19AI096109, P30AI073961, P30AI073961, U19AI096109,
   P30AI073961, P30AI073961, P30AI073961, U19AI096109, U19AI096109,
   U19AI096109, U19AI096109, P30AI073961, U19AI096109, UM1AI069476,
   U19AI096109, P30AI073961, UM1AI069476, U19AI096109, P30AI073961,
   P30AI073961, UM1AI069476, P30AI073961, P30AI073961, U19AI096109,
   P30AI073961, P30AI073961, P30AI073961, P30AI073961, UM1AI069476,
   P30AI073961, U19AI096109, U19AI096109, U19AI096109, P30AI073961,
   P30AI073961, P30AI073961, P30AI073961, U19AI096109, U19AI096109,
   P30AI073961, P30AI073961, U19AI096109, P30AI073961, P30AI073961,
   P30AI073961, U19AI096109, P30AI073961, U19AI096109, P30AI073961,
   U19AI096109, P30AI073961, P30AI073961, P30AI073961, P30AI073961,
   P30AI073961, P30AI073961, U19AI096109, P30AI073961, P30AI073961,
   P30AI073961, U19AI096109, U19AI096109, U19AI096109, P30AI073961,
   U19AI096109, UM1AI069476, U19AI096109, P30AI073961, U19AI096109,
   U19AI096109, U19AI096109, P30AI073961, P30AI073961, U19AI096109,
   P30AI073961, P30AI073961] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Mental Health (NIMH) [R01MH093306, R01MH093306, R01MH093306,
   R01MH093306, R01MH093306] Funding Source: NIH RePORTER
FX Supported by Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico-CNPq (grant number 480875/2010-33); by Fundacao de Amparo a
   Pesquisa do Estado do Rio de Janeiro-FAPERJ (grant numbers
   E-26/103.095/2011 and E-26/100.299/2011 to C.P.B.P.); and by National
   Institutes of Allergy and Infectious Diseases of the National Institutes
   of Health (grant number U19 AI096109 to M. Stevenson).
CR Andrade A, 2008, CLIN INFECT DIS, V46, pE78, DOI 10.1086/529387
   [Anonymous], 1995, EP INF COMP PROGR VE
   Bello G, 2009, J MED VIROL, V81, P1681, DOI 10.1002/jmv.21565
   Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818
   Passaes CPB, 2009, INFECT GENET EVOL, V9, P474, DOI 10.1016/j.meegid.2009.01.008
   Boufassa F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018726
   Calarota SA, 2008, J IMMUNOL, V180, P5907, DOI 10.4049/jimmunol.180.9.5907
   Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0
   Cortes FH, 2013, VACCINE, V31, P1106, DOI 10.1016/j.vaccine.2012.12.023
   Emu B, 2008, J VIROL, V82, P5398, DOI 10.1128/JVI.02176-07
   Fellay J, 2007, SCIENCE, V317, P944, DOI 10.1126/science.1143767
   Graf EH, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001300
   Hatano H, 2009, J VIROL, V83, P329, DOI 10.1128/JVI.01763-08
   Hayashida T, 2008, AIDS RES HUM RETROV, V24, P495, DOI 10.1089/aid.2007.0150
   Hersperger AR, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000917
   Hunt PW, 2008, J INFECT DIS, V197, P126, DOI 10.1086/524143
   Karlsson AC, 2004, AIDS, V18, P981, DOI 10.1097/00002030-200404300-00005
   Klatt NR, 2013, IMMUNOL REV, V254, P326, DOI 10.1111/imr.12065
   Lambotte O, 2005, CLIN INFECT DIS, V41, P1053, DOI 10.1086/433188
   Lambotte O, 2009, AIDS, V23, P897, DOI 10.1097/QAD.0b013e328329f97d
   Lecuroux C, 2014, J VIROL, V88, P176, DOI 10.1128/JVI.02098-13
   Madec Y, 2005, AIDS, V19, P2001, DOI 10.1097/01.aids.0000194134.28135.cd
   Teixeira SLM, 2009, INFECT GENET EVOL, V9, P638, DOI 10.1016/j.meegid.2009.03.007
   Mens H, 2010, J VIROL, V84, P12971, DOI 10.1128/JVI.00387-10
   Migueles SA, 2000, P NATL ACAD SCI USA, V97, P2709, DOI 10.1073/pnas.050567397
   Migueles SA, 2008, IMMUNITY, V29, P1009, DOI 10.1016/j.immuni.2008.10.010
   O'Connell KA, 2010, J VIROL, V84, P7018, DOI 10.1128/JVI.00548-10
   Okulicz JF, 2009, J INFECT DIS, V200, P1714, DOI 10.1086/646609
   Owen RE, 2010, AIDS, V24, P1095, DOI 10.1097/QAD.0b013e3283377a1e
   Parekh BS, 2002, AIDS RES HUM RETROV, V18, P295, DOI 10.1089/088922202753472874
   Pereyra F, 2008, J INFECT DIS, V197, P563, DOI 10.1086/526786
   Pereyra F, 2012, AIDS, V26, P2409, DOI 10.1097/QAD.0b013e32835a9950
   Pereyra FP, 2010, SCIENCE, V330, P1551, DOI 10.1126/science.1195271
   Pereyra F, 2009, J INFECT DIS, V200, P984, DOI 10.1086/605446
   Saez-Cirion A, 2007, P NATL ACAD SCI USA, V104, P6776, DOI 10.1073/pnas.0611244104
   Saez-Cirion A, 2009, J IMMUNOL, V182, P7828, DOI 10.4049/jimmunol.0803928
   Sedaghat AR, 2009, CLIN INFECT DIS, V49, P1763, DOI 10.1086/648081
   Sharkey M, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001303
   Teixeira SLM, 2014, GENES IMMUN, V15, P256, DOI 10.1038/gene.2014.14
   Tomescu C, 2012, AIDS, V26, P1869, DOI 10.1097/QAD.0b013e32835861b0
   Velasco-de-Castro CA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087622
   Wendel SK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055525
   Williams LD, 2011, J VIROL, V85, P2316, DOI 10.1128/JVI.01476-10
NR 43
TC 24
Z9 24
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD APR 1
PY 2015
VL 68
IS 4
BP 377
EP 385
DI 10.1097/QAI.0000000000000500
PG 9
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA CE1RC
UT WOS:000351588600008
PM 25564106
OA Green Published, Green Accepted
DA 2020-12-01
ER

PT J
AU Cabello, M
   Junqueira, DM
   Bello, G
AF Cabello, Marina
   Junqueira, Dennis Maletich
   Bello, Gonzalo
TI Dissemination of nonpandemic Caribbean HIV-1 subtype B clades in Latin
   America
SO AIDS
LA English
DT Article
DE HIV-1; Latin America; nonpandemic; phylogeography; subtype B
ID POPULATION-DYNAMICS; ALGORITHMS
AB Objective: To estimate the prevalence of the HIV-1 subtype B pandemic (B-PANDEMIC) and Caribbean (B-CAR) clades in Latin America and to reconstruct the spatiotemporal dynamics of dissemination of the B-CAR clades in the region.
   Design: A total of 7654 HIV-1 subtype B pol sequences collected from 18 different Latin American countries between 1989 and 2011 were analyzed together with subtype B reference sequences representative of the B-PANDEMIC (US/France = 300) and the B-CAR (Caribbean = 279, Panama = 37) clades.
   Methods: Phylogeographic and evolutionary parameters were estimated from sequence data using maximum likelihood and Bayesian coalescent-based methods.
   Results: Nonpandemic B-CAR strains were probably disseminated from the Caribbean islands of Hispaniola and Trinidad and Tobago into Latin America since the early 1970s. The B-CAR strains reached nearly all countries from Latin America here analyzed and in some of them were spread locally, although their overall prevalence in the region is low. The B-PANDEMIC clade comprises more than 90% of subtype B infections in most countries analyzed, with exception of Suriname, French Guyana and probably Guyana, where both B-PANDEMIC and B-CAR clades seem to circulate at a similar prevalence.
   Conclusion: This study demonstrates that nonpandemic subtype B lineages of Caribbean origin have been disseminated into Latin America shortly after the estimated introduction of subtype B in the continent. Despite their early dissemination, the B-CAR strains account for a minor fraction of current HIV-1 subtype B infections in the region that are mainly driven by spreading of the globally disseminated B-PANDEMIC clade. Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved.
C1 [Cabello, Marina; Bello, Gonzalo] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, BR-21045900 Rio De Janeiro, Brazil.
   [Junqueira, Dennis Maletich] Fundacao Estadual Prod & Pesquisa Saude, Ctr Desenvolvimento Cient & Tecnol, Porto Alegre, RS, Brazil.
   [Junqueira, Dennis Maletich] Uniritter Laureate Int Univ, Dept Ciencias Saude, Porto Alegre, RS, Brazil.
   [Junqueira, Dennis Maletich] Univ Fed Rio Grande do Sul, Programa Posgrad Genet & Biol Mol PPGBM, Porto Alegre, RS, Brazil.
RP Bello, G (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, Ave Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM gbellobr@gmail.com
RI Bello, Gonzalo/E-6842-2013; Bentancor, Gonzalo Jose Bello/N-7377-2019
OI Bentancor, Gonzalo Jose Bello/0000-0002-2724-2793; Junqueira,
   Dennis/0000-0003-1576-484X
FU Public Health Service grants from the FAPERJ [E-26/110.439/2014];
   CNPqNational Council for Scientific and Technological Development (CNPq)
   [472896/2012-1]; Instituto Oswaldo Cruz-FIOCRUZ
FX Source of funding: This work was supported by Public Health Service
   grants E-26/110.439/2014 from the FAPERJ and 472896/2012-1 from the
   CNPq. M.C. was funded by a fellowship from Instituto Oswaldo
   Cruz-FIOCRUZ.
CR Anisimova M, 2006, SYST BIOL, V55, P539, DOI 10.1080/10635150600755453
   Bielejec F, 2011, BIOINFORMATICS, V27, P2910, DOI 10.1093/bioinformatics/btr481
   Borland R, 2004, HIV AIDS MOBILE POPU
   Cabello M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106045
   Chen J.J., 2011, MODEL SIMUL ENG, V2011, P1, DOI DOI 10.1371/J0URNAL.P0NE.0025286
   de Oliveira T, 2005, BIOINFORMATICS, V21, P3797, DOI 10.1093/bioinformatics/bti607
   de Ycaza M M, 1985, Rev Med Panama, V10, P66
   Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/msi103
   Drummond AJ, 2002, GENETICS, V161, P1307
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   Ferreira MAR, 2008, CAN J STAT, V36, P355, DOI 10.1002/cjs.5550360302
   Gilbert MTP, 2007, P NATL ACAD SCI USA, V104, P18566, DOI 10.1073/pnas.0705329104
   Guindon S, 2005, NUCLEIC ACIDS RES, V33, pW557, DOI 10.1093/nar/gki352
   Guindon S, 2010, SYST BIOL, V59, P307, DOI 10.1093/sysbio/syq010
   Hemelaar J, 2011, AIDS, V25, P679, DOI 10.1097/QAD.0b013e328342ff93
   Hue S, 2005, P NATL ACAD SCI USA, V102, P4425, DOI 10.1073/pnas.0407534102
   Junqueira DM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027489
   Lemey P, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000520
   Mendoza Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095360
   Murillo W, 2013, J VIROL, V87, P7463, DOI 10.1128/JVI.01602-12
   Posada D, 2008, MOL BIOL EVOL, V25, P1253, DOI 10.1093/molbev/msn083
   Rambaut A, TRACER V1 6
   Suchard MA, 2009, BIOINFORMATICS, V25, P1370, DOI 10.1093/bioinformatics/btp244
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   UNAIDS, 2011, GLOB HIV AIDS RESP P
   UNAIDS, 2013, REP GLOB AIDS EP
   Zehender G, 2010, JAIDS-J ACQ IMM DEF, V55, P156, DOI 10.1097/QAI.0b013e3181eb3002
NR 28
TC 11
Z9 11
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD FEB 20
PY 2015
VL 29
IS 4
BP 483
EP 492
DI 10.1097/QAD.0000000000000552
PG 10
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA CA6FG
UT WOS:000349004400010
PM 25630042
OA Green Published
DA 2020-12-01
ER

PT J
AU Cabello, M
   Mendoza, Y
   Bello, G
AF Cabello, Marina
   Mendoza, Yaxelis
   Bello, Gonzalo
TI Spatiotemporal Dynamics of Dissemination of Non-Pandemic HIV-1 Subtype B
   Clades in the Caribbean Region
SO PLOS ONE
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIRETROVIRAL DRUG-RESISTANCE; DIAGNOSED
   CUBAN PATIENTS; HIGH GENETIC DIVERSITY; MOLECULAR EPIDEMIOLOGY;
   PUERTO-RICO; EVOLUTIONARY HISTORY; POPULATION-DYNAMICS;
   MAXIMUM-LIKELIHOOD; RECOMBINANT FORMS
AB The Human immunodeficiency virus type-1 (HIV-1) epidemic in the Caribbean region is mostly driven by subtype B; but information about the pattern of viral spread in this geographic region is scarce and different studies point to quite divergent models of viral dissemination. In this study, we reconstructed the spatiotemporal and population dynamics of the HIV-1 subtype B epidemic in the Caribbean. A total of 1,806 HIV-1 subtype B pol sequences collected from 17 different Caribbean islands between 1996 and 2011 were analyzed together with sequences from the United States (n = 525) and France (n = 340) included as control. Maximum Likelihood phylogenetic analyses revealed that HIV-1 subtype B infections in the Caribbean are driven by dissemination of the pandemic clade (B-PANDEMIC) responsible for most subtype B infections across the world, and older non-pandemic lineages (B-CAR) characteristics of the Caribbean region. The non-pandemic B-CAR strains account for >40% of HIV-1 infections in most Caribbean islands; with exception of Cuba and Puerto Rico. Bayesian phylogeographic analyses indicate that B-CAR strains probably arose in the island of Hispaniola (Haiti/Dominican Republic) around the middle 1960s and were later disseminated to Trinidad and Tobago and to Jamaica between the late 1960s and the early 1970s. In the following years, the B-CAR strains were also disseminated from Hispaniola and Trinidad and Tobago to other Lesser Antilles islands at multiple times. The B-CAR clades circulating in Hispaniola, Jamaica and Trinidad and Tobago appear to have experienced an initial phase of exponential growth, with mean estimated growth rates of 0.35-0.45 year(-1), followed by a more recent stabilization since the middle 1990s. These results demonstrate that non-pandemic subtype B lineages have been widely disseminated through the Caribbean since the late 1960s and account for an important fraction of current HIV-1 infections in the region.
C1 [Cabello, Marina; Bello, Gonzalo] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, BR-21045900 Rio De Janeiro, Brazil.
   [Mendoza, Yaxelis] Gorgas Mem Inst Hlth Studies, Dept Genom & Proteom, Panama City, Panama.
   [Mendoza, Yaxelis] Acharya Nagarjuna Univ, Dept Biotechnol, Guntur City, Andhra Pradesh, India.
   [Mendoza, Yaxelis] Univ Panama, Dept Genet & Mol Biol, Panama City, Panama.
   [Mendoza, Yaxelis] INDICASAT AIP, INDICASAT AIP,City Knowledge,Clayton, Panama City, Panama.
RP Bello, G (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, BR-21045900 Rio De Janeiro, Brazil.
EM gbellobr@gmail.com
RI Bello, Gonzalo/E-6842-2013; Bentancor, Gonzalo Jose Bello/N-7377-2019
OI Bentancor, Gonzalo Jose Bello/0000-0002-2724-2793
FU FAPERJCarlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ) [E-26/111.758/2012, 472896/2012-1]; Instituto
   Oswaldo Cruz - FIOCRUZ; CNPqNational Council for Scientific and
   Technological Development (CNPq) [472896/2012-1]
FX This work was supported by Public Health Service grants
   E-26/111.758/2012 from the FAPERJ and 472896/2012-1 from the CNPq. MC
   was funded by a fellowship from Instituto Oswaldo Cruz -FIOCRUZ. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Abecasis AB, 2009, J VIROL, V83, P12917, DOI 10.1128/JVI.01022-09
   Anisimova M, 2006, SYST BIOL, V55, P539, DOI 10.1080/10635150600755453
   Baele G, 2012, MOL BIOL EVOL, V29, P2157, DOI 10.1093/molbev/mss084
   BARTHOLOMEW C, 1987, JAMA-J AM MED ASSOC, V257, P2604, DOI 10.1001/jama.257.19.2604
   BARTHOLOMEW C, 1983, W INDIAN MED J, V32, P177
   Bello G, 2008, AIDS, V22, P1993, DOI 10.1097/QAD.0b013e328315e0aa
   Bello G, 2007, INFECT GENET EVOL, V7, P263, DOI 10.1016/j.meegid.2006.11.002
   Bello G, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-22
   Bielejec F, 2011, BIOINFORMATICS, V27, P2910, DOI 10.1093/bioinformatics/btr481
   Passaes CPB, 2009, INFECT GENET EVOL, V9, P474, DOI 10.1016/j.meegid.2009.01.008
   Chen JHK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025286
   Cleghorn FR, 2000, P NATL ACAD SCI USA, V97, P10532, DOI 10.1073/pnas.97.19.10532
   Cohen J, 2006, SCIENCE, V313, P473, DOI 10.1126/science.313.5786.473
   Veras NMC, 2011, AIDS RES HUM RETROV, V27, P1173, DOI [10.1089/aid.2010.0333, 10.1089/AID.2010.0333]
   Collins-Fairclough AM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019995
   Cuevas MT, 2002, AIDS, V16, P1643, DOI 10.1097/00002030-200208160-00010
   Dalai SC, 2009, AIDS, V23, P2523, DOI 10.1097/QAD.0b013e3283320ef3
   de Arazoza H, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-130
   de Oliveira T, 2005, BIOINFORMATICS, V21, P3797, DOI 10.1093/bioinformatics/bti607
   de Oliveira T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009311
   Delatorre E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074072
   Delatorre E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072448
   Delatorre E, 2013, AIDS, V27, P1313, DOI 10.1097/QAD.0b013e32835f1df4
   Delatorre EO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041904
   Deren S, 2003, AM J PUBLIC HEALTH, V93, P812, DOI 10.2105/AJPH.93.5.812
   Deren S, 2007, J URBAN HEALTH, V84, P243, DOI 10.1007/s11524-006-9151-5
   Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/msi103
   Drummond AJ, 2002, GENETICS, V161, P1307
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   Faria NR, 2012, INFECT GENET EVOL, V12, P453, DOI 10.1016/j.meegid.2011.04.028
   Ferreira MAR, 2008, CAN J STAT, V36, P355, DOI 10.1002/cjs.5550360302
   Figueras MA, 2001, LAT AM STUD ASS LASA
   Figueroa JP, 2008, W INDIAN MED J, V57, P195
   Gilbert MTP, 2007, P NATL ACAD SCI USA, V104, P18566, DOI 10.1073/pnas.0705329104
   Gittens MV, 2003, AIDS RES HUM RETROV, V19, P313, DOI 10.1089/088922203764969519
   Guindon S, 2005, NUCLEIC ACIDS RES, V33, pW557, DOI 10.1093/nar/gki352
   Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520
   Hamilton CLC, 2012, AIDS RES HUM RETROV, V28, P923, DOI [10.1089/aid.2011.0312, 10.1089/AID.2011.0312]
   Heslop OD, 2009, W INDIAN MED J, V58, P195
   Huang Y, 2010, BIOINFORMATICS, V26, P680, DOI 10.1093/bioinformatics/btq003
   Hue S, 2005, P NATL ACAD SCI USA, V102, P4425, DOI 10.1073/pnas.0407534102
   Junqueira DM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027489
   KOENIG RE, 1987, JAMA-J AM MED ASSOC, V257, P631, DOI 10.1001/jama.257.5.631
   Kouri V, 2012, J CLIN VIROL, V55, P348, DOI 10.1016/j.jcv.2012.08.019
   Lemey P, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000520
   Li WZ, 2006, BIOINFORMATICS, V22, P1658, DOI 10.1093/bioinformatics/btl158
   Machado LY, 2013, AIDS RES HUM RETROV, V29, P411, DOI [10.1089/aid.2012.0183, 10.1089/AID.2012.0183]
   Machado LY, 2012, AIDS RES HUM RETROV, V28, P956, DOI [10.1089/aid.2011.0295, 10.1089/AID.2011.0295]
   Mendoza Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095360
   Minin VN, 2008, J MATH BIOL, V56, P391, DOI 10.1007/s00285-007-0120-8
   Murillo W, 2013, J VIROL, V87, P7463, DOI 10.1128/JVI.01602-12
   MURPHY EL, 1988, J ACQ IMMUN DEF SYND, V1, P143
   Nadai Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004814
   Narain J P, 1989, Bull Pan Am Health Organ, V23, P42
   Noel RJ, 2003, CELL MOL BIOL, V49, P1193
   Pagan I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069218
   PAPE JW, 1983, NEW ENGL J MED, V309, P945, DOI 10.1056/NEJM198310203091603
   Paraskevis D, 2007, J INFECT DIS, V196, P1167, DOI 10.1086/521677
   Perez L, 2013, INFECT GENET EVOL, V16, P144, DOI 10.1016/j.meegid.2013.02.002
   Perez L, 2006, AIDS RES HUM RETROV, V22, P724, DOI 10.1089/aid.2006.22.724
   Posada D, 2008, MOL BIOL EVOL, V25, P1253, DOI 10.1093/molbev/msn083
   Rambaut A, 2007, TRACER V1 6
   Rambaut A, 2009, FIGTREE V1 4 TREE FI
   Robbins KE, 2003, J VIROL, V77, P6359, DOI 10.1128/JVI.77.11.6359-6366.2003
   Rojas Patria, 2011, J Int Assoc Physicians AIDS Care (Chic), V10, P306, DOI 10.1177/1545109710397770
   Roye ME, 2011, AIDS RES HUM RETROV, V27, P91, DOI 10.1089/aid.2010.0106
   Salemi M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001390
   Sepulveda-Torres Ldel C, 2012, AIDS RES TREAT, V2012
   Suchard MA, 2009, BIOINFORMATICS, V25, P1370, DOI 10.1093/bioinformatics/btp244
   Talbi C, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001166
   Nunes MRT, 2012, EMERG INFECT DIS, V18, P1858, DOI 10.3201/eid1811.120217
   UNAIDS, 2013, REP GLOB AIDS EP
   Vaughan HE, 2003, AIDS RES HUM RETROV, V19, P929, DOI 10.1089/088922203322493120
   Zehender G, 2010, JAIDS-J ACQ IMM DEF, V55, P156, DOI 10.1097/QAI.0b013e3181eb3002
NR 75
TC 19
Z9 19
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 22
PY 2014
VL 9
IS 8
AR e106045
DI 10.1371/journal.pone.0106045
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AO3LL
UT WOS:000341230600110
PM 25148215
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU de Pina-Araujo, IIM
   Guimaraes, ML
   Bello, G
   Vicente, ACP
   Morgado, MG
AF de Pina-Araujo, Isabel Ines M.
   Guimaraes, Monick L.
   Bello, Gonzalo
   Vicente, Ana Carolina P.
   Morgado, Mariza G.
TI Profile of the HIV Epidemic in Cape Verde: Molecular Epidemiology and
   Drug Resistance Mutations among HIV-1 and HIV-2 Infected Patients from
   Distinct Islands of the Archipelago
SO PLOS ONE
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-2; SUB-SAHARAN AFRICA; GENETIC DIVERSITY;
   ANTIRETROVIRAL THERAPY; NAIVE INDIVIDUALS; GUINEA-BISSAU; DISEASE
   PROGRESSION; SUBTYPE-A; RECOMBINANT; TRANSMISSION
AB HIV-1 and HIV-2 have been detected in Cape Verde since 1987, but little is known regarding the genetic diversity of these viruses in this archipelago, located near the West African coast. In this study, we characterized the molecular epidemiology of HIV-1 and HIV-2 and described the occurrence of drug resistance mutations (DRM) among antiretroviral therapy naive (ARTn) patients and patients under treatment (ARTexp) from different Cape Verde islands. Blood samples, socio-demographic and clinical-laboratory data were obtained from 221 HIV-positive individuals during 2010-2011. Phylogenetic and bootscan analyses of the pol region (1300 bp) were performed for viral subtyping. HIV-1 and HIV-2 DRM were evaluated for ARTn and ARTexp patients using the Stanford HIV Database and HIV-GRADE e.V. Algorithm Homepage, respectively. Among the 221 patients (169 [76.5%] HIV-1, 43 [19.5%] HIV-2 and 9 [4.1%] HIV-1/HIV-2 co-infections), 67% were female. The median ages were 34 (IQR = 1-75) and 47 (IQR = 12-84) for HIV-1 and HIV-2, respectively. HIV-1 infections were due to subtypes G (36.6%), CRF02_AG (30.6%), F1 (9.7%), URFs (10.4%), B (5.2%), CRF05_DF (3.0%), C (2.2%), CRF06_cpx (0.7%), CRF25_cpx (0.7%) and CRF49_cpx (0.7%), whereas all HIV-2 infections belonged to group A. Transmitted DRM (TDRM) was observed in 3.4% (2/58) of ARTn HIV-1-infected patients (1.7% NRTI, 1.7% NNRTI), but not among those with HIV-2. Among ARTexp patients, DRM was observed in 47.8% (33/69) of HIV-1 (37.7% NRTI, 37.7% NNRTI, 7.4% PI, 33.3% for two classes) and 17.6% (3/17) of HIV-2-infections (17.6% NRTI, 11.8% PI, 11.8% both). This study indicates that Cape Verde has a complex and unique HIV-1 molecular epidemiological scenario dominated by HIV-1 subtypes G, CRF02_AG and F1 and HIV-2 subtype A. The occurrence of TDRM and the relatively high level of DRM among treated patients are of concern. Continuous monitoring of patients on ART, including genotyping, are public policies to be implemented.
C1 [de Pina-Araujo, Isabel Ines M.; Guimaraes, Monick L.; Bello, Gonzalo; Morgado, Mariza G.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, Rio De Janeiro, RJ, Brazil.
   [Vicente, Ana Carolina P.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Genet Mol Microorganismos, Rio De Janeiro, RJ, Brazil.
RP de Pina-Araujo, IIM (corresponding author), Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, Rio De Janeiro, RJ, Brazil.
EM iniza.araujo@adm.unicv.edu.cv; mmorgado@ioc.fiocruz.br
RI Bentancor, Gonzalo Jose Bello/N-7377-2019; Bello, Gonzalo/E-6842-2013
OI Bentancor, Gonzalo Jose Bello/0000-0002-2724-2793; Monteiro de Pina
   Araujo, Isabel Ines/0000-0001-7766-1059
FU PROAFRICA/CNPqNational Council for Scientific and Technological
   Development (CNPq) [490468/2008-0]; Oswaldo Cruz Institute/Fiocruz; Cape
   Verde University; Cape Verde Ministry of Health; CAPES PEC-PG
   ProgramCAPES; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [UM1AI106701, UM1AI106701, UM1AI106701,
   UM1AI106701, UM1AI106701, UM1AI106701] Funding Source: NIH RePORTER
FX This work was sponsored by the PROAFRICA/CNPq grant number
   490468/2008-0. Oswaldo Cruz Institute/Fiocruz, Cape Verde University and
   Cape Verde Ministry of Health also supported the conduction of this
   project. IIMPA is supported by a fellowship from the CAPES PEC-PG
   Program. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Abecasis AB, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-7
   ADJORLOLOJOHNSON G, 1994, JAMA-J AM MED ASSOC, V272, P462, DOI 10.1001/jama.272.6.462
   Afonso JM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042996
   Aghokeng AF, 2011, AIDS, V25, P2183, DOI 10.1097/QAD.0b013e32834bbbe9
   Andersson S, 1999, VIROLOGY, V262, P312, DOI 10.1006/viro.1999.9867
   ANDREASSON PA, 1993, AIDS, V7, P989, DOI 10.1097/00002030-199307000-00013
   Ayouba A, 2013, AIDS, V27, P2488, DOI 10.1097/01.aids.0000432443.22684.50
   Ayouba A, 2009, AIDS RES HUM RETROV, V25, P1193, DOI 10.1089/aid.2009.0142
   BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183
   Charpentier C, 2011, ANTIVIR THER, V16, P429, DOI 10.3851/IMP1754
   CLAVEL F, 1986, SCIENCE, V233, P343, DOI 10.1126/science.2425430
   Cohen MS, 2012, CURR OPIN HIV AIDS, V7, P99, DOI 10.1097/COH.0b013e32834f5cf2
   Cuevas MT, 2002, AIDS, V16, P1643, DOI 10.1097/00002030-200208160-00010
   de Oliveira T, 2005, BIOINFORMATICS, V21, P3797, DOI 10.1093/bioinformatics/bti607
   de Silva TI, 2013, AIDS, V27, P125, DOI 10.1097/QAD.0b013e32835ab12c
   Derache A, 2008, J ANTIMICROB CHEMOTH, V62, P456, DOI 10.1093/jac/dkn234
   Direccao Geral de Saude PdLcaSSdE Ministerio da Saude de Cabo Verde, 2007, SIT EP VIH SIDA CAB
   Easterbrook PJ, 2010, J INT AIDS SOC, V13, DOI 10.1186/1758-2652-13-4
   Esbjornsson J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017025
   Esteves A, 2003, AIDS RES HUM RETROV, V19, P511, DOI 10.1089/088922203766774568
   Faria NR, 2012, J GEN VIROL, V93, P889, DOI 10.1099/vir.0.038638-0
   Foley B, 2013, LAUR1326007
   Freimanis GL, 2012, J CLIN VIROL, V53, P350, DOI 10.1016/j.jcv.2011.12.026
   Gifford RJ, 2009, BIOINFORMATICS, V25, P1197, DOI 10.1093/bioinformatics/btp134
   Gottlieb GS, 2009, CLIN INFECT DIS, V48, P476, DOI 10.1086/596504
   Gupta RK, 2012, LANCET, V380, P1250, DOI 10.1016/S0140-6736(12)61038-1
   Hamel DJ, 2007, AIDS RES HUM RETROV, V23, P1189, DOI 10.1089/aid.2007.0037
   Hamers RL, 2012, CLIN INFECT DIS, V54, P1660, DOI 10.1093/cid/cis254
   Hamers RL, 2011, LANCET INFECT DIS, V11, P750, DOI 10.1016/S1473-3099(11)70149-9
   Hemelaar J, 2011, AIDS, V25, P679, DOI 10.1097/QAD.0b013e328342ff93
   Ibe S, 2010, JAIDS-J ACQ IMM DEF, V54, P241, DOI 10.1097/QAI.0b013e3181dc98c1
   Imamichi H, 2009, AIDS RES HUM RETROV, V25, P45, DOI 10.1089/aid.2008.0111
   Instituto Nacional de Estatistica de Cabo Verde MdSdCVeMI, 2008, SEG INQ DEM SAUD REP
   Alcantara LCJ, 2009, NUCLEIC ACIDS RES, V37, pW634, DOI 10.1093/nar/gkp455
   Kaleebu P, 2001, AIDS, V15, P293, DOI 10.1097/00002030-200102160-00001
   Lihana RW, 2012, AIDS REV, V14, P83
   Liu TF, 2006, CLIN INFECT DIS, V42, P1608, DOI 10.1086/503914
   Maueia C, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-408
   Meloni ST, 2004, J VIROL, V78, P12438, DOI 10.1128/JVI.78.22.12438-12445.2004
   Menendez-Arias L, 2014, ANTIVIR RES, V102, P70, DOI 10.1016/j.antiviral.2013.12.001
   Morgado MG, 2002, MEM I OSWALDO CRUZ, V97, P143, DOI 10.1590/S0074-02762002000200001
   Oliveira V, 2012, AIDS RES HUM RETROV, V28, P510, DOI [10.1089/aid.2011.0174, 10.1089/AID.2011.0174]
   Organization WH, 2013, CONS GUID US ANT DRU, P272
   Palm AA, 2013, J INFECT DIS
   Palma AC, 2007, INFECT GENET EVOL, V7, P391, DOI 10.1016/j.meegid.2007.01.009
   Parreira R, 2000, AIDS RES HUM RETROV, V16, P1307, DOI 10.1089/08892220050117069
   Peeters M, 1998, AIDS RES HUM RETROV, V14, P51, DOI 10.1089/aid.1998.14.51
   Poulsen AG, 2000, SCAND J INFECT DIS, V32, P169, DOI 10.1080/003655400750045286
   Price MA, 2011, AIDS RES HUM RETROV, V27, P5, DOI 10.1089/aid.2010.0030
   Ray S, 2003, SIMPLOT V3 5 1
   Rodes B, 2000, J CLIN MICROBIOL, V38, P1370
   Sacktor N, 2009, CLIN INFECT DIS, V49, P780, DOI 10.1086/605284
   Ssemwanga D, 2012, AIDS RES HUM RETROV, V28, P1784, DOI [10.1089/aid.2012.0090, 10.1089/AID.2012.0090]
   Tamura K, 2013, MOL BIOL EVOL, V30, P2725, DOI [10.1093/molbev/mst197, 10.1093/molbev/msr121]
   Tang MW, 2012, DRUGS, V72, pE1, DOI 10.2165/11633630-000000000-00000
   Thiam M, 2013, J CLIN MICROBIOL, V51, P578, DOI 10.1128/JCM.02452-12
   Toure-Kane C, 2000, AIDS RES HUM RETROV, V16, P603, DOI 10.1089/088922200309025
   UNAIDS, 2013, UNAIDS REP MOR THAN
   UNAIDS, 2013, GLOB REP UNAIDS REP
   Vallari A, 2011, J VIROL, V85, P1403, DOI 10.1128/JVI.02005-10
   van der Loeff MFS, 2006, INT J EPIDEMIOL, V35, P1322, DOI 10.1093/ije/dyl037
   Vercauteren J, 2013, J ANTIMICROB CHEMOTH, V68, P911, DOI 10.1093/jac/dks470
   Verde INdEdC, 2010, 4 REC GER POP HAB CE
   Verde MdSdC, 2004, DIR GER SAUD PDLCA
   WILKINS A, 1991, AIDS, V5, P1529, DOI 10.1097/00002030-199112000-00018
   WILKINS A, 1993, AIDS, V7, P1119, DOI 10.1097/00002030-199308000-00015
NR 66
TC 9
Z9 9
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 24
PY 2014
VL 9
IS 4
AR e96201
DI 10.1371/journal.pone.0096201
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AG6CB
UT WOS:000335505000072
PM 24763617
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Mendoza, Y
   Martinez, AA
   Mewa, JC
   Gonzalez, C
   Garcia-Morales, C
   Avila-Rios, S
   Reyes-Teran, G
   Armien, B
   Pascale, JM
   Bello, G
AF Mendoza, Yaxelis
   Martinez, Alexander A.
   Castillo Mewa, Juan
   Gonzalez, Claudia
   Garcia-Morales, Claudia
   Avila-Rios, Santiago
   Reyes-Teran, Gustavo
   Armien, Blas
   Pascale, Juan M.
   Bello, Gonzalo
TI Human Immunodeficiency Virus Type 1 (HIV-1) Subtype B Epidemic in Panama
   Is Mainly Driven by Dissemination of Country-Specific Clades
SO PLOS ONE
LA English
DT Article
ID TRANSMITTED DRUG-RESISTANCE; POPULATION-DYNAMICS; MAXIMUM-LIKELIHOOD;
   CENTRAL-AMERICA; SEQUENCES; PREVALENCE; MUTATIONS; INFERENCE; HIV/AIDS;
   HONDURAS
AB The Human immunodeficiency virus type-1 (HIV-1) subtype B is the most predominant clade in Central America; but information about the evolutionary history of this virus in this geographic region is scarce. In this study, we reconstructed the spatiotemporal and population dynamics of the HIV-1 subtype B epidemic in Panama. A total of 761 HIV-1 subtype B pol sequences obtained in Panama between 2004 and 2013 were combined with subtype B pol sequences from the Americas and Europe. Maximum Likelihood phylogenetic analyses revealed that HIV-1 subtype B infections in Panama derived from the dissemination of multiple founder viruses. Most Panamanian subtype B viruses (94.5%) belong to the pandemic viral strain proposed as originated in the US, whereas others (5.5%) were intermixed among non-pandemic Caribbean strains. The bulk (76.6%) of subtype B sequences from Panama grouped within 12 country-specific clades that were not detected in other Central American countries. Bayesian coalescent-based analyses suggest that most Panamanian clades probably originated between the early 1970s and the early 1980s. The root location of major Panamanian clades was traced to the most densely populated districts of Panama province. Major Panamanian clades appear to have experienced one or two periods of exponential growth of variable duration between the 1970s and the 2000s, with median growth rates from 0.2 to 0.4 year(-1). Thus, the HIV-1 subtype B epidemic in Panama is driven by the expansion of local viral strains that were introduced from the Caribbean and other American countries at an early stage of the AIDS pandemic.
C1 [Mendoza, Yaxelis; Martinez, Alexander A.; Castillo Mewa, Juan; Gonzalez, Claudia; Pascale, Juan M.] Gorgas Mem Inst Hlth Studies, Dept Genom & Prote, Panama City, Panama.
   [Mendoza, Yaxelis; Martinez, Alexander A.] Acharya Nagarjuna Univ, Dept Biotechnol, Guntur City, Andhra Pradesh, India.
   [Mendoza, Yaxelis] Univ Panama, Dept Genet & Mol Biol, Panama City, Panama.
   [Mendoza, Yaxelis; Martinez, Alexander A.] City Knowledge, INDICASAT AIP, Panama City, Panama.
   [Garcia-Morales, Claudia; Avila-Rios, Santiago; Reyes-Teran, Gustavo] Inst Nacl Enfermedades Resp, Ctr Invest Enfermedades Infecciosas, Mexico City, DF, Mexico.
   [Bello, Gonzalo] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, BR-21045900 Rio De Janeiro, Brazil.
   [Armien, Blas] Gorgas Mem Inst Hlth Studies, Dept Emerging & Zoonot Infect Dis, Panama City, Panama.
RP Bello, G (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, BR-21045900 Rio De Janeiro, Brazil.
EM gbellobr@gmail.com
RI Martinez, Alexander/F-9601-2012; Avila-Rios, Santiago/AAB-4383-2020;
   Bello, Gonzalo/E-6842-2013; Bentancor, Gonzalo Jose Bello/N-7377-2019
OI Martinez, Alexander/0000-0002-7816-3040; Bentancor, Gonzalo Jose
   Bello/0000-0002-2724-2793
FU Department of Genomics and Proteomics (ICGES); Ministry of Health
   (Panama); International Atomic Energy Agency (IAEA)International Atomic
   Energy Agency [PAN-6011]; Instituto para la Formacion de Recursos
   Humanos (IFARHU); Secretaria Nacional de Ciencia y Tecnologia (SENACYT)
FX The project was supported in part by the Department of Genomics and
   Proteomics (ICGES) and the Ministry of Health (Panama) and Project
   PAN-6011 from the International Atomic Energy Agency (IAEA). YM was
   funded by a fellowship from Instituto para la Formacion de Recursos
   Humanos (IFARHU) and Secretaria Nacional de Ciencia y Tecnologia
   (SENACYT). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Ahumada-Ruiz S, 2008, AIDS RES HUM RETROV, V24, P1461, DOI 10.1089/aid.2008.0153
   Ahumada-Ruiz S, 2009, INFECT GENET EVOL, V9, P933, DOI 10.1016/j.meegid.2009.06.013
   Anisimova M, 2006, SYST BIOL, V55, P539, DOI 10.1080/10635150600755453
   Avila-Rios S, 2011, REV PANAM SALUD PUBL, V30, P641, DOI 10.1590/S1020-49892011001200024
   Baele G, 2012, MOL BIOL EVOL, V29, P2157, DOI 10.1093/molbev/mss084
   Bielejec F, 2011, BIOINFORMATICS, V27, P2910, DOI 10.1093/bioinformatics/btr481
   Castillo J, 2011, REV PANAM SALUD PUBL, V30, P649, DOI 10.1590/S1020-49892011001200025
   *CDC, 1981, MMWR-MORBID MORTAL W, V30, P250
   *CDC, 1981, MMWR-MORBID MORTAL W, V30, P305
   Chen JHK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025286
   Cleghorn FR, 2000, P NATL ACAD SCI USA, V97, P10532, DOI 10.1073/pnas.97.19.10532
   de Oliveira T, 2005, BIOINFORMATICS, V21, P3797, DOI 10.1093/bioinformatics/bti607
   de Ycaza M M, 1985, Rev Med Panama, V10, P66
   Delatorre E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072448
   Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/msi103
   Drummond AJ, 2002, GENETICS, V161, P1307
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   Gilbert MTP, 2007, P NATL ACAD SCI USA, V104, P18566, DOI 10.1073/pnas.0705329104
   Guindon S, 2005, NUCLEIC ACIDS RES, V33, pW557, DOI 10.1093/nar/gki352
   Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520
   Holguin A, 2013, CLIN MICROBIOL INFEC, V17, P1469
   Holguin A, 2011, PEDIATR INFECT DIS J, V30, pE82, DOI 10.1097/INF.0b013e3182117289
   Hue S, 2005, P NATL ACAD SCI USA, V102, P4425, DOI 10.1073/pnas.0407534102
   Junqueira DM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027489
   Lara C, 1997, J CLIN MICROBIOL, V35, P783, DOI 10.1128/JCM.35.3.783-784.1997
   Lemey P, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000520
   Lloyd B, 2008, AIDS RES HUM RETROV, V24, P529, DOI 10.1089/aid.2007.0172
   Mendoza Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085153
   Murillo W, 2010, HIV MED, V11, P95, DOI 10.1111/j.1468-1293.2009.00747.x
   Murillo W, 2013, J VIROL, V87, P7463, DOI 10.1128/JVI.01602-12
   Murillo W, 2012, J MED VIROL, V84, P1514, DOI 10.1002/jmv.23381
   Murillo W, 2010, J CLIN VIROL, V49, P239, DOI 10.1016/j.jcv.2010.03.013
   Nadai Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004814
   Pagan I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069218
   Posada D, 2008, MOL BIOL EVOL, V25, P1253, DOI 10.1093/molbev/msn083
   Rambaut A, 2007, TRACER V1 4
   Rambaut A, 2009, FIGTREE V1 4 TREE FI
   Renjifo B, 1999, VIRUS RES, V60, P191, DOI 10.1016/S0168-1702(99)00014-3
   Republica de Panama: Ministerio de Salud, 2012, B EST AN 2011
   Robbins KE, 2003, J VIROL, V77, P6359, DOI 10.1128/JVI.77.11.6359-6366.2003
   Salemi M, 2001, FASEB J, V15, P276, DOI 10.1096/fj.00-0449fje
   StatsDirect Ltd, 2013, STATSDIRECT STAT SOF
   Taylor-Castillo L, 2010, REV PANAM SALUD PUBL, V27, P23, DOI 10.1590/S1020-49892010000100004
   Teva I, 2012, REV MED CHILE, V140, P50, DOI /S0034-98872012000100007
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Thomson MM, 2005, AIDS REV, V7, P210
   UNAIDS, 2013, GLOB FACT SHEET
   UNAIDS, 2013, GLOB REP REP GLOB AI
   Zehender G, 2010, JAIDS-J ACQ IMM DEF, V55, P156, DOI 10.1097/QAI.0b013e3181eb3002
NR 50
TC 15
Z9 15
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 18
PY 2014
VL 9
IS 4
AR e95360
DI 10.1371/journal.pone.0095360
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AG2DP
UT WOS:000335226500092
PM 24748274
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Fioretti, JM
   Bello, G
   Rocha, MS
   Victoria, M
   Leite, JPG
   Miagostovich, MP
AF Fioretti, Julia Monassa
   Bello, Gonzalo
   Rocha, Monica Simoes
   Victoria, Matias
   Gagliardi Leite, Jose Paulo
   Miagostovich, Marize Pereira
TI Temporal Dynamics of Norovirus GII.4 Variants in Brazil between 2004 and
   2012
SO PLOS ONE
LA English
DT Article
ID NORWALK-LIKE VIRUSES; RIO-DE-JANEIRO; ACUTE GASTROENTERITIS; MOLECULAR
   EPIDEMIOLOGY; MAXIMUM-LIKELIHOOD; EPOCHAL EVOLUTION; GENETIC DIVERSITY;
   UNITED-STATES; GENOGROUP-I; OUTBREAKS
AB Noroviruses (NoVs) are the major cause of acute gastroenteritis outbreaks, and, despite a wide genetic diversity, genotype II.4 is the most prevalent strain worldwide. Mutations and homologous recombination have been proposed as mechanisms driving the epochal evolution of the GII.4, with the emergence of new variants in 1-3-year intervals causing global epidemics. There are no data reporting the dynamics of GII.4 variants along a specific period in Brazil. Therefore, to improve the understanding of the comportment of these variants in the country, the aim of this study was to evaluate the circulation of NoV GII.4 variants during a 9-year period in 3 out of 5 Brazilian regions. A total of 147 samples were sequenced, and a phylogenetic analysis of subdomain P2 demonstrated the circulation of six GII.4 variants, Asia_2003, Hunter_2004, Den Haag_2006b, Yerseke_2006a, New Orleans_2009, and Sydney_2012, during this period. The most prevalent variant was Den Haag_2006b, circulating in different Brazilian regions from 2006 to 2011. A Bayesian coalescent analysis was used to calculate the mean evolutionary rate of subdomain P2 as 7.3x10(-3) (5.85x10(-3) -8.82x10(-3)) subst./site/year. These analyses also demonstrated that clade Den Haag_2006b experienced a rapid expansion in 2005 and another in 2008 after a period of decay. The evaluation of the temporal dynamics of NoV GII.4 in Brazil revealed a similar pattern, with few exceptions, to the worldwide observation. These data highlight the importance of surveillance for monitoring the emergence of new strains of NoV GII.4 and its impact on cases of acute gastroenteritis.
C1 [Fioretti, Julia Monassa; Rocha, Monica Simoes; Gagliardi Leite, Jose Paulo; Miagostovich, Marize Pereira] Inst Oswaldo Cruz Fiocruz, Lab Virol Comparada & Ambiental, Rio De Janeiro, Brazil.
   [Bello, Gonzalo] Inst Oswaldo Cruz Fiocruz, Lab AIDS & Imunol Mol, Rio De Janeiro, Brazil.
   [Victoria, Matias] Univ La Republ, Lab Virol Mol Reg Norte, Ciudad De Salto, Uruguay.
RP Fioretti, JM (corresponding author), Inst Oswaldo Cruz Fiocruz, Lab Virol Comparada & Ambiental, Rio De Janeiro, Brazil.
EM juliafior@ioc.fiocruz.br
RI Bello, Gonzalo/E-6842-2013; Bentancor, Gonzalo Jose Bello/N-7377-2019;
   Victoria, Matias/ABE-1729-2020; LEITE, JOSE PAULO
   GAGLIARDI/AAY-1230-2020
OI Bentancor, Gonzalo Jose Bello/0000-0002-2724-2793; 
FU Excellence Program of Research (PROEP-CNPq/IOC); General Coordination of
   Laboratories/Secretary of Health Surveillance, Ministry of Health
FX This work was funded by Excellence Program of Research (PROEP-CNPq/IOC)
   and General Coordination of Laboratories/Secretary of Health
   Surveillance, Ministry of Health. MP Miagostovich, JPG Leite and G Bello
   are CNPq fellows. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Anisimova M, 2006, SYST BIOL, V55, P539, DOI 10.1080/10635150600755453
   Aragao GC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056608
   Belliot G, 2010, J CLIN MICROBIOL, V48, P994, DOI 10.1128/JCM.01888-09
   Beuret C, 2002, APPL ENVIRON MICROB, V68, P1925, DOI 10.1128/AEM.68.4.1925-1931.2002
   Fernandez MDB, 2012, SCI TOTAL ENVIRON, V437, P262, DOI 10.1016/j.scitotenv.2012.08.033
   Bok K, 2009, J VIROL, V83, P11890, DOI 10.1128/JVI.00864-09
   Boon D, 2011, J VIROL, V85, P8656, DOI 10.1128/JVI.00472-11
   Borges AMT, 2006, MEM I OSWALDO CRUZ, V101, P721, DOI 10.1590/S0074-02762006000700003
   Bull RA, 2006, J CLIN MICROBIOL, V44, P327, DOI 10.1128/JCM.44.2.327-333.2006
   Bull RA, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000831
   Campos GS, 2008, ARCH VIROL, V153, P1125, DOI 10.1007/s00705-008-0078-x
   Cao S, 2007, J VIROL, V81, P5949, DOI 10.1128/JVI.00219-07
   Centers for Disease Control and Prevention (CDC), 2013, MMWR Morb Mortal Wkly Rep, V62, P41
   Chen R, 2006, P NATL ACAD SCI USA, V103, P8048, DOI 10.1073/pnas.0600421103
   de Rougemont A, 2011, J VIROL, V85, P4057, DOI 10.1128/JVI.02077-10
   Debbink K, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002921
   DINGLE KE, 1995, J GEN VIROL, V76, P2349, DOI 10.1099/0022-1317-76-9-2349
   Donaldson EF, 2008, IMMUNOL REV, V225, P190, DOI 10.1111/j.1600-065X.2008.00680.x
   Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/msi103
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   Eden JS, 2010, J CLIN VIROL, V49, P265, DOI 10.1016/j.jcv.2010.09.001
   Fankhauser RL, 1998, J INFECT DIS, V178, P1571, DOI 10.1086/314525
   Ferreira MSR, 2010, J MED VIROL, V82, P1442, DOI 10.1002/jmv.21831
   Fioretti JM, 2011, MEM I OSWALDO CRUZ, V106, P942, DOI 10.1590/S0074-02762011000800008
   Galeano ME, 2013, J CLIN VIROL, V58, P378, DOI 10.1016/j.jcv.2013.07.008
   Gallimore CI, 2007, ARCH VIROL, V152, P1295, DOI 10.1007/s00705-007-0954-9
   Gallimore CI, 2004, BRAZ J MED BIOL RES, V37, P321, DOI 10.1590/S0100-879X2004000300005
   Glass RI, 2009, NEW ENGL J MED, V361, P1776, DOI 10.1056/NEJMra0804575
   Barreira DMPG, 2010, J CLIN VIROL, V47, P60, DOI 10.1016/j.jcv.2009.11.012
   Guindon S, 2005, NUCLEIC ACIDS RES, V33, pW557, DOI 10.1093/nar/gki352
   Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520
   Hall AJ, 2013, EMERG INFECT DIS, V19, P1305, DOI 10.3201/eid1908.130482
   Koelle K, 2006, SCIENCE, V314, P1898, DOI 10.1126/science.1132745
   Kroneman A, 2013, ARCH VIROL, V158, P2059, DOI 10.1007/s00705-013-1708-5
   Larsson MM, 2006, J INFECT DIS, V194, P1422, DOI 10.1086/508430
   Leshem E, 2013, EMERG INFECT DIS, V19, P1231, DOI 10.3201/eid1908.130458
   Lindesmith LC, 2008, PLOS MED, V5, P269, DOI 10.1371/journal.pmed.0050031
   Lopman B, 2004, LANCET, V363, P682, DOI 10.1016/S0140-6736(04)15641-9
   MacLean A, 2013, EURO SURVEILL, V18
   Meijer A, 2012, EUROSURVEILLANCE, V17, P2
   Morillo SG, 2011, REV INST MED TROP SP, V53, P119, DOI 10.1590/S0036-46652011000200011
   Motomura K, 2008, J VIROL, V82, P11247, DOI 10.1128/JVI.00897-08
   Motomura K, 2010, J VIROL, V84, P8085, DOI 10.1128/JVI.02125-09
   Noel JS, 1999, J INFECT DIS, V179, P1334, DOI 10.1086/314783
   Okada M, 2006, ARCH VIROL, V151, P1635, DOI 10.1007/s00705-006-0739-6
   Parker TD, 2005, J VIROL, V79, P7402, DOI 10.1128/JVI.79.12.7402-7409.2005
   Patel MM, 2009, J CLIN VIROL, V44, P1, DOI 10.1016/j.jcv.2008.10.009
   Posada D, 2008, MOL BIOL EVOL, V25, P1253, DOI 10.1093/molbev/msn083
   Prasad BVV, 1999, SCIENCE, V286, P287, DOI 10.1126/science.286.5438.287
   Rambaut A., 2009, FIGTREE V1 3 1 TREE
   Ribeiro LR, 2008, MEM I OSWALDO CRUZ, V103, P201, DOI 10.1590/S0074-02762008000200013
   Ferreira MSR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033754
   Seto Y, 2005, MICROBIOL IMMUNOL, V49, P275, DOI 10.1111/j.1348-0421.2005.tb03718.x
   Siebenga J, 2008, EUROSURVEILLANCE, P13
   Siebenga JJ, 2007, J VIROL, V81, P9932, DOI 10.1128/JVI.00674-07
   Siebenga JJ, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000884
   Siebenga JJ, 2009, J INFECT DIS, V200, P802, DOI 10.1086/605127
   Silva LD, 2013, MEM I O CRUZ, V11
   Swanstrom J, 2012, PLOS PATHOG, V8
   Tamura K, 2013, MOL BIOL EVOL, V30, P2725, DOI [10.1093/molbev/mst197, 10.1093/molbev/msr121]
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Tran TNH, 2013, J CLIN VIROL, V56, P185, DOI 10.1016/j.jcv.2012.11.011
   Tu ETV, 2008, CLIN INFECT DIS, V46, P413, DOI 10.1086/525259
   Vega E, 2011, EMERG INFECT DIS, V17, P1389, DOI 10.3201/eid1708.101837
   Vicentini F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069348
   Vinje J, 2004, J VIROL METHODS, V116, P109, DOI 10.1016/j.jviromet.2003.11.001
   Widdowson MA, 2004, J INFECT DIS, V190, P27, DOI 10.1086/420888
   Wright PJ, 1998, J MED VIROL, V55, P312, DOI 10.1002/(SICI)1096-9071(199808)55:4&lt;312::AID-JMV10&gt;3.0.CO;2-G
   Yen C, 2011, CLIN INFECT DIS, V53, P568, DOI 10.1093/cid/cir478
   Zheng DP, 2006, VIROLOGY, V346, P312, DOI 10.1016/j.virol.2005.11.015
NR 71
TC 30
Z9 31
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 25
PY 2014
VL 9
IS 3
AR e92988
DI 10.1371/journal.pone.0092988
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AE0SD
UT WOS:000333675600120
PM 24667283
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Mendoza, Y
   Bello, G
   Mewa, JC
   Martinez, AA
   Gonzalez, C
   Garcia-Morales, C
   Avila-Rios, S
   Reyes-Teran, G
   Pascale, JM
AF Mendoza, Yaxelis
   Bello, Gonzalo
   Castillo Mewa, Juan
   Martinez, Alexander A.
   Gonzalez, Claudia
   Garcia-Morales, Claudia
   Avila-Rios, Santiago
   Reyes-Teran, Gustavo
   Pascale, Juan M.
TI Molecular Epidemiology of HIV-1 in Panama: Origin of Non-B Subtypes in
   Samples Collected from 2007 to 2013
SO PLOS ONE
LA English
DT Article
ID ANTIRETROVIRAL DRUG-RESISTANCE; CIRCULATING RECOMBINANT FORMS;
   GENOTYPING SYSTEM; GENETIC DIVERSITY; IDENTIFICATION; SURVEILLANCE;
   PERFORMANCE; PREVALENCE; INFECTION; SEQUENCES
AB Phylogenetic studies have suggested that the HIV-1 epidemic in the Americas is mainly dominated by HIV subtype B. However, countries of South America and the Caribbean have recently reported changes in their circulating HIV-1 genetic profiles. The aim of this study was to characterize the molecular profile of the HIV-1 epidemic in Panama by the analysis of 655 polymerase gene (pol) sequences that were obtained from HIV-infected Panamanians diagnosed between 1987 and 2013. Blood samples were collected from recently infected, antiretroviral drug-naive and treatment-experienced subjects since mid-2007 to 2013. Viral RNA from plasma was extracted and sequences of HIV protease and reverse transcriptase genes were obtained. Bootscanning and phylogenetic methods were used for HIV subtyping and to trace the putative origin of non-B subtype strains. Our results showed that HIV-1 infections in Panama are dominated by subtype B (98.9%). The remaining 1.1% is represented by a diverse collection of recombinant variants including: three URFs_BC, one CRF20_BG, and one CRF28/29_BF, in addition to one subtype F1 and one subtype C, none of which were previously reported in Panama. The non-B subtype variants detected in Panama were probably introduced from Brazil (subtype F1 and CRF28/29_BF), Cuba (CRF20_BG), Dominican Republic (URFs_BC) and India (subtype C). Panama is the geographical vertex that connects the North with South America and the Caribbean through trade and cultural relations, which may explain the observed introductions of non-B subtype HIV-1 variants from both the Caribbean and South America into this Central American country.
C1 [Mendoza, Yaxelis; Castillo Mewa, Juan; Martinez, Alexander A.; Gonzalez, Claudia; Pascale, Juan M.] Gorgas Mem Inst Hlth Studies, Dept Genom & Prote, Panama City, Panama.
   [Mendoza, Yaxelis; Martinez, Alexander A.] Acharya Nagarjuna Univ, Dept Biotechnol, Guntur City, Andhra Pradesh, India.
   [Mendoza, Yaxelis] Univ Panama, Dept Genet & Mol Biol, Panama City, Panama.
   [Mendoza, Yaxelis; Martinez, Alexander A.] INDICASAT AIP, Panama City, Panama.
   [Bello, Gonzalo] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, BR-21045900 Rio De Janeiro, Brazil.
   [Garcia-Morales, Claudia; Avila-Rios, Santiago; Reyes-Teran, Gustavo] Inst Nacl Enfermedades Resp, Ctr Invest Enfermedades Infecciosas, Mexico City, DF, Mexico.
RP Mendoza, Y (corresponding author), Gorgas Mem Inst Hlth Studies, Dept Genom & Prote, Panama City, Panama.
EM yaxelis_mendoza@yahoo.com
RI Martinez, Alexander/F-9601-2012; Bentancor, Gonzalo Jose
   Bello/N-7377-2019; Avila-Rios, Santiago/AAB-4383-2020; Bello,
   Gonzalo/E-6842-2013
OI Martinez, Alexander/0000-0002-7816-3040; Bentancor, Gonzalo Jose
   Bello/0000-0002-2724-2793; 
FU Department of Genomics and Proteomics (ICGES); Ministry of Health
   (Panama); International Atomic Energy Agency (IAEA)International Atomic
   Energy Agency [PAN-6011]; Secretaria Nacional de Ciencia y Tecnologia
   (SENACYT); Instituto para la Formacion de Recursos Humanos (IFARHU)
FX The project was supported in part by Department of Genomics and
   Proteomics (ICGES) and the Ministry of Health (Panama) and Project
   PAN-6011 from the International Atomic Energy Agency (IAEA). YM was
   funded by a fellowship from Secretaria Nacional de Ciencia y Tecnologia
   (SENACYT) and Instituto para la Formacion de Recursos Humanos (IFARHU).
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Ahumada-Ruiz S, 2008, AIDS RES HUM RETROV, V24, P1461, DOI 10.1089/aid.2008.0153
   Ahumada-Ruiz S, 2009, INFECT GENET EVOL, V9, P933, DOI 10.1016/j.meegid.2009.06.013
   Anisimova M, 2006, SYST BIOL, V55, P539, DOI 10.1080/10635150600755453
   [Anonymous], 2011, B EST 2010 MIN SAL, P113
   [Anonymous], 2012, B EST 2002 2011 RES
   [Anonymous], 2010, EST PROYECC POBL TOT
   [Anonymous], 2000, GACETA OFICIAL, V23, P964
   [Anonymous], 2012, MOV INT PAS EST PAN
   Bello G, 2011, AIDS RES TREAT, V2011, DOI 10.1155/2011/154945
   Bongertz V, 2000, J ACQ IMMUN DEF SYND, V23, P184
   Brindeiro RM, 2003, AIDS, V17, P1063, DOI 10.1097/00002030-200305020-00016
   Carr JK, 2001, AIDS, V15, pF41, DOI 10.1097/00002030-200110190-00002
   CARR JK, 1998, REFERENCE SEQUENCES
   Castillero JR, 2011, DIAGNOSTICO REDES RE
   Castillo J, 2011, REV PANAM SALUD PUBL, V30, P649, DOI 10.1590/S1020-49892011001200025
   De Mendoza C, 2009, AIDS RES HUM RETROV, V25, P967, DOI 10.1089/aid.2008.0166
   de Oliveira T, 2005, BIOINFORMATICS, V21, P3797, DOI 10.1093/bioinformatics/bti607
   De Sa DJ, 2006, AIDS RES HUM RETROV, V22, P1
   de Sa DJ, 2008, AIDS RES HUM RETROV, V24, P347, DOI 10.1089/aid.2007.0203
   Geretti AM, 2006, CURR OPIN INFECT DIS, V19, P1, DOI 10.1097/01.qco.0000200293.45532.68
   Gonzalez-Alba JM, 2011, J VIROL, V85, P10755, DOI 10.1128/JVI.00454-11
   Guerrero Delgado G A, 1994, Rev Med Panama, V19, P186
   Guindon S, 2010, SYST BIOL, V59, P307, DOI 10.1093/sysbio/syq010
   Hakre S, 2013, SEX TRANSM INFECT, V89, P156, DOI 10.1136/sextrans-2012-050557
   Hemelaar J, 2012, TRENDS MOL MED, V18, P182, DOI 10.1016/j.molmed.2011.12.001
   Holguin A, 2008, J CLIN MICROBIOL, V46, P2918, DOI 10.1128/JCM.02414-07
   Kouri V, 2012, J CLIN VIROL, V55, P348, DOI 10.1016/j.jcv.2012.08.019
   Lole KS, 1999, J VIROL, V73, P152, DOI 10.1128/JVI.73.1.152-160.1999
   Machado LY, 2012, AIDS RES HUM RETROV, V28, P956, DOI [10.1089/aid.2011.0295, 10.1089/AID.2011.0295]
   Manak M, 2012, AIDS RES HUM RETROV, V28, P594, DOI [10.1089/aid.2011.0271, 10.1089/AID.2011.0271]
   Martinez H, 2012, INFORM NACL PROGRESO
   MEYERHANS A, 1989, CELL, V58, P901, DOI 10.1016/0092-8674(89)90942-2
   Ministero della Salute, 2009, PRACT GUID MEAS ENH, P1
   Nadai Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004814
   Neogi U, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039819
   NOWAK MA, 1990, AIDS, V4, P1095, DOI 10.1097/00002030-199011000-00007
   Perez L, 2013, INFECT GENET EVOL, V16, P144, DOI 10.1016/j.meegid.2013.02.002
   Ratha D., 2011, MIGRATION REMITTANCE
   REEVES WC, 1988, AM J TROP MED HYG, V39, P398
   Salustiano Cavalcanti AM, 2007, MEM I OSWALDO CRUZ, V102, P785
   Cavalcanti AMS, 2012, MEM I OSWALDO CRUZ, V107, P450, DOI 10.1590/S0074-02762012000400002
   Shen CL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025956
   Sierra M, 2007, JAIDS-J ACQ IMM DEF, V45, P151, DOI 10.1097/QAI.0b013e318046ea47
   Sierra Maria, 2005, Infection Genetics and Evolution, V5, P209, DOI 10.1016/j.meegid.2004.07.010
   Simon F, 1998, NAT MED, V4, P1032, DOI 10.1038/2017
   Smyth RP, 2012, VIRUS RES, V169, P415, DOI 10.1016/j.virusres.2012.06.015
   Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092
   Taylor-Castillo L, 2010, REV PANAM SALUD PUBL, V27, P23, DOI 10.1590/S1020-49892010000100004
   Teixeira SLM, 2004, J CLIN VIROL, V31, P221, DOI 10.1016/j.jcv.2004.03.016
   Teva I, 2012, REV MED CHILE, V140, P50, DOI /S0034-98872012000100007
   Thiam M, 2013, J VIROL METHODS, V188, P97, DOI 10.1016/j.jviromet.2012.11.044
   Thomson MM, 2005, AIDS REV, V7, P210
   Tupinambas U, 2013, MEM I OSWALDO CRUZ, V108, P470, DOI 10.1590/S0074-0276108042013012
   UNAIDS, 2012, GLOB REP REP GLOB AI
NR 54
TC 6
Z9 7
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 13
PY 2014
VL 9
IS 1
AR e85153
DI 10.1371/journal.pone.0085153
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 292SL
UT WOS:000329922500045
PM 24454808
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Souza, WM
   Bello, G
   Amarilla, AA
   Alfonso, HL
   Aquino, VH
   Figueiredo, LTM
AF Souza, W. M.
   Bello, G.
   Amarilla, A. A.
   Alfonso, H. L.
   Aquino, V. H.
   Figueiredo, L. T. M.
TI Phylogeography and evolutionary history of rodent-borne hantaviruses
SO INFECTION GENETICS AND EVOLUTION
LA English
DT Article
DE Hantavirus; Rodent-borne; Evolution; Phylogeography
ID KOREAN HEMORRHAGIC-FEVER; RIO-MAMORE VIRUS; PYGMY RICE RAT;
   OLIGORYZOMYS-MICROTIS; PULMONARY SYNDROME; GENETIC-CHARACTERIZATION;
   WESTERN PARAGUAY; ETIOLOGIC AGENT; CD-HIT; IDENTIFICATION
AB Hantavirus (Family Bunyaviridae) are mostly associated to rodents and transmitted to man by inhalation of aerosolized infected excreta of these animals. The human infection by hantaviruses can lead to severe diseases such as hemorrhagic fever with renal syndrome (HFRS) in Asia and Europe, and pulmonary syndrome (HPS) in the Americas. To determine the origin, spreading and evolutionary dynamics of rodent-borne hantaviruses, 190 sequences of nucleoprotein (N) of hantaviruses identified in 30 countries, from 1985 to 2010, were retrieved from the GenBank and analyzed using the BEAST program. Our evolutionary analysis indicates that current genetic diversity of N gene of rodent-borne hantaviruses probably was originated around 2000 years ago. Hantavirus harbored by Murinae and Arvicolinae subfamilies, probably, were originated in Asia 500-700 years ago and later spread toward Siberia, Europe, Africa and North America. Hantavirus carried by Neotominae subfamily, probably, emerged 500-600 years ago in Central America and spread toward North America. Finally, hantaviruses associated to Sigmodontinae occurred in Brazil 400 years ago and were, probably, originated from Neotominae-associated virus from northern South America. These data offer subsidies to understand the time-scale and worldwide dissemination dynamics of rodent-borne hantaviruses. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Souza, W. M.; Figueiredo, L. T. M.] Univ Sao Paulo, Sch Med Ribeirao Preto, Virol Res Ctr, BR-14049900 Sao Paulo, Brazil.
   [Bello, G.] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, BR-21045900 Rio De Janeiro, Brazil.
   [Amarilla, A. A.; Alfonso, H. L.; Aquino, V. H.] Univ Sao Paulo, Fac Ciencias Farmaceut, Dept Anal Clin Toxicol & Bromatol, BR-14049900 Sao Paulo, Brazil.
RP Souza, WM (corresponding author), Univ Sao Paulo, Sch Med Ribeirao Preto, Virol Res Ctr, Av Bandeirantes 3900, BR-14049900 Sao Paulo, Brazil.
EM wmarciel@hotmail.com; ltmfigue@fmrp.usp.br
RI Aquino, Victor Hugo/C-1922-2012; Bello, Gonzalo/E-6842-2013; Bentancor,
   Gonzalo Jose Bello/N-7377-2019; de Souza, William Marciel/D-3044-2017
OI Aquino, Victor Hugo/0000-0003-1910-0776; Bentancor, Gonzalo Jose
   Bello/0000-0002-2724-2793; de Souza, William Marciel/0000-0002-0025-8293
CR Arai S, 2008, P NATL ACAD SCI USA, V105, P16296, DOI 10.1073/pnas.0808942105
   Bharadwaj M, 1997, AM J TROP MED HYG, V57, P368, DOI 10.4269/ajtmh.1997.57.368
   Chu YK, 2006, AM J TROP MED HYG, V75, P1127, DOI 10.4269/ajtmh.2006.75.1127
   Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/msi103
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   Drummond AJ, 2012, MOL BIOL EVOL, V29, P1969, DOI 10.1093/molbev/mss075
   Duffy S, 2008, NAT REV GENET, V9, P267, DOI 10.1038/nrg2323
   Faria NR, 2012, J GEN VIROL, V93, P889, DOI 10.1099/vir.0.038638-0
   Figueiredo LTM, 2009, EMERG INFECT DIS, V15, P561, DOI 10.3201/eid1504.080289
   Guo WP, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003159
   Holmes EC, 2008, ANNU REV MICROBIOL, V62, P307, DOI 10.1146/annurev.micro.62.081307.162912
   Huang Y, 2010, BIOINFORMATICS, V26, P680, DOI 10.1093/bioinformatics/btq003
   Hughes AL, 2000, MOL BIOL EVOL, V17, P1558, DOI 10.1093/oxfordjournals.molbev.a026254
   Hugot JP, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-72
   Jaaskelainen KM, 2007, J MED VIROL, V79, P1527, DOI 10.1002/jmv.20948
   Johansson P, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-15
   Johnson AM, 1997, VIROLOGY, V238, P115, DOI 10.1006/viro.1997.8840
   Jonsson CB, 2010, CLIN MICROBIOL REV, V23, P412, DOI 10.1128/CMR.00062-09
   Kariwa H, 1999, VIRUS RES, V59, P219, DOI 10.1016/S0168-1702(98)00141-5
   Kariwa H, 2012, VIRUS RES, V163, P486, DOI 10.1016/j.virusres.2011.11.013
   Klempa B, 2012, J VIROL, V86, P3819, DOI 10.1128/JVI.05879-11
   LEE HW, 1982, J INFECT DIS, V146, P638, DOI 10.1093/infdis/146.5.638
   LEE HW, 1978, J INFECT DIS, V137, P298, DOI 10.1093/infdis/137.3.298
   Lemey P, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000520
   Li WZ, 2006, BIOINFORMATICS, V22, P1658, DOI 10.1093/bioinformatics/btl158
   Lopez N, 1996, VIROLOGY, V220, P223, DOI 10.1006/viro.1996.0305
   Morzunov SP, 1998, J VIROL, V72, P57, DOI 10.1128/JVI.72.1.57-64.1998
   Nemirov K, 2002, VIRUS RES, V90, P207, DOI 10.1016/S0168-1702(02)00179-X
   NICHOL ST, 1993, SCIENCE, V262, P914, DOI 10.1126/science.8235615
   Papa A, 2012, ANTIVIR RES, V95, P104, DOI 10.1016/j.antiviral.2012.05.011
   Parada A, 2013, MOL PHYLOGENET EVOL, V66, P960, DOI 10.1016/j.ympev.2012.12.001
   Posada D, 2008, MOL BIOL EVOL, V25, P1253, DOI 10.1093/molbev/msn083
   Powers AM, 1999, AM J TROP MED HYG, V61, P92, DOI 10.4269/ajtmh.1999.61.92
   Ramsden C, 2009, MOL BIOL EVOL, V26, P143, DOI 10.1093/molbev/msn234
   Ramsden C, 2008, MOL BIOL EVOL, V25, P1488, DOI 10.1093/molbev/msn093
   Richter MH, 2010, VECTOR-BORNE ZOONOT, V10, P613, DOI 10.1089/vbz.2009.0115
   Salemi M, 2005, J VIROL, V79, P11343, DOI 10.1128/JVI.79.17.11343-11352.2005
   Schlegel M, 2012, VECTOR-BORNE ZOONOT, V12, P503, DOI 10.1089/vbz.2011.0784
   Steppan SJ, 2004, SYST BIOL, V53, P533, DOI 10.1080/10635150490468701
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Vaheri A, 2013, NAT REV MICROBIOL, V11, P539, DOI 10.1038/nrmicro3066
   Vera-Otarola J, 2012, J VIROL, V86, P2176, DOI 10.1128/JVI.06223-11
   Vincent MJ, 2000, VIROLOGY, V277, P14, DOI 10.1006/viro.2000.0563
   Weiss S, 2012, EMERG INFECT DIS, V18, P159, DOI 10.3201/eid1801.111026
   Worobey M, 2010, SCIENCE, V329, P1487, DOI 10.1126/science.1193550
NR 45
TC 18
Z9 18
U1 1
U2 25
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567-1348
EI 1567-7257
J9 INFECT GENET EVOL
JI Infect. Genet. Evol.
PD JAN
PY 2014
VL 21
BP 198
EP 204
DI 10.1016/j.meegid.2013.11.015
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA AC1RN
UT WOS:000332273800022
PM 24287104
DA 2020-12-01
ER

PT J
AU Pimentel, VF
   Morgado, MG
   Bello, G
   Guimaraes, MDC
   Castilho, EA
   Veloso, VG
   Guimaraes, ML
AF Pimentel, Victor F.
   Morgado, Mariza G.
   Bello, Gonzalo
   Guimaraes, Mark D. C.
   Castilho, Euclides A.
   Veloso, Valdilea G.
   Guimaraes, Monick L.
TI Temporal Trends and Molecular Epidemiology of HIV Type 1 Infection in
   Rio de Janeiro, Brazil
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; SUBTYPE-B; DRUG-RESISTANCE; SAO-PAULO;
   EVOLUTIONARY RATES; SLOWER PROGRESSION; V3 REGION; PREVALENCE; STRAINS;
   IDENTIFICATION
AB HIV-1 molecular epidemiology studies carried out in Rio de Janeiro, Brazil have identified the prevalence of subtypes B, F1 and BF1 recombinants. A high percentage of HIV-1 subtype B isolates in Rio de Janeiro harbor the GWG motif at the V3 tip (B variant) instead of the canonical GPG motif (B variant). To trace the dynamics of the HIV-1 variants over time in different exposure categories in Rio de Janeiro, the HIV-1 proviral DNA from heterosexual men (HET) and men who have sex with men (MSM) from two distinct time periods (1990-1992 and 2008-2010) were extracted, and the env-gp120 region was amplified. Neighbor-joining phylogenetic analysis was performed to determine the viral subtype, and Bayesian analysis was used to trace the HIV-1 transmission networks. A predominance of subtype B was observed in both study periods, independent of the exposure risk category. An increase of non-B subtypes was observed in the HET group, but these subtypes were maintained among the MSM group. The distribution of HIV-1 subtype B signatures in the first and second periods studied were, respectively, HET (GPG) [44.8-51.5%], (GWG) [13.8-33.3%], and (GXG) [41.4-15.2%] and MSM (GPG) [34-50%], (GWG) [55.3-30.6%], and (GXG) [10.7-19.4%]. In the first period, an association between GWG and MSM was verified while a significant reduction of this association was observed during the second period. The phylogenetic tree and the BaTS program detected the clustering of isolates only according to the B signatures but not by exposure risk category. Our findings indicate a stable prevalence of HIV-1 subtypes B and F over time in Rio de Janeiro and further suggest that the B subclade of subtype B was possibly introduced into the MSM group in this area of Brazil.
C1 [Pimentel, Victor F.; Morgado, Mariza G.; Bello, Gonzalo; Guimaraes, Monick L.] Inst Oswaldo Cruz, BR-20001 Rio De Janeiro, Brazil.
   [Guimaraes, Mark D. C.] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil.
   [Castilho, Euclides A.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Veloso, Valdilea G.] Fiocruz MS, Evandro Chagas Res Inst, BR-21040360 Rio De Janeiro, Brazil.
RP Guimaraes, ML (corresponding author), Fiocruz MS, Lab AIDS & Imunol Mol, Inst Oswaldo Cruz, Av Brasil 4365,Leonidas Deane Bldg,Room 413, BR-21040360 Rio De Janeiro, Brazil.
EM monicklg@ioc.fiocruz.br
RI DE CASTILHO, EUCLIDES AYRES/K-7906-2016; Bello, Gonzalo/E-6842-2013;
   Bentancor, Gonzalo Jose Bello/N-7377-2019
OI Bentancor, Gonzalo Jose Bello/0000-0002-2724-2793; Castilho,
   Euclides/0000-0002-7352-8784
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); FAPERJCarlos Chagas Filho Foundation for Research Support of the
   State of Rio de Janeiro (FAPERJ)
FX We acknowledge Dr. Vera Bongertz for reviewing our manuscript and
   providing helpful suggestions. We thank all volunteers for their
   participation. This study was supported in part by CNPq and FAPERJ
   grants.
CR Alcalde R, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-156
   Sucupira MCA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030292
   Araujo AF, 2010, AIDS RES HUM RETROV, V26, P1249, DOI 10.1089/aid.2010.0068
   Bello G, 2007, INFECT GENET EVOL, V7, P263, DOI 10.1016/j.meegid.2006.11.002
   Bongertz V, 2000, J ACQ IMMUN DEF SYND, V23, P184
   Brazilian Ministry of Healthy, 2011, B EPIDEMIOLOGICO AID
   Brigido LFM, 2011, AIDS RES HUM RETROV, V27, P339, DOI 10.1089/aid.2010.0157
   Cabral VP, 2006, MEM I OSWALDO CRUZ, V101, P881, DOI 10.1590/S0074-02762006000800010
   Caride E, 2001, VIRUS GENES, V23, P193, DOI 10.1023/A:1011812810397
   Carvalho BC, 2011, AIDS RES HUM RETROV, V27, P1081, DOI [10.1089/aid.2010.0334, 10.1089/AID.2010.0334]
   Casseb J, 1998, BRAZ J MED BIOL RES, V31, P1243, DOI 10.1590/S0100-879X1998001000002
   Casseb Jorge, 2002, International Journal of Infectious Diseases, V6, P164, DOI 10.1016/S1201-9712(02)90105-0
   CHU SY, 1992, AM J PUBLIC HEALTH, V82, P220, DOI 10.2105/AJPH.82.2.220
   Couto-Fernandez JC, 2006, AIDS RES HUM RETROV, V22, P207, DOI 10.1089/aid.2006.22.207
   Couto-Fernandez JC, 2005, MEM I OSWALDO CRUZ, V100, P73, DOI 10.1590/S0074-02762005000100014
   Covas DT, 1998, J ACQ IMMUN DEF SYND, V19, P74, DOI 10.1097/00042560-199809010-00012
   de Brito A, 2006, CLIN INFECT DIS, V43, P1476, DOI 10.1086/508875
   Delatorre EO, 2012, AIDS RES HUM RETROV, V28, P1369, DOI 10.1089/aid.2011.0381
   DELWART EL, 1993, SCIENCE, V262, P1257, DOI 10.1126/science.8235655
   Diaz RS, 2008, VIROLOGY, V381, P184, DOI 10.1016/j.virol.2008.08.014
   Franca RFO, 2011, AIDS RES HUM RETROV, V27, P903, DOI [10.1089/aid.2010.0266, 10.1089/AID.2010.0266]
   Guimaraes MDC, 1997, ARCH INTERN MED, V157, P1362, DOI 10.1001/archinte.157.12.1362
   GUIMARAES MDC, 1995, AM J EPIDEMIOL, V142, P538, DOI 10.1093/oxfordjournals.aje.a117672
   Guimaraes ML, 2001, J CLIN VIROL, V21, P143, DOI 10.1016/S1386-6532(01)00158-5
   Guimaraes ML, 2010, INFECT GENET EVOL, V10, P1094, DOI 10.1016/j.meegid.2010.07.001
   Guiniaraes ML, 2002, AIDS RES HUM RETROV, V18, P1261, DOI 10.1089/088922202320886307
   Hemelaar J, 2011, AIDS, V25, P679, DOI 10.1097/QAD.0b013e328342ff93
   KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581
   Machado LFA, 2009, AIDS RES HUM RETROV, V25, P961, DOI 10.1089/aid.2009.0027
   MORGADO MG, 1994, AIDS RES HUM RETROV, V10, P569, DOI 10.1089/aid.1994.10.569
   Morgado MG, 1998, J ACQ IMMUN DEF SYND, V18, P488, DOI 10.1097/00042560-199808150-00011
   Morgado MG, 1996, MEM I OSWALDO CRUZ, V91, P339, DOI 10.1590/S0074-02761996000300015
   Parker J, 2008, INFECT GENET EVOL, V8, P239, DOI 10.1016/j.meegid.2007.08.001
   Posada D, 2008, MOL BIOL EVOL, V25, P1253, DOI 10.1093/molbev/msn083
   POTTS KE, 1993, AIDS, V7, P1191, DOI 10.1097/00002030-199309000-00007
   Ray S, 2009, SIMPLOT V3 5 1
   Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180
   SABINO EC, 1994, J VIROL, V68, P6340, DOI 10.1128/JVI.68.10.6340-6346.1994
   Santoro-Lopes G, 2000, AIDS RES HUM RETROV, V16, P953, DOI 10.1089/08892220050058362
   SLATKIN M, 1989, GENETICS, V123, P603
   Stefani MMA, 2007, J CLIN VIROL, V39, P205, DOI 10.1016/j.jcv.2007.04.012
   Tamura K, 2013, MOL BIOL EVOL, V30, P2725, DOI [10.1093/molbev/mst197, 10.1093/molbev/msr121]
   Teixeira SLM, 2006, J MED VIROL, V78, P764, DOI 10.1002/jmv.20621
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Wang TH, 2001, J VIROL, V75, P11686, DOI 10.1128/JVI.75.23.11686-11699.2001
NR 45
TC 9
Z9 9
U1 0
U2 10
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD DEC 1
PY 2013
VL 29
IS 12
BP 1553
EP 1561
DI 10.1089/aid.2013.0050
PG 9
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 255CX
UT WOS:000327218000004
PM 23987184
DA 2020-12-01
ER

PT J
AU Delatorre, E
   Couto-Fernandez, JC
   Guimaraes, ML
   Cardoso, LPV
   de Alcantara, KC
   Stefani, MMD
   Romero, H
   Freire, CCM
   Iamarino, A
   Zanotto, PMD
   Morgado, MG
   Bello, G
AF Delatorre, Edson
   Couto-Fernandez, Jose C.
   Guimaraes, Monick Lindenmayer
   Vaz Cardoso, Ludimila Paula
   de Alcantara, Keila Correia
   de Araujo Stefani, Mariane Martins
   Romero, Hector
   Freire, Caio C. M.
   Iamarino, Atila
   Zanotto, Paolo M. de A.
   Morgado, Mariza G.
   Bello, Gonzalo
TI Tracing the Origin and Northward Dissemination Dynamics of HIV-1 Subtype
   C in Brazil
SO PLOS ONE
LA English
DT Article
ID RIO-DE-JANEIRO; ANTIRETROVIRAL DRUG-RESISTANCE; MODERATE PREVALENCE;
   PREGNANT-WOMEN; MOLECULAR EPIDEMIOLOGY; PHYLOGENETIC ANALYSIS; GENETIC
   DIVERSITY; MATO-GROSSO; SAO-PAULO; TYPE-1
AB Previous studies indicate that the HIV-1 subtype C epidemic in southern Brazil was initiated by the introduction of a single founder strain probably originating from east Africa. However, the exact country of origin of such a founder strain as well as the origin of the subtype C viruses detected outside the Brazilian southern region remains unknown. HIV-1 subtype C pol sequences isolated in the southern, southeastern and central-western Brazilian regions (n = 209) were compared with a large number (n similar to 2,000) of subtype C pol sequences of African origin. Maximum-likelihood analyses revealed that most HIV-1 subtype C Brazilian sequences branched in a single monophyletic clade (CBR-I), nested within a larger monophyletic lineage characteristic of east Africa. Bayesian analyses indicate that the CBR-I clade most probably originated in Burundi and was introduced into the Parana state (southern region) around the middle 1970s, after which it rapidly disseminated to neighboring regions. The states of Parana and Santa Catarina have been the most important hubs of subtype C dissemination, and routine travel and spatial accessibility seems to have been the major driving forces of this process. Five additional introductions of HIV-1 subtype C strains probably originated in eastern (n = 2), southern (n = 2) and central (n = 1) African countries were detected in the Rio de Janeiro state (southeastern region). These results indicate a continuous influx of HIV-1 subtype C strains of African origin into Brazil and also unveil the existence of unrecognized transmission networks linking this country to east Africa.
C1 [Delatorre, Edson; Couto-Fernandez, Jose C.; Guimaraes, Monick Lindenmayer; Morgado, Mariza G.; Bello, Gonzalo] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, BR-21045900 Rio De Janeiro, Brazil.
   [Vaz Cardoso, Ludimila Paula; de Alcantara, Keila Correia; de Araujo Stefani, Mariane Martins] Univ Fed Goias, Inst Patol Trop & Saude Publ, Goiania, Go, Brazil.
   [Romero, Hector] Univ Republica, Fac Ciencias, Secc Biomatemat, Lab Org & Evoluc Genoma, Montevideo, Uruguay.
   [Freire, Caio C. M.; Iamarino, Atila; Zanotto, Paolo M. de A.] Univ Sao Paulo, Inst Ciencias Biomed, Dept Microbiol, Lab Evolucao Mol & Bioinformat, BR-05508 Sao Paulo, Brazil.
RP Bello, G (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, BR-21045900 Rio De Janeiro, Brazil.
EM gbellobr@gmail.com
RI Freire, Caio/C-8248-2014; Delatorre, Edson/J-8330-2015; Bello,
   Gonzalo/E-6842-2013; de A. Zanotto, Paolo M./B-9286-2019; Bentancor,
   Gonzalo Jose Bello/N-7377-2019
OI Freire, Caio/0000-0002-7723-4230; Delatorre, Edson/0000-0002-5746-0820;
   de A. Zanotto, Paolo M./0000-0002-8167-0625; Bentancor, Gonzalo Jose
   Bello/0000-0002-2724-2793; ALCANTARA, KEILA CORREIA/0000-0002-4477-2833;
   Iamarino, Atila/0000-0003-3904-0248; Couto-Fernandez, Jose
   Carlos/0000-0001-7091-9774
FU FAPERJCarlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ) [E-26/111.758/2012]; CNPqNational Council for
   Scientific and Technological Development (CNPq) [472896/2012-1]
FX This work was supported by Public Health Service grants
   E-26/111.758/2012 from the FAPERJ and 472896/2012-1 from the CNPq. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Alcantara KC, 2013, J MED VIROL, V85, P396, DOI 10.1002/jmv.23474
   Alcantara KC, 2012, J CLIN VIROL, V54, P15, DOI 10.1016/j.jcv.2012.01.011
   Anisimova M, 2006, SYST BIOL, V55, P539, DOI 10.1080/10635150600755453
   Archer J, 2007, AIDS, V21, P1693, DOI 10.1097/QAD.0b013e32825eabd0
   Barreto CC, 2006, JAIDS-J ACQ IMM DEF, V41, P338
   Bello G, 2008, AIDS, V22, P1993, DOI 10.1097/QAD.0b013e328315e0aa
   Bello G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035649
   Bello G, 2011, AIDS RES TREAT, V2011, DOI 10.1155/2011/154945
   Bielejec F, 2011, BIOINFORMATICS, V27, P2910, DOI 10.1093/bioinformatics/btr481
   Brigido LFM, 2011, AIDS RES HUM RETROV, V27, P339, DOI 10.1089/aid.2010.0157
   Carvalho BC, 2011, AIDS RES HUM RETROV, V27, P1081, DOI [10.1089/aid.2010.0334, 10.1089/AID.2010.0334]
   Veras NMC, 2011, J GEN VIROL, V92, P1698, DOI 10.1099/vir.0.028951-0
   Couto-Fernandez JC, 2006, AIDS RES HUM RETROV, V22, P207, DOI 10.1089/aid.2006.22.207
   Couto-Fernandez JC, 2005, MEM I OSWALDO CRUZ, V100, P73, DOI 10.1590/S0074-02762005000100014
   da Silveira AA, 2012, AIDS RES HUM RETROV, V28, P304, DOI 10.1089/aid.2011.0128
   de Oliveira T, 2005, BIOINFORMATICS, V21, P3797, DOI 10.1093/bioinformatics/bti607
   de Oliveira T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009311
   de Sa DJ, 2008, AIDS RES HUM RETROV, V24, P347, DOI 10.1089/aid.2007.0203
   Delatorre EO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041904
   Delatorre EO, 2012, AIDS RES HUM RETROV, V28, P1369, DOI 10.1089/aid.2011.0381
   Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/msi103
   Drummond AJ, 2002, GENETICS, V161, P1307
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   Ferreira AS, 2011, J MED VIROL, V83, P1301, DOI 10.1002/jmv.22128
   Fontella R, 2008, AIDS, V22, P2001, DOI 10.1097/QAD.0b013e3283108f69
   FRANSEN S, 2010, PAPER SERIES MIGRATI
   Graf T, 2013, VIROLOGY, V435, P170, DOI 10.1016/j.virol.2012.08.048
   Guindon S, 2005, NUCLEIC ACIDS RES, V33, pW557, DOI 10.1093/nar/gki352
   Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520
   Hemelaar J, 2011, AIDS, V25, P679, DOI 10.1097/QAD.0b013e328342ff93
   Inocencio LA, 2009, J INT AIDS SOC, V12, DOI 10.1186/1758-2652-12-20
   Lemey P, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000520
   Morgado MG, 1998, J ACQ IMMUN DEF SYND, V18, P488, DOI 10.1097/00042560-199808150-00011
   Paradis E, 2004, BIOINFORMATICS, V20, P289, DOI 10.1093/bioinformatics/btg412
   Pilotto JH, 2013, AIDS RES HUM RETROV, V29, P681, DOI [10.1089/aid.2011.0333, 10.1089/AID.2011.0333]
   Posada D, 2008, MOL BIOL EVOL, V25, P1253, DOI 10.1093/molbev/msn083
   Rambaut A, 2007, TRACER V1 4
   Rambaut A., 2009, FIGTREE V1 3 1 TREE
   Ronquist F, 2012, SYST BIOL, V61, P539, DOI 10.1093/sysbio/sys029
   Sanabani S, 2006, AIDS RES HUM RETROV, V22, P171, DOI 10.1089/aid.2006.22.171
   Sanchez R, 2011, NUCLEIC ACIDS RES, V39, pW470, DOI 10.1093/nar/gkr408
   Schmidt HA, 2002, BIOINFORMATICS, V18, P502, DOI 10.1093/bioinformatics/18.3.502
   Strimmer K, 1997, P NATL ACAD SCI USA, V94, P6815, DOI 10.1073/pnas.94.13.6815
   Suchard MA, 2001, MOL BIOL EVOL, V18, P1001, DOI 10.1093/oxfordjournals.molbev.a003872
   Team RC, 2012, R LANG ENV STAT COMP
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Cardoso LPV, 2011, AIDS RES HUM RETROV, V27, P1349, DOI 10.1089/aid.2011.0153
   Cardoso LPV, 2010, J MED VIROL, V82, P351, DOI 10.1002/jmv.21722
   Cardoso LPV, 2009, J CLIN VIROL, V46, P134, DOI 10.1016/j.jcv.2009.07.009
   de Castro CAV, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-224
   Xia X, 2001, J HERED, V92, P371, DOI 10.1093/jhered/92.4.371
NR 52
TC 14
Z9 15
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 12
PY 2013
VL 8
IS 9
AR e74072
DI 10.1371/journal.pone.0074072
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 242KO
UT WOS:000326240100084
PM 24069269
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Delatorre, E
   Bello, G
AF Delatorre, Edson
   Bello, Gonzalo
TI Phylodynamics of the HIV-1 Epidemic in Cuba
SO PLOS ONE
LA English
DT Article
ID CIRCULATING RECOMBINANT FORMS; GENETIC DIVERSITY; MOLECULAR
   EPIDEMIOLOGY; DRUG-RESISTANCE; ANTIRETROVIRAL DRUGS;
   POPULATION-DYNAMICS; MAXIMUM-LIKELIHOOD; HIV/AIDS EPIDEMIC; SUBTYPE-B;
   TYPE-1
AB Previous studies have shown that the HIV-1 epidemic in Cuba displayed a complex molecular epidemiologic profile with circulation of several subtypes and circulating recombinant forms (CRF); but the evolutionary and population history of those viral variants remains unknown. HIV-1 pol sequences of the most prevalent Cuban lineages (subtypes B, C and G, CRF18_cpx, CRF19_cpx, and CRFs20/23/24_BG) isolated between 1999 and 2011 were analyzed. Maximum-likelihood analyses revealed multiple introductions of subtype B (n >= 66), subtype C (n >= 10), subtype G (n >= 8) and CRF18_cpx (n >= 2) viruses in Cuba. The bulk of HIV-1 infections in this country, however, was caused by dissemination of a few founder strains probably introduced from North America/Europe (clades BCU-I and BCU-II), east Africa (clade CCU-I) and central Africa (clades G(CU), CRF18(CU) and CRF19(CU)), or locally generated (clades CRFs20/23/24_BG). Bayesian-coalescent analyses show that the major HIV-1 founder strains were introduced into Cuba during 1985-1995; whereas the CRFs_BG strains emerged in the second half of the 1990s. Most HIV-1 Cuban clades appear to have experienced an initial period of fast exponential spread during the 1990s and early 2000s, followed by a more recent decline in growth rate. The median initial growth rate of HIV-1 Cuban clades ranged from 0.4 year(-1) to 1.6 year(-1). Thus, the HIV-1 epidemic in Cuba has been a result of the successful introduction of a few viral strains that began to circulate at a rather late time of the AIDS pandemic, but then were rapidly disseminated through local transmission networks.
C1 [Delatorre, Edson; Bello, Gonzalo] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, BR-21045900 Rio De Janeiro, Brazil.
RP Bello, G (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, BR-21045900 Rio De Janeiro, Brazil.
EM gbellobr@gmail.com
RI Bentancor, Gonzalo Jose Bello/N-7377-2019; Delatorre, Edson/J-8330-2015;
   Bello, Gonzalo/E-6842-2013
OI Bentancor, Gonzalo Jose Bello/0000-0002-2724-2793; Delatorre,
   Edson/0000-0002-5746-0820; 
FU Public Health Service from the FAPERJ [E-26/111.758/2012]; CNPqNational
   Council for Scientific and Technological Development (CNPq)
   [472896/2012-1]
FX This work was supported by Public Health Service grants
   E-26/111.758/2012 from the FAPERJ and 472896/2012-1 from the CNPq. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Afonso JM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042996
   Anderson T, 2009, REV PANAM SALUD PUBL, V26, P78, DOI 10.1590/S1020-49892009000700012
   Anisimova M, 2006, SYST BIOL, V55, P539, DOI 10.1080/10635150600755453
   Baele G, 2012, MOL BIOL EVOL, V29, P2157, DOI 10.1093/molbev/mss084
   Bartolo I, 2009, INFECT GENET EVOL, V9, P672, DOI 10.1016/j.meegid.2008.05.003
   Bello G, 2007, INFECT GENET EVOL, V7, P263, DOI 10.1016/j.meegid.2006.11.002
   Bello G, 2012, INFECT GENET EVOL, V12, P1079, DOI 10.1016/j.meegid.2012.03.014
   Bello G, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-22
   Bello G, 2009, AIDS RES HUM RETROV, V25, P1065, DOI 10.1089/aid.2009.0106
   Carr JK, 2001, VIROLOGY, V286, P168, DOI 10.1006/viro.2001.0976
   Casado G, 2005, JAIDS-J ACQ IMM DEF, V40, P532, DOI 10.1097/01.qai.0000186363.27587.c0
   Chen JHK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025286
   Cuevas MT, 2002, AIDS, V16, P1643, DOI 10.1097/00002030-200208160-00010
   de Arazoza H, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-130
   de Oliveira T, 2005, BIOINFORMATICS, V21, P3797, DOI 10.1093/bioinformatics/bti607
   Delatorre E, 2013, AIDS
   Delatorre EO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041904
   Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/msi103
   Drummond AJ, 2002, GENETICS, V161, P1307
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   Figueras MA, 2001, LAT AM STUD ASS LASA
   Gilbert MTP, 2007, P NATL ACAD SCI USA, V104, P18566, DOI 10.1073/pnas.0705329104
   Guindon S, 2005, NUCLEIC ACIDS RES, V33, pW557, DOI 10.1093/nar/gki352
   Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520
   Hansen H, 2001, Med Anthropol, V19, P259
   Hsieh YH, 2001, AIDS, V15, P426, DOI 10.1097/00002030-200102160-00023
   Hue S, 2005, P NATL ACAD SCI USA, V102, P4425, DOI 10.1073/pnas.0407534102
   Junqueira DM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027489
   Kalish ML, 2004, EMERG INFECT DIS, V10, P1227
   Kouri V, 2012, J CLIN VIROL, V55, P348, DOI 10.1016/j.jcv.2012.08.019
   Machado LY, 2013, AIDS RES HUM RETROV, V29, P411, DOI [10.1089/aid.2012.0183, 10.1089/AID.2012.0183]
   Machado LY, 2012, AIDS RES HUM RETROV, V28, P956, DOI [10.1089/aid.2011.0295, 10.1089/AID.2011.0295]
   Marechal V, 2006, AIDS RES HUM RETROV, V22, P1036, DOI 10.1089/aid.2006.22.1036
   Niama FR, 2006, INFECT GENET EVOL
   Perez L, 2013, INFECT GENET EVOL, V16, P144, DOI 10.1016/j.meegid.2013.02.002
   Perez L, 2006, AIDS RES HUM RETROV, V22, P724, DOI 10.1089/aid.2006.22.724
   PEREZSTABLE EJ, 1991, AM J PUBLIC HEALTH, V81, P563, DOI 10.2105/AJPH.81.5.563
   Pircher M, 2012, AIDS RES HUM RETROV, V28, P1798, DOI [10.1089/aid.2012.0083, 10.1089/AID.2012.0083]
   Posada D, 2008, MOL BIOL EVOL, V25, P1253, DOI 10.1093/molbev/msn083
   Powell R, 2010, VIRUSES-BASEL, V2, P639, DOI 10.3390/v2020639
   Rambaut A, 2007, TRACER V1 4
   Rambaut A, 2009, FIGTREE V1 4 0 TREE
   Ray SC, 1999, SIMPLOT V2 5 0
   Ristic N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017485
   Robbins KE, 2003, J VIROL, V77, P6359, DOI 10.1128/JVI.77.11.6359-6366.2003
   Salemi M, 2005, J MOL EVOL, V60, P598, DOI 10.1007/s00239-004-0206-5
   Salemi M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001390
   Sierra M, 2007, JAIDS-J ACQ IMM DEF, V45, P151, DOI 10.1097/QAI.0b013e318046ea47
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Thomson MA, 2005, AIDS, V19, P1155, DOI 10.1097/01.aids.0000176215.95119.1d
   Thomson MM, 2005, AIDS REV, V7, P210
   Tully DC, 2010, AIDS, V24, P1577, DOI 10.1097/QAD.0b013e32833999e1
   UNAIDS, 2012, COUNTR PROGR REP
   UNAIDS, 2013, AIDS INFO DATABASE
   Vergne L, 2003, VIROLOGY, V310, P254, DOI 10.1016/S0042-6822(03)00167-3
   Vidal N, 2000, J VIROL, V74, P10498, DOI 10.1128/JVI.74.22.10498-10507.2000
   Walker Polly R., 2005, Infection Genetics and Evolution, V5, P199, DOI 10.1016/j.meegid.2004.06.011
   Zehender G, 2010, JAIDS-J ACQ IMM DEF, V55, P156, DOI 10.1097/QAI.0b013e3181eb3002
NR 59
TC 20
Z9 20
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 9
PY 2013
VL 8
IS 9
AR e72448
DI 10.1371/journal.pone.0072448
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 244QV
UT WOS:000326405300011
PM 24039765
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Villalba, JA
   Bello, G
   Maes, M
   Sulbaran, YF
   Garzaro, D
   Loureiro, CL
   Rangel, HR
   de Waard, JH
   Pujol, FH
AF Villalba, Julian A.
   Bello, Gonzalo
   Maes, Mailis
   Sulbaran, Yoneira F.
   Garzaro, Domingo
   Loureiro, Carmen L.
   Rangel, Hector R.
   de Waard, Jacobus H.
   Pujol, Flor H.
TI HIV-1 epidemic in Warao Amerindians from Venezuela: spatial
   phylodynamics and epidemiological patterns
SO AIDS
LA English
DT Article
DE Amerindians; epidemiology; HIV-1; phylogeography
ID POPULATION HISTORY; HIGH PREVALENCE; ACCURATE; SYPHILIS
AB Objectives:We previously reported HIV-1 infection in Warao Amerindians from Venezuela. The aim of this study was to evaluate the extent and the dynamic of HIV-1 dissemination in eight Warao communities.Design and Setting:HIV-1 infection was evaluated in 576 Warao Amerindians from the Orinoco Delta. Partial HIV-1 pol sequences were analyzed to reconstruct the spatiotemporal and demographic dynamics of the epidemic.Results:HIV-1 antibodies were present in 9.55% of Warao Amerindians, ranging from 0 to 22%. A significantly higher prevalence was found in men (15.6%) compared with women (2.6%), reaching up to 35% in men from one community. All but one isolates were classified as subtype B. Warao's HIV-1 subtype-B epidemic resulted from a single viral introduction at around the early 2000s. After an initial phase of slow growth, the subtype B started to spread at a fast rate (0.8/year) following two major routes of migration within the communities.Conclusion:A dramatic high prevalence was documented in almost all the communities of Warao Amerindians from the Orinoco Delta tested for HIV-1 infection. This epidemic resulted from the dissemination of a single HIV-1 subtype B founder strain introduced about 10 years ago and its size is probably doubling every year, creating a situation that can be devastating for this vulnerable Amerindian group.
C1 [Villalba, Julian A.] Direcc Reg Salud Estado Delta Amacuro, Tucupita, Venezuela.
   [Villalba, Julian A.] Lovelace Resp Res Inst, Albuquerque, NM USA.
   [Bello, Gonzalo] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, BR-21045900 Rio De Janeiro, Brazil.
   [Maes, Mailis; de Waard, Jacobus H.] Inst Venezolano Invest Cient, Inst Biomed, Lab TB, Caracas 1020A, Venezuela.
   [Sulbaran, Yoneira F.; Garzaro, Domingo; Loureiro, Carmen L.; Rangel, Hector R.; Pujol, Flor H.] Inst Venezolano Invest Cient, Mol Virol Lab, Caracas 1020A, Venezuela.
RP Pujol, FH (corresponding author), Inst Venezolano Invest Cient, Ctr Microbiol & Biol, Mol Virol Lab, Apdo 20632, Caracas 1020A, Venezuela.
EM fhpujol@gmail.com
RI Bentancor, Gonzalo Jose Bello/N-7377-2019; Villalba,
   Julian/AAK-4222-2020; Rangel, Hector/E-5575-2010; Bello,
   Gonzalo/E-6842-2013; Pujol, Flor H/E-5687-2010
OI Bentancor, Gonzalo Jose Bello/0000-0002-2724-2793; Villalba,
   Julian/0000-0001-9230-8747; Rangel, Hector/0000-0001-5937-9690; Pujol,
   Flor H/0000-0001-6086-6883; Loureiro Marino, Carmen
   Luisa/0000-0003-3665-1107; de Waard, Jacobus H./0000-0003-4118-1015
FU Grant Ley Organica de Ciencia Tecnologia e Innovacion (LOCTI), Venezuela
FX This work was supported by Grant Ley Organica de Ciencia Tecnologia e
   Innovacion (LOCTI), Venezuela.
CR Anisimova M, 2006, SYST BIOL, V55, P539, DOI 10.1080/10635150600755453
   Ayala-Lafee C, 2008, MONOGRAFIA LA SALLE, V51
   Barral B, 1972, MI BATALLA DIOS REFL
   Bartlett EC, 2008, INT J INFECT DIS, V12, pE89, DOI 10.1016/j.ijid.2008.03.036
   Bielejec F, 2011, BIOINFORMATICS, V27, P2910, DOI 10.1093/bioinformatics/btr481
   Butler JC, 2001, EMERG INFECT DIS, V7, P554
   Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/msi103
   Drummond AJ, 2002, GENETICS, V161, P1307
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   Fernández de Larrea Carlos, 2002, Invest. clín, V43, P35
   Guindon S, 2005, NUCLEIC ACIDS RES, V33, pW557, DOI 10.1093/nar/gki352
   Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520
   Hue S, 2005, P NATL ACAD SCI USA, V102, P4425, DOI 10.1073/pnas.0407534102
   Instituto Nacional de Estadistica, 2001, 13 CENS NAC POBL VIV
   Lavandero J, 2010, DELTA AMACURO CONFER
   Lemey P, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000520
   Mazin R., 2011, DESACATOS, V35, P87
   Ministerio del Poder Popular para la Salud, 2007, SAL IND VEN, VII
   Pan American Health Organization, PROM SAL SEX PREV VI
   Posada D, 2008, MOL BIOL EVOL, V25, P1253, DOI 10.1093/molbev/msn083
   Rangel HR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040626
   Republica Bolivariana de Venezuela, 2010, INF NAC REL AV IMPL
   Robbins KE, 2003, J VIROL, V77, P6359, DOI 10.1128/JVI.77.11.6359-6366.2003
   Shindo N, 2002, AIDS RES HUM RETROV, V18, P71, DOI 10.1089/088922202753394736
   UNAIDS, 2010, GLOB REP UNAIDS REP
   Verhagen LM, 2012, PEDIATR INFECT DIS J, V31, P255, DOI 10.1097/INF.0b013e31823eed8e
   Wilbert J, 1993, MYSTIC ENDOWMENT REL
   Wilbert J, 1980, DEMOGRAPHIC BIOL STU, V45
   Zavaleta C, 2007, AM J TROP MED HYG, V76, P703, DOI 10.4269/ajtmh.2007.76.703
NR 30
TC 10
Z9 11
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD JUL 17
PY 2013
VL 27
IS 11
BP 1783
EP 1791
DI 10.1097/QAD.0b013e3283601bdb
PG 9
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 250HL
UT WOS:000326841200012
PM 23435304
DA 2020-12-01
ER

PT J
AU Mello, FCA
   Araujo, OC
   Lago, BV
   Motta-Castro, ARC
   Moraes, MTB
   Gomes, SA
   Bello, G
   Araujo, NM
AF Mello, Francisco C. A.
   Araujo, Oscar C.
   Lago, Barbara V.
   Motta-Castro, Ana Rita C.
   Moraes, Marcia Terezinha B.
   Gomes, Selma A.
   Bello, Gonzalo
   Araujo, Natalia M.
TI Phylogeography and evolutionary history of hepatitis B virus genotype F
   in Brazil
SO VIROLOGY JOURNAL
LA English
DT Article
DE Hepatitis B virus; Genotype F; Bayesian framework; Phylogeography;
   Brazil
ID MOLECULAR CHARACTERIZATION; GENETIC DIVERSITY; COMPLETE GENOME; HBV
   GENOTYPE; POPULATION; IDENTIFICATION; AMERINDIANS; MUTATIONS; INFECTION;
   STRAINS
AB Background: Hepatitis B virus (HBV) genotype F (HBV/F) is considered to be indigenous to the Americas, but its emergence and spread in the continent remain unknown. Previously, only two HBV/F complete genome sequences from Brazil were available, limiting the contribution of Brazilian isolates to the phylogenetic studies of HBV/F. The present study was carried out to assess the proportion and geographic distributions of HBV/F subgenotypes in Brazil, to determine the full-length genomic sequences of HBV/F isolates from different Brazilian geographic regions, and to investigate the detailed evolutionary history and phylogeography of HBV/F in Brazil.
   Methods: Complete HBV/F genomes isolated from 12 Brazilian patients, representing the HBV/F subgenotypes circulating in Brazil, were sequenced and analyzed together with sequences retrieved from GenBank, using the Bayesian coalescent and phylogeographic framework.
   Results: Phylogenetic analysis using all Brazilian HBV/F S-gene sequences available in GenBank showed that HBV/F2a is found at higher frequencies countrywide and corresponds to all sequences isolated in the Brazilian Amazon Basin. In addition, the evolutionary analysis using complete genome sequences estimated an older median ancestral age for the Brazilian HBV/F2a compared to the Brazilian HBV/F1b and HBV/F4 subgenotypes, suggesting that HBV/F2a represents the original native HBV of Brazil. The phylogeographic patterns suggested a north-to-south flow of HBV/F2a from Venezuela to Brazil, whereas HBV/F1b and HBV/F4 strains appeared to have spread from Argentina to Brazil.
   Conclusions: This study suggests a plausible route of introduction of HBV/F subgenotypes in Brazil and demonstrates the usefulness of recently developed computational tools for investigating the evolutionary history of HBV.
C1 [Mello, Francisco C. A.; Araujo, Oscar C.; Lago, Barbara V.; Moraes, Marcia Terezinha B.; Gomes, Selma A.; Araujo, Natalia M.] Fiocruz MS, Inst Oswaldo Cruz, Mol Virol Lab, BR-21045900 Rio De Janeiro, RJ, Brazil.
   [Motta-Castro, Ana Rita C.] Univ Fed Mato Grosso do Sul, Dept Biochem & Pharm, Campo Grande, MS, Brazil.
   [Bello, Gonzalo] Fiocruz MS, Lab AIDS & Mol Immunol, Inst Oswaldo Cruz, BR-21045900 Rio De Janeiro, RJ, Brazil.
RP Araujo, NM (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Mol Virol Lab, BR-21045900 Rio De Janeiro, RJ, Brazil.
EM nmaraujo@ioc.fiocruz.br
RI Araujo, Natalia M/B-6596-2013; motta-castro, ana rita c/O-2075-2017;
   Bentancor, Gonzalo Jose Bello/N-7377-2019; Bello, Gonzalo/E-6842-2013;
   Araujo, Oscar/N-3146-2013; gomes, selma A/D-2762-2015
OI Bentancor, Gonzalo Jose Bello/0000-0002-2724-2793; Araujo,
   Oscar/0000-0002-9681-2980; Motta-Castro, Ana Rita/0000-0003-3070-1337;
   Gomes, Selma/0000-0003-0233-3370
CR Mora MVA, 2011, INFECT GENET EVOL, V11, P103, DOI 10.1016/j.meegid.2010.10.003
   Alvarado-Esquivel C, 2006, WORLD J GASTROENTERO, V12, P6540, DOI 10.3748/wjg.v12.i40.6540
   Araujo NM, 2013, J GEN VIROL, V94, P150, DOI 10.1099/vir.0.047324-0
   Araujo NM, 2011, INFECT GENET EVOL, V11, P1199, DOI 10.1016/j.meegid.2011.04.017
   Araujo NM, 2004, ARCH VIROL, V149, P1383, DOI 10.1007/s00705-003-0269-4
   Arauz-Ruiz P, 2002, J GEN VIROL, V83, P2059, DOI 10.1099/0022-1317-83-8-2059
   Dias ALB, 2012, REV SOC BRAS MED TRO, V45, P9, DOI 10.1590/S0037-86822012000100003
   Bertolini DA, 2000, VIRUS REV RES, V05, P101
   Bertolini DA, 2012, INFECT GENET EVOL, V12, P1295, DOI 10.1016/j.meegid.2012.04.009
   Blitz L, 1998, J CLIN MICROBIOL, V36, P648, DOI 10.1128/JCM.36.3.648-651.1998
   Bollyky PL, 1999, J MOL EVOL, V49, P130, DOI 10.1007/PL00006526
   Bottecchia M, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-11
   Campos Rodolfo H, 2005, J Clin Virol, V34 Suppl 2, pS8, DOI 10.1016/S1386-6532(05)80028-9
   Castilho MD, 2012, AM J TROP MED HYG, V87, P768, DOI 10.4269/ajtmh.2012.12-0083
   Cloherty GA, 2013, J CLIN MICROBIOL, V51, P1260, DOI 10.1128/JCM.03003-12
   Conde Simone Regina Souza da Silva, 2004, Rev. Soc. Bras. Med. Trop., V37, P33, DOI 10.1590/S0037-86822004000700005
   Devesa M, 2008, J MED VIROL, V80, P20, DOI 10.1002/jmv.21024
   Drummond AJ, 2002, GENETICS, V161, P1307
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Ganem D, 2001, FIELDS VIROLOGY, V2, P2923
   Gomes-Gouvea MS, 2009, J GEN VIROL, V90, P2638, DOI 10.1099/vir.0.013615-0
   GUNTHER S, 1995, J VIROL, V69, P5437
   Han AY, 2013, BIOORG MED CHEM LETT, V23, P1310, DOI 10.1016/j.bmcl.2012.12.097
   Hannoun C, 2000, J GEN VIROL, V81, P75, DOI 10.1099/0022-1317-81-1-75
   Huang YH, 2013, J HEPATOL, V58, P1068, DOI 10.1016/j.jhep.2013.01.014
   Huy TTT, 2008, J VIROL, V82, P5657, DOI 10.1128/JVI.02556-07
   Kay A, 2007, VIRUS RES, V127, P164, DOI 10.1016/j.virusres.2007.02.021
   Kiesslich D, 2009, J INFECT DIS, V199, P1608, DOI 10.1086/598955
   Kojima Y, 2013, EPIDEMIOL INFECT, P1
   Kowalec K, 2013, J VIRAL HEPATITIS, V20, P122, DOI 10.1111/j.1365-2893.2012.01632.x
   Kramvis A, 2005, VACCINE, V23, P2409, DOI 10.1016/j.vaccine.2004.10.045
   Lemey P, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000520
   Leone FGPY, 2003, VIRUS GENES, V27, P103, DOI 10.1023/A:1025184704955
   Livingston SE, 2007, J INFECT DIS, V195, P5, DOI 10.1086/509894
   Mello FCA, 2007, BMC MICROBIOL, V7, DOI 10.1186/1471-2180-7-103
   Moraes MTB, 1999, BRAZ J MED BIOL RES, V32, P45, DOI 10.1590/S0100-879X1999000100006
   Motta-Castro A, 2008, ARCH VIROL, V153, P2197, DOI 10.1007/s00705-008-0237-0
   Nakano T, 2001, J GEN VIROL, V82, P359, DOI 10.1099/0022-1317-82-2-359
   NAUMANN H, 1993, J GEN VIROL, V74, P1627, DOI 10.1099/0022-1317-74-8-1627
   NEEL JV, 1994, P NATL ACAD SCI USA, V91, P10737, DOI 10.1073/pnas.91.22.10737
   Norder H, 2004, INTERVIROLOGY, V47, P289, DOI 10.1159/000080872
   Olinger CM, 2008, EMERG INFECT DIS, V14, P1777, DOI 10.3201/eid1411.080437
   Osiowy C, 2006, J VIROL, V80, P10307, DOI 10.1128/JVI.00996-06
   Paraskevis D, 2013, HEPATOLOGY, V57, P908, DOI 10.1002/hep.26079
   Revill P, 2013, ANTIVIR THER, V18, P1, DOI 10.3851/IMP2542
   RIBEIRO Darcy, 1995, POVO BRASILEIRO FORM
   Stannard DE, 1993, AMERICAN HOLOCAUST T, P10016
   Stuyver L, 2000, J GEN VIROL, V81, P67, DOI 10.1099/0022-1317-81-1-67
   Tamura K, 2013, MOL BIOL EVOL, V30, P2725, DOI [10.1093/molbev/mst197, 10.1093/molbev/msr121]
   Tatematsu K, 2009, J VIROL, V83, P10538, DOI 10.1128/JVI.00462-09
   Telenta PFS, 1997, J CLIN MICROBIOL, V35, P1873, DOI 10.1128/JCM.35.7.1873-1875.1997
   Torres C, 2011, MOL PHYLOGENET EVOL, V59, P114, DOI 10.1016/j.ympev.2011.01.010
   Venegas M, 2011, J MED VIROL, V83, P1530, DOI 10.1002/jmv.22129
   Victoria FD, 2008, BRAZ J INFECT DIS, V12, P27, DOI 10.1590/S1413-86702008000100008
   von Meltzer M, 2008, VIRUS GENES, V37, P225, DOI 10.1007/s11262-008-0261-x
   Wang HY, 2010, J VIROL, V84, P3454, DOI 10.1128/JVI.02164-09
   Zhou Y, 2007, J MOL EVOL, V65, P197, DOI 10.1007/s00239-007-0054-1
NR 57
TC 18
Z9 18
U1 0
U2 8
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1743-422X
J9 VIROL J
JI Virol. J.
PD JUL 16
PY 2013
VL 10
AR 236
DI 10.1186/1743-422X-10-236
PG 8
WC Virology
SC Virology
GA 201VX
UT WOS:000323172200001
PM 23855930
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU da Silva, MFM
   Gomez, MM
   Rose, TL
   Volotao, ED
   Carvalho-Costa, FA
   Bello, G
   Leite, JPG
AF Marques da Silva, Marcelle Figueira
   Gomez, Mariela Martinez
   Rose, Tatiana Lundgren
   Volotao, Eduardo de Mello
   Carvalho-Costa, Filipe Anibal
   Bello, Gonzalo
   Gagliardi Leite, Jose Paulo
TI VP8*P[8] lineages of group A rotaviruses circulating over 20 years in
   Brazil: Proposal of six different sub-lineages for P[8]-3 clade
SO INFECTION GENETICS AND EVOLUTION
LA English
DT Article
DE Gastroenteritis; Group A rotavirus; Phylogenetic analysis; P[8]lineages;
   P[8]-3 sub-lineages
ID STRAINS; DIVERSITY; EVOLUTION; SEQUENCE; HUMANS; GENE; PCR
AB Group A rotaviruses (RVA) is the most important cause of severe gastroenteritis among children worldwide. Vaccination is considered the best alternative among public health measures to reduce and prevent the global burden caused by RVA infections. Rotarix (TM), a monovalent vaccine based on a human strain with a G1P[8]-1 specificity, was introduced in the National Brazilian Immunization Programs (NIP) in March, 2006. RVA P[8] is the most prevalent P genotype worldwide and four distinct phylogenetic lineages: P[8]-1, -2, -3, and -4 have been described. In the current study phylogenetic analysis of the VP8* gene of 135 RVA P[8] Brazilian strains, in combination with G1, G3, G5 or G9 VP7 genotype, collected from 1986 to 2011 were carried out for a better understanding of the evolution of this viral genotype in Brazil. Lineages P[8]-1, P[8]-2, and P[8]-3 were observed circulating in Brazil. In 2001 these three P[8] lineages co-circulated simultaneously and this is the first report in South America to date. Considering the P[8] lineage and the G genotype, all G3 strains were related to lineage P[8]-3, whereas the G9 strains were related to P[8]-2 and P[8]-3 and G1 and G5 were related to P[8]-1, P[8]-2, and P[8]-3. In addition, the phylogenetic analysis based on estimate of genetic distances between P[8]-3 strains and the definition of a 1.5% cutoff value (with relevant statistical support) it was possible to propose a new classification for the P[8]-3 lineage into six different sub-lineages: P[8]-3.1 to P[8]-3.6. These findings reinforce the notion of the existence of constraints within specific RVA strains populations. The results obtained in this study reinforce the importance of a continuous RVA surveillance of circulating strains in order to predict the possible variants that will circulate in a country, assess the effects of vaccination on RVA circulating strains, and ultimately help in the design, challenges, and prospects of RVA vaccines. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Marques da Silva, Marcelle Figueira; Gomez, Mariela Martinez; Rose, Tatiana Lundgren; Volotao, Eduardo de Mello; Carvalho-Costa, Filipe Anibal; Gagliardi Leite, Jose Paulo] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Comparat & Environm Virol, Minist Hlth, BR-21040360 Rio De Janeiro, Brazil.
   [Bello, Gonzalo] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab AIDS & Mol Immunol, Minist Hlth, BR-21040360 Rio De Janeiro, Brazil.
RP da Silva, MFM (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab Virol Comparada & Ambiental, Ave Brasil 4365, BR-21040360 Rio De Janeiro, Brazil.
EM marcelle@ioc.fiocruz.br
RI Silva-Sales, Marcelle/D-9809-2015; Bentancor, Gonzalo Jose
   Bello/N-7377-2019; Bello, Gonzalo/E-6842-2013; LEITE, JOSE PAULO
   GAGLIARDI/AAY-1230-2020
OI Silva-Sales, Marcelle/0000-0002-4275-9627; Bentancor, Gonzalo Jose
   Bello/0000-0002-2724-2793; 
FU Oswaldo Cruz Institute/Fiocruz; National Council for Scientific and
   Technological Development (CNPq)National Council for Scientific and
   Technological Development (CNPq); PAPES VI FIOCRUZ - CNPq; General
   Coordination of Public Health Laboratories, Secretary of Health
   Surveillance - Ministry of Health (CGLAB/SVS); Carlos Chagas Filho
   Foundation for Research Support of the State of Rio de Janeiro
   (FAPERJ)Carlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); CAPESCAPES
FX We would like to thank Rosane Maria Santos de Assis and Alexandre Madri
   Fialho for technical assistance. This study was supported/sponsored by
   Oswaldo Cruz Institute/Fiocruz, National Council for Scientific and
   Technological Development (CNPq), PAPES VI FIOCRUZ - CNPq, General
   Coordination of Public Health Laboratories, Secretary of Health
   Surveillance - Ministry of Health (CGLAB/SVS), Carlos Chagas Filho
   Foundation for Research Support of the State of Rio de Janeiro (FAPERJ)
   and CAPES.
CR Araujo IT, 2007, J MED VIROL, V79, P995, DOI 10.1002/jmv.20918
   Arista S, 2006, J VIROL, V80, P10724, DOI 10.1128/JVI.00340-06
   BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990
   Cunliffe NA, 2001, J CLIN MICROBIOL, V39, P836, DOI 10.1128/JCM.39.3.836-843.2001
   Desselberger U, 1996, ARCH VIROL, P37
   Estes MK, 2007, FIELDS VIROLOGY, V5, P1917, DOI DOI 10.1007/978-3-642-69159-1_3
   Leite JPG, 2008, MEM I OSWALDO CRUZ, V103, P745, DOI 10.1590/S0074-02762008000800001
   GENTSCH JR, 1992, J CLIN MICROBIOL, V30, P1365, DOI 10.1128/JCM.30.6.1365-1373.1992
   Heiman EM, 2008, J VIROL, V82, P11106, DOI 10.1128/JVI.01402-08
   Iturriza-Gomara M, 2000, J CLIN MICROBIOL, V38, P898
   Iturriza-Gomara M, 2001, J VIROL, V75, P3696, DOI 10.1128/JVI.75.8.3696-3705.2001
   Kirkwood CD, 1996, ARCH VIROL, V141, P587, DOI 10.1007/BF01718319
   Leite JPG, 1996, ARCH VIROL, V141, P2365, DOI 10.1007/BF01718637
   Tort LFL, 2010, J CLIN VIROL, V47, P345, DOI 10.1016/j.jcv.2009.12.018
   da Silva MFM, 2011, J MED VIROL, V83, P357, DOI 10.1002/jmv.21968
   Matthijnssens J, 2012, CURR OPIN VIROL, V2, P426, DOI 10.1016/j.coviro.2012.04.007
   Stupka JA, 2012, J CLIN VIROL, V54, P162, DOI 10.1016/j.jcv.2012.02.011
   Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092
   Tamura K, 2013, MOL BIOL EVOL, V30, P2725, DOI [10.1093/molbev/mst197, 10.1093/molbev/msr121]
   Tate JE, 2010, EXPERT REV VACCINES, V9, P395, DOI 10.1586/ERV.10.17
NR 20
TC 16
Z9 16
U1 0
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567-1348
EI 1567-7257
J9 INFECT GENET EVOL
JI Infect. Genet. Evol.
PD JUN
PY 2013
VL 16
BP 200
EP 205
DI 10.1016/j.meegid.2013.01.004
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA 166PM
UT WOS:000320569500026
PM 23352888
DA 2020-12-01
ER

PT J
AU Delatorre, E
   Bello, G
AF Delatorre, Edson
   Bello, Gonzalo
TI Spatiotemporal dynamics of the HIV-1 CRF06_cpx epidemic in western
   Africa
SO AIDS
LA English
DT Article
DE CRF06_cpx; HIV-1; phylodynamics; western Africa
ID DRUG-RESISTANCE MUTATIONS; MOLECULAR EPIDEMIOLOGY; HIGH PREVALENCE;
   NAIVE PATIENTS; SUBTYPE; DIVERSITY; PHYLODYNAMICS; TRANSMISSION;
   EVOLUTION; CRF02-AG
AB Objective: To investigate the origin and spatiotemporal dynamics of dissemination of the HIV-1 CRF06_cpx clade in western Africa.
   Design: A total of 180 HIV-1 CRF06_cpx-like pol sequences isolated from 12 different countries from west and west-central Africa over a period of 16 years (1995-2010) were analyzed.
   Methods: Evolutionary, phylogeographic and demographic parameters were jointly estimated from sequence data using a Bayesian coalescent-based method and combined with molecular epidemiology and spatial accessibility data.
   Results: The CRF06_cpx most probably emerged in Burkina Faso in 1979 (19701985). From Burkina Faso, the virus was first disseminated to Mali and Nigeria during the 1980s and later to other countries from west and west-central Africa. Demographic reconstruction indicates that the CRF06_cpx epidemic grew exponentially during the 1980s, with a median growth rate of 0.82 year(-1) (0.60-1.09 year(-1)), and after stabilize. We found a negative correlation between CRF06_cpx prevalence and the geographical distance to Burkina Faso's capital. Regional accessibility information agrees with the overall geographical range of the CRF06_cpx, but not fully explains the highly heterogeneous distribution pattern of this CRF at regional level.
   Conclusion: The CRF06_cpx epidemic in western Africa probably emerged at the late 1970s and grew during the 1980s at a rate comparable to the HIV-1 epidemics in the United States and Europe. Burkina Faso seems to be the most important epicenter of dissemination of the HIV-1 CRF06_cpx strain at regional level. The explanation for the current geographical distribution of CRF06_cpx is probably multifactorial. (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins AIDS 2013, 27:1313-1320
C1 [Delatorre, Edson; Bello, Gonzalo] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, BR-21045900 Rio De Janeiro, RJ, Brazil.
RP Bello, G (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, Av Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
EM gbellobr@gmail.com
RI Bentancor, Gonzalo Jose Bello/N-7377-2019; Bello, Gonzalo/E-6842-2013;
   Delatorre, Edson/J-8330-2015
OI Bentancor, Gonzalo Jose Bello/0000-0002-2724-2793; Delatorre,
   Edson/0000-0002-5746-0820
CR Ayouba A, 2009, AIDS RES HUM RETROV, V25, P1193, DOI 10.1089/aid.2009.0142
   Bello G, 2011, AIDS RES TREAT, V2011, DOI 10.1155/2011/154945
   Bielejec F, 2011, BIOINFORMATICS, V27, P2910, DOI 10.1093/bioinformatics/btr481
   Chamberland A, 2012, SEX TRANSM INFECT, V88, P179, DOI 10.1136/sextrans-2011-050209
   Chaplin B, 2011, AIDS RES HUM RETROV, V27, P71, DOI 10.1089/aid.2010.0050
   Charpentier C, 2011, ANTIVIR THER, V16, P429, DOI 10.3851/IMP1754
   Dagnra AY, 2011, J INT AIDS SOC, V14, DOI 10.1186/1758-2652-14-30
   de Oliveira T, 2005, BIOINFORMATICS, V21, P3797, DOI 10.1093/bioinformatics/bti607
   Delatorre EO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041904
   Delgado E, 2008, JAIDS-J ACQ IMM DEF, V48, P599, DOI 10.1097/QAI.0b013e3181806c0e
   Derache A, 2008, J ANTIMICROB CHEMOTH, V62, P456, DOI 10.1093/jac/dkn234
   Diop-Ndiaye H, 2010, AIDS RES HUM RETROV, V26, P1133, DOI 10.1089/aid.2009.0295
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   Esbjornsson J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017025
   Faria NR, 2012, INFECT GENET EVOL, V12, P453, DOI 10.1016/j.meegid.2011.04.028
   Fischetti L, 2004, J MED VIROL, V73, P158, DOI 10.1002/jmv.20070
   Gray RR, 2009, AIDS, V23, pF9, DOI 10.1097/QAD.0b013e32832faf61
   Guindon S, 2010, SYST BIOL, V59, P307, DOI 10.1093/sysbio/syq010
   Hamel DJ, 2007, AIDS RES HUM RETROV, V23, P1189, DOI 10.1089/aid.2007.0037
   Hemelaar J, 2011, AIDS, V25, P679, DOI 10.1097/QAD.0b013e328342ff93
   Hue S, 2005, P NATL ACAD SCI USA, V102, P4425, DOI 10.1073/pnas.0407534102
   Jung M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033579
   Lihana RW, 2012, AIDS REV, V14, P83
   Lole KS, 1999, J VIROL, V73, P152, DOI 10.1128/JVI.73.1.152-160.1999
   Maiga AI, 2013, AIDS RES HUM RETROV, V29, P182, DOI [10.1089/aid.2012.0118, 10.1089/AID.2012.0118]
   Mamadou S, 2002, AIDS RES HUM RETROV, V18, P723, DOI 10.1089/088922202760072357
   Montavon C, 2002, J ACQ IMMUN DEF SYND, V29, P522, DOI 10.1097/00126334-200204150-00014
   Ouedraogo-Traore R, 2003, AIDS, V17, P441, DOI 10.1097/00002030-200302140-00019
   Posada D, 2008, MOL BIOL EVOL, V25, P1253, DOI 10.1093/molbev/msn083
   Salemi M, 2005, J MOL EVOL, V60, P598, DOI 10.1007/s00239-004-0206-5
   Tatem AJ, 2012, AIDS, V26, P2351, DOI 10.1097/QAD.0b013e328359a904
   Tebit DM, 2009, J MED VIROL, V81, P1691, DOI 10.1002/jmv.21600
   Toni TD, 2007, AIDS RES HUM RETROV, V23, P1155, DOI 10.1089/aid.2007.0072
   Tully DC, 2010, AIDS, V24, P1577, DOI 10.1097/QAD.0b013e32833999e1
   Vergne L, 2006, ANTIVIR THER, V11, P575
   Walker Polly R., 2005, Infection Genetics and Evolution, V5, P199, DOI 10.1016/j.meegid.2004.06.011
   Yaotse DA, 2009, INFECT GENET EVOL, V9, P646, DOI 10.1016/j.meegid.2009.04.002
   Zehender G, 2010, JAIDS-J ACQ IMM DEF, V55, P156, DOI 10.1097/QAI.0b013e3181eb3002
NR 39
TC 10
Z9 10
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD MAY 15
PY 2013
VL 27
IS 8
BP 1313
EP 1320
DI 10.1097/QAD.0b013e32835f1df4
PG 8
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 133RG
UT WOS:000318156400014
PM 23343915
DA 2020-12-01
ER

PT J
AU Alcantara, KC
   Reis, MNG
   Cardoso, LPV
   Bello, G
   Stefani, MMA
AF Alcantara, Keila Correia
   Guarda Reis, Monica Nogueira
   Vaz Cardoso, Ludimila Paula
   Bello, Gonzalo
   Araujo Stefani, Mariane Martins
TI Increasing heterosexual transmission of HIV-1 subtype C in Inland
   Central Western Brazil
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE HIV-1 subtype C; heterosexual transmission; pregnant women; Brazil
ID IMMUNODEFICIENCY-VIRUS TYPE-1; TO-CHILD TRANSMISSION; PREGNANT-WOMEN;
   GENETIC DIVERSITY; DRUG-RESISTANCE; SOUTHERN BRAZIL; MOLECULAR
   CHARACTERIZATION; SAO-PAULO; PREVALENCE; EPIDEMIC
AB The molecular epidemiology of HIV-1 in Brazil is complex and heterogeneous because several subtypes co-circulate with some important regional differences. This study evaluated HIV-1 subtypes amongst pregnant women living in the metropolitan area and in the interior cities from central western Brazil. From June 2008 to June 2010, 86.9% of confirmed cases of HIV-1 infection amongst pregnant women (172 out of 198 cases) were recruited in Goiania/Goias state. The HIV-1 pol gene was sequenced after nested-PCR. HIV-1 subtypes were assigned by REGA, phylogenetic, and bootscan analyses. The median age of participants was 26 years (1541 years range); 58.7% of participants were diagnosed during prenatal care and 51.7% of participants came from >50 interior cities within Goias state. Amongst the 131 HIV-1 pol sequences, 64.9% were subtype B, 13.0% were BF1 recombinant, 11.4% were subtype C, 7.6% were subtype F1, and 2.3% were BC recombinant. According to the HIV-1 diagnosis date (19942010), a significant increase in subtype C and a decrease of BF1 mosaics were observed over time. All subtype C patients lived in interior cities where the highest prevalence of subtype C outside southern Brazil was observed (18.4%). Phylogenetic analysis revealed multiple independent introductions of the Brazilian subtype C clade from the southern/southeastern regions of Brazil. The HIV-1 epidemic in women from central western Brazil infected by the heterosexual route is characterized by an unexpectedly high prevalence of subtype C viruses highly related to those circulating in southern/southeastern Brazil. These findings highlight the importance of molecular surveillance programs outside large metropolitan regions in Brazil. J. Med. Virol. 85:396404, 2013. (c) 2012 Wiley Periodicals, Inc.
C1 [Alcantara, Keila Correia; Guarda Reis, Monica Nogueira; Vaz Cardoso, Ludimila Paula; Araujo Stefani, Mariane Martins] Univ Fed Goias, Trop Pathol & Publ Hlth Inst, Goiania, Go, Brazil.
   [Bello, Gonzalo] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, Rio De Janeiro, RJ, Brazil.
RP Stefani, MMA (corresponding author), Univ Fed Goias, Trop Pathol & Publ Hlth Inst, Goiania, Go, Brazil.
EM mariane.stefani@pq.cnpq.br
RI Bello, Gonzalo/E-6842-2013; Bentancor, Gonzalo Jose Bello/N-7377-2019
OI Bentancor, Gonzalo Jose Bello/0000-0002-2724-2793; ALCANTARA, KEILA
   CORREIA/0000-0002-4477-2833
FU UNESCO AIDS/STD National Program, Brazilian Ministry of Health [310-06];
   Ministry of Health/Council for Scientific and Technological Development
   (MS/MCT/CNPq/SCTIE-DECIT/CT-Saude) [022/2007]; FAPEG [200910267000696];
   CNPqNational Council for Scientific and Technological Development (CNPq)
   [141820/2006-3, 304869/2008-2]
FX Grant sponsor: UNESCO AIDS/STD National Program, Brazilian Ministry of
   Health; Grant number: #310-06; Grant sponsor: Ministry of Health/Council
   for Scientific and Technological Development
   (MS/MCT/CNPq/SCTIE-DECIT/CT-Saude); Grant number: #022/2007; Grant
   sponsor: FAPEG; Grant number: #200910267000696; Grant sponsor: CNPq;
   Grant numbers: #141820/2006-3. #304869/2008-2.
CR Abraha A, 2009, J VIROL, V83, P5592, DOI 10.1128/JVI.02051-08
   Alcantara KC, 2009, T ROY SOC TROP MED H, V103, P620, DOI 10.1016/j.trstmh.2009.03.016
   Alcantara KC, 2012, J CLIN VIROL, V54, P15, DOI 10.1016/j.jcv.2012.01.011
   Anisimova M, 2006, SYST BIOL, V55, P539, DOI 10.1080/10635150600755453
   Bello G, 2008, AIDS, V22, P1993, DOI 10.1097/QAD.0b013e328315e0aa
   Bello G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035649
   Passaes CPB, 2009, INFECT GENET EVOL, V9, P474, DOI 10.1016/j.meegid.2009.01.008
   Brigido LFM, 2011, AIDS RES HUM RETROV, V27, P339, DOI 10.1089/aid.2010.0157
   Carvalho BC, 2011, AIDS RES HUM RETROV, V27, P1081, DOI [10.1089/aid.2010.0334, 10.1089/AID.2010.0334]
   Veras NMC, 2011, J GEN VIROL, V92, P1698, DOI 10.1099/vir.0.028951-0
   Costa ZB, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-116
   de Oliveira T, 2005, BIOINFORMATICS, V21, P3797, DOI 10.1093/bioinformatics/bti607
   de Oliveira T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009311
   Ferreira JLD, 2008, MEM I OSWALDO CRUZ, V103, P800, DOI 10.1590/S0074-02762008000800010
   De Sa DJ, 2006, AIDS RES HUM RETROV, V22, P1
   Fontella R, 2008, AIDS, V22, P2001, DOI 10.1097/QAD.0b013e3283108f69
   Graf T, 2011, J CLIN VIROL, V51, P186, DOI 10.1016/j.jcv.2011.04.011
   Guindon S, 2005, NUCLEIC ACIDS RES, V33, pW557, DOI 10.1093/nar/gki352
   Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520
   John-Stewart GC, 2005, J INFECT DIS, V192, P492, DOI 10.1086/431514
   KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581
   Locateli D, 2007, J MED VIROL, V79, P1455, DOI 10.1002/jmv.20955
   Lole KS, 1999, J VIROL, V73, P152, DOI 10.1128/JVI.73.1.152-160.1999
   Machado LFA, 2009, AIDS RES HUM RETROV, V25, P961, DOI 10.1089/aid.2009.0027
   Posada D, 2008, MOL BIOL EVOL, V25, P1253, DOI 10.1093/molbev/msn083
   Renjifo B, 2004, AIDS, V18, P1629, DOI 10.1097/01.aids.0000131392.68597.34
   Rodrigues R, 2010, AIDS RES HUM RETROV, V26, P351, DOI 10.1089/aid.2009.0214
   Ryan CE, 2007, AIDS RES HUM RETROV, V23, P941, DOI 10.1089/aid.2007.0043
   Sanabani SS, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-74
   Silveira J, 2012, J CLIN VIROL, V54, P36, DOI 10.1016/j.jcv.2012.01.017
   Soares EAJM, 2005, AIDS, V19, pS81, DOI 10.1097/01.aids.0000191497.00928.e4
   Soares EAJM, 2003, JAIDS-J ACQ IMM DEF, V34, P520, DOI 10.1097/00126334-200312150-00012
   Stefani MMA, 2007, J CLIN VIROL, V39, P205, DOI 10.1016/j.jcv.2007.04.012
   Stefani MMA, 2000, J ACQ IMMUN DEF SYND, V23, P205
   Stratford D, 2000, SOC SCI MED, V50, P737, DOI 10.1016/S0277-9536(99)00335-4
   Sugihantono A, 2003, AIDS PATIENT CARE ST, V17, P595, DOI 10.1089/108729103322555980
   Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092
   Tubiana R, 2010, CLIN INFECT DIS, V50, P585, DOI 10.1086/650005
   Cardoso LPV, 2010, J MED VIROL, V82, P351, DOI 10.1002/jmv.21722
   Cardoso LPV, 2009, J CLIN VIROL, V46, P134, DOI 10.1016/j.jcv.2009.07.009
NR 40
TC 8
Z9 8
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD MAR
PY 2013
VL 85
IS 3
BP 396
EP 404
DI 10.1002/jmv.23474
PG 9
WC Virology
SC Virology
GA 076HH
UT WOS:000313946600003
PM 23172151
DA 2020-12-01
ER

PT J
AU Cortes, FH
   Bello, G
   Vorsatz, C
   Pilotto, JH
   Guimaraes, ML
   Grinsztejn, B
   Veloso, VG
   Pinto, AR
   Morgado, MG
AF Cortes, Fernanda Heloise
   Bello, Gonzalo
   Vorsatz, Carla
   Pilotto, Jose Henrique
   Guimaraes, Monick Lindenmeyer
   Grinsztejn, Beatriz
   Veloso, Valdilea Goncalves
   Pinto, Aguinaldo Roberto
   Morgado, Mariza Goncalves
TI Higher cross-subtype IFN-gamma ELISpot responses to Gag and Nef peptides
   in Brazilian HIV-1 subtype B- and F1-than in C-infected subjects
SO VACCINE
LA English
DT Article
DE T-cell response; Gag; Net; Consensus versus isolate sequences;
   Cross-reactivity; HIV-1 subtypes
ID HUMAN-IMMUNODEFICIENCY-VIRUS; T-CELL RESPONSES; GENETIC DIVERSITY;
   IMMUNE-RESPONSES; DRUG-RESISTANCE; CLADE; INDIVIDUALS; REACTIVITY;
   CONSENSUS; VACCINE
AB HIV-1 diversity has been considered a huge challenge for the HIV-1 vaccine development. To overcome it, immunogens based on centralized sequences, as consensus, have been tested. In Brazil, the co-circulation of three subtypes offers a suitable scenario to test T cell cross-subtype responses to consensus sequences. Furthermore, we included peptides based on closest viral isolates (CVI) from each subtype analyzed to compare with T cell responses detected against the consensus sequences. The study included 32 subjects infected with HIV-1 subtype B (n = 13),C (n = 11), and F1 (n = 8). Gag and Nef-specific T cell responses were evaluated by IFN-gamma-ELISpot assay. Peptides based on CVI sequences were similar to consensus in both reducing genetic distance and detecting T cell responses. A high cross-subtype response between B and F1 in both regions was observed in HIV-1 subtype B and F1-infected subjects. We also found no significant difference in responses to subtype B and C consensus peptides among subtype B-infected subjects. In contrast, the magnitude of T cell responses to consensus C peptides in the Gag region was higher than to consensus B peptides among HIV-1 subtype C-infected subjects. Regarding Nef, subtype C-infected subjects showed higher values to consensus C than to consensus F1 peptides. Moreover, subtype F1-infected subjects presented lower responses to subtype C peptides than to subtype F1 and B. A similar level of responses was detected with group M based peptides in subtype B and F1 infected subjects. However, among subtype C infected subjects, this set of peptides detected lower levels of response than consensus C. Overall, the level of cross-subtype response between subtypes B and F1 was higher than between subtype C and B or C and F1. Our data suggests that the barrier of genetic diversity in HIV-1 group M for vaccine design may be dependent on the subtypes involved. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Cortes, Fernanda Heloise; Bello, Gonzalo; Pilotto, Jose Henrique; Guimaraes, Monick Lindenmeyer; Morgado, Mariza Goncalves] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Aids & Imunol Mol, BR-21040360 Rio De Janeiro, RJ, Brazil.
   [Vorsatz, Carla; Grinsztejn, Beatriz; Veloso, Valdilea Goncalves] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas IPEC, BR-21040360 Rio De Janeiro, RJ, Brazil.
   [Pilotto, Jose Henrique] Hosp Geral Nova Iguacu, BR-26030380 Nova Iguacu, RJ, Brazil.
   [Pinto, Aguinaldo Roberto] Univ Fed Santa Catarina, Dept Microbiol Imunol & Parasitol, Ctr Ciencias Biol, BR-88040900 Florianopolis, SC, Brazil.
RP Morgado, MG (corresponding author), Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Aids & Imunol Mol, Ave Brasil 4365, BR-21040360 Rio De Janeiro, RJ, Brazil.
EM mmorgado@ioc.fiocruz.br
RI Bello, Gonzalo/E-6842-2013; Cortes, Fernanda/AAF-9254-2020; Bentancor,
   Gonzalo Jose Bello/N-7377-2019; Pilotto, Jose Henrique/AAD-9773-2019;
   Pinto, Aguinaldo Roberto/R-6625-2016
OI Bentancor, Gonzalo Jose Bello/0000-0002-2724-2793; Pilotto, Jose
   Henrique/0000-0003-0521-8597; Pinto, Aguinaldo
   Roberto/0000-0002-0991-8876
FU Department of STD; AIDS; Viral Hepatitis/Brazilian Ministry of Health;
   CNPq FellowshipNational Council for Scientific and Technological
   Development (CNPq)
FX This work was supported by Department of STD, AIDS and Viral
   Hepatitis/Brazilian Ministry of Health. Fernanda Heloise Cortes is
   recipient of a CNPq Fellowship. We thank all the patients that
   participated in this study, the Program for Technological Development in
   Tools for Health-PDTIS/FIOCRUZ for use of its facilities and Vera
   Bongertz for critical reviewing of the manuscript.
CR Aguayo N, 2008, REV SOC BRAS MED TRO, V41, P225, DOI 10.1590/S0037-86822008000300001
   Artenstein AW, 1996, AIDS RES HUM RETROV, V12, P557, DOI 10.1089/aid.1996.12.557
   Bansal A, 2006, AIDS, V20, P353, DOI 10.1097/01.aids.0000206501.16783.67
   Betts MR, 1997, J VIROL, V71, P8908, DOI 10.1128/JVI.71.11.8908-8911.1997
   Bongertz V, 2005, MEM I OSWALDO CRUZ, V100, P85, DOI 10.1590/S0074-02762005000100016
   Boutwell CL, 2010, J INFECT DIS, V202, pS309, DOI 10.1086/655653
   Brown SA, 2006, AIDS RES HUM RETROV, V22, P188, DOI 10.1089/aid.2006.22.188
   Calarota SA, 2008, J IMMUNOL, V180, P5907, DOI 10.4049/jimmunol.180.9.5907
   Caride E, 2000, VIROLOGY, V275, P107, DOI 10.1006/viro.2000.0487
   Coplan PM, 2005, J INFECT DIS, V191, P1427, DOI 10.1086/428450
   Cunha-Neto E, 2008, AIDS RES HUM RETROV, V24, P124
   Ferreira AS, 2011, J MED VIROL, V83, P1301, DOI 10.1002/jmv.22128
   Fischer W, 2007, NAT MED, V13, P100, DOI 10.1038/nm1461
   Frahm N, 2004, J VIROL, V78, P2187, DOI 10.1128/JVI.78.5.2187-2200.2004
   Frahm N, 2008, AIDS, V22, P447, DOI 10.1097/QAD.0b013e3282f42412
   Gao F, 2005, J VIROL, V79, P1154, DOI 10.1128/JVI.79.2.1154-1163.2005
   Gao Feng, 2004, Expert Rev Vaccines, V3, pS161, DOI 10.1586/14760584.3.4.S161
   Garber DA, 2004, LANCET INFECT DIS, V4, P397, DOI 10.1016/S1473-3099(04)01056-4
   Gaschen B, 2002, SCIENCE, V296, P2354, DOI 10.1126/science.1070441
   Geels MJ, 2005, J VIROL, V79, P11247, DOI 10.1128/JVI.79.17.11247-11258.2005
   Girard MP, 2011, VACCINE, V29, P6191, DOI [10.1016/j.vaccine.2011.08.031, 10.1016/j.vaccine.2011.06.085]
   Gomez-Carrillo M, 2006, AIDS RES HUM RETROV, V22, P1186, DOI 10.1089/aid.2006.22.1186
   Graf T, 2011, J CLIN VIROL, V51, P186, DOI 10.1016/j.jcv.2011.04.011
   Gupta SB, 2006, JAIDS-J ACQ IMM DEF, V42, P135, DOI 10.1097/01.qai.0000223017.01568.e7
   Heyndrickx L, 2000, J VIROL, V74, P363, DOI 10.1128/JVI.74.1.363-370.2000
   Kesturu GS, 2006, VIROLOGY, V348, P437, DOI 10.1016/j.virol.2005.11.055
   Korber B, 2001, BRIT MED BULL, V58, P19, DOI 10.1093/bmb/58.1.19
   Kothe DL, 2006, VIROLOGY, V352, P438, DOI 10.1016/j.virol.2006.05.011
   Lee CN, 1998, AIDS RES HUM RETROV, V14, P807, DOI 10.1089/aid.1998.14.807
   Machado LFA, 2009, AIDS RES HUM RETROV, V25, P961, DOI 10.1089/aid.2009.0027
   McKinnon LR, 2005, JAIDS-J ACQ IMM DEF, V40, P245, DOI 10.1097/01.qai.0000184858.16447.04
   Montano SM, 2005, JAIDS-J ACQ IMM DEF, V40, P57, DOI 10.1097/01.qai.0000159667.72584.8b
   Morgado MG, 1998, J ACQ IMMUN DEF SYND, V18, P488, DOI 10.1097/00042560-199808150-00011
   Nickle DC, 2003, SCIENCE, V299, P1515
   Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492
   Salvi R, 1998, J VIROL, V72, P3646, DOI 10.1128/JVI.72.5.3646-3657.1998
   Santra S, 2008, P NATL ACAD SCI USA, V105, P10489, DOI 10.1073/pnas.0803352105
   Serwanga J, 2012, AIDS RES HUM RETROV, V28, P384, DOI [10.1089/aid.2011.0175, 10.1089/AID.2011.0175]
   Sierra Maria, 2005, Infection Genetics and Evolution, V5, P209, DOI 10.1016/j.meegid.2004.07.010
   Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092
   Thakar MR, 2005, J INFECT DIS, V192, P749, DOI 10.1086/432547
   Turk G, 2008, J VIROL, V82, P2853, DOI 10.1128/JVI.02260-07
   Williams F, 2001, HUM IMMUNOL, V62, P645, DOI 10.1016/S0198-8859(01)00247-6
   Yan J, 2011, VACCINE, V29, P7173, DOI 10.1016/j.vaccine.2011.05.076
   Yu XG, 2005, AIDS, V19, P1449, DOI 10.1097/01.aids.0000183126.32077.c8
   Zembe L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026096
NR 46
TC 6
Z9 6
U1 1
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD FEB
PY 2013
VL 31
IS 7
BP 1106
EP 1112
DI 10.1016/j.vaccine.2012.12.023
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 083TA
UT WOS:000314486900016
PM 23261042
DA 2020-12-01
ER

PT J
AU Lampe, E
   Lewis-Ximenez, L
   Espirito-Santo, MP
   Delvaux, NM
   Pereira, SA
   Peres-da-Silva, A
   Martins, RMB
   Soares, MA
   Santos, AF
   Vidal, LL
   Germano, FN
   de Martinez, AMB
   Basso, R
   Pinho, JRR
   Malta, FM
   Gomes-Gouvea, M
   Moliterno, RA
   Bertolini, DA
   Fujishima, MAT
   Bello, G
AF Lampe, Elisabeth
   Lewis-Ximenez, Lia
   Espirito-Santo, Marcia P.
   Delvaux, Nathalia M.
   Pereira, Sergio A.
   Peres-da-Silva, Allan
   Martins, Regina M. B.
   Soares, Marcelo A.
   Santos, Andre F.
   Vidal, Luanna L.
   Germano, Fabiana N.
   de Martinez, Ana Maria B.
   Basso, Rossana
   Rebello Pinho, Joao R.
   Malta, Fernanda M.
   Gomes-Gouvea, Michele
   Moliterno, Ricardo A.
   Bertolini, Dennis A.
   Fujishima, Mayara A. T.
   Bello, Gonzalo
TI Genetic diversity of HCV in Brazil
SO ANTIVIRAL THERAPY
LA English
DT Article
ID HEPATITIS-C-VIRUS; INJECTING DRUG-USERS; HEMODIALYSIS-PATIENTS;
   RISK-FACTORS; GENOTYPES; INFECTION; PREVALENCE; PROTEASE; TRANSMISSION;
   ACCURATE
AB Background: Many studies have documented the molecular epidemiological scenario of HCV within individual Brazilian states, but we still have an incomplete understanding of the dispersion dynamics of the virus in different regions throughout the country.
   Methods: A total of 676 HCV NS5B gene sequences of subtypes 1a (n=321), 1b (n=170) and 3a (n=185), isolated from seven different Brazilian states covering four out of five regions were analysed in the present study. We also analysed 22 HCV NS5B gene sequences of minor genetic variants including genotype 2 (n=13), genotype 4 (n=6) and subtype 5a (n=3). Brazilian HCV sequences were aligned with sequences of non-Brazilian origin and subjected to maximum likelihood phylogenetic analyses.
   Results: These analyses revealed that the Brazilian HCV epidemic resulted from multiple introductions and autochthonous transmission of subtypes 1a, 1b, 3a and genotypes 2, 4 and 5. Brazilian HCV subtype 1a epidemic is dominated by the dissemination of one major clade; while Brazilian HCV subtypes 1b and 3a epidemics are characterized by concurrent dissemination of several independent HCV lineages. Some HCV Brazilian lineages of subtypes 1a, 1b, 2b and 3a were successful in becoming established and disseminated through several regions in the country. Despite significant phylogenetic intermixing of Brazilian sequences, the distribution of HCV strains from different states across lineages was not completely homogeneous.
   Conclusions: These results demonstrate the existence of multiple introductions and local propagation of both prevalent and uncommon HCV genetic variants in Brazil and identify some major Brazilian HCV clades with nationwide dissemination. This study also suggests that the observed HCV diversity in Brazil has been shaped by both frequent viral migration among regions and in situ viral dissemination.
C1 [Lampe, Elisabeth; Lewis-Ximenez, Lia; Espirito-Santo, Marcia P.; Delvaux, Nathalia M.; Pereira, Sergio A.; Peres-da-Silva, Allan] Fiocruz MS, Inst Oswaldo Cruz, Lab Hepatites Virais, BR-21045900 Rio De Janeiro, Brazil.
   [Martins, Regina M. B.] Univ Fed Goias, Inst Patol Trop & Saude Publ, Goiania, Go, Brazil.
   [Soares, Marcelo A.; Santos, Andre F.; Vidal, Luanna L.; Germano, Fabiana N.] Univ Fed Rio de Janeiro, Dept Genet, Rio De Janeiro, Brazil.
   [de Martinez, Ana Maria B.; Basso, Rossana] Univ Fed Rio Grande, Fac Med, Rio Grande, Brazil.
   [Rebello Pinho, Joao R.; Malta, Fernanda M.; Gomes-Gouvea, Michele] Univ Sao Paulo, Fac Med, Dept Gastroenterol, BR-09500900 Sao Paulo, Brazil.
   [Moliterno, Ricardo A.; Bertolini, Dennis A.; Fujishima, Mayara A. T.] Univ Estadual Maringa, Dept Ciencias Basicas Saude, Maringa, Parana, Brazil.
   [Moliterno, Ricardo A.; Bertolini, Dennis A.; Fujishima, Mayara A. T.] Univ Estadual Maringa, Dept Anal Clin & Biomed, Maringa, Parana, Brazil.
   [Bello, Gonzalo] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, BR-21045900 Rio De Janeiro, Brazil.
RP Lampe, E (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab Hepatites Virais, BR-21045900 Rio De Janeiro, Brazil.
EM elampe@ioc.fiocruz.br
RI Pinho, Joao R. R./G-2850-2012; Bentancor, Gonzalo Jose
   Bello/N-7377-2019; Santos, Andre FA/I-5734-2016; Soares, Marcelo
   A/G-5662-2010; Malta, Fernanda/B-1316-2013; Bello, Gonzalo/E-6842-2013
OI Pinho, Joao R. R./0000-0003-3999-0489; Bentancor, Gonzalo Jose
   Bello/0000-0002-2724-2793; Malta, Fernanda/0000-0001-8887-5060; ,
   Germano, FN/0000-0002-3474-0643
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)CAPES; Fundacao Carlos Chagas Filho de Amparo a Pesquisa do
   Estado do Rio de Janeiro (FAPERJ)Carlos Chagas Filho Foundation for
   Research Support of the State of Rio de Janeiro (FAPERJ); Programa de
   Excelencia em Pesquisa - PROEP/FIOCRUZ
FX This work was supported by grants from the `Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico' (CNPq) the `Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior' (CAPES) the `Fundacao
   Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro'
   (FAPERJ) and `Programa de Excelencia em Pesquisa - PROEP/FIOCRUZ'. The
   authors wish also to thank `Plataforma Genomica de Sequenciamento de
   DNA/PDTIS-FIOCRUZ' for DNA sequencing.
CR Oliveira MDA, 2009, J CLIN VIROL, V44, P200, DOI 10.1016/j.jcv.2008.12.008
   Anisimova M, 2006, SYST BIOL, V55, P539, DOI 10.1080/10635150600755453
   Bae A, 2010, ANTIMICROB AGENTS CH, V54, P5288, DOI 10.1128/AAC.00777-10
   Brazil Health Ministry, VIR HEP NUMB
   Campiotto S, 2005, BRAZ J MED BIOL RES, V38, P41, DOI 10.1590/S0100-879X2005000100007
   Carneiro MAS, 2007, J MED VIROL, V79, P1325, DOI 10.1002/jmv.20932
   Freitas SZ, 2008, MEM I OSWALDO CRUZ, V103, P405, DOI 10.1590/S0074-02762008000400016
   Guindon S, 2005, NUCLEIC ACIDS RES, V33, pW557, DOI 10.1093/nar/gki352
   Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520
   Halfon P, 2011, J HEPATOL, V55, P192, DOI 10.1016/j.jhep.2011.01.011
   Hauri AM, 2004, INT J STD AIDS, V15, P7, DOI 10.1258/095646204322637182
   Holland PV, 1996, J CLIN MICROBIOL, V34, P2372, DOI 10.1128/JCM.34.10.2372-2378.1996
   Kuiken C, 2005, BIOINFORMATICS, V21, P379, DOI 10.1093/bioinformatics/bth485
   Lampe E, 2010, INFECT GENET EVOL, V10, P886, DOI 10.1016/j.meegid.2010.05.010
   Lavanchy D, 2011, CLIN MICROBIOL INFEC, V17, P107, DOI 10.1111/j.1469-0691.2010.03432.x
   Lenz O, 2012, J HEPATOL, V56, pS5, DOI 10.1016/S0168-8278(12)60023-3
   Lopes Carmen L R, 2009, Rev. Saúde Pública, V43, P43, DOI 10.1590/S0034-89102009000800008
   Martins Regina M.B., 2006, Rev. Inst. Med. trop. S. Paulo, V48, P53, DOI 10.1590/S0036-46652006000100012
   Martins RMB, 1998, MEM I OSWALDO CRUZ, V93, P299, DOI 10.1590/S0074-02761998000300004
   Oliveira MLA, 2009, EPIDEMIOL INFECT, V137, P970, DOI 10.1017/S0950268808001970
   Oliveira MLA, 1999, BRAZ J MED BIOL RES, V32, P279, DOI 10.1590/S0100-879X1999000300005
   Pereira LMMB, 2002, J MED VIROL, V67, P27, DOI 10.1002/jmv.2188
   Peres-da-Silva A, 2012, MEM I OSWALDO CRUZ, V107, P254, DOI 10.1590/S0074-02762012000200016
   Perez RM, 2003, J MED VIROL, V69, P489, DOI 10.1002/jmv.10336
   Pickett BE, 2011, J VIRAL HEPATITIS, V18, P608, DOI 10.1111/j.1365-2893.2010.01342.x
   Posada D, 2008, MOL BIOL EVOL, V25, P1253, DOI 10.1093/molbev/msn083
   Pybus Oliver G, 2005, Infect Genet Evol, V5, P131, DOI 10.1016/j.meegid.2004.08.001
   Ribeiro LC, 2009, ARCH VIROL, V154, P665, DOI 10.1007/s00705-008-0279-3
   RODRIGUEZ F, 1990, J THEOR BIOL, V142, P485, DOI 10.1016/S0022-5193(05)80104-3
   Romano CM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011170
   Silva LK, 2000, AM J TROP MED HYG, V62, P257, DOI 10.4269/ajtmh.2000.62.257
   Simmonds P, 2005, HEPATOLOGY, V42, P962, DOI 10.1002/hep.20819
   STUYVER L, 1993, J GEN VIROL, V74, P1093, DOI 10.1099/0022-1317-74-6-1093
   Tanaka Y, 2005, J HEPATOL, V42, P47, DOI 10.1016/j.jhep.2004.09.023
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Vieira DS, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-165
   Zarife MAS, 2006, T ROY SOC TROP MED H, V100, P663, DOI 10.1016/j.trstmh.2005.09.009
NR 37
TC 19
Z9 19
U1 0
U2 2
PU INT MEDICAL PRESS LTD
PI LONDON
PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND
SN 1359-6535
J9 ANTIVIR THER
JI Antivir. Ther.
PY 2013
VL 18
IS 3
BP 435
EP 444
DI 10.3851/IMP2606
PN B
PG 10
WC Infectious Diseases; Pharmacology & Pharmacy; Virology
SC Infectious Diseases; Pharmacology & Pharmacy; Virology
GA AG2FM
UT WOS:000335231500003
PM 23792792
DA 2020-12-01
ER

PT J
AU Almeida, SEM
   de Medeiros, RM
   Junqueira, DM
   Graf, T
   Passaes, CPB
   Bello, G
   Morgado, MG
   Guimaraes, ML
AF Almeida, Sabrina E. M.
   de Medeiros, Rubia M.
   Junqueira, Dennis M.
   Graef, Tiago
   Passaes, Caroline P. B.
   Bello, Gonzalo
   Morgado, Mariza G.
   Guimaraes, Monick L.
TI Temporal dynamics of HIV-1 circulating subtypes in distinct exposure
   categories in southern Brazil
SO VIROLOGY JOURNAL
LA English
DT Article
DE HIV-1; Brazil; Subtypes; Exposure categories; Temporal dynamics
ID PRIMARY ANTIRETROVIRAL RESISTANCE; EVOLUTIONARY HISTORY; GENETIC
   DIVERSITY; HIGH PREVALENCE; NAIVE PATIENTS; TRANSMISSION; ASSOCIATION;
   MUTATIONS; STRAINS
AB Background: The HIV-1 epidemic in Brazil is predominantly driven by subtype B. However, in Brazilian Southern region subtype C prevails and a relatively high AIDS incidence rate is observed. The aim of the present study was to assess the temporal dynamics of HIV-1 subtypes circulating in patients from distinct exposure categories in Southern Brazil. For this purpose 166 HIV-1 samples collected at the years of 1998 (group I) and 2005-2008 (group II) were analyzed.
   Results: Analysis of group I revealed statistically significant (p < 0.05) associations between MSM and subtype B as well as between IDU and subtype C; while no statistical significant association between HIV-1 subtypes and exposure category was verified for group II. An overall temporal increase in the prevalence of subtype C and BC recombinants was observed in both HET and MSM populations, accompanied by a proportional decrease in the prevalence of the pure subtype B.
   Conclusions: The present study shows an association between HIV subtypes and exposure categories at the middle 1990s in Southern Brazil. Our findings suggest that MSM and IDU populations might have played a major role in the introduction and initial dissemination of subtypes B and C, respectively, in Southern Brazil. This study also suggests a trend towards homogenization of HIV-1 strains across distinct exposure categories as a consequence of an overall increase in the prevalence of subtype C and BC recombinants in both HET and MSM populations.
C1 [Almeida, Sabrina E. M.; de Medeiros, Rubia M.; Junqueira, Dennis M.; Graef, Tiago] FEPPS, Ctr Desenvolvimento Tecn Cientif CDCT, BR-90610000 Porto Alegre, RS, Brazil.
   [Passaes, Caroline P. B.; Bello, Gonzalo; Morgado, Mariza G.; Guimaraes, Monick L.] Inst Oswaldo Cruz FIOCRUZ, Lab AIDS & Imunol Mol, BR-21040900 Rio De Janeiro, RJ, Brazil.
   [de Medeiros, Rubia M.; Junqueira, Dennis M.] Univ Fed Rio Grande do Sul, Ctr Ciencias Biol, Dept Genet, Programa Posgrad Genet & Biol Mol, BR-91501970 Porto Alegre, RS, Brazil.
   [Graef, Tiago] Univ Fed Santa Catarina, Ctr Ciencias Biol, Dept Microbiol Imunol & Parasitol, Programa Posgrad Biotecnol & Biociencias, BR-88040970 Florianopolis, SC, Brazil.
RP Almeida, SEM (corresponding author), FEPPS, Ctr Desenvolvimento Tecn Cientif CDCT, Av Ipiranga 5400,3 Andar, BR-90610000 Porto Alegre, RS, Brazil.
EM sabrina.gene@gmail.com
RI de Medeiros, Rubia M/L-2761-2015; Bentancor, Gonzalo Jose
   Bello/N-7377-2019; Bello, Gonzalo/E-6842-2013; Passaes,
   Caroline/AAH-3392-2020; Graf, Tiago/S-8535-2019
OI de Medeiros, Rubia M/0000-0001-7403-5650; Bentancor, Gonzalo Jose
   Bello/0000-0002-2724-2793; Passaes, Caroline/0000-0002-0813-2521; Graf,
   Tiago/0000-0003-4921-7975
CR Bello G, 2006, AIDS, V20, P763, DOI 10.1097/01.aids.0000216377.84313.52
   Bello G, 2008, AIDS, V22, P1993, DOI 10.1097/QAD.0b013e328315e0aa
   Bello G, 2007, INFECT GENET EVOL, V7, P263, DOI 10.1016/j.meegid.2006.11.002
   Bello G, 2009, AIDS RES HUM RETROV, V25, P1065, DOI 10.1089/aid.2009.0106
   Bergenstrom AM, 2010, AIDS, V24, pS20, DOI 10.1097/01.aids.0000390086.14941.91
   Passaes CPB, 2009, INFECT GENET EVOL, V9, P474, DOI 10.1016/j.meegid.2009.01.008
   Brazilian Ministry of health, 2011, BRAZ MIN HLTH AIDS E
   Brazilian Ministry of health, COORD DST AIDS BRAS
   Brigido LFM, 2005, AIDS RES HUM RETROV, V21, P673, DOI 10.1089/aid.2005.21.673
   Brigido LFM, 2007, AIDS RES HUM RETROV, V23, P1579, DOI 10.1089/aid.2007.0102
   de Medeiros RM, 2011, J MED VIROL, V83, P1682, DOI 10.1002/jmv.22188
   Dias CF, 2009, REV INST MED TROP SP, V51, P191, DOI 10.1590/S0036-46652009000400003
   da Silva MMG, 2010, BRAZ J INFECT DIS, V14, P495, DOI 10.1590/S1413-86702010000500012
   Graf T, 2011, J CLIN VIROL, V51, P186, DOI 10.1016/j.jcv.2011.04.011
   Guiniaraes ML, 2002, AIDS RES HUM RETROV, V18, P1261, DOI 10.1089/088922202320886307
   KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581
   Machado LFA, 2009, AIDS RES HUM RETROV, V25, P961, DOI 10.1089/aid.2009.0027
   Toledo PVM, 2010, BRAZ J INFECT DIS, V14, P230, DOI 10.1590/S1413-86702010000300006
   Monteiro-Cunha JP, 2011, AIDS RES HUM RETROV, V27, P623, DOI [10.1089/AID.2010.0126, 10.1089/aid.2010.0126]
   Ng KT, 2012, J VIROL, V86, P11405, DOI 10.1128/JVI.01949-12
   Pedroso C, 2007, JAIDS-J ACQ IMM DEF, V45, P251, DOI 10.1097/QAI.0b013e318050d8b0
   Raboni SM, 2010, MEM I OSWALDO CRUZ, V105, P1044, DOI 10.1590/S0074-02762010000800015
   Ray S, SIMPLOT COMPUTER PRO
   Rodrigues R, 2006, VIRUS RES, V116, P201, DOI 10.1016/j.virusres.2005.10.004
   Santos AF, 2007, JAIDS-J ACQ IMM DEF, V45, P328
   Silveira J, 2012, J CLIN VIROL, V54, P36, DOI 10.1016/j.jcv.2012.01.017
   Simon D, 2010, REV SAUDE PUBL, V44, P1094, DOI 10.1590/S0034-89102010005000039
   Soares EAJM, 2005, AIDS, V19, pS81, DOI 10.1097/01.aids.0000191497.00928.e4
   Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092
   Tebit DM, 2011, LANCET INFECT DIS, V11, P45, DOI 10.1016/S1473-3099(10)70186-9
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Cardoso LPV, 2009, J CLIN VIROL, V46, P134, DOI 10.1016/j.jcv.2009.07.009
   World Health Organization, 2010, WHO GLOB REP UNAIDS
   Xia X, 2001, J HERED, V92, P371, DOI 10.1093/jhered/92.4.371
NR 34
TC 17
Z9 17
U1 2
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1743-422X
J9 VIROL J
JI Virol. J.
PD DEC 12
PY 2012
VL 9
AR 306
DI 10.1186/1743-422X-9-306
PG 7
WC Virology
SC Virology
GA 081IU
UT WOS:000314313300001
PM 23234345
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Afonso, JM
   Morgado, MG
   Bello, G
AF Morais Afonso, Joana
   Morgado, Mariza G.
   Bello, Gonzalo
TI Evidence of multiple introductions of HIV-1 subtype C in Angola
SO INFECTION GENETICS AND EVOLUTION
LA English
DT Article
DE HIV-1; Subtype C; Angola; Phylogeography
ID IMMUNODEFICIENCY-VIRUS TYPE-1; MAXIMUM-LIKELIHOOD; GENETIC DIVERSITY;
   SEQUENCES; INFERENCE; ACCURATE; HISTORY; ROMANIA; BRAZIL; F1
AB HIV-1 subtype C is the most prevalent group M clade in southern Africa and some eastern African countries. Subtype C is also the most frequent subtype in Angola (southwestern Africa), with an estimated prevalence of 10-20%. In order to better understand the origin of the HIV-1 subtype C strains circulating in Angola, 31 subtype C pol sequences of Angolan origin were compared with 1950 subtype C pol sequences sampled in other African countries. Phylogenetic analyses reveal that the Angolan subtype C sequences were distributed in 16 different lineages that were widely dispersed among other African strains. Ten subtype C Angolan lineages were composed by only one sequence, while the remaining six clades contain between two and seven sequences. Bayesian phylogeographic analysis indicates that most Angolan clades probably originated in different southern African countries with the exception of one lineage that most likely originated in Burundi. Evolutionary analysis suggests that those Angolan subtype C clades composed by >= 2 sequences were introduced into the country between the late 1970s and the mid 2000s. The median estimated time frame for the origin of those Angolan lineages coincides with periods of positive migration influx in Angola that were preceded by phases of negative migratory outflow. These results demonstrate that the Angolan subtype C epidemic resulted from multiple introductions of subtype C viruses mainly imported from southern African countries over the last 30 years, some of which have been locally disseminated establishing several autochthonous transmission networks. This study also suggests that population mobility between Angola and southern African countries during civil war (1974-2002) may have played a key role in the emergence of the Angolan subtype C epidemic. (c) 2012 Elsevier B.V. All rights reserved.
C1 [Morais Afonso, Joana; Morgado, Mariza G.; Bello, Gonzalo] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, BR-21045900 Rio De Janeiro, RJ, Brazil.
   [Morais Afonso, Joana] Univ Agostinho Neto, Fac Med, Luanda, Angola.
RP Bello, G (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, Av Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
EM gbello@ioc.fiocruz.br
RI Bello, Gonzalo/E-6842-2013; Bentancor, Gonzalo Jose Bello/N-7377-2019
OI Bentancor, Gonzalo Jose Bello/0000-0002-2724-2793
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); FAPERJCarlos Chagas Filho Foundation for Research Support of the
   State of Rio de Janeiro (FAPERJ); Organization for Women in Science for
   the Developing World (OWSDW) Program
FX We wish to thank Dr. Vera Bongertz for critical review of the manuscript
   and two anonymous reviewers for comments. This study was supported by
   CNPq and FAPERJ Grants. J.M.A. was supported by the Organization for
   Women in Science for the Developing World (OWSDW) Program.
CR Abecasis A., 2005, Infection Genetics and Evolution, V5, P231, DOI 10.1016/j.meegid.2004.07.007
   Castelbranco EPAF, 2010, AIDS RES HUM RETROV, V26, P1313, DOI 10.1089/aid.2010.0111
   Anisimova M, 2006, SYST BIOL, V55, P539, DOI 10.1080/10635150600755453
   Bartolo I, 2005, AIDS RES HUM RETROV, V21, P306, DOI 10.1089/aid.2005.21.306
   Bartolo I, 2009, INFECT GENET EVOL, V9, P672, DOI 10.1016/j.meegid.2008.05.003
   Bello G, 2008, AIDS, V22, P1993, DOI 10.1097/QAD.0b013e328315e0aa
   Bello G, 2012, INFECT GENET EVOL, V12, P1079, DOI 10.1016/j.meegid.2012.03.014
   Dalai SC, 2009, AIDS, V23, P2523, DOI 10.1097/QAD.0b013e3283320ef3
   de Oliveira T, 2005, BIOINFORMATICS, V21, P3797, DOI 10.1093/bioinformatics/bti607
   Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/msi103
   Drummond AJ, 2002, GENETICS, V161, P1307
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   Guimaraes ML, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-39
   Guindon S, 2005, NUCLEIC ACIDS RES, V33, pW557, DOI 10.1093/nar/gki352
   Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520
   Hemelaar J, 2011, AIDS, V25, P679, DOI 10.1097/QAD.0b013e328342ff93
   Lemey P, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000520
   Mehta SR, 2011, INFECT GENET EVOL, V11, P975, DOI 10.1016/j.meegid.2011.03.009
   Posada D, 2008, MOL BIOL EVOL, V25, P1253, DOI 10.1093/molbev/msn083
   Rambaut A, 2007, TRACER V1 4
   Rambaut A., 2009, FIGTREE V1 3 1 TREE
   Rousseau CM, 2007, J VIROL, V81, P4492, DOI 10.1128/JVI.02050-06
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Vidal N, 2000, J VIROL, V74, P10498, DOI 10.1128/JVI.74.22.10498-10507.2000
NR 25
TC 7
Z9 7
U1 0
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567-1348
J9 INFECT GENET EVOL
JI Infect. Genet. Evol.
PD OCT
PY 2012
VL 12
IS 7
BP 1458
EP 1465
DI 10.1016/j.meegid.2012.05.005
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA 024MZ
UT WOS:000310114600018
PM 22634597
DA 2020-12-01
ER

PT J
AU Delatorre, EO
   Bello, G
   Eyer-Silva, WA
   Chequer-Fernandez, SL
   Morgado, MG
   Couto-Fernandez, JC
AF Delatorre, Edson Oliveira
   Bello, Gonzalo
   Eyer-Silva, Walter A.
   Chequer-Fernandez, Saada L.
   Morgado, Mariza G.
   Couto-Fernandez, Jose Carlos
TI Evidence of Multiple Introductions and Autochthonous Transmission of the
   HIV Type 1 CRF02_AG Clade in Brazil
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID RIO-DE-JANEIRO; DRUG-RESISTANCE; INFECTED INDIVIDUALS;
   MAXIMUM-LIKELIHOOD; SAO-PAULO; PREVALENCE; MUTATIONS; DIVERSITY;
   ACCURATE; SUBTYPES
AB HIV-1 CRF02_AG is the most prevalent intersubtype recombinant form worldwide. Six HIV-1 samples from patients living in Rio de Janeiro, Brazil, were subtyped as CRF02_AG at the pol gene between 2004 and 2011. To trace the origin of these viruses, they were compared with 793 CRF02_AG pot sequences of African origin and another four Brazilian CRF02_AG pol sequences previously described. Phylogenetic analysis reveals that there have been at least four introductions of the CRF02_AG clade in Brazil, as signified by the presence of four phylogenetically distinct lineages, probably originated from western African countries (Benin, Ghana, and Guinea-Bissau). At least two CRF02_AG Brazilian lineages were successful in getting established and disseminated throughout the Rio de Janeiro state, with evidence of both horizontal and vertical transmission. Continuous epidemiological surveillance of HIV-1 strains circulating in Brazil is of paramount importance to the early detection of newly emerging viral lineages.
C1 [Delatorre, Edson Oliveira; Bello, Gonzalo; Chequer-Fernandez, Saada L.; Morgado, Mariza G.; Couto-Fernandez, Jose Carlos] Inst Oswaldo Cruz Fiocruz, Lab AIDS & Imunol Mol, BR-21045900 Rio De Janeiro, RJ, Brazil.
   [Eyer-Silva, Walter A.] Hosp Univ Gafree Guinle, Rio De Janeiro, Brazil.
RP Delatorre, EO (corresponding author), Inst Oswaldo Cruz Fiocruz, Lab AIDS & Imunol Mol, Av Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
EM edsonod@ioc.fiocruz.br; gbello@ioc.fiocruz.br
RI de Araujo Eyer-Silva, Walter/J-6264-2019; Bello, Gonzalo/E-6842-2013;
   Bentancor, Gonzalo Jose Bello/N-7377-2019; Delatorre, Edson/J-8330-2015
OI Bentancor, Gonzalo Jose Bello/0000-0002-2724-2793; Delatorre,
   Edson/0000-0002-5746-0820; Eyer-Silva, Walter de
   Araujo/0000-0001-6386-666X; Couto-Fernandez, Jose
   Carlos/0000-0001-7091-9774
CR Anisimova M, 2006, SYST BIOL, V55, P539, DOI 10.1080/10635150600755453
   Barreto CC, 2006, JAIDS-J ACQ IMM DEF, V41, P338
   Bongertz V, 2000, J ACQ IMMUN DEF SYND, V23, P184
   Brigido LFM, 2011, AIDS RES HUM RETROV, V27, P339, DOI 10.1089/aid.2010.0157
   Brindeiro RM, 2003, AIDS, V17, P1063, DOI 10.1097/00002030-200305020-00016
   Caride E, 2000, VIROLOGY, V275, P107, DOI 10.1006/viro.2000.0487
   Couto-Fernandez JC, 2006, AIDS RES HUM RETROV, V22, P207, DOI 10.1089/aid.2006.22.207
   Couto-Fernandez JC, 2005, MEM I OSWALDO CRUZ, V100, P73, DOI 10.1590/S0074-02762005000100014
   Eyer-Silva WA, 2007, MEM I OSWALDO CRUZ, V102, P809, DOI 10.1590/S0074-02762007005000112
   Guindon S, 2005, NUCLEIC ACIDS RES, V33, pW557, DOI 10.1093/nar/gki352
   Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520
   Guiniaraes ML, 2002, AIDS RES HUM RETROV, V18, P1261, DOI 10.1089/088922202320886307
   Hemelaar J, 2011, AIDS, V25, P679, DOI 10.1097/QAD.0b013e328342ff93
   Machado LFA, 2009, AIDS RES HUM RETROV, V25, P961, DOI 10.1089/aid.2009.0027
   Morgado MG, 1998, J ACQ IMMUN DEF SYND, V18, P488, DOI 10.1097/00042560-199808150-00011
   Pires IL, 2004, J CLIN MICROBIOL, V42, P426, DOI 10.1128/JCM.42.1.426-430.2004
   Posada D, 2008, MOL BIOL EVOL, V25, P1253, DOI 10.1093/molbev/msn083
NR 17
TC 10
Z9 10
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 2012
VL 28
IS 10
BP 1369
EP 1372
DI 10.1089/aid.2011.0381
PG 4
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 013TV
UT WOS:000309329700031
PM 22333001
DA 2020-12-01
ER

PT J
AU de Araujo, JMG
   Bello, G
   Romero, H
   Nogueira, RMR
AF Galvao de Araujo, Joselio Maria
   Bello, Gonzalo
   Romero, Hector
   Ribeiro Nogueira, Rita Maria
TI Origin and Evolution of Dengue Virus Type 3 in Brazil
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID RIO-DE-JANEIRO; GENETIC-CHARACTERIZATION; MOLECULAR EPIDEMIOLOGY;
   PHYLOGENETIC INFERENCE; POPULATION-DYNAMICS; MAXIMUM-LIKELIHOOD;
   HEMORRHAGIC-FEVER; SUBTYPE-III; SURVEILLANCE; EMERGENCE
AB The incidence of dengue fever and dengue hemorrhagic fever in Brazil experienced a significant increase since the emergence of dengue virus type-3 (DENV-3) at the early 2000s. Despite the major public health concerns, there have been very few studies of the molecular epidemiology and time-scale of this DENV lineage in Brazil. In this study, we investigated the origin and dispersion dynamics of DENV-3 genotype III in Brazil by examining a large number (n = 107) of E gene sequences sampled between 2001 and 2009 from diverse Brazilian regions. These Brazilian sequences were combined with 457 DENV-3 genotype III E gene sequences from 29 countries around the world. Our phylogenetic analysis reveals that there have been at least four introductions of the DENV-3 genotype III in Brazil, as signified by the presence of four phylogenetically distinct lineages. Three lineages (BR-I, BR-II, and BR-III) were probably imported from the Lesser Antilles (Caribbean), while the fourth one (BR-IV) was probably introduced from Colombia or Venezuela. While lineages BR-I and BRII succeeded in getting established and disseminated in Brazil and other countries from the Southern Cone, lineages BR-III and BR-IV were only detected in one single individual each from the North region. The phylogeographic analysis indicates that DENV-3 lineages BR-I and BR-II were most likely introduced into Brazil through the Southeast and North regions around 1999 (95% HPD: 1998-2000) and 2001 (95% HPD: 2000-2002), respectively. These findings show that importation of DENV-3 lineages from the Caribbean islands into Brazil seems to be relatively frequent. Our study further suggests that the North and Southeast Brazilian regions were the most important hubs of introduction and spread of DENV-3 lineages and deserve an intense epidemiological surveillance.
C1 [Galvao de Araujo, Joselio Maria] Univ Fed Rio Grande do Norte, Lab Mol Biol Infect Dis & Canc, BR-59072970 Natal, RN, Brazil.
   [Bello, Gonzalo] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, BR-21045900 Rio De Janeiro, Brazil.
   [Romero, Hector] Univ Republica, Fac Ciencias, Secc Biomatemat, Lab Org & Evoluc Genoma, Montevideo, Uruguay.
   [Ribeiro Nogueira, Rita Maria] Fiocruz MS, Inst Oswaldo Cruz, Lab Flavivirus, BR-21045900 Rio De Janeiro, Brazil.
RP de Araujo, JMG (corresponding author), Univ Fed Rio Grande do Norte, Lab Mol Biol Infect Dis & Canc, BR-59072970 Natal, RN, Brazil.
EM joselio@cb.ufrn.br
RI Araujo, Joselio M G/B-5502-2013; Bentancor, Gonzalo Jose
   Bello/N-7377-2019; Bello, Gonzalo/E-6842-2013
OI Araujo, Joselio M G/0000-0003-3548-2786; Bentancor, Gonzalo Jose
   Bello/0000-0002-2724-2793; 
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico -
   CNPqNational Council for Scientific and Technological Development (CNPq)
   [501564/03-9]; FAPERJCarlos Chagas Filho Foundation for Research Support
   of the State of Rio de Janeiro (FAPERJ) [E-26/152490/2002]
FX This work was supported by grants from the Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico - CNPq (grant no. 501564/03-9)
   and FAPERJ (grant no. E-26/152490/2002). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Amarilla AA, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-113
   Aquino VH, 2006, AM J TROP MED HYG, V75, P710, DOI 10.4269/ajtmh.2006.75.710
   Araujo JMG, 2009, INFECT GENET EVOL, V9, P716, DOI 10.1016/j.meegid.2008.10.005
   *CDC, 1995, MMWR-MORBID MORTAL W, V44, P21
   Cologna R, 2005, J VIROL, V79, P853, DOI 10.1128/JVI.79.2.853-859.2005
   Dash PK, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-55
   Dorji T, 2009, EMERG INFECT DIS, V15, P1630, DOI 10.3201/eid1510.090123
   Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/msi103
   Drummond AJ, 2002, GENETICS, V161, P1307
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   Franco L, 2010, EURO SURVEILL, V15
   GUBLER DJ, 1984, AM J TROP MED HYG, V33, P158, DOI 10.4269/ajtmh.1984.33.158
   Gubler DJ, 1998, CLIN MICROBIOL REV, V11, P480, DOI 10.1128/CMR.11.3.480
   Gubler Duane J., 2002, Trends in Microbiology, V10, P100, DOI 10.1016/S0966-842X(01)02288-0
   Guindon S, 2005, NUCLEIC ACIDS RES, V33, pW557, DOI 10.1093/nar/gki352
   Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520
   Guzman Maria G., 1996, Boletin de la Oficina Sanitaria Panamericana, V121, P102
   IGARASHI A, 1978, J GEN VIROL, V40, P531, DOI 10.1099/0022-1317-40-3-531
   Villabona-Arenas CJ, 2009, TROP MED INT HEALTH, V14, P1241, DOI 10.1111/j.1365-3156.2009.02339.x
   Kanakaratne N, 2009, EMERG INFECT DIS, V15, P192, DOI 10.3201/eid1502.080926
   Kochel T, 2008, INFECT GENET EVOL, V8, P682, DOI 10.1016/j.meegid.2008.06.008
   Lemey P, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000520
   Messer WB, 2003, EMERG INFECT DIS, V9, P800
   Miagostovich MP, 2006, MEM I OSWALDO CRUZ, V101, P307, DOI 10.1590/S0074-02762006000300015
   Miagostovich MP, 2002, BRAZ J MED BIOL RES, V35, P869, DOI 10.1590/S0100-879X2002000800002
   Mondini A, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000448
   Nogueira RMR, 2011, MEM I OSWALDO CRUZ, V106, P255, DOI 10.1590/S0074-02762011000300001
   Nogueira RMR, 2005, EMERG INFECT DIS, V11, P1376
   Nogueira RMR, 2001, MEM I OSWALDO CRUZ, V96, P925, DOI 10.1590/S0074-02762001000700007
   Oliveira MF, 2010, EMERG INFECT DIS, V16, P576, DOI 10.3201/eid1603.090996
   Peyrefitte CN, 2005, EMERG INFECT DIS, V11, P757, DOI 10.3201/eid1105.040959
   Peyrefitte CN, 2003, J CLIN MICROBIOL, V41, P5195, DOI 10.1128/JCM.41.11.5195-5198.2003
   Posada D, 2008, MOL BIOL EVOL, V25, P1253, DOI 10.1093/molbev/msn083
   Rambaut A, 2007, TRACER V1 4
   Ramirez A, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-329
   Rico-Hesse R, 2010, CURR TOP MICROBIOL, V338, P45, DOI 10.1007/978-3-642-02215-9_4
   Rodriguez-Roche R, 2005, EMERG INFECT DIS, V11, P773
   Romano CM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011811
   Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180
   Siqueira JB, 2005, EMERG INFECT DIS, V11, P48, DOI 10.3201/eid1101.031091
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Usuku S, 2001, ARCH VIROL, V146, P1381, DOI 10.1007/s007050170098
   Vu TTH, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000757
NR 44
TC 13
Z9 13
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD SEP
PY 2012
VL 6
IS 9
AR e1784
DI 10.1371/journal.pntd.0001784
PG 10
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 016OH
UT WOS:000309528100008
PM 22970331
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Afonso, JM
   Bello, G
   Guimaraes, ML
   Sojka, M
   Morgado, MG
AF Afonso, Joana Morais
   Bello, Gonzalo
   Guimaraes, Monick L.
   Sojka, Marta
   Morgado, Mariza G.
TI HIV-1 Genetic Diversity and Transmitted Drug Resistance Mutations among
   Patients from the North, Central and South Regions of Angola
SO PLOS ONE
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; CIRCULATING RECOMBINANT; SURVEILLANCE;
   VARIABILITY; PREVENTION; AFRICA; ORIGIN
AB Background: Angola presents a very complex HIV-1 epidemic characterized by the co-circulation of several HIV-1 group M subtypes, intersubtype recombinants and unclassified (U) variants. The viral diversity outside the major metropolitan regions (Luanda and Cabinda) and the prevalence of transmitted drug resistance mutations (DRM) since the introduction of HAART in 2004, however, has been barely studied.
   Methods: One hundred and one individuals from the Central (n = 44), North (n = 35), and South (n = 22) regions of Angola were diagnosed as HIV-1 positive and had their blood collected between 2008 and 2010, at one of the National Referral Centers for HIV diagnosis, the Kifangondo Medical Center, located in the border between the Luanda and Bengo provinces. Angolan samples were genotyped based on phylogenetic and bootscanning analyses of the pol (PR/RT) gene and their drug resistance profile was analyzed.
   Results: Among the 101 samples analyzed, 51% clustered within a pure group M subtype, 42% were classified as intersubtype recombinants, and 7% were denoted as U. We observed an important variation in the prevalence of different HIV-1 genetic variants among country regions, with high frequency of subtype F1 in the North (20%), intersubtype recombinants in the Central (42%), and subtype C in the South (45%). Statistically significant difference in HIV-1 clade distribution was only observed in subtype C prevalence between North vs South (p = 0.0005) and Central vs South (p = 0.0012) regions. DRM to NRTI and/or NNRTI were detected in 16.3% of patients analyzed.
   Conclusions: These results demonstrate a heterogeneous distribution of HIV-1 genetic variants across different regions in Angola and also revealed an unexpected high frequency of DRM to RT inhibitors in patients that have reported no antiretroviral usage, which may decrease the efficiency of the standard first-line antiretroviral regimens currently used in the country.
C1 [Afonso, Joana Morais; Bello, Gonzalo; Guimaraes, Monick L.; Morgado, Mariza G.] Inst Oswaldo Cruz FIOCRUZ, Lab AIDS & Imunol Mol, Rio De Janeiro, Brazil.
   [Afonso, Joana Morais] Univ Agostinho Neto, Fac Med, Luanda, Angola.
   [Sojka, Marta] Sao Lucas Med Ctr, Kifangondo, Angola.
RP Afonso, JM (corresponding author), Inst Oswaldo Cruz FIOCRUZ, Lab AIDS & Imunol Mol, Rio De Janeiro, Brazil.
EM jmafonso.7@gmail.com; mmorgado@ioc.fiocruz.br
RI Bello, Gonzalo/E-6842-2013; Bentancor, Gonzalo Jose Bello/N-7377-2019
OI Bentancor, Gonzalo Jose Bello/0000-0002-2724-2793
FU Laboratory of Aids and Molecular Immunology, Oswaldo Cruz Institute,
   Oswaldo Cruz Foundation; OWSDW (Organization for Women in Science for
   the Developing World), Faculty of Medicine - University Agostinho Neto,
   Angola
FX The present study received the following financial support: Laboratory
   of Aids and Molecular Immunology, Oswaldo Cruz Institute, Oswaldo Cruz
   Foundation; OWSDW (Organization for Women in Science for the Developing
   World), Faculty of Medicine - University Agostinho Neto, Angola. These
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Abecasis A., 2005, Infection Genetics and Evolution, V5, P231, DOI 10.1016/j.meegid.2004.07.007
   Castelbranco EPAF, 2010, AIDS RES HUM RETROV, V26, P1313, DOI 10.1089/aid.2010.0111
   [Anonymous], 1998, HIV DRUG RES DAT
   Bartolo I, 2005, AIDS RES HUM RETROV, V21, P306, DOI 10.1089/aid.2005.21.306
   Bartolo I, 2009, ANTIMICROB AGENTS CH, V53, P3156, DOI 10.1128/AAC.00110-09
   Bartolo I, 2009, INFECT GENET EVOL, V9, P672, DOI 10.1016/j.meegid.2008.05.003
   Bello G, 2008, AIDS, V22, P1993, DOI 10.1097/QAD.0b013e328315e0aa
   Bennett DE, 2008, ANTIVIR THER, V13, P25
   Bennett DE, 2008, ANTIVIR THER, V13, P1
   Garrido C, 2008, J ANTIMICROB CHEMOTH, V61, P694, DOI 10.1093/jac/dkm515
   Jordan MR, 2008, ANTIVIR THER, V13, P15
   KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581
   Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150
   Ministry of Health-Republic of Angola, UNGASS REP 2010
   Ministry of Health-Republic of Angola, GUID ANT TREATM ANG
   Niama FR, 2009, AIDS RES HUM RETROV, V25, P1345, DOI 10.1089/aid.2009.0169
   Nkengasong JN, 2004, AIDS REV, V6, P4
   Peeters M, 2003, AIDS, V17, P2547, DOI 10.1097/00002030-200312050-00002
   Ray S., SIMPLOT V2 5 0
   SANTOSFERREIRA MO, 1990, J ACQ IMMUN DEF SYND, V3, P780
   Tamura K, 2013, MOL BIOL EVOL, V30, P2725, DOI [10.1093/molbev/mst197, 10.1093/molbev/msr121]
   Thomson MA, 2005, AIDS, V19, P1155, DOI 10.1097/01.aids.0000176215.95119.1d
   UNAIDS, 2010, EP FACT SHEET HIV AI
   USAID, 2011, HIV AIDS HLTH PROF A
   van de Vijver D, 2007, EPIDEMIOLOGY TRANSMI, P17
   Vidal N, 2000, J VIROL, V74, P10498, DOI 10.1128/JVI.74.22.10498-10507.2000
NR 26
TC 17
Z9 18
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 29
PY 2012
VL 7
IS 8
AR e42996
DI 10.1371/journal.pone.0042996
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 997ZC
UT WOS:000308206000015
PM 22952625
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Delatorre, EO
   Bello, G
AF Delatorre, Edson Oliveira
   Bello, Gonzalo
TI Phylodynamics of HIV-1 Subtype C Epidemic in East Africa
SO PLOS ONE
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; GENETIC DIVERSITY; POL GENE; INTERSUBTYPE
   RECOMBINANTS; MOLECULAR EPIDEMIOLOGY; PHYLOGENETIC ANALYSIS;
   DRUG-RESISTANCE; PREGNANT-WOMEN; ADDIS-ABABA; POPULATION
AB The HIV-1 subtype C accounts for an important fraction of HIV infections in east Africa, but little is known about the genetic characteristics and evolutionary history of this epidemic. Here we reconstruct the origin and spatiotemporal dynamics of the major HIV-1 subtype C clades circulating in east Africa. A large number (n = 1,981) of subtype C pol sequences were retrieved from public databases to explore relationships between strains from the east, southern and central African regions. Maximum-likelihood phylogenetic analysis of those sequences revealed that most (> 70%) strains from east Africa segregated in a single regional-specific monophyletic group, here called C-EA. A second major Ethiopian subtype C lineage and a large collection of minor Kenyan and Tanzanian subtype C clades of southern African origin were also detected. A Bayesian coalescent-based method was then used to reconstruct evolutionary parameters and migration pathways of the C-EA African lineage. This analysis indicates that the C-EA clade most probably originated in Burundi around the early 1960s, and later spread to Ethiopia, Kenya, Tanzania and Uganda, giving rise to major country-specific monophyletic sub-clusters between the early 1970s and early 1980s. The results presented here demonstrate that a substantial proportion of subtype C infections in east Africa resulted from dissemination of a single HIV local variant, probably originated in Burundi during the 1960s. Burundi was the most important hub of dissemination of that subtype C clade in east Africa, fueling the origin of new local epidemics in Ethiopia, Kenya, Tanzania and Uganda. Subtype C lineages of southern African origin have also been introduced in east Africa, but seem to have had a much more restricted spread.
C1 [Delatorre, Edson Oliveira; Bello, Gonzalo] Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, BR-20001 Rio De Janeiro, Brazil.
RP Delatorre, EO (corresponding author), Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, BR-20001 Rio De Janeiro, Brazil.
EM gbellobr@gmail.com
RI Delatorre, Edson/J-8330-2015; Bello, Gonzalo/E-6842-2013; Bentancor,
   Gonzalo Jose Bello/N-7377-2019
OI Delatorre, Edson/0000-0002-5746-0820; Bentancor, Gonzalo Jose
   Bello/0000-0002-2724-2793
FU Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de
   Janeiro and Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico grants
FX This study was supported by Fundacao Carlos Chagas Filho de Amparo a
   Pesquisa do Estado do Rio de Janeiro and Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico grants. The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Abebe A, 1997, AIDS RES HUM RETROV, V13, P1071, DOI 10.1089/aid.1997.13.1071
   Abebe A, 2001, AIDS, V15, P1555, DOI 10.1097/00002030-200108170-00013
   Abebe A, 2001, AIDS RES HUM RETROV, V17, P657, DOI 10.1089/088922201300119770
   Abebe A, 2000, AIDS RES HUM RETROV, V16, P1909, DOI 10.1089/08892220050195865
   Anisimova M, 2006, SYST BIOL, V55, P539, DOI 10.1080/10635150600755453
   Ayele W, 2010, AIDS RES HUM RETROV, V26, P805, DOI 10.1089/aid.2009.0152
   Bello G, 2008, AIDS, V22, P1993, DOI 10.1097/QAD.0b013e328315e0aa
   Bielejec F, 2011, BIOINFORMATICS, V27, P2910, DOI 10.1093/bioinformatics/btr481
   Bredell H, 2007, AIDS RES HUM RETROV, V23, P477, DOI 10.1089/aid.2006.0232
   Brennan CA, 1997, AIDS, V11, P1823, DOI 10.1097/00002030-199715000-00006
   Dalai SC, 2009, AIDS, V23, P2523, DOI 10.1097/QAD.0b013e3283320ef3
   de Oliveira T, 2005, BIOINFORMATICS, V21, P3797, DOI 10.1093/bioinformatics/bti607
   de Oliveira T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009311
   Deho L, 2008, AIDS RES HUM RETROV, V24, P323, DOI 10.1089/aid.2007.0233
   Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/msi103
   Drummond AJ, 2002, GENETICS, V161, P1307
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   Fontella R, 2008, AIDS, V22, P2001, DOI 10.1097/QAD.0b013e3283108f69
   FRANSEN S, 2010, PAPER SERIES MIGRATI
   Gale CV, 2006, AIDS RES HUM RETROV, V22, P985, DOI 10.1089/aid.2006.22.985
   Gray RR, 2009, AIDS, V23, pF9, DOI 10.1097/QAD.0b013e32832faf61
   Guindon S, 2005, NUCLEIC ACIDS RES, V33, pW557, DOI 10.1093/nar/gki352
   Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520
   Hamers RL, 2011, LANCET INFECT DIS, V11, P750, DOI 10.1016/S1473-3099(11)70149-9
   Hemelaar J, 2011, AIDS, V25, P679, DOI 10.1097/QAD.0b013e328342ff93
   Herbeck JT, 2007, AIDS RES HUM RETROV, V23, P755, DOI 10.1089/aid.2006.0237.A
   Herbinger KH, 2006, AIDS RES HUM RETROV, V22, P599, DOI 10.1089/aid.2006.22.599
   Hu DJ, 2000, EMERG INFECT DIS, V6, P609, DOI 10.3201/eid0606.000609
   Hue S, 2012, AIDS RES HUM RETROV, V28, P220, DOI 10.1089/aid.2011.0048
   Hussein M, 2000, J ACQ IMMUN DEF SYND, V23, P120
   Kageha S, 2012, AIDS RES HUM RETROV, V28, P228, DOI 10.1089/aid.2011.0089
   Kassu A, 2007, AIDS RES HUM RETROV, V23, P564, DOI 10.1089/aid.2006.0270
   Khamadi SA, 2005, AIDS RES HUM RETROV, V21, P810, DOI 10.1089/aid.2005.21.810
   Khamadi SA, 2009, AIDS RES HUM RETROV, V25, P919, DOI 10.1089/aid.2009.0005
   Khamadi SA, 2008, AIDS RES HUM RETROV, V24, P1561, DOI 10.1089/aid.2008.0085
   Kiwelu IE, 2003, AIDS RES HUM RETROV, V19, P57, DOI 10.1089/08892220360473970
   Koch N, 2001, AIDS RES HUM RETROV, V17, P269, DOI 10.1089/088922201750063205
   Lahuerta M, 2008, AIDS RES HUM RETROV, V24, P327, DOI 10.1089/aid.2007.0134
   Lemey P, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000520
   Lihana RW, 2006, AIDS RES HUM RETROV, V22, P1172, DOI 10.1089/aid.2006.22.1172
   Maslin JR, 2005, JAIDS-J ACQ IMM DEF, V39, P129
   Mosha F, 2011, AIDS RES HUM RETROV, V27, P377, DOI 10.1089/aid.2010.0113
   Neilson JR, 1999, J VIROL, V73, P4393, DOI 10.1128/JVI.73.5.4393-4403.1999
   Novitsky V, 2010, VIRUSES-BASEL, V2, P33, DOI 10.3390/v2010033
   Nyagaka B, 2011, AIDS RES HUM RETROVI
   Nyombi BM, 2008, AIDS RES HUM RETROV, V24, P761, DOI 10.1089/aid.2007.0311
   Oyaro M, 2011, AIDS RES HUM RETROV, V27, P257, DOI 10.1089/aid.2010.0061
   Parreira R, 2006, MICROBES INFECT, V8, P2442, DOI 10.1016/j.micinf.2006.05.005
   Pollakis G, 2003, AIDS RES HUM RETROV, V19, P999, DOI 10.1089/088922203322588350
   Posada D, 2008, MOL BIOL EVOL, V25, P1253, DOI 10.1093/molbev/msn083
   Rainwater S, 2005, AIDS RES HUM RETROV, V21, P1060, DOI 10.1089/aid.2005.21.1060
   Rambaut A, 2007, TRACER V1 4
   Rambaut A., 2009, FIGTREE V1 3 1 TREE
   Rayfield MA, 1998, AIDS, V12, P521, DOI 10.1097/00002030-199805000-00014
   Renjifo B, 1998, AIDS RES HUM RETROV, V14, P635, DOI 10.1089/aid.1998.14.635
   Sanchez R, 2011, NUCLEIC ACIDS RES, V39, pW470, DOI 10.1093/nar/gkr408
   Schmidt HA, 2002, BIOINFORMATICS, V18, P502, DOI 10.1093/bioinformatics/18.3.502
   Servais J, 2004, AIDS RES HUM RETROV, V20, P279, DOI 10.1089/088922204322996518
   Ssemwanga D, 2011, AIDS RES HUM RETROVI
   Strimmer K, 1997, P NATL ACAD SCI USA, V94, P6815, DOI 10.1073/pnas.94.13.6815
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Thomson MM, 2011, VIROLOGY, V415, P30, DOI 10.1016/j.virol.2011.03.021
   Tully DC, 2010, AIDS, V24, P1577, DOI 10.1097/QAD.0b013e32833999e1
   Vidal N, 2007, AIDS RES HUM RETROV, V23, P175, DOI 10.1089/aid.2006.0126
   Xia X, 2001, J HERED, V92, P371, DOI 10.1093/jhered/92.4.371
   Yang CF, 2004, AIDS RES HUM RETROV, V20, P565, DOI 10.1089/088922204323087822
NR 67
TC 24
Z9 25
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 27
PY 2012
VL 7
IS 7
AR e41904
DI 10.1371/journal.pone.0041904
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 981ER
UT WOS:000306950200126
PM 22848653
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Rangel, HR
   Maes, M
   Villalba, J
   Sulbaran, Y
   de Waard, JH
   Bello, G
   Pujol, FH
AF Rangel, Hector R.
   Maes, Mailis
   Villalba, Julian
   Sulbaran, Yoneira
   de Waard, Jacobus H.
   Bello, Gonzalo
   Pujol, Flor H.
TI Evidence of at Least Two Introductions of HIV-1 in the Amerindian Warao
   Population from Venezuela
SO PLOS ONE
LA English
DT Article
ID MOLECULAR EPIDEMIOLOGY; MAXIMUM-LIKELIHOOD; PERUVIAN AMAZON; SUBTYPE-B;
   TUBERCULOSIS; COMMUNITIES; PREVENTION; DIVERSITY; SEQUENCES; INFERENCE
AB Background: The Venezuelan Amerindians were, until recently, free of human immunodeficiency virus (HIV) infection. However, in 2007, HIV-1 infection was detected for the first time in the Warao Amerindian population living in the Eastern part of Venezuela, in the delta of the Orinoco river. The aim of this study was to analyze the genetic diversity of the HIV-1 circulating in this population.
   Methodology/Principal Findings: The pol genomic region was sequenced for 16 HIV-1 isolates and for some of them, sequences from env, vif and nef genomic regions were obtained. All HIV-1 isolates were classified as subtype B, with exception of one that was classified as subtype C. The 15 subtype B isolates exhibited a high degree of genetic similarity and formed a highly supported monophyletic cluster in each genomic region analyzed. Evolutionary analyses of the pol genomic region indicated that the date of the most recent common ancestor of the Waraos subtype B clade dates back to the late 1990s.
   Conclusions/Significance: At least two independent introductions of HIV-1 have occurred in the Warao Amerindians from Venezuela. The HIV-1 subtype B was successfully established and got disseminated in the community, while no evidence of local dissemination of the HIV-1 subtype C was detected in this study. These results warrant further surveys to evaluate the burden of this disease, which can be particularly devastating in this Amerindian population, with a high prevalence of tuberculosis, hepatitis B, among other infectious diseases, and with limited access to primary health care.
C1 [Rangel, Hector R.; Sulbaran, Yoneira; Pujol, Flor H.] Inst Venezolano Invest Cient, Ctr Microbiol & Biol Celular, Lab Virol Mol, Caracas, Venezuela.
   [Maes, Mailis; Villalba, Julian; de Waard, Jacobus H.] Cent Univ Venezuela, Inst Biomed, Lab TB, Caracas, Venezuela.
   [Bello, Gonzalo] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, BR-21045900 Rio De Janeiro, Brazil.
RP Rangel, HR (corresponding author), Inst Venezolano Invest Cient, Ctr Microbiol & Biol Celular, Lab Virol Mol, Caracas, Venezuela.
EM fhpujol@gmail.com
RI Bello, Gonzalo/E-6842-2013; Bentancor, Gonzalo Jose Bello/N-7377-2019;
   Rangel, Hector/E-5575-2010; Villalba, Julian/AAK-4222-2020; Pujol, Flor
   H/E-5687-2010
OI Bentancor, Gonzalo Jose Bello/0000-0002-2724-2793; Rangel,
   Hector/0000-0001-5937-9690; Villalba, Julian/0000-0001-9230-8747; Pujol,
   Flor H/0000-0001-6086-6883; de Waard, Jacobus H./0000-0003-4118-1015
FU Grant Ley Organica de Ciencia, Tecnologia e Innovacion from Fondo
   Nacional de Ciencia y Tecnologia, Venezuela
FX This work was supported by Grant Ley Organica de Ciencia, Tecnologia e
   Innovacion from Fondo Nacional de Ciencia y Tecnologia, Venezuela. The
   authors wish to thank Shell SA de Venezuela for the operational part in
   the Delta. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Abadia E, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-122
   Anisimova M, 2006, SYST BIOL, V55, P539, DOI 10.1080/10635150600755453
   Bartlett EC, 2008, INT J INFECT DIS, V12, pE89, DOI 10.1016/j.ijid.2008.03.036
   Bastos FI, 2008, INT J EPIDEMIOL, V37, P729, DOI 10.1093/ije/dyn127
   Bello G, 2007, INFECT GENET EVOL, V7, P263, DOI 10.1016/j.meegid.2006.11.002
   Burks DJ, 2011, CULT HEALTH SEX, V13, P283, DOI 10.1080/13691058.2010.525666
   Centers for Disease Control and Prevention, 1992, MMWR RECOMM REP, V41, P1
   Devesa M, 2004, J MED VIROL, V72, P377, DOI 10.1002/jmv.20015
   Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/msi103
   Drummond AJ, 2002, GENETICS, V161, P1307
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   Fernández de Larrea Carlos, 2002, Invest. clín, V43, P35
   Guindon S, 2005, NUCLEIC ACIDS RES, V33, pW557, DOI 10.1093/nar/gki352
   Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520
   Halpern M, 2010, REV PANAM SALUD PUBL, V28, P107, DOI 10.1590/S1020-49892010000800006
   Hue S, 2005, P NATL ACAD SCI USA, V102, P4425, DOI 10.1073/pnas.0407534102
   Lavandero J, 2010, DELTA AMACURO C ARTI
   Maes M, 2008, TUBERCULOSIS, V88, P490, DOI 10.1016/j.tube.2008.04.003
   Mazin R., 2011, DESACATOS, V35, P87
   Posada D, 2008, MOL BIOL EVOL, V25, P1253, DOI 10.1093/molbev/msn083
   Rambaut A, 2007, TRACER V1 4
   Rambaut A., 2009, FIGTREE V1 3 1 TREE
   Rangel HR, 2009, INTERCIENCIA, V34, P163
   Rangel HR, 2009, AIDS RES HUM RETROV, V25, P347, DOI 10.1089/aid.2008.0241
   Shindo N, 2002, AIDS RES HUM RETROV, V18, P71, DOI 10.1089/088922202753394736
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   UNAIDS, 2010, GLOB REP UNAIDS REP
   Vaughan HE, 2003, AIDS RES HUM RETROV, V19, P929, DOI 10.1089/088922203322493120
   Vernon IS, 2002, PUBLIC HEALTH REP, V117, pS96
   Wilbert J, 1993, MYSTIC ENDOWNMENT RE
   Zavaleta C, 2007, AM J TROP MED HYG, V76, P703, DOI 10.4269/ajtmh.2007.76.703
NR 32
TC 7
Z9 7
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 12
PY 2012
VL 7
IS 7
AR e40626
DI 10.1371/journal.pone.0040626
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 973NH
UT WOS:000306366400042
PM 22808212
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Bello, G
   Afonso, JM
   Morgado, MG
AF Bello, Gonzalo
   Afonso, Joana Morais
   Morgado, Mariza G.
TI Phylodynamics of HIV-1 subtype F1 in Angola, Brazil and Romania
SO INFECTION GENETICS AND EVOLUTION
LA English
DT Article
DE HIV-1; Subtype F1; Angola; Brazil; Romania; Demographic history
ID RIO-DE-JANEIRO; MOLECULAR EPIDEMIOLOGY; EVOLUTIONARY HISTORY; RESISTANCE
   MUTATIONS; CONGO SUGGESTS; DRUG-USERS; PREVALENCE; DIVERSITY; INFECTION;
   KINSHASA
AB The HIV-1 subtype F1 is exceptionally prevalent in Angola. Brazil and Romania. The epidemiological context in which the spread of HIV occurred was highly variable from one country to another, mainly due to the existence of a long-term civil war in Angola and the contamination of a large number of children in Romania. Here we apply phylogenetic and Bayesian coalescent-based methods to reconstruct the phylodynamic patterns of HIV-1 subtype F1 in such different epidemiological settings. The phylogenetic analyses of HIV-1 subtype F1 pol sequences sampled worldwide confirmed that most sequences from Angola, Brazil and Romania segregated in country-specific monophyletic groups, while most subtype F1 sequences from Romanian children branched as a monophyletic sub-cluster (Romania-CH) nested within sequences from adults. The inferred time of the most recent common ancestor of the different subtype F1 clades were as follow: Angola = 1983 (1978-1989), Brazil = 1977 (1972-1981), Romania adults = 1980 (1973-1987), and Romania-CH = 1985(1978-1989). All subtype F1 clades showed a demographic history best explained by a model of logistic population growth. Although the expansion phase of subtype F1 epidemic in Angola (mid 1980s to early 2000s) overlaps with the civil war period (1975-2002), the mean estimated growth rate of the Angolan F1 clade (0.49 year(-1)) was not exceptionally high, but quite similar to that estimated for the Brazilian (0.69 year(-1)) and Romanian adult (0.36 year(-1)) subtype F1 clades. The Romania-CH subtype F1 lineage, by contrast, displayed a short and explosive dissemination phase, with a median growth rate (2.47 year(-1)) much higher than that estimated for adult populations. This result supports the idea that the AIDS epidemic that affected the Romanian children was mainly caused by the spread of the HIV through highly efficient parenteral transmission networks, unlike adult populations where HIV is predominantly transmitted through sexual route. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Bello, Gonzalo; Afonso, Joana Morais; Morgado, Mariza G.] IOC FIOCRUZ, Lab AIDS & Imunol Mol, BR-21040900 Rio De Janeiro, Brazil.
   [Afonso, Joana Morais] Univ Agostinho Neto, Fac Med, Luanda, Angola.
RP Bello, G (corresponding author), IOC FIOCRUZ, Lab AIDS & Imunol Mol, Av Brasil 4365,Leonidas Deane Bldg,Room 413, BR-21040900 Rio De Janeiro, Brazil.
EM gbello@ioc.fiocruz.br
RI Bello, Gonzalo/E-6842-2013; Bentancor, Gonzalo Jose Bello/N-7377-2019
OI Bentancor, Gonzalo Jose Bello/0000-0002-2724-2793
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); FAPERJCarlos Chagas Filho Foundation for Research Support of the
   State of Rio de Janeiro (FAPERJ); Organization for Women in Science for
   the Developing World (OWSDW)
FX This study was supported by CNPq and FAPERJ grants. J.M.A. was supported
   by the Organization for Women in Science for the Developing World
   (OWSDW) Program.
CR Abecasis A., 2005, Infection Genetics and Evolution, V5, P231, DOI 10.1016/j.meegid.2004.07.007
   Castelbranco EPAF, 2010, AIDS RES HUM RETROV, V26, P1313, DOI 10.1089/aid.2010.0111
   Anisimova M, 2006, SYST BIOL, V55, P539, DOI 10.1080/10635150600755453
   Apetrei C, 2003, AIDS RES HUM RETROV, V19, P1155, DOI 10.1089/088922203771881266
   Apetrei C, 1998, AIDS, V12, P1079, DOI 10.1097/00002030-199809000-00015
   Apetrei C, 1997, AIDS RES HUM RETROV, V13, P363, DOI 10.1089/aid.1997.13.363
   Aulicino PC, 2007, AIDS RES HUM RETROV, V23, P1176, DOI 10.1089/aid.2007.0038
   BANDEA CI, 1995, EMERG INFECT DIS, V1, P91
   Bartolo I, 2009, INFECT GENET EVOL, V9, P672, DOI 10.1016/j.meegid.2008.05.003
   Bello G, 2006, AIDS, V20, P763, DOI 10.1097/01.aids.0000216377.84313.52
   Bello G, 2008, AIDS, V22, P1993, DOI 10.1097/QAD.0b013e328315e0aa
   Bello G, 2007, INFECT GENET EVOL, V7, P263, DOI 10.1016/j.meegid.2006.11.002
   Passaes CPB, 2009, INFECT GENET EVOL, V9, P474, DOI 10.1016/j.meegid.2009.01.008
   Bongertz V, 2000, J ACQ IMMUN DEF SYND, V23, P184
   Brindeiro RM, 2003, AIDS, V17, P1063, DOI 10.1097/00002030-200305020-00016
   Danziger R, 1996, AIDS CARE, V8, P701, DOI 10.1080/09540129650125416
   de Oliveira T, 2005, BIOINFORMATICS, V21, P3797, DOI 10.1093/bioinformatics/bti607
   Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/msi103
   Drummond AJ, 2002, GENETICS, V161, P1307
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   Gisselquist David, 2004, SAHARA J, V1, P114
   Guimaraes ML, 2001, J CLIN VIROL, V21, P143, DOI 10.1016/S1386-6532(01)00158-5
   Guimaraes ML, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-39
   Guindon S, 2005, NUCLEIC ACIDS RES, V33, pW557, DOI 10.1093/nar/gki352
   Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520
   Hankins CA, 2002, AIDS, V16, P2245, DOI 10.1097/00002030-200211220-00003
   Hemelaar J, 2011, AIDS, V25, P679, DOI 10.1097/QAD.0b013e328342ff93
   HERSH BS, 1993, AIDS, V7, P1617, DOI 10.1097/00002030-199312000-00012
   HERSH BS, 1991, LANCET, V338, P645, DOI 10.1016/0140-6736(91)91230-R
   Hue S, 2005, P NATL ACAD SCI USA, V102, P4425, DOI 10.1073/pnas.0407534102
   Kalish ML, 2004, EMERG INFECT DIS, V10, P1227
   Korber B, 2000, SCIENCE, V288, P1789, DOI 10.1126/science.288.5472.1789
   Lacerda HR, 2007, MEM I OSWALDO CRUZ, V102, P693, DOI [10.1590/S0074-02762007005000109, 10.1590/S0074-02762007000600006]
   Mbisa J.L., AIDS RES HU IN PRESS
   Mehta SR, 2011, INFECT GENET EVOL, V11, P975, DOI 10.1016/j.meegid.2011.03.009
   Mokili JLK, 1999, AIDS RES HUM RETROV, V15, P655, DOI 10.1089/088922299310953
   Morgado MG, 1998, J ACQ IMMUN DEF SYND, V18, P488, DOI 10.1097/00042560-199808150-00011
   Op De Coul E, 2000, AIDS RES HUM RETROV, V16, P327
   Paraschiv S, 2009, INT J INFECT DIS, V13, P81, DOI 10.1016/j.ijid.2008.03.032
   Paraschiv S, 2007, INT J INFECT DIS, V11, P123, DOI 10.1016/j.ijid.2005.11.006
   Paraskevis D, 2007, J INFECT DIS, V196, P1167, DOI 10.1086/521677
   PATRASCU IV, 1990, LANCET, V335, P672, DOI 10.1016/0140-6736(90)90466-I
   Posada D, 2008, MOL BIOL EVOL, V25, P1253, DOI 10.1093/molbev/msn083
   Raboni SM, 2010, MEM I OSWALDO CRUZ, V105, P1044, DOI 10.1590/S0074-02762010000800015
   Rambaut A, 2007, TRACER V1 4
   Rambaut A., 2009, FIGTREE V1 3 1 TREE
   Ray S., SIMPLOT V2 5 0
   Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180
   Ruta Simona, 2008, International Journal of Environmental Studies, V65, P501, DOI 10.1080/00207230802291629
   Sabino EC, 1996, AIDS, V10, P1579, DOI 10.1097/00002030-199611000-00018
   Salama P, 2001, AIDS, V15, pS4, DOI 10.1097/00002030-200104003-00002
   Salemi M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001390
   Strand RT, 2007, INT J STD AIDS, V18, P467, DOI 10.1258/095646207781147300
   Suchard MA, 2001, MOL BIOL EVOL, V18, P1001, DOI 10.1093/oxfordjournals.molbev.a003872
   Teixeira SLM, 2004, J CLIN VIROL, V31, P221, DOI 10.1016/j.jcv.2004.03.016
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Vicente ACP, 2000, J ACQ IMMUN DEF SYND, V23, P327
   Vidal N, 2000, J VIROL, V74, P10498, DOI 10.1128/JVI.74.22.10498-10507.2000
   Vidal N, 2005, JAIDS-J ACQ IMM DEF, V40, P456, DOI 10.1097/01.qai.0000159670.18326.94
   Worobey M, 2008, NATURE, V455, P661, DOI 10.1038/nature07390
   Yang CF, 2005, AIDS RES HUM RETROV, V21, P661, DOI 10.1089/aid.2005.21.661
NR 62
TC 20
Z9 20
U1 0
U2 7
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567-1348
EI 1567-7257
J9 INFECT GENET EVOL
JI Infect. Genet. Evol.
PD JUL
PY 2012
VL 12
IS 5
BP 1079
EP 1086
DI 10.1016/j.meegid.2012.03.014
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA 948RF
UT WOS:000304519600023
PM 22484759
DA 2020-12-01
ER

PT J
AU Bello, G
   Zanotto, PMD
   Iamarino, A
   Graf, T
   Pinto, AR
   Couto-Fernandez, JC
   Morgado, MG
AF Bello, Gonzalo
   Zanotto, Paolo M. de A.
   Iamarino, Atila
   Graef, Tiago
   Pinto, Aguinaldo R.
   Couto-Fernandez, Jose C.
   Morgado, Mariza G.
TI Phylogeographic Analysis of HIV-1 Subtype C Dissemination in Southern
   Brazil
SO PLOS ONE
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; MOLECULAR EPIDEMIOLOGY; GENETIC
   DIVERSITY; DRUG-RESISTANCE; CLADE-C; PHYLOGENETICS; INDIVIDUALS;
   PREVALENCE; MUTATIONS; INFERENCE
AB The HIV-1 subtype C has spread efficiently in the southern states of Brazil (Rio Grande do Sul, Santa Catarina and Parana). Phylogeographic studies indicate that the subtype C epidemic in southern Brazil was initiated by the introduction of a single founder virus population at some time point between 1960 and 1980, but little is known about the spatial dynamics of viral spread. A total of 135 Brazilian HIV-1 subtype C pol sequences collected from 1992 to 2009 at the three southern state capitals (Porto Alegre, Florianopolis and Curitiba) were analyzed. Maximum-likelihood and Bayesian methods were used to explore the degree of phylogenetic mixing of subtype C sequences from different cities and to reconstruct the geographical pattern of viral spread in this country region. Phylogeographic analyses supported the monophyletic origin of the HIV-1 subtype C clade circulating in southern Brazil and placed the root of that clade in Curitiba (Parana state). This analysis further suggested that Florianopolis (Santa Catarina state) is an important staging post in the subtype C dissemination displaying high viral migration rates from and to the other cities, while viral flux between Curitiba and Porto Alegre (Rio Grande do Sul state) is very low. We found a positive correlation (r(2) = 0.64) between routine travel and viral migration rates among localities. Despite the intense viral movement, phylogenetic intermixing of subtype C sequences from different Brazilian cities is lower than expected by chance. Notably, a high proportion (67%) of subtype C sequences from Porto Alegre branched within a single local monophyletic sub-cluster. These results suggest that the HIV-1 subtype C epidemic in southern Brazil has been shaped by both frequent viral migration among states and in situ dissemination of local clades.
C1 [Bello, Gonzalo; Couto-Fernandez, Jose C.; Morgado, Mariza G.] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, BR-21045900 Rio De Janeiro, Brazil.
   [Bello, Gonzalo] Univ Fed Rio de Janeiro, IMPPG, Dept Virol, Rio De Janeiro, Brazil.
   [Zanotto, Paolo M. de A.; Iamarino, Atila] Univ Sao Paulo, Inst Ciencias Biomed, Dept Microbiol, LEMB, Sao Paulo, Brazil.
   [Graef, Tiago; Pinto, Aguinaldo R.] Univ Fed Santa Catarina, Dept Microbiol Immunol & Parasitol, Florianopolis, SC, Brazil.
RP Bello, G (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, BR-21045900 Rio De Janeiro, Brazil.
EM gbellobr@gmail.com
RI de A. Zanotto, Paolo M./B-9286-2019; Bello, Gonzalo/E-6842-2013;
   Bentancor, Gonzalo Jose Bello/N-7377-2019; Graf, Tiago/S-8535-2019;
   Pinto, Aguinaldo Roberto/R-6625-2016
OI de A. Zanotto, Paolo M./0000-0002-8167-0625; Bentancor, Gonzalo Jose
   Bello/0000-0002-2724-2793; Graf, Tiago/0000-0003-4921-7975; Iamarino,
   Atila/0000-0003-3904-0248; Pinto, Aguinaldo Roberto/0000-0002-0991-8876;
   Couto-Fernandez, Jose Carlos/0000-0001-7091-9774
FU FAPERJCarlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); CNPqNational Council for Scientific and
   Technological Development (CNPq)
FX This study was supported by FAPERJ and CNPq grants. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Anisimova M, 2006, SYST BIOL, V55, P539, DOI 10.1080/10635150600755453
   Bello G, 2008, AIDS, V22, P1993, DOI 10.1097/QAD.0b013e328315e0aa
   Bello G, 2009, AIDS RES HUM RETROV, V25, P1065, DOI 10.1089/aid.2009.0106
   Brazilian Ministry of Health, 2011, AIDS EP B
   Brazilian Ministry of Tourism, 2009, EX REP CHAR SIZ DOM
   Brigido LFM, 2007, AIDS RES HUM RETROV, V23, P1579, DOI 10.1089/aid.2007.0102
   Brindeiro RM, 2003, AIDS, V17, P1063, DOI 10.1097/00002030-200305020-00016
   Veras NMC, 2011, J GEN VIROL, V92, P1698, DOI 10.1099/vir.0.028951-0
   Couto-Fernandez JC, 2005, MEM I OSWALDO CRUZ, V100, P73, DOI 10.1590/S0074-02762005000100014
   de Oliveira T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009311
   Ferreira JLD, 2008, MEM I OSWALDO CRUZ, V103, P800, DOI 10.1590/S0074-02762008000800010
   Drummond AJ, 2002, GENETICS, V161, P1307
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   Fontella R, 2008, AIDS, V22, P2001, DOI 10.1097/QAD.0b013e3283108f69
   da Silva MMG, 2010, BRAZ J INFECT DIS, V14, P495, DOI 10.1590/S1413-86702010000500012
   Graf T, 2011, J CLIN VIROL, V51, P186, DOI 10.1016/j.jcv.2011.04.011
   Guindon S, 2005, NUCLEIC ACIDS RES, V33, pW557, DOI 10.1093/nar/gki352
   Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520
   Lemey P, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000520
   Locateli D, 2007, J MED VIROL, V79, P1455, DOI 10.1002/jmv.20955
   Machado LFA, 2009, AIDS RES HUM RETROV, V25, P961, DOI 10.1089/aid.2009.0027
   Toledo PVM, 2010, BRAZ J INFECT DIS, V14, P230, DOI 10.1590/S1413-86702010000300006
   Minin VN, 2008, MOL BIOL EVOL, V25, P1459, DOI 10.1093/molbev/msn090
   Morgado MG, 1998, MEM I OSWALDO CRUZ, V93, P383, DOI 10.1590/S0074-02761998000300020
   Pagel M, 2004, SYST BIOL, V53, P673, DOI 10.1080/10635150490522232
   Parker J, 2008, INFECT GENET EVOL, V8, P239, DOI 10.1016/j.meegid.2007.08.001
   Posada D, 2008, MOL BIOL EVOL, V25, P1253, DOI 10.1093/molbev/msn083
   Raboni SM, 2010, MEM I OSWALDO CRUZ, V105, P1044, DOI 10.1590/S0074-02762010000800015
   Rambaut A, 2007, TRACER V1 4
   Rambaut A., 2009, FIGTREE V1 3 1 TREE
   Rodrigues R, 2006, VIRUS RES, V116, P201, DOI 10.1016/j.virusres.2005.10.004
   Rodrigues R, 2010, AIDS RES HUM RETROV, V26, P351, DOI 10.1089/aid.2009.0214
   Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180
   Salustiano Cavalcanti AM, 2007, MEM I OSWALDO CRUZ, V102, P785
   Santos AF, 2007, JAIDS-J ACQ IMM DEF, V45, P328
   Simon D, 2010, REV SAUDE PUBLICA
   SLATKIN M, 1989, GENETICS, V123, P603
   Soares EAJM, 2003, JAIDS-J ACQ IMM DEF, V34, P520, DOI 10.1097/00126334-200312150-00012
   Stefani MMA, 2007, J CLIN VIROL, V39, P205, DOI 10.1016/j.jcv.2007.04.012
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Wang TH, 2001, J VIROL, V75, P11686, DOI 10.1128/JVI.75.23.11686-11699.2001
NR 42
TC 17
Z9 18
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 18
PY 2012
VL 7
IS 4
AR e35649
DI 10.1371/journal.pone.0035649
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 959XD
UT WOS:000305350600108
PM 22530062
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Aulicino, PC
   Gomez-Carrillo, M
   Bello, G
   Rocco, C
   Mangano, A
   Carr, J
   Sen, L
   Foley, B
AF Aulicino, Paula C.
   Gomez-Carrillo, Manuel
   Bello, Gonzalo
   Rocco, Carlos
   Mangano, Andrea
   Carr, Jean
   Sen, Luisa
   Foley, Brian
TI Characterization of full-length HIV-1 CRF17_BF genomes and comparison to
   the prototype CRF12_BF strains
SO INFECTION GENETICS AND EVOLUTION
LA English
DT Article
DE HIV-1 subtypes; Argentina; BF recombinants; HIV diversity; Molecular
   epidemiology; CRF17_BF
ID IDENTIFICATION; VIRUS
AB The aim of this work is to characterize the full-length intersubtype recombinant structure of the HIV-1 Circulating Recombinant Form CRF17_BF. A single genome of CRF17_BF was originally described in 2001 as being largely similar to CRF12_BF. Since then, more genomes of CRF17_BF have been sequenced but not adequately described in publications. Here we describe CRF17_BF as a genuine CRF, and analyze its recombination pattern based on bootscan analyses, subtype signature patterns, and phylogenetic reconstruction of subtype-delimited segments. We show that CRF17_BF can be distinguished from CRF12_BF in several regions of the genome, including vpu, pol, env and nef. A complete and accurate characterization and description of recombination breakpoints in CRFs is required for a proper surveillance of HIV-1 genotypes, and important for epidemiological purposes. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Aulicino, Paula C.; Rocco, Carlos; Mangano, Andrea; Sen, Luisa] Hosp Pediat JP Garrahan, Lab Biol Celular & Retrovirus, CONICET, RA-1245 Buenos Aires, DF, Argentina.
   [Gomez-Carrillo, Manuel] Univ Buenos Aires, Sch Med, Dept Microbiol, Natl Reference Ctr AIDS, Buenos Aires, DF, Argentina.
   [Bello, Gonzalo] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, BR-21045900 Rio De Janeiro, Brazil.
   [Carr, Jean] Univ Maryland, Sch Med, Inst Human Virol, Dept Epidemiol & Prevent, Baltimore, MD 21201 USA.
   [Foley, Brian] Los Alamos Natl Lab, Theoret Biol Grp, Los Alamos, NM 87545 USA.
RP Aulicino, PC (corresponding author), Hosp Pediat JP Garrahan, Lab Biol Celular & Retrovirus, CONICET, Combate Pozos 1881, RA-1245 Buenos Aires, DF, Argentina.
EM pauauli@gmail.com
RI Foley, Brian T/N-4527-2018; Bentancor, Gonzalo Jose Bello/N-7377-2019;
   Bello, Gonzalo/E-6842-2013
OI Foley, Brian T/0000-0002-1086-0296; Bentancor, Gonzalo Jose
   Bello/0000-0002-2724-2793; 
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [Y01 AI008309] Funding Source: Medline
CR Aguayo N, 2008, REV SOC BRAS MED TRO, V41, P225, DOI 10.1590/S0037-86822008000300001
   Aulicino PC, 2011, INFECT GENET EVOL, V11, P349, DOI 10.1016/j.meegid.2010.11.008
   Carr JK, 2001, AIDS, V15, pF41, DOI 10.1097/00002030-200110190-00002
   Delgado E, 2010, AIDS RES HUM RETROV, V26, P821, DOI 10.1089/aid.2010.0006
   Fernandez-Garcia A, 2010, AIDS RES HUM RETROV, V26, P827, DOI 10.1089/aid.2009.0311
   Hraber P, 2008, J GEN VIROL, V89, P2098, DOI 10.1099/vir.0.83657-0
   Laguna-Torres V. Alberto, 2005, Rev. perú. med. exp. salud publica, V22, P12
   Lole KS, 1999, J VIROL, V73, P152, DOI 10.1128/JVI.73.1.152-160.1999
   Magiorkinis G., 2005, Infection Genetics and Evolution, V5, P225, DOI 10.1016/j.meegid.2004.05.010
   Ruchansky D, 2009, AIDS RES HUM RETROV, V25, P351, DOI 10.1089/aid.2008.0248
   Sierra Maria, 2005, Infection Genetics and Evolution, V5, P209, DOI 10.1016/j.meegid.2004.07.010
   Tamura K, 2013, MOL BIOL EVOL, V30, P2725, DOI [10.1093/molbev/mst197, 10.1093/molbev/msr121]
   Zhang CY, 2008, INFECT GENET EVOL, V8, P693, DOI 10.1016/j.meegid.2008.04.001
   Zhang M, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-25
NR 14
TC 3
Z9 3
U1 0
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567-1348
EI 1567-7257
J9 INFECT GENET EVOL
JI Infect. Genet. Evol.
PD MAR
PY 2012
VL 12
IS 2
BP 443
EP 447
DI 10.1016/j.meegid.2012.01.003
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA 921XT
UT WOS:000302512100032
PM 22266022
OA Green Accepted
DA 2020-12-01
ER

PT J
AU Graf, T
   Passaes, CPB
   Ferreira, LGE
   Grisard, EC
   Morgado, MG
   Bello, G
   Pinto, AR
AF Graef, Tiago
   Passaes, Caroline P. B.
   Ferreira, Luis G. E.
   Grisard, Edmundo C.
   Morgado, Mariza G.
   Bello, Gonzalo
   Pinto, Aguinaldo R.
TI HIV-1 genetic diversity and drug resistance among treatment naive
   patients from Southern Brazil: An association of HIV-1 subtypes with
   exposure categories
SO JOURNAL OF CLINICAL VIROLOGY
LA English
DT Article
DE HIV-1; Molecular epidemiology; Drug resistance mutations; Southern
   Brazil
ID PRIMARY ANTIRETROVIRAL RESISTANCE; IMMUNODEFICIENCY-VIRUS TYPE-1;
   CLADE-C; MOLECULAR CHARACTERIZATION; LOW-PREVALENCE; MUTATIONS;
   SURVEILLANCE; INTEGRASE; STATE; SUBSTITUTIONS
AB Background: The AIDS epidemic in Southern Brazil has unique features, showing co-circulation of HIV-1 subtypes C, B and recombinant forms. Florianopolis has the second highest AIDS incidence among Brazilian capitals, but limited information is available about HIV molecular epidemiology and prevalence of primary drug resistance.
   Objectives: To investigate the molecular epidemiology of HIV-1 in Florianopolis and to describe the prevalence of primary HIV-1 drug resistance mutations (DMRs).
   Study design: Epidemiological and clinical data from 82 untreated patients from Florianopolis (2008-2009) were analyzed. The HIV-1 subtype at envelope, protease, reverse transcriptase and integrase regions were determined by phylogenetic and bootscaning analyses and the drug resistance profile were analyzed at the Stanford HIV Drug Resistance Database.
   Results: The most frequent HIV-1 genetic form was subtype C (65.8%) followed by mosaics BC (18.3%), subtype B (13.4%), subtype F1 (1.2%) and BCF1 recombinant (1.2%). HIV-1 subtype C and BC recombinants were much more frequent in the heterosexual exposure category, whereas subtype B was more common in the MSM exposure category. DRMs were seen in 11% of the sequences, 2.4% of them were related to PI, 5% to NRTI, 3.6% to NNRTI and 1.2% was related to INTI.
   Conclusions: The present study confirms the high prevalence of subtype C and BC recombinants in Santa Catarina State and revealed a significant difference in the subtype distribution among distinct virus exposure categories. This study also shows a relative high prevalence of protease/reverse transcriptase primary drug resistance mutations and corroborates the usefulness of the integrase inhibitors in southern Brazil. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Graef, Tiago; Grisard, Edmundo C.; Pinto, Aguinaldo R.] Univ Fed Santa Catarina, Dept Microbiol Imunol & Parasitol, Ctr Ciencias Biol, BR-88040900 Florianopolis, SC, Brazil.
   [Passaes, Caroline P. B.; Morgado, Mariza G.; Bello, Gonzalo] Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, BR-21045900 Rio De Janeiro, Brazil.
   [Ferreira, Luis G. E.] Hosp Reg Homero Miranda Gomes, BR-88103901 Sao Jose, SC, Brazil.
RP Pinto, AR (corresponding author), Univ Fed Santa Catarina, Dept Microbiol Imunol & Parasitol, Ctr Ciencias Biol, BR-88040900 Florianopolis, SC, Brazil.
EM pintoar@ccb.ufsc.br
RI Graf, Tiago/S-8535-2019; Bello, Gonzalo/E-6842-2013; Passaes,
   Caroline/AAH-3392-2020; Grisard, Edmundo C/AAS-9429-2020; Bentancor,
   Gonzalo Jose Bello/N-7377-2019; Grisard, Edmundo C/A-7338-2015; Pinto,
   Aguinaldo Roberto/R-6625-2016
OI Graf, Tiago/0000-0003-4921-7975; Passaes, Caroline/0000-0002-0813-2521;
   Grisard, Edmundo C/0000-0001-8916-8296; Bentancor, Gonzalo Jose
   Bello/0000-0002-2724-2793; Grisard, Edmundo C/0000-0001-8916-8296;
   Pinto, Aguinaldo Roberto/0000-0002-0991-8876
FU Fundacao de Apoio a Pesquisa Cientifica e Tecnologica do Estado de Santa
   Catarina (FAPESC)
FX The authors are grateful to the Medical Staff for support during
   recruitment, to Patricia H. Stoco and Aline D. Schlindwein for helping
   with sequencing, and to Fundacao de Apoio a Pesquisa Cientifica e
   Tecnologica do Estado de Santa Catarina (FAPESC) for financial support.
CR Sucupira MCA, 2007, AIDS PATIENT CARE ST, V21, P116, DOI 10.1089/apc.2006.0079
   BELLO G, 2010, RETROVIROLOGY, V22, P7
   Bello G, 2008, AIDS, V22, P1993, DOI 10.1097/QAD.0b013e328315e0aa
   Bennett DE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004724
   Passaes CPB, 2009, INFECT GENET EVOL, V9, P474, DOI 10.1016/j.meegid.2009.01.008
   Bongertz V, 2000, J ACQ IMMUN DEF SYND, V23, P184
   Brasil. Ministerio da Saude, 2010, B EP AIDS DST
   BRIGIDO LF, 2010, AIDS RES HUM RETROV, V26, P1
   Brigido LFM, 2007, AIDS RES HUM RETROV, V23, P1579, DOI 10.1089/aid.2007.0102
   Brindeiro RM, 2003, AIDS, V17, P1063, DOI 10.1097/00002030-200305020-00016
   Cabral VP, 2006, MEM I OSWALDO CRUZ, V101, P881, DOI 10.1590/S0074-02762006000800010
   Ceccherini-Silberstein F, 2010, J ANTIMICROB CHEMOTH, V65, P2305, DOI 10.1093/jac/dkq326
   Couto-Fernandez JC, 1999, J ACQ IMMUN DEF SYND, V22, P288
   Ferreira JLD, 2008, MEM I OSWALDO CRUZ, V103, P800, DOI 10.1590/S0074-02762008000800010
   de Sa DJ, 2009, AIDS RES HUM RETROV, V25, P925, DOI 10.1089/aid.2009.0073
   DELWART EL, 1995, PCR METH APPL, V4, pS202
   Ersching J, 2009, REV MED VIROL, V19, P301, DOI 10.1002/rmv.625
   Gadelha SR, 2003, MEM I OSWALDO CRUZ, V98, P461, DOI 10.1590/S0074-02762003000400005
   Inocencio LA, 2009, J INT AIDS SOC, V12, DOI 10.1186/1758-2652-12-20
   KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581
   Lataillade M, 2007, ANTIVIR THER, V12, P563
   Locateli D, 2007, J MED VIROL, V79, P1455, DOI 10.1002/jmv.20955
   Lole KS, 1999, J VIROL, V73, P152, DOI 10.1128/JVI.73.1.152-160.1999
   Machado LFA, 2009, AIDS RES HUM RETROV, V25, P961, DOI 10.1089/aid.2009.0027
   Toledo PVM, 2010, BRAZ J INFECT DIS, V14, P230, DOI 10.1590/S1413-86702010000300006
   Payne BAI, 2008, J ANTIMICROB CHEMOTH, V62, P464, DOI 10.1093/jac/dkn228
   Pedroso C, 2007, JAIDS-J ACQ IMM DEF, V45, P251, DOI 10.1097/QAI.0b013e318050d8b0
   Rhee SY, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-74
   Rodrigues R, 2006, VIRUS RES, V116, P201, DOI 10.1016/j.virusres.2005.10.004
   Rodrigues R, 2010, AIDS RES HUM RETROV, V26, P351, DOI 10.1089/aid.2009.0214
   Santos AF, 2007, JAIDS-J ACQ IMM DEF, V45, P328
   Shafer RW, 2007, AIDS, V21, P215, DOI 10.1097/QAD.0b013e328011e691
   Soares EAJM, 2003, JAIDS-J ACQ IMM DEF, V34, P520, DOI 10.1097/00126334-200312150-00012
   Sprinz E, 2009, AIDS RES HUM RETROV, V25, P861, DOI 10.1089/aid.2009.0012
   Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092
   Tamura K, 2013, MOL BIOL EVOL, V30, P2725, DOI [10.1093/molbev/mst197, 10.1093/molbev/msr121]
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Cardoso LPV, 2009, J CLIN VIROL, V46, P134, DOI 10.1016/j.jcv.2009.07.009
   Veras NMC, 2007, AIDS RES HUM RETROV, V23, P1481, DOI 10.1089/aid.2007.0145
NR 39
TC 32
Z9 32
U1 0
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1386-6532
J9 J CLIN VIROL
JI J. Clin. Virol.
PD JUL
PY 2011
VL 51
IS 3
BP 186
EP 191
DI 10.1016/j.jcv.2011.04.011
PG 6
WC Virology
SC Virology
GA 779NJ
UT WOS:000291784700008
PM 21622023
DA 2020-12-01
ER

PT J
AU Aulicino, PC
   Bello, G
   Guimaraes, ML
   Ruchansky, D
   Rocco, C
   Mangano, A
   Morgado, MG
   Sen, L
AF Aulicino, Paula C.
   Bello, Gonzalo
   Guimaraes, Monick L.
   Ruchansky, Dora
   Rocco, Carlos
   Mangano, Andrea
   Morgado, Mariza G.
   Sen, Luisa
TI Longitudinal analysis of HIV-1 BF1 recombinant strains in vertically
   infected children from Argentina reveals a decrease in CRF12_BF pol gene
   mosaic patterns and high diversity of BF unique recombinant forms
SO INFECTION GENETICS AND EVOLUTION
LA English
DT Article
DE HIV-1 subtypes; Argentina; BF recombinants; HIV diversity; Molecular
   epidemiology; CRF12_BF
ID PHYLOGENETIC INFERENCE; MAXIMUM-LIKELIHOOD; SOUTH-AMERICA; TYPE-1;
   IDENTIFICATION; SUBTYPE; PARAGUAY; URUGUAY; BRAZIL
AB The HIV-1 epidemic associated to BF1 recombinants in South America is both complex and intriguing, with an underestimated diversity of recombinant structures. Our aim was to explore the characteristics and temporal dynamics of the HIV-1 BF1 epidemic in Argentina, through the study of 172 HIV-1 pol BF1 recombinant sequences obtained from HIV-1 vertically infected patients born from 1986 to 2008. Recombination patterns were characterized by bootscanning, subtype signature analysis, and phylogenetic approaches. Proportion of sequences sharing common ancestry and recombination breakpoints with the Circulating Recombinant Form (CRF) CRF12_BF was compared against sequences with a non-CRF12_BF pattern in three study periods, and by fitting the data to a logistic model. Twenty-eight HIV-1 pol BF1 mosaic structures were identified, including four of the seven South-American CRF_BF-like patterns. However, common ancestry of these sequences with reference CRF strains only confirmed the presence of CRF12_BF (51.1%) and CRF17_BF (1.2%) among the Argentine BF pol sequences. Most non-CRF_BF-like recombinant patterns shared at least one common recombination breakpoint with CRF12_BF. The number of transmissions caused by CRF12_BF viruses decreased in a linear way over time, from 69% in the period 1986-1993 to 46% in 2001-2008. In conclusion, the diversity of HIV-1 pol BF1 recombinant structures in Argentina is much more complex than previously described, with at least two CRFs_BF and 26 BF1 unique recombinant forms. For the first time, we provide evidence of a decrease in the proportion of CRF12_BF viruses transmitted from mother-to-child since the start of the epidemic to the present time in Argentina. (c) 2010 Elsevier B.V. All rights reserved.
C1 [Aulicino, Paula C.; Rocco, Carlos; Mangano, Andrea; Sen, Luisa] Hosp Pediat JP Garrahan, Lab Biol Celular & Retrovirus, CONICET, RA-1245 Buenos Aires, DF, Argentina.
   [Bello, Gonzalo; Guimaraes, Monick L.; Morgado, Mariza G.] Fiocruz MS, Lab AIDS & Imunol Mol, Inst Oswaldo Cruz, BR-21045900 Rio De Janeiro, Brazil.
   [Ruchansky, Dora] MSP, Lab Nacl Referencia VIH SIDA, Dept Labs Salud Publ, Montevideo, Uruguay.
RP Aulicino, PC (corresponding author), Hosp Pediat JP Garrahan, Lab Biol Celular & Retrovirus, CONICET, Combate de los Pozos 1881, RA-1245 Buenos Aires, DF, Argentina.
EM paulicino@garrahan.gov.ar
RI Bentancor, Gonzalo Jose Bello/N-7377-2019; Bello, Gonzalo/E-6842-2013
OI Bentancor, Gonzalo Jose Bello/0000-0002-2724-2793; 
FU Agencia Nacional de Promocion Cientifica y TecnologicaANPCyT [PICT
   2004-25830]; CONICETConsejo Nacional de Investigaciones Cientificas y
   Tecnicas (CONICET) [PIP 6057]; CNPqNational Council for Scientific and
   Technological Development (CNPq) [490585/2007-8]
FX The authors gratefully thank Dr. Vera Bongertz for language correction,
   Mrs. Carmen Galvez, Mrs. Natalia Beltramone, and Mr. Rodrigo Canepa for
   technical assistance. P.C.A, G.B., M.L.G., and D.R. did laboratory work
   and sequence analysis; A.M., and C.R. contributed to obtain study
   samples and actively participated in group discussions; C.R. performed
   statistical analyses; L.S. and M.M. directed the investigations. This
   study was supported by the Argentine Awards PICT 2004-25830 from Agencia
   Nacional de Promocion Cientifica y Tecnologica, and PIP 6057 from
   CONICET; and by the Brazilian PROSUL grant 490585/2007-8 from CNPq.
CR Aguayo N, 2008, REV SOC BRAS MED TRO, V41, P225, DOI 10.1590/S0037-86822008000300001
   Aulicino PC, 2007, AIDS RES HUM RETROV, V23, P1176, DOI 10.1089/aid.2007.0038
   Aulicino PC, 2006, MEDICINA-BUENOS AIRE, V66, P319
   Aulicino PC, 2010, ANTIVIR THER, V15, P641, DOI 10.3851/IMP1571
   Aulicino PC, 2005, AIDS RES HUM RETROV, V21, P894, DOI 10.1089/aid.2005.21.894
   Aulicino PC, 2005, AIDS RES HUM RETROV, V21, P158, DOI 10.1089/aid.2005.21.158
   Bello G, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-22
   Carr JK, 2001, AIDS, V15, pF41, DOI 10.1097/00002030-200110190-00002
   Carrillo MG, 2002, AIDS RES HUM RETROV, V18, P477, DOI 10.1089/088922202317406619
   CARRILLO MG, 2006, AIDS RES HUM RETROV, V22, P1186
   Carrion G, 2004, AIDS RES HUM RETROV, V20, P1022, DOI 10.1089/aid.2004.20.1022
   De Sa DJ, 2006, AIDS RES HUM RETROV, V22, P1
   Delgado E, 2010, AIDS RES HUM RETROV, V26, P821, DOI 10.1089/aid.2010.0006
   Dilernia DA, 2007, AIDS RES HUM RETROV, V23, P1201, DOI 10.1089/aid.2007.0068
   Gomez-Carrillo M, 2004, AIDS RES HUM RETROV, V20, P885, DOI 10.1089/0889222041725172
   Guimaraes ML, 2008, AIDS, V22, P433, DOI 10.1097/QAD.0b013e3282f47ad0
   Guindon S, 2005, NUCLEIC ACIDS RES, V33, pW557, DOI 10.1093/nar/gki352
   Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520
   Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150
   Laguna-Torres V. Alberto, 2005, Rev. perú. med. exp. salud publica, V22, P12
   Lole KS, 1999, J VIROL, V73, P152, DOI 10.1128/JVI.73.1.152-160.1999
   Pando MA, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-59
   Quarleri JF, 2004, AIDS RES HUM RETROV, V20, P1100, DOI 10.1089/aid.2004.20.1100
   Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180
   Ruchansky D, 2009, AIDS RES HUM RETROV, V25, P351, DOI 10.1089/aid.2008.0248
   Sierra Maria, 2005, Infection Genetics and Evolution, V5, P209, DOI 10.1016/j.meegid.2004.07.010
   Thomson MM, 2002, J GEN VIROL, V83, P107, DOI 10.1099/0022-1317-83-1-107
NR 27
TC 15
Z9 15
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567-1348
J9 INFECT GENET EVOL
JI Infect. Genet. Evol.
PD MAR
PY 2011
VL 11
IS 2
BP 349
EP 357
DI 10.1016/j.meegid.2010.11.008
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA 740FO
UT WOS:000288777200013
PM 21130901
DA 2020-12-01
ER

PT J
AU da Silva, MFM
   Tort, LFL
   Gomez, MM
   Assis, RMS
   Volotao, ED
   de Mendonca, MCL
   Bello, G
   Leite, JPG
AF Marques da Silva, Marcelle Figueira
   Lopez Tort, Luis Fernando
   Gomez, Mariela Martinez
   Santos Assis, Rosane Maria
   Volotao, Eduardo de Mello
   Lima de Mendonca, Marcos Cesar
   Bello, Gonzalo
   Gagliardi Leite, Jose Paulo
TI VP7 Gene of Human Rotavirus A Genotype G5: Phylogenetic Analysis Reveals
   the Existence of Three Different Lineages Worldwide
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE gastroenteritis; group A rotavirus; genotype G5 lineages; phylogenetic
   analysis
ID PORCINE ROTAVIRUS; MOLECULAR CHARACTERIZATION; INTERSPECIES
   TRANSMISSION; NUCLEOTIDE-SEQUENCE; STRAINS; IDENTIFICATION; DIARRHEA;
   DIVERSITY; BEARING; CHILD
AB Group A rotavirus (RV-A) genotype G5, which is common in pigs, was also detected in children with severe diarrhea in Brazil, Argentina, Paraguay, Cameroon, China, Thailand, and Vietnam. To evaluate the evolutionary relationship among RV-A G5 strains, the VP7 and VP4 genes of 28 Brazilian RV-A G5 human strains, sampled between 1986 and 2005, were sequenced and compared with other RV-A G5 strains currently circulating worldwide in animals and humans. The phylogenetic analysis of RV-A G5 VP7 gene s.:rains demonstrates the existence of three main lineages: (a) Lineage I: Brazilian strains grouped with three porcine strains from Thailand; (b) Lineage II: porcine, bovine, and equine strains from different regions; (c) Lineage Ill: human strains isolated in Asia and Africa, and two porcine strains from Argentina. The VP8* (*non-typable) subunit of VP4 gene sequencing showed that all P[8] strains fell into three major genetic lineages: P[8]-1; P[8]-2; and P[8]-3. These results showed that the RV-A G5 strains circulating in humans are the result of two independent zoonotic transmission events, most likely from pigs. J. Med. Virol. 83:357-366,2011. (C) 2010 Wiley-Liss, Inc.
C1 [Marques da Silva, Marcelle Figueira; Lopez Tort, Luis Fernando; Gomez, Mariela Martinez; Santos Assis, Rosane Maria; Volotao, Eduardo de Mello; Lima de Mendonca, Marcos Cesar; Gagliardi Leite, Jose Paulo] Fiocruz MS, Inst Oswaldo Cruz, Lab Comparat & Environm Virol, BR-21040360 Rio De Janeiro, Brazil.
   [Bello, Gonzalo] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Mol Immunol, BR-21040360 Rio De Janeiro, Brazil.
RP Leite, JPG (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab Virol Comparada & Ambiental, Ave Brasil 4365, BR-21040360 Rio De Janeiro, Brazil.
EM jpgleite@ioc.fiocruz.br
RI LEITE, JOSE PAULO GAGLIARDI/AAY-1230-2020; Bentancor, Gonzalo Jose
   Bello/N-7377-2019; Silva-Sales, Marcelle/D-9809-2015; Bello,
   Gonzalo/E-6842-2013
OI Bentancor, Gonzalo Jose Bello/0000-0002-2724-2793; Silva-Sales,
   Marcelle/0000-0002-4275-9627; Lopez Tort, Luis
   Fernando/0000-0001-9252-5135; GOMEZ, MARIELA/0000-0002-5740-9005
FU Oswaldo Cruz Institute-FIOCRUZ through National Council for Scientific
   and Technological Development (CNPq)National Council for Scientific and
   Technological Development (CNPq); General Coordination of Public Health
   Laboratories Secretary of Health Surveillance; FAPERJCarlos Chagas Filho
   Foundation for Research Support of the State of Rio de Janeiro (FAPERJ)
FX Grant sponsor: Oswaldo Cruz Institute-FIOCRUZ, through Project PAPES
   V/FIOCRUZ-National Council for Scientific and Technological Development
   (CNPq); Grant sponsor: General Coordination of Public Health
   Laboratories Secretary of Health Surveillance (CGLAB/SVS/MH); Grant
   sponsor: FAPERJ.
CR Abe M, 2009, VIRUS RES, V144, P250, DOI 10.1016/j.virusres.2009.05.005
   Ahmed K, 2007, EMERG INFECT DIS, V13, P1232, DOI 10.3201/eid1308.061038
   Alfieri AA, 1996, ARCH VIROL, V141, P2353, DOI 10.1007/BF01718636
   Ansaldi F, 2007, J CLIN MICROBIOL, V45, P1011, DOI 10.1128/JCM.02054-06
   Aoki ST, 2009, SCIENCE, V324, P1444, DOI 10.1126/science.1170481
   Araujo IT, 2007, J MED VIROL, V79, P995, DOI 10.1002/jmv.20918
   Arista S, 2005, J MED VIROL, V77, P587, DOI 10.1002/jmv.20496
   Blanchard H, 2007, J MOL BIOL, V367, P1215, DOI 10.1016/j.jmb.2007.01.028
   Bohne-Lang A, 2005, NUCLEIC ACIDS RES, V33, pW705, DOI 10.1093/nar/gki438
   Bok K, 2001, J MED VIROL, V65, P190, DOI 10.1002/jmv.2020
   BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990
   Chan-It W, 2008, J CLIN MICROBIOL, V46, P1169, DOI 10.1128/JCM.00856-07
   CIARLET M, 1995, ARCH VIROL, V140, P437, DOI 10.1007/BF01718422
   Ciarlet M, 2001, VIRUS GENES, V22, P5, DOI 10.1023/A:1008175716816
   Ciarlet M, 1997, J VIROL, V71, P8213, DOI 10.1128/JVI.71.11.8213-8220.1997
   Collins PJ, 2010, VET RES, V41, DOI 10.1051/vetres/2010045
   Coluchi N, 2002, J CLIN MICROBIOL, V40, P1709, DOI 10.1128/JCM.40.5.1709-1714.2002
   Cunliffe NA, 2001, J CLIN MICROBIOL, V39, P836, DOI 10.1128/JCM.39.3.836-843.2001
   DAS BK, 1994, J CLIN MICROBIOL, V32, P1820, DOI 10.1128/JCM.32.7.1820-1822.1994
   Duan ZJ, 2007, J CLIN MICROBIOL, V45, P1614, DOI 10.1128/JCM.00032-07
   DYALLSMITH ML, 1986, P NATL ACAD SCI USA, V83, P3465, DOI 10.1073/pnas.83.10.3465
   Esona MD, 2009, EMERG INFECT DIS, V15, P83, DOI 10.3201/eid1501.080899
   Esona MD, 2004, J CLIN MICROBIOL, V42, P441, DOI 10.1128/JCM.42.1.441-444.2004
   Leite JPG, 2008, MEM I OSWALDO CRUZ, V103, P745, DOI 10.1590/S0074-02762008000800001
   Gentsch JR, 2005, J INFECT DIS, V192, pS146, DOI 10.1086/431499
   GENTSCH JR, 1992, J CLIN MICROBIOL, V30, P1365, DOI 10.1128/JCM.30.6.1365-1373.1992
   GOUVEA V, 1994, J CLIN MICROBIOL, V32, P1408, DOI 10.1128/JCM.32.5.1408-1409.1994
   Gouvea V, 1999, VIRUS RES, V59, P141, DOI 10.1016/S0168-1702(98)00124-5
   Ha TPM, 2009, J CLIN MICROBIOL, V47, P3329, DOI 10.1128/JCM.01583-08
   Hall T.A., 1999, NUCL ACIDS S SER, V41, P95, DOI DOI 10.1021/BK-1999-0734.CH008
   JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275
   KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581
   Kirkwood CD, 1996, ARCH VIROL, V141, P587, DOI 10.1007/BF01718319
   Kirkwood CD, 2003, EXPERT OPIN BIOL TH, V3, P97, DOI 10.1517/eobt.3.1.97.20948
   KOBAYASHI N, 1991, J GEN VIROL, V72, P1855, DOI 10.1099/0022-1317-72-8-1855
   Li DD, 2008, J CLIN VIROL, V42, P141, DOI 10.1016/j.jcv.2007.12.013
   LI WH, 1993, J MOL EVOL, V36, P96, DOI 10.1007/BF02407308
   Tort LFL, 2010, J CLIN VIROL, V47, P345, DOI 10.1016/j.jcv.2009.12.018
   Martella V, 2007, J CLIN MICROBIOL, V45, P577, DOI 10.1128/JCM.02262-06
   Martella V, 2006, VIROLOGY, V346, P301, DOI 10.1016/j.virol.2005.11.001
   Matthijnssens J, 2008, ARCH VIROL, V153, P1621, DOI 10.1007/s00705-008-0155-1
   Matthijnssens J, 2008, J VIROL, V82, P3204, DOI 10.1128/JVI.02257-07
   Matthijnssens J, 2009, FUTURE MICROBIOL, V4, P1303, DOI 10.2217/FMB.09.96
   NAKAGOMI O, 1993, MICROBIOL IMMUNOL, V37, P337, DOI 10.1111/j.1348-0421.1993.tb03220.x
   Otto TD, 2008, GENET MOL RES, V7, P861, DOI 10.4238/vol7-3X-Meeting04
   PADILLANORIEGA L, 1995, VIROLOGY, V206, P148, DOI 10.1016/S0042-6822(95)80029-8
   PAMILO P, 1993, MOL BIOL EVOL, V10, P271
   Park SH, 2006, J CLIN MICROBIOL, V44, P4101, DOI 10.1128/JCM.01196-06
   Pond SLK, 2005, BIOINFORMATICS, V21, P676, DOI 10.1093/bioinformatics/bti079
   Santos N, 2005, REV MED VIROL, V15, P29, DOI 10.1002/rmv.448
   Schumann T, 2009, VIROLOGY, V386, P334, DOI 10.1016/j.virol.2009.01.040
   Solberg OD, 2009, VIROLOGY, V385, P58, DOI 10.1016/j.virol.2008.11.026
   Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092
   TANIGUCHI K, 1989, J VIROL, V63, P4101, DOI 10.1128/JVI.63.9.4101-4106.1989
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Ursu K, 2009, ARCH VIROL, V154, P1365, DOI 10.1007/s00705-009-0439-0
NR 56
TC 20
Z9 20
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD FEB
PY 2011
VL 83
IS 2
BP 357
EP 366
DI 10.1002/jmv.21968
PG 10
WC Virology
SC Virology
GA 699QS
UT WOS:000285678500024
PM 21181934
DA 2020-12-01
ER

PT J
AU Lampe, E
   Espirito-Santo, MP
   Martins, RMB
   Bello, G
AF Lampe, Elisabeth
   Espirito-Santo, Marcia P.
   Martins, Regina M. B.
   Bello, Gonzalo
TI Epidemic history of Hepatitis C virus in Brazil
SO INFECTION GENETICS AND EVOLUTION
LA English
DT Article
DE Brazil; HCV; Epidemic subtypes; Evolutionary history; Demographic
   history
ID INJECTING DRUG-USERS; GENOTYPE 1B; HEPATOCELLULAR-CARCINOMA; MOLECULAR
   EPIDEMIOLOGY; HEMODIALYSIS-PATIENTS; RAPID TRANSMISSION; GENETIC
   HISTORY; GLOBAL BURDEN; BLOOD-DONORS; RISK-FACTORS
AB Hepatitis C virus (HCV) subtypes 1a, 1b and 3a are the most prevalent strains in Brazil, but very little is known about the epidemic history of these subtypes in the country. A total of 231 HCV NS5B gene sequences (subtype 1a = 89, subtype 1b = 56, and subtype 3a = 86) isolated in Brazil between 1995 and 2007 were analyzed in the present study. Sequences (328-pb) were subjected to phylogenetic analyses and statistical tests of phylogenetic mixing by sampling location and risk group. Our results revealed important variations in the pattern of HCV transmission among subtypes. Transmission of subtype 1a was characterized by dissemination of one major Brazilian lineage with a random virus exchange between different geographical regions but not between IDU and non-IDU populations. Transmission of subtype 1b was characterized by concurrent dissemination of multiple HCV lineages with a restricted virus exchange between country regions and risk groups. Transmission of subtype 3a was characterized by simultaneous spreading of multiple HCV lineages and random phylogenetic mixing by risk group and sampling location. Epidemic histories of major subtypes 1a, 1b and 3a Brazilian clades were estimated using a Bayesian coalescent approach. Our results indicate that all major HCV Brazilian clades probably start to circulate in the country during the second half of the 20th century and displayed roughly similar epidemic histories characterized by an initial phase of exponential expansion and by reduction of growth rates since 1980-1995. This suggests that the expansion of HCV may have been effectively controlled in Brazil. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Bello, Gonzalo] Inst Oswaldo Cruz FIOCRUZ, Lab AIDS & Imunol Mol, BR-21045900 Rio De Janeiro, Brazil.
   [Lampe, Elisabeth; Espirito-Santo, Marcia P.] Inst Oswaldo Cruz FIOCRUZ, Lab Hepatites Virais, BR-21045900 Rio De Janeiro, Brazil.
   [Martins, Regina M. B.] Univ Fed Goias, Inst Patol Trop & Saude Publ, Goiania, Go, Brazil.
RP Bello, G (corresponding author), Inst Oswaldo Cruz FIOCRUZ, Lab AIDS & Imunol Mol, Av Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM gbello@ioc.fiocruz.br
RI Bentancor, Gonzalo Jose Bello/N-7377-2019; Bello, Gonzalo/E-6842-2013
OI Bentancor, Gonzalo Jose Bello/0000-0002-2724-2793; 
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior'
   (CAPES)CAPES; FIOCRUZ; Brazilian CNPq/FIOCRUZNational Council for
   Scientific and Technological Development (CNPq)
FX The authors thank Dr. Vera Bongertz for critical review of the
   manuscript and the article referees for advice on data analyses. We also
   wish to thank "Plataforma Genomica-Sequenciamento de DNA/PDTIS-FIOCRUZ''
   for DNA sequencing. This work was supported by grants from the "Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico'' (CNPq); the
   "Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior'' (CAPES);
   and "Programa Papes V'' from FIOCRUZ. G. B. was funded by a fellowship
   from the Brazilian CNPq/FIOCRUZ "Pesquisador Visitante'' Program.
CR Oliveira MDA, 2009, J CLIN VIROL, V44, P200, DOI 10.1016/j.jcv.2008.12.008
   Amorim RMS, 2004, MEM I OSWALDO CRUZ, V99, P895, DOI 10.1590/S0074-02762004000800019
   Anisimova M, 2006, SYST BIOL, V55, P539, DOI 10.1080/10635150600755453
   Carneiro MAS, 2007, J MED VIROL, V79, P1325, DOI 10.1002/jmv.20932
   Cochrane A, 2002, J INFECT DIS, V186, P1212, DOI 10.1086/344314
   Di Lello F, 2008, J MED VIROL, V80, P619, DOI 10.1002/jmv.21112
   Di Lello FA, 2009, J MED VIROL, V81, P1887, DOI 10.1002/jmv.21607
   Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/msi103
   Drummond AJ, 2002, GENETICS, V161, P1307
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   Ferraro D, 2008, J MED VIROL, V80, P1723, DOI 10.1002/jmv.21276
   FOCACCIA R, 1998, BRAZ J INFECT DIS, V2, P269
   Freitas SZ, 2008, MEM I OSWALDO CRUZ, V103, P405, DOI 10.1590/S0074-02762008000400016
   Golemba MD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008751
   Guindon S, 2005, NUCLEIC ACIDS RES, V33, pW557, DOI 10.1093/nar/gki352
   Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520
   Hauri AM, 2004, INT J STD AIDS, V15, P7, DOI 10.1258/095646204322637182
   Holland PV, 1996, J CLIN MICROBIOL, V34, P2372, DOI 10.1128/JCM.34.10.2372-2378.1996
   Khan A, 2009, J MED VIROL, V81, P1189, DOI 10.1002/jmv.21466
   Kuiken C, 2005, BIOINFORMATICS, V21, P379, DOI 10.1093/bioinformatics/bth485
   Lavanchy D, 2009, LIVER INT, V29, P74, DOI 10.1111/j.1478-3231.2008.01934.x
   Lopes Carmen L R, 2009, Rev. Saúde Pública, V43, P43, DOI 10.1590/S0034-89102009000800008
   Magiorkinis G, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000198
   Markov PV, 2009, J GEN VIROL, V90, P2086, DOI 10.1099/vir.0.011569-0
   Martins Regina M.B., 2006, Rev. Inst. Med. trop. S. Paulo, V48, P53, DOI 10.1590/S0036-46652006000100012
   Martins RMB, 1998, MEM I OSWALDO CRUZ, V93, P299, DOI 10.1590/S0074-02761998000300004
   Mathei C, 2008, J VIRAL HEPATITIS, V15, P399, DOI 10.1111/j.1365-2893.2007.00950.x
   Morice Y, 2006, J MED VIROL, V78, P1296, DOI 10.1002/jmv.20692
   Nakano T, 2006, J GEN VIROL, V87, P73, DOI 10.1099/vir.0.81360-0
   Nakano T, 2004, J INFECT DIS, V190, P1098, DOI 10.1086/422606
   Njouom R, 2007, INFECT GENET EVOL, V7, P361, DOI 10.1016/j.meegid.2006.10.003
   Njouom R, 2009, J GEN VIROL, V90, P2452, DOI 10.1099/vir.0.011981-0
   Oliveira MLA, 2009, EPIDEMIOL INFECT, V137, P970, DOI 10.1017/S0950268808001970
   Oliveira MLA, 1999, BRAZ J MED BIOL RES, V32, P279, DOI 10.1590/S0100-879X1999000300005
   Parker J, 2008, INFECT GENET EVOL, V8, P239, DOI 10.1016/j.meegid.2007.08.001
   Pereira LMMB, 2002, J MED VIROL, V67, P27, DOI 10.1002/jmv.2188
   Perez RM, 2003, J MED VIROL, V69, P489, DOI 10.1002/jmv.10336
   Posada D, 2008, MOL BIOL EVOL, V25, P1253, DOI 10.1093/molbev/msn083
   Pouillot R, 2008, INFECT GENET EVOL, V8, P676, DOI 10.1016/j.meegid.2008.06.001
   Pybus OG, 2001, SCIENCE, V292, P2323, DOI 10.1126/science.1058321
   Pybus Oliver G, 2005, Infect Genet Evol, V5, P131, DOI 10.1016/j.meegid.2004.08.001
   Pybus OG, 2009, J VIROL, V83, P1071, DOI 10.1128/JVI.01501-08
   Rambaut A, 2007, TRACER V1 4
   RODRIGUEZ F, 1990, J THEOR BIOL, V142, P485, DOI 10.1016/S0022-5193(05)80104-3
   ROMAO JE, 2009, NEFRO SP ANO 5, P6
   Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180
   Salemi M, 2002, J MOL EVOL, V54, P62, DOI 10.1007/s00239-001-0018-9
   Silva LK, 2000, AM J TROP MED HYG, V62, P257, DOI 10.4269/ajtmh.2000.62.257
   Simmonds P, 2005, HEPATOLOGY, V42, P962, DOI 10.1002/hep.20819
   Simmonds P, 2004, J GEN VIROL, V85, P3173, DOI 10.1099/vir.0.80401-0
   SLATKIN M, 1989, GENETICS, V123, P603
   STUYVER L, 1993, J GEN VIROL, V74, P1093, DOI 10.1099/0022-1317-74-6-1093
   Tanaka Y, 2005, J HEPATOL, V42, P47, DOI 10.1016/j.jhep.2004.09.023
   Tanaka Y, 2002, P NATL ACAD SCI USA, V99, P15584, DOI 10.1073/pnas.242608099
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   van Asten L, 2004, J INFECT DIS, V189, P292, DOI 10.1086/380821
   Verbeeck J, 2006, J VIROL, V80, P4220, DOI 10.1128/JVI.80.9.4220-4226.2006
   Wang TH, 2001, J VIROL, V75, P11686, DOI 10.1128/JVI.75.23.11686-11699.2001
   Zarife MAS, 2006, T ROY SOC TROP MED H, V100, P663, DOI 10.1016/j.trstmh.2005.09.009
NR 60
TC 21
Z9 21
U1 0
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567-1348
EI 1567-7257
J9 INFECT GENET EVOL
JI Infect. Genet. Evol.
PD OCT
PY 2010
VL 10
IS 7
BP 886
EP 895
DI 10.1016/j.meegid.2010.05.010
PG 10
WC Infectious Diseases
SC Infectious Diseases
GA 659XD
UT WOS:000282599700005
PM 20663735
DA 2020-12-01
ER

PT J
AU Bello, G
   Aulicino, PC
   Ruchansky, D
   Guimaraes, ML
   Lopez-Galindez, C
   Casado, C
   Chiparelli, H
   Rocco, C
   Mangano, A
   Sen, L
   Morgado, MG
AF Bello, Gonzalo
   Aulicino, Paula C.
   Ruchansky, Dora
   Guimaraes, Monick L.
   Lopez-Galindez, Cecilio
   Casado, Concha
   Chiparelli, Hector
   Rocco, Carlos
   Mangano, Andrea
   Sen, Luisa
   Morgado, Mariza G.
TI Phylodynamics of HIV-1 Circulating Recombinant Forms 12_BF and 38_BF in
   Argentina and Uruguay
SO RETROVIROLOGY
LA English
DT Article
ID ANTIRETROVIRAL DRUG-RESISTANCE; LENGTH GENOME SEQUENCES; RIO-DE-JANEIRO;
   BF RECOMBINANTS; EVOLUTIONARY HISTORY; SUBTYPE-B; MOLECULAR
   CHARACTERISTICS; PHYLOGENETIC INFERENCE; MAXIMUM-LIKELIHOOD; POPULATION
   HISTORY
AB Background: Although HIV-1 CRF12_BF and CRF38_BF are two epidemiologically important recombinant lineages circulating in Argentina and Uruguay, little is known about their population dynamics.
   Methods: A total of 120 "CRF12_BF-like" and 20 "CRF38_BF-like" pol recombinant sequences collected in Argentina and Uruguay from 1997 to 2009 were subjected to phylogenetic and Bayesian coalescent-based analyses to estimate evolutionary and demographic parameters.
   Results: Phylogenetic analyses revealed that CRF12_BF viruses from Argentina and Uruguay constitute a single epidemic with multiple genetic exchanges among countries; whereas circulation of the CRF38_BF seems to be confined to Uruguay. The mean estimated substitution rate of CRF12_BF at pol gene (2.5 x 10-3 substitutions/site/year) was similar to that previously described for subtype B. According to our estimates, CRF12_BF and CRF38_BF originated at 1983 (1978-1988) and 1986 (1981-1990), respectively. After their emergence, the CRF12_BF and CRF38_BF epidemics seem to have experienced a period of rapid expansion with initial growth rates of around 1.2 year(-1) and 0.9 year(-1), respectively. Later, the rate of spread of these CRFs_BF seems to have slowed down since the mid-1990s.
   Conclusions: Our results suggest that CRF12_BF and CRF38_BF viruses were generated during the 1980s, shortly after the estimated introduction of subtype F1 in South America (similar to 1975-1980). After an initial phase of fast exponential expansion, the rate of spread of both CRFs_BF epidemics seems to have slowed down, thereby following a demographic pattern that resembles those previously reported for the HIV-1 epidemics in Brazil, USA, and Western Europe.
C1 [Bello, Gonzalo; Guimaraes, Monick L.; Morgado, Mariza G.] Fiocruz MS, Lab AIDS & Imunol Mol, Inst Oswaldo Cruz, BR-21045900 Rio De Janeiro, Brazil.
   [Aulicino, Paula C.; Rocco, Carlos; Mangano, Andrea; Sen, Luisa] Hosp Pediat JP Garrahan, Lab Biol Celular & Retrovirus, CONICET, Buenos Aires, DF, Argentina.
   [Ruchansky, Dora; Chiparelli, Hector] MSP, Lab Nacl Referencia VIH SIDA, Serv Nacl, Lab Salud Publ, Montevideo, Uruguay.
   [Lopez-Galindez, Cecilio; Casado, Concha] Inst Salud Carlos III, Serv Virol Mol, Ctr Nacl Microbiol, Madrid, Spain.
RP Bello, G (corresponding author), Fiocruz MS, Lab AIDS & Imunol Mol, Inst Oswaldo Cruz, BR-21045900 Rio De Janeiro, Brazil.
EM gbello@ioc.fiocruz.br
RI Casado, Concepcion/F-3060-2016; Bello, Gonzalo/E-6842-2013;
   Lopez-Galindez, Cecilio/A-3603-2008; Bentancor, Gonzalo Jose
   Bello/N-7377-2019
OI Casado, Concepcion/0000-0003-3412-2877; Lopez-Galindez,
   Cecilio/0000-0002-2324-9584; Bentancor, Gonzalo Jose
   Bello/0000-0002-2724-2793
FU Brazilian CNPq/PROSULNational Council for Scientific and Technological
   Development (CNPq) [490585/2007-8]; "Agencia Nacional de Promocion
   Cientifica y Tecnologica"ANPCyT [PICT 2004-25830]; CONICETConsejo
   Nacional de Investigaciones Cientificas y Tecnicas (CONICET) [PIP 6057];
   "Plan Nacional del SIDA" [SAF 2005/03833, SAF 2007/61036]; "Fondo de
   Investigaciones Sanitarias de la Seguridad Social (FISss)" [173];
   Brazilian CNPq/FIOCRUZNational Council for Scientific and Technological
   Development (CNPq)
FX We wish to thank Dr Edward C. Holmes and Dr Vera Bongertz for critical
   reviewing of the manuscript. This study was supported by the Brazilian
   CNPq/PROSUL grant 490585/2007-8. Work in the "Laboratorio de Biologia
   Celular y Retrovirus" was supported by the "Agencia Nacional de
   Promocion Cientifica y Tecnologica" Award PICT 2004-25830, and CONICET
   Award PIP 6057. Work in the "Centro Nacional de Microbiologia" was
   supported by grants SAF 2005/03833 and SAF 2007/61036 of the "Plan
   Nacional del SIDA", and by the "Red Tematica Cooperativa de
   Investigacion en SIDA (Red de grupos 173)" of the "Fondo de
   Investigaciones Sanitarias de la Seguridad Social (FISss)". GB was
   funded by a fellowship from the Brazilian CNPq/FIOCRUZ "Pesquisador
   Visitante" Program.
CR Aguayo N, 2008, REV SOC BRAS MED TRO, V41, P225, DOI 10.1590/S0037-86822008000300001
   Aulicino PC, 2007, J VIROL, V81, P427, DOI 10.1128/JVI.01403-06
   Aulicino PC, 2007, AIDS RES HUM RETROV, V23, P1176, DOI 10.1089/aid.2007.0038
   Bello G, 2006, AIDS, V20, P763, DOI 10.1097/01.aids.0000216377.84313.52
   Bello G, 2008, AIDS, V22, P1993, DOI 10.1097/QAD.0b013e328315e0aa
   Bello G, 2007, INFECT GENET EVOL, V7, P263, DOI 10.1016/j.meegid.2006.11.002
   Bello G, 2009, AIDS RES HUM RETROV, V25, P1065, DOI 10.1089/aid.2009.0106
   Passaes CPB, 2009, INFECT GENET EVOL, V9, P474, DOI 10.1016/j.meegid.2009.01.008
   BLOWER S, 1991, J ACQ IMMUN DEF SYND, V4, P920
   Brennan CA, 2007, AIDS RES HUM RETROV, V23, P1434, DOI 10.1089/aid.2007.0121
   Brigido LFM, 2005, AIDS RES HUM RETROV, V21, P673, DOI 10.1089/aid.2005.21.673
   Carr JK, 2001, AIDS, V15, pF41, DOI 10.1097/00002030-200110190-00002
   Carrillo MG, 2002, AIDS RES HUM RETROV, V18, P477, DOI 10.1089/088922202317406619
   De Sa DJ, 2005, AIDS RES HUM RETROV, V21, P145, DOI 10.1089/aid.2005.21.145
   De Sa DJ, 2006, AIDS RES HUM RETROV, V22, P1
   de Sa DJ, 2008, AIDS RES HUM RETROV, V24, P347, DOI 10.1089/aid.2007.0203
   Dilernia DA, 2007, AIDS RES HUM RETROV, V23, P1201, DOI 10.1089/aid.2007.0068
   Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/msi103
   Drummond AJ, 2002, GENETICS, V161, P1307
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   Espinosa A, 2004, JAIDS-J ACQ IMM DEF, V36, P630, DOI 10.1097/00126334-200405010-00012
   Gomez-Carrillo M, 2006, AIDS RES HUM RETROV, V22, P1186, DOI 10.1089/aid.2006.22.1186
   Guimaraes ML, 2008, AIDS, V22, P433, DOI 10.1097/QAD.0b013e3282f47ad0
   Guimaraes ML, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-39
   Guindon S, 2005, NUCLEIC ACIDS RES, V33, pW557, DOI 10.1093/nar/gki352
   Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520
   Guiniaraes ML, 2002, AIDS RES HUM RETROV, V18, P1261, DOI 10.1089/088922202320886307
   Hierholzer J, 2002, AIDS RES HUM RETROV, V18, P1339, DOI 10.1089/088922202320935410
   Hue S, 2005, P NATL ACAD SCI USA, V102, P4425, DOI 10.1073/pnas.0407534102
   KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581
   Paraskevis D, 2007, J INFECT DIS, V196, P1167, DOI 10.1086/521677
   Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817
   Quarleri JF, 2004, AIDS RES HUM RETROV, V20, P1100, DOI 10.1089/aid.2004.20.1100
   Rambaut A, 2007, TRACER V1 4
   Ray S., SIMPLOT V2 5 0
   Rios M, 2007, J MED VIROL, V79, P647, DOI 10.1002/jmv.20881
   Robbins KE, 2003, J VIROL, V77, P6359, DOI 10.1128/JVI.77.11.6359-6366.2003
   Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180
   Ruchansky D, 2009, AIDS RES HUM RETROV, V25, P351, DOI 10.1089/aid.2008.0248
   Salemi M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001390
   Sanabani S, 2006, INFECT GENET EVOL, V6, P368, DOI 10.1016/j.meegid.2006.01.003
   Sierra Maria, 2005, Infection Genetics and Evolution, V5, P209, DOI 10.1016/j.meegid.2004.07.010
   Suchard MA, 2001, MOL BIOL EVOL, V18, P1001, DOI 10.1093/oxfordjournals.molbev.a003872
   Tavare S., 1986, LECT MATH LIFE SCI, V17, P57, DOI DOI 10.1016/J.MARPOLBUL.2009.11.011
   Teixeira SLM, 2004, J CLIN VIROL, V31, P221, DOI 10.1016/j.jcv.2004.03.016
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Thomson MM, 2000, AIDS, V14, P897, DOI 10.1097/00002030-200005050-00020
   Thomson MM, 2004, AIDS RES HUM RETROV, V20, P1126, DOI 10.1089/aid.2004.20.1126
   Thomson MM, 2002, J GEN VIROL, V83, P107, DOI 10.1099/0022-1317-83-1-107
   Walker Polly R., 2005, Infection Genetics and Evolution, V5, P199, DOI 10.1016/j.meegid.2004.06.011
   Worobey M, 2008, NATURE, V455, P661, DOI 10.1038/nature07390
NR 52
TC 36
Z9 36
U1 0
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PD MAR 22
PY 2010
VL 7
AR 22
DI 10.1186/1742-4690-7-22
PG 9
WC Virology
SC Virology
GA 584LQ
UT WOS:000276753800001
PM 20307282
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Passaes, CPB
   Guimaraes, ML
   Bello, G
   Morgado, MG
AF Bittencourt Passaes, Caroline Pereira
   Guimaraes, Monick Lindenmeyer
   Bello, Gonzalo
   Morgado, Mariza Goncalves
TI Near Full-Length Genome Characterization of HIV Type 1 Unique BC
   Recombinant Forms from Southern Brazil
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; SUBTYPE-C; STRAINS
AB In southern Brazil, CRF31_BC is the major HIV-1 recombinant form and URFs_BC occurs very infrequently. The near full-length genomes of four samples displaying a similar recombination profile in the integrase region and different profiles in the protease/reverse transcriptase regions were analyzed to elucidate their mosaic structure and to describe for the first time the near full-length genomes of URFs_BC circulating in Brazil. For this purpose, overlapping PCR amplifications followed by direct sequencing were carried out. Despite the observation that these samples share a similar recombination profile in the integrase region, phylogenetic, bootscan, and informative site analyses revealed that the four samples displayed distinct mosaic structures. Additional recombination events occurred mainly in the gag, reverse transcriptase, and env regions. Our data provide the first description of the near full-length genomes of URFs_BC in Brazil and offer important insights about the complexity of HIV-1 recombinant strains currently in circulation in the south of Brazil.
C1 [Bittencourt Passaes, Caroline Pereira; Guimaraes, Monick Lindenmeyer; Bello, Gonzalo; Morgado, Mariza Goncalves] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, BR-21040900 Rio De Janeiro, Brazil.
RP Morgado, MG (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, Av Brasil 4365 Leonidas Deane Bldg,Room 413, BR-21040900 Rio De Janeiro, Brazil.
EM mmorgado@ioc.fiocruz.br
RI Passaes, Caroline/AAH-3392-2020; Bentancor, Gonzalo Jose
   Bello/N-7377-2019; Bello, Gonzalo/E-6842-2013
OI Passaes, Caroline/0000-0002-0813-2521; Bentancor, Gonzalo Jose
   Bello/0000-0002-2724-2793; 
FU PAPES IV/FIOCRUZ/CNPqNational Council for Scientific and Technological
   Development (CNPq); FAPERJCarlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ)
FX We acknowledge Dr. Vera Bongertz for review and suggestions and Dr.
   Sabrina Almeida for providing part of the biological material. This
   study was supported in part by PAPES IV/FIOCRUZ/CNPq and FAPERJ grants.
CR Aulicino PC, 2005, AIDS RES HUM RETROV, V21, P894, DOI 10.1089/aid.2005.21.894
   Passaes CPB, 2009, INFECT GENET EVOL, V9, P474, DOI 10.1016/j.meegid.2009.01.008
   Brigido LFM, 2007, AIDS RES HUM RETROV, V23, P1579, DOI 10.1089/aid.2007.0102
   Carrion G, 2004, AIDS RES HUM RETROV, V20, P1022, DOI 10.1089/aid.2004.20.1022
   Gao F, 1996, J VIROL, V70, P1651, DOI 10.1128/JVI.70.3.1651-1667.1996
   Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754
   Morgado MG, 2002, MEM I OSWALDO CRUZ, V97, P143, DOI 10.1590/S0074-02762002000200001
   Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817
   Rambaut A, 2007, TRACER V1 4
   RAY S, SIMPLOT V3 5 1
   Rodenburg CM, 2001, AIDS RES HUM RETROV, V17, P161, DOI 10.1089/08892220150217247
   Sanabani S, 2006, AIDS RES HUM RETROV, V22, P171, DOI 10.1089/aid.2006.22.171
   Santos AF, 2007, JAIDS-J ACQ IMM DEF, V45, P328
   Santos AF, 2006, AIDS, V20, P2011
   Sierra Maria, 2005, Infection Genetics and Evolution, V5, P209, DOI 10.1016/j.meegid.2004.07.010
   Soares EAJM, 2003, JAIDS-J ACQ IMM DEF, V34, P520, DOI 10.1097/00126334-200312150-00012
   Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Zhang CY, 2008, INFECT GENET EVOL, V8, P693, DOI 10.1016/j.meegid.2008.04.001
NR 19
TC 11
Z9 11
U1 0
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD DEC
PY 2009
VL 25
IS 12
BP 1339
EP 1344
DI 10.1089/aid.2009.0167
PG 6
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 530QW
UT WOS:000272608400018
PM 19954300
DA 2020-12-01
ER

PT J
AU Bello, G
   Guimaraes, ML
   Passaes, CPB
   Almeida, SEM
   Veloso, VG
   Morgado, MG
AF Bello, Gonzalo
   Guimaraes, Monick L.
   Passaes, Caroline P. B.
   Matos Almeida, Sabrina E.
   Veloso, Valdilea G.
   Morgado, Mariza G.
TI Short Communication: Evidences of Recent Decline in the Expansion Rate
   of the HIV Type 1 Subtype C and CRF31_BC Epidemics in Southern Brazil
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; ANTIRETROVIRAL DRUG-RESISTANCE;
   NEWLY-DIAGNOSED INDIVIDUALS; EVOLUTIONARY HISTORY; MOLECULAR
   CHARACTERISTICS; POPULATION HISTORY; BLOOD-DONORS; SAO-PAULO; AIDS;
   SURVEILLANCE
AB The HIV-1 epidemic in southern Brazil is characterized by the high prevalence of subtype C and CRF31_BC infections but little is known about the population dynamics of these strains over time. We used a total of 82 env and 72 pol HIV-1 subtype C sequences collected from 1991 to 2006 and 47 pol CRF31_BC sequences collected from 1998 to 2006 from Brazilian patients to reconstruct the demographic history of these HIV-1 strains. Estimations of demographic history were performed using a Bayesian Markov Chain Monte Carlo coalescent-based approach as implemented in the BEAST program. Our analyses indicate that subtype C and CRF31_BC epidemics experienced an initial period of fast exponential spread in the southern Brazilian population during the 1980s and early 1990s, but the spreading rate of these epidemics seems to have slowed down since the middle 1990s. The initial mean exponential growth rate of the subtype C epidemic was estimated to be around 0.70-0.90/year, whereas the estimated population growth rate of CRF31_BC was 1.3/year, more than two times higher than that previously described for this CRF. These results suggest for the first time that the growth rate of subtype C and CRF31_BC epidemics has been changing over time in southern Brazil with evidence for a deceleration in recent years. During the expansion phase, the CRF31_BC seems to have spread at a rate much higher than Brazilian parental subtypes B and C.
C1 [Bello, Gonzalo; Guimaraes, Monick L.; Passaes, Caroline P. B.; Morgado, Mariza G.] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, BR-21045900 Rio De Janeiro, Brazil.
   [Matos Almeida, Sabrina E.] Fundacao Estadual Prod & Pesquisa Saude, Ctr Desenvolvimento Cient & Tecnol, Porto Alegre, RS, Brazil.
   [Veloso, Valdilea G.] Fiocruz MS, Inst Pesquisa Clin Evandro Chagas, BR-21045900 Rio De Janeiro, Brazil.
RP Bello, G (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, Av Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM gbello@ioc.fiocruz.br
RI Bentancor, Gonzalo Jose Bello/N-7377-2019; Veloso, Valdilea
   Goncalves/J-6189-2012; Passaes, Caroline/AAH-3392-2020; Bello,
   Gonzalo/E-6842-2013
OI Bentancor, Gonzalo Jose Bello/0000-0002-2724-2793; Passaes,
   Caroline/0000-0002-0813-2521; 
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); FAPERJCarlos Chagas Filho Foundation for Research Support of the
   State of Rio de Janeiro (FAPERJ); CNPq/FIOCRUZNational Council for
   Scientific and Technological Development (CNPq)
FX We wish to thank Dr. Vera Bongertz for helpful discussions and for
   critical reviewing of the manuscript. This study was supported by CNPq
   and FAPERJ grants. G. B. was funded by a fellowship from the Brazilian
   CNPq/FIOCRUZ "Pesquisador Visitante" Program.
CR Aguayo N, 2008, REV SOC BRAS MED TRO, V41, P225, DOI 10.1590/S0037-86822008000300001
   Aulicino PC, 2007, J VIROL, V81, P427, DOI 10.1128/JVI.01403-06
   Barreto CC, 2006, JAIDS-J ACQ IMM DEF, V41, P338
   Bello G, 2006, AIDS, V20, P763, DOI 10.1097/01.aids.0000216377.84313.52
   Bello G, 2008, AIDS, V22, P1993, DOI 10.1097/QAD.0b013e328315e0aa
   Bello G, 2007, INFECT GENET EVOL, V7, P263, DOI 10.1016/j.meegid.2006.11.002
   Passaes CPB, 2009, INFECT GENET EVOL, V9, P474, DOI 10.1016/j.meegid.2009.01.008
   *BRAZ MIN HLTH, 2008, AIDS EP B
   Brigido LFM, 2005, AIDS RES HUM RETROV, V21, P673, DOI 10.1089/aid.2005.21.673
   Brigido LFM, 2007, AIDS RES HUM RETROV, V23, P1579, DOI 10.1089/aid.2007.0102
   Brindeiro RM, 2003, AIDS, V17, P1063, DOI 10.1097/00002030-200305020-00016
   Brito Ana Maria de, 2005, Braz J Infect Dis, V9, P9, DOI 10.1590/S1413-86702005000100004
   Dilernia DA, 2007, AIDS RES HUM RETROV, V23, P1201, DOI 10.1089/aid.2007.0068
   Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/msi103
   Drummond AJ, 2002, GENETICS, V161, P1307
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   Fonseca MGP, 2007, CAD SAUDE PUBLICA, V23, pS333, DOI 10.1590/S0102-311X2007001500002
   Gomez-Carrillo M, 2006, AIDS RES HUM RETROV, V22, P1186, DOI 10.1089/aid.2006.22.1186
   Guiniaraes ML, 2002, AIDS RES HUM RETROV, V18, P1261, DOI 10.1089/088922202320886307
   Hacker Mariana A., 2006, Cad. Saúde Pública, V22, P751, DOI 10.1590/S0102-311X2006000400014
   Hue S, 2005, P NATL ACAD SCI USA, V102, P4425, DOI 10.1073/pnas.0407534102
   Locateli D, 2007, J MED VIROL, V79, P1455, DOI 10.1002/jmv.20955
   Rambaut A, 2007, TRACER V1 4
   Robbins KE, 2003, J VIROL, V77, P6359, DOI 10.1128/JVI.77.11.6359-6366.2003
   Rodrigues R, 2006, VIRUS RES, V116, P201, DOI 10.1016/j.virusres.2005.10.004
   Ruchansky D, 2009, AIDS RES HUM RETROV, V25, P351, DOI 10.1089/aid.2008.0248
   Sa-Ferreira JA, 2007, TRANSFUSION, V47, P97, DOI 10.1111/j.1537-2995.2007.01069.x
   Salemi M, 2005, J MOL EVOL, V60, P598, DOI 10.1007/s00239-004-0206-5
   Salemi M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001390
   Santos AF, 2007, JAIDS-J ACQ IMM DEF, V45, P328
   Santos AF, 2006, AIDS, V20, P2011
   Soares EAJM, 2005, AIDS, V19, pS81, DOI 10.1097/01.aids.0000191497.00928.e4
   Soares EAJM, 2003, JAIDS-J ACQ IMM DEF, V34, P520, DOI 10.1097/00126334-200312150-00012
   Soares MA, 2003, AIDS, V17, P11, DOI 10.1097/00002030-200301030-00004
   Suchard MA, 2001, MOL BIOL EVOL, V18, P1001, DOI 10.1093/oxfordjournals.molbev.a003872
   Szwarcwald C L, 2000, Cad Saude Publica, V16, P7
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Walker Polly R., 2005, Infection Genetics and Evolution, V5, P199, DOI 10.1016/j.meegid.2004.06.011
NR 39
TC 19
Z9 19
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD NOV
PY 2009
VL 25
IS 11
BP 1065
EP 1069
DI 10.1089/aid.2009.0106
PG 5
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 524ZF
UT WOS:000272182200003
PM 19895209
DA 2020-12-01
ER

PT J
AU Bello, G
   Velasco-de-Castro, CA
   Bongertz, V
   Rodrigues, CAS
   Giacoia-Gripp, CBW
   Pilotto, JH
   Grinsztejn, B
   Veloso, VG
   Morgado, MG
AF Bello, Gonzalo
   Velasco-de-Castro, Carlos A.
   Bongertz, Vera
   Santos Rodrigues, Caio A.
   Giacoia-Gripp, Carmem B. W.
   Pilotto, Jose H.
   Grinsztejn, Beatriz
   Veloso, Valdilea G.
   Morgado, Mariza G.
TI Immune Activation and Antibody Responses in Non-Progressing Elite
   Controller Individuals Infected With HIV-1
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE HIV controllers; long-term non-progressors; chronic activation; binding
   antibodies; antibody avidity
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; LONG-TERM
   NONPROGRESSORS; T-CELL-ACTIVATION; VIRAL REPLICATION; DISEASE
   PROGRESSION; ENZYME-IMMUNOASSAY; TYPE-1 INFECTION; AVIDITY INDEX; RNA
   LEVELS
AB An extremely rare subset of patients infected with HIV-1 designated as "non-progressing elite controllers" appears to be able to maintain stable CD4 + T-cell counts and a median plasma viremia below the detection limit of current ultrasensitive assays (10 years in the absence of antiretroviral therapy. Lymphocyte subsets (CD4 +, CD8 +), immune activation markers (HLA-DR +, CD38 +, Beta-2-microglobulin), and HIV-specific antibody responses were longitudinally examined in four non-progressing elite controllers over more than 5 years. Two control groups of seronegative healthy individuals and untreated patients infected with HIV-1 presenting detectable viremia were also included. None of the non-progressing elite controllers displayed the high T-cell activation levels generally seen in the seropositive individuals, keeping them within the normal range. Three non-progressing elite controllers showed no significant immune system abnormalities when compared to seronegative individuals, displaying a low proportion of HIV-1-specific binding antibodies and low avidity index, similar to those observed for individuals infected recently with HIV-1. One non-progressing elite controller exhibited CD8 + T-cell counts and beta 2-M levels above normal ranges and developed a low but "mature" (high-avidity) HIV-1-specific antibody response. Thus, the non-progressing elite controllers are able to maintain normal T-cell activation levels, which may contribute to prevent, or greatly reduce,the damage of the immune system typically induced by the HIV-1 overtime. They are, however, immunologically heterogeneous and very low levels of antigen exposure seem to occur in these patients, sufficient for sustaining a low, but detectable, HIV-1-specific immunity. J. Med Virol. 81:1681-1690,2009. (C) 2009 Wiley-Liss, Inc.
C1 [Bello, Gonzalo; Velasco-de-Castro, Carlos A.; Bongertz, Vera; Santos Rodrigues, Caio A.; Giacoia-Gripp, Carmem B. W.; Morgado, Mariza G.] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, BR-21045900 Rio De Janeiro, Brazil.
   [Pilotto, Jose H.; Grinsztejn, Beatriz; Veloso, Valdilea G.] Fiocruz MS, Inst Pesquisa Clin Evandro Chagas, BR-21045900 Rio De Janeiro, Brazil.
RP Morgado, MG (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, Av Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM mmorgado@ioc.fiocruz.br
RI Bentancor, Gonzalo Jose Bello/N-7377-2019; Pilotto, Jose
   Henrique/AAD-9773-2019; Bello, Gonzalo/E-6842-2013; Veloso, Valdilea
   Goncalves/J-6189-2012
OI Bentancor, Gonzalo Jose Bello/0000-0002-2724-2793; Pilotto, Jose
   Henrique/0000-0003-0521-8597; 
FU National Institute for Biological Standards Control, UK
FX We wish to thank Dr. David Watkins for helpful discussions and for
   critical review of the manuscript. We thank the National Institute for
   Biological Standards & Control, UK, for the kind donation of HIV-1 SF162
   and Dr. Eva-Maria Fenyo, Lund University, Sweden, for the kind donation
   of HIV-1 IIIB.
CR Altfeld M, 2003, AIDS, V17, P2581, DOI 10.1097/00002030-200312050-00005
   Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112
   Babiker A, 2000, LANCET, V355, P1131
   Bailey JR, 2006, J VIROL, V80, P4758, DOI 10.1128/JVI.80.10.4758-4770.2006
   Barker E, 1998, BLOOD, V92, P3105, DOI 10.1182/blood.V92.9.3105.421k46_3105_3114
   Bello G, 2005, J GEN VIROL, V86, P355, DOI 10.1099/vir.0.80410-0
   Bello G, 2007, AIDS RES HUM RETROV, V23, P1242, DOI 10.1089/aid.2007.0074
   Binley JM, 2000, J INFECT DIS, V182, P945, DOI 10.1086/315774
   Bisset LR, 1998, AIDS, V12, P2115, DOI 10.1097/00002030-199816000-00006
   Bongertz V, 2007, MEM I OSWALDO CRUZ, V102, P817, DOI 10.1590/S0074-02762007005000119
   Bouscarat F, 1998, AIDS, V12, P1267, DOI 10.1097/00002030-199811000-00007
   Buchbinder S, 1999, MICROBES INFECT, V1, P1113, DOI 10.1016/S1286-4579(99)00204-X
   Deeks SG, 2007, IMMUNITY, V27, P406, DOI 10.1016/j.immuni.2007.08.010
   Delwart EL, 1997, J VIROL, V71, P7498, DOI 10.1128/JVI.71.10.7498-7508.1997
   FERBAS J, 1995, J INFECT DIS, V172, P329, DOI 10.1093/infdis/172.2.329
   Giorgi JV, 1998, AIDS, V12, P1833, DOI 10.1097/00002030-199814000-00015
   Greenough TC, 1999, NEW ENGL J MED, V340, P236, DOI 10.1056/NEJM199901213400314
   HAGERVORST E, 1995, J INFECT DIS, V171, P811
   Hare CB, 2006, CLIN INFECT DIS, V42, P700, DOI 10.1086/500215
   Hatano H, 2009, J VIROL, V83, P329, DOI 10.1128/JVI.01763-08
   Hayashida T, 2008, AIDS RES HUM RETROV, V24, P495, DOI 10.1089/aid.2007.0150
   Hunt PW, 2008, J INFECT DIS, V197, P126, DOI 10.1086/524143
   Jin X, 2000, MOL MED, V6, P803, DOI 10.1007/BF03402195
   Kassutto S, 2005, CLIN INFECT DIS, V40, P868, DOI 10.1086/428127
   Killian MS, 2006, AIDS RES HUM RETROV, V22, P640, DOI 10.1089/aid.2006.22.640
   Laeyendecker O, 2008, JAIDS-J ACQ IMM DEF, V48, P211, DOI 10.1097/QAI.0b013e3181743980
   Lambotte O, 2005, CLIN INFECT DIS, V41, P1053, DOI 10.1086/433188
   Learmont JC, 1999, NEW ENGL J MED, V340, P1715, DOI 10.1056/NEJM199906033402203
   Lefrere JJ, 1999, J INFECT DIS, V180, P526, DOI 10.1086/314906
   Lefrere JJ, 1997, BLOOD, V90, P1133, DOI 10.1182/blood.V90.3.1133.1133_1133_1140
   LIFSON AR, 1991, J INFECT DIS, V163, P959, DOI 10.1093/infdis/163.5.959
   Loffredo JT, 2007, J VIROL, V81, P8827, DOI 10.1128/JVI.00895-07
   Madec Y, 2005, AIDS, V19, P2001, DOI 10.1097/01.aids.0000194134.28135.cd
   Madec Y, 2005, CLIN INFECT DIS, V40, P1350, DOI 10.1086/429318
   Markowitz M, 1999, J INFECT DIS, V179, P527, DOI 10.1086/314628
   MOOSTERBOER N, 2005, VIROLOGY, V339, P70
   Morris L, 1998, J EXP MED, V188, P233, DOI 10.1084/jem.188.2.233
   Parekh BS, 2005, INDIAN J MED RES, V121, P510
   Pereyra F, 2008, J INFECT DIS, V197, P563, DOI 10.1086/526786
   Rodes B, 2004, AIDS, V18, P1109, DOI [10.1097/00002030-200405210-00004, 10.1097/01.aids.0000125962.16506.f9]
   Sajadi MM, 2007, AIDS, V21, P517
   Selleri M, 2007, JAIDS-J ACQ IMM DEF, V46, P145, DOI 10.1097/QAI.0b013e318120039b
   SHEPPARD HW, 1993, AIDS, V7, P1159, DOI 10.1097/00002030-199309000-00002
   Shioda T, 1997, J VIROL, V71, P4871, DOI 10.1128/JVI.71.7.4871-4881.1997
   Suligoi B, 2003, JAIDS-J ACQ IMM DEF, V32, P424, DOI 10.1097/00126334-200304010-00012
   Suligoi B, 2002, J CLIN MICROBIOL, V40, P4015, DOI 10.1128/JCM.40.11.4015-4020.2002
   Verity EE, 2007, J VIROL, V81, P9268, DOI 10.1128/JVI.00650-07
   Wang B, 2003, VIROLOGY, V312, P135, DOI 10.1016/S0042-6822(03)00159-4
   Wang B, 2002, VIROLOGY, V304, P246, DOI 10.1006/viro.2002.1706
   Wolinsky SM, 1996, SCIENCE, V272, P537, DOI 10.1126/science.272.5261.537
   Zaunders JJ, 1999, AIDS RES HUM RETROV, V15, P1519, DOI 10.1089/088922299309801
NR 51
TC 28
Z9 29
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD OCT
PY 2009
VL 81
IS 10
BP 1681
EP 1690
DI 10.1002/jmv.21565
PG 10
WC Virology
SC Virology
GA 489BV
UT WOS:000269395400001
PM 19697415
DA 2020-12-01
ER

PT J
AU Passaes, CPB
   Bello, G
   Lorete, RS
   Almeida, SEM
   Junqueira, DM
   Veloso, VG
   Morgado, MG
   Guimares, ML
AF Bittencourt Passaes, Caroline Pereira
   Bello, Gonzalo
   Lorete, Roberta S.
   Matos Almeida, Sabrina E.
   Junqueira, Dennis Maletich
   Veloso, Valdilea G.
   Morgado, Mariza G.
   Guimares, Monick Lindenmeyer
TI Genetic characterization of HIV-1 BC recombinants and evolutionary
   history of the CRF31_BC in Southern Brazil
SO INFECTION GENETICS AND EVOLUTION
LA English
DT Article
DE Brazil; HIV-1; Subtype C; CRF31_BC; Second generation recombinants;
   Evolutionary history
ID IMMUNODEFICIENCY-VIRUS TYPE-1; SUBTYPE-C; INTERSUBTYPE RECOMBINATION;
   MOLECULAR EPIDEMIOLOGY; IDENTIFICATION; SEQUENCES; STATE; INFECTIONS;
   PREVALENCE; RESISTANCE
AB To evaluate the recombination profiles and evolutionary history of HIV-1 BC recombinants in Southern Brazil, 81 isolates collected in the city of Porto Alegre (Rio Grande do Sul State) from 1998 to 2006 previously subtyped as C (env-gp120/C2V3) were screened in the protease-reverse transcriptase (pr/rt), integrase and gp41 genomic regions. Detailed phylogenetic, bootscan and informative site analyses were performed to trace the subtype classification. The evolutionary rate and divergence time of the Brazilian CRF31_BC epidemic were estimated using a Bayesian Markov Chain Monte Carlo framework. Analysis of the four target regions identified: 43 isolates as "pure" subtype C, 23 as CRF31_BC, and 15 as unique BC recombinant forms (URFs_BC). Recombination breakpoints were mainly localized in the rt gene and 100% of the recombinant samples could be detected analyzing only this region. Most URFs_BC (86.7%) contained small subtype B fragments (<= 160 nt) in the rt region and shared one of the recombination breakpoints with CRF31_BC. In conclusion, despite the high co-prevalence of subtypes B and C in Porto Alegre, the diversity of BC recombinant forms circulating in this region was extremely low. Most BC recombinants were CRF31_BC and URFs_BC that appeared to be second generation recombinants derived from CRF31_BC and subtype C strains, confirming the importance of this CRF in this region. The emergence of the CRF31_BC was estimated to be around 1988 (1982-1992). (C) 2009 Elsevier B.V. All rights reserved.
C1 [Bittencourt Passaes, Caroline Pereira; Bello, Gonzalo; Lorete, Roberta S.; Morgado, Mariza G.; Guimares, Monick Lindenmeyer] IOC FIOCRUZ, Lab AIDS & Imunol Mol, BR-21040900 Rio De Janeiro, Brazil.
   [Matos Almeida, Sabrina E.; Junqueira, Dennis Maletich] Fundacao Estadual Prod & Pesquisa Saude, Ctr Desenvolvimento Cient & Tecnol, Porto Alegre, RS, Brazil.
   [Veloso, Valdilea G.] Fiocruz MS, Inst Pesquisa Clin Evandro Chagas, BR-21045900 Rio De Janeiro, Brazil.
RP Guimares, ML (corresponding author), IOC FIOCRUZ, Lab AIDS & Imunol Mol, Av Brasil 4365,Leonidas Deane Bldg,Room 413, BR-21040900 Rio De Janeiro, Brazil.
EM monicklg@ioc.fiocruz.br
RI Passaes, Caroline/AAH-3392-2020; Veloso, Valdilea Goncalves/J-6189-2012;
   Bello, Gonzalo/E-6842-2013; Bentancor, Gonzalo Jose Bello/N-7377-2019
OI Passaes, Caroline/0000-0002-0813-2521; Bentancor, Gonzalo Jose
   Bello/0000-0002-2724-2793; Junqueira, Dennis/0000-0003-1576-484X
FU PAPES IV/FIOCRUZ/CNPqNational Council for Scientific and Technological
   Development (CNPq); FAPERJCarlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ)
FX We acknowledge Dr Vera Bongertz for review and suggestions. This study
   was supported in part by PAPES IV/FIOCRUZ/CNPq and FAPERJ grants.
CR Bello G, 2006, AIDS, V20, P763, DOI 10.1097/01.aids.0000216377.84313.52
   Bello G, 2008, AIDS, V22, P1993, DOI 10.1097/QAD.0b013e328315e0aa
   Bello G, 2007, INFECT GENET EVOL, V7, P263, DOI 10.1016/j.meegid.2006.11.002
   Bongertz V, 2000, J ACQ IMMUN DEF SYND, V23, P184
   Brigido LFM, 2005, AIDS RES HUM RETROV, V21, P673, DOI 10.1089/aid.2005.21.673
   Brigido LFM, 2007, AIDS RES HUM RETROV, V23, P1579, DOI 10.1089/aid.2007.0102
   Brindeiro RM, 2003, AIDS, V17, P1063, DOI 10.1097/00002030-200305020-00016
   Cabral VP, 2006, MEM I OSWALDO CRUZ, V101, P881, DOI 10.1590/S0074-02762006000800010
   Chin MPS, 2008, J MOL BIOL, V377, P1324, DOI 10.1016/j.jmb.2008.02.003
   Chin MPS, 2007, VIROLOGY, V363, P437, DOI 10.1016/j.virol.2007.01.034
   Chin MPS, 2005, P NATL ACAD SCI USA, V102, P9002, DOI 10.1073/pnas.0502522102
   Couto-Fernandez JC, 1999, J ACQ IMMUN DEF SYND, V22, P288
   de Medeiros LB, 2006, MEM I OSWALDO CRUZ, V101, P845, DOI 10.1590/S0074-02762006000800004
   De Sa DJ, 2005, AIDS RES HUM RETROV, V21, P145, DOI 10.1089/aid.2005.21.145
   De Sa DJ, 2006, AIDS RES HUM RETROV, V22, P1
   Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/msi103
   Drummond AJ, 2002, GENETICS, V161, P1307
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   Gadelha SR, 2003, MEM I OSWALDO CRUZ, V98, P461, DOI 10.1590/S0074-02762003000400005
   Guimaraes ML, 2008, AIDS, V22, P433, DOI 10.1097/QAD.0b013e3282f47ad0
   Guiniaraes ML, 2002, AIDS RES HUM RETROV, V18, P1261, DOI 10.1089/088922202320886307
   HASEGAWA M, 1985, J MOL EVOL, V22, P160, DOI 10.1007/BF02101694
   Hue S, 2005, P NATL ACAD SCI USA, V102, P4425, DOI 10.1073/pnas.0407534102
   KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581
   Lacerda HR, 2007, MEM I OSWALDO CRUZ, V102, P693, DOI [10.1590/S0074-02762007005000109, 10.1590/S0074-02762007000600006]
   Locateli D, 2007, J MED VIROL, V79, P1455, DOI 10.1002/jmv.20955
   Magiorkinis G, 2003, J GEN VIROL, V84, P2715, DOI 10.1099/vir.0.19180-0
   Paraskevis D, 2007, J INFECT DIS, V196, P1167, DOI 10.1086/521677
   Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817
   Rambaut A, 2007, TRACER V1 4
   Ramos A, 1999, EMERG INFECT DIS, V5, P65, DOI 10.3201/eid0501.990108
   Ray S, 2009, SIMPLOT V3 5 1
   Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180
   Salemi M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001390
   SANABANI S, 2006, INFECT GENET EVOL
   Santos AF, 2007, JAIDS-J ACQ IMM DEF, V45, P328
   Santos AF, 2006, AIDS, V20, P2011
   Sierra Maria, 2005, Infection Genetics and Evolution, V5, P209, DOI 10.1016/j.meegid.2004.07.010
   Soares EAJM, 2003, JAIDS-J ACQ IMM DEF, V34, P520, DOI 10.1097/00126334-200312150-00012
   Soares MA, 2003, AIDS, V17, P11, DOI 10.1097/00002030-200301030-00004
   Stefani MMA, 2000, J ACQ IMMUN DEF SYND, V23, P205
   Suchard MA, 2001, MOL BIOL EVOL, V18, P1001, DOI 10.1093/oxfordjournals.molbev.a003872
   Tavare S., 1986, LECT MATH LIFE SCI, V17, P57, DOI DOI 10.1016/J.MARPOLBUL.2009.11.011
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Thomson MM, 2004, AIDS RES HUM RETROV, V20, P1126, DOI 10.1089/aid.2004.20.1126
   Veras NMC, 2007, AIDS RES HUM RETROV, V23, P1481, DOI 10.1089/aid.2007.0145
   Vicente ACP, 2000, J ACQ IMMUN DEF SYND, V23, P327
   Xia X, 2001, J HERED, V92, P371, DOI 10.1093/jhered/92.4.371
NR 49
TC 26
Z9 26
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567-1348
EI 1567-7257
J9 INFECT GENET EVOL
JI Infect. Genet. Evol.
PD JUL
PY 2009
VL 9
IS 4
BP 474
EP 482
DI 10.1016/j.meegid.2009.01.008
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA 458SW
UT WOS:000267044800011
PM 19460312
DA 2020-12-01
ER

PT J
AU Araujo, JMG
   Nogueira, RMR
   Schatzmayr, HG
   Zanotto, PMD
   Bello, G
AF Araujo, Joselio M. G.
   Nogueira, Rita M. R.
   Schatzmayr, Hermann G.
   Zanotto, Paolo M. de A.
   Bello, Gonzalo
TI Phylogeography and evolutionary history of dengue virus type 3
SO INFECTION GENETICS AND EVOLUTION
LA English
DT Article; Proceedings Paper
CT 13th International Bioinformatics Workshop on Virus Evolution and
   Molecular Epidemiology
CY SEP 09-14, 2007-2009
CL Lisbon, PORTUGAL
DE Dengue virus type 3; Phylogeography; Evolutionary history
ID MOLECULAR EPIDEMIOLOGY; HEMORRHAGIC-FEVER; PHYLOGENETIC ANALYSIS;
   POPULATION-DYNAMICS; THAILAND; EMERGENCE; BANGKOK; CIRCULATION;
   BANGLADESH; SEROTYPE-3
AB In this study, we revisited the phylogeography of the three of major DENV-3 genotypes and estimated its rate of evolution, based on the analysis of the envelope (E) gene of 200 strains isolated from 31 different countries around the world over a time period of 50 years (1956-2006). Our phylogenetic analysis revealed a geographical subdivision of DENV-3 population in several country-specific clades. Migration patterns of the main DENV-3 genotypes showed that genotype I was mainly circumspect to the maritime portion of Southeast-Asia and South Pacific, genotype 11 stayed within continental areas in South-East Asia, while genotype III spread across Asia, East Africa and into the Americas. No evidence for rampant co-circulation of distinct genotypes in a single locality was found, suggesting that some factors, other than geographic proximity, may limit the continual dispersion and reintroduction of new DENV-3 variants. Estimates of the evolutionary rate revealed no significant differences among major DENV-3 genotypes. The mean evolutionary rate of DENV-3 in areas with long-term endemic transmissions (i.e., Indonesia and Thailand) was similar to that observed in the Americas, which have been experiencing a more recent dengue spread. We estimated the origin of DENV-3 virus around 1890, and the emergence of current diversity of main DENV-3 genotypes between the middle 1960s and the middle 1970s, coinciding with human population growth, urbanization, and massive human movement, and with the description of the first cases of DENV-3 hemorrhagic fever in Asia. (C) 2008 Elsevier B.V. All rights reserved.
C1 [Araujo, Joselio M. G.; Nogueira, Rita M. R.; Schatzmayr, Hermann G.] Fiocruz MS, Inst Oswaldo Cruz, Lab Flavivirus, BR-21045900 Rio De Janeiro, Brazil.
   [Zanotto, Paolo M. de A.] Univ Sao Paulo, ICB 2, Inst Biomed Sci, Dept Microbiol,Lab Mol Evolut & Bioinformat, BR-05508 Sao Paulo, Brazil.
   [Bello, Gonzalo] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Mol Immunol, BR-21045900 Rio De Janeiro, Brazil.
RP Araujo, JMG (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab Flavivirus, Av Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM joselio@ioc.fiocruz.br
RI Bello, Gonzalo/E-6842-2013; Vandamme, Anne-Mieke/I-4127-2012; Araujo,
   Joselio M G/B-5502-2013; de A. Zanotto, Paolo M./B-9286-2019; Bentancor,
   Gonzalo Jose Bello/N-7377-2019
OI Vandamme, Anne-Mieke/0000-0002-6594-2766; Araujo, Joselio M
   G/0000-0003-3548-2786; de A. Zanotto, Paolo M./0000-0002-8167-0625;
   Bentancor, Gonzalo Jose Bello/0000-0002-2724-2793
CR Adams B, 2006, P NATL ACAD SCI USA, V103, P14234, DOI 10.1073/pnas.0602768103
   Anderson JR, 2006, AM J TROP MED HYG, V75, P886, DOI 10.4269/ajtmh.2006.75.886
   Aquino VH, 2006, AM J TROP MED HYG, V75, P710, DOI 10.4269/ajtmh.2006.75.710
   Armstrong PM, 2001, VECTOR-BORNE ZOONOT, V1, P159, DOI 10.1089/153036601316977769
   BrisenoGarcia B, 1996, EMERG INFECT DIS, V2, P133, DOI 10.3201/eid0202.960210
   Carrington CVF, 2005, J VIROL, V79, P14680, DOI 10.1128/JVI.79.23.14680-14687.2005
   *CDC, 1995, MMWR-MORBID MORTAL W, V44, P21
   CHUNGUE E, 1993, J GEN VIROL, V74, P2765, DOI 10.1099/0022-1317-74-12-2765
   Cologna R, 2005, J VIROL, V79, P853, DOI 10.1128/JVI.79.2.853-859.2005
   Cologna R, 2003, J VIROL, V77, P3929, DOI 10.1128/JVI.77.7.3929-3938.2003
   Diaz FJ, 2006, ARCH MED RES, V37, P760, DOI 10.1016/j.arcmed.2006.02.004
   Drummond A.J., 2006, BEAST V1 4
   Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/msi103
   Drummond AJ, 2002, GENETICS, V161, P1307
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   Goncalvez AP, 2002, VIROLOGY, V303, P110, DOI 10.1006/viro.2002.1686
   GUBLER DJ, 1979, AM J TROP MED HYG, V28, P701, DOI 10.4269/ajtmh.1979.28.701
   Gubler DJ, 1998, CLIN MICROBIOL REV, V11, P480, DOI 10.1128/CMR.11.3.480
   Gubler DJ, 2004, COMP IMMUNOL MICROB, V27, P319, DOI 10.1016/j.cimid.2004.03.013
   Gubler Duane J., 2002, Trends in Microbiology, V10, P100, DOI 10.1016/S0966-842X(01)02288-0
   Guzman Maria G., 1996, Boletin de la Oficina Sanitaria Panamericana, V121, P102
   HAMMON WM, 1960, SCIENCE, V131, P1102, DOI 10.1126/science.131.3407.1102
   Holmes EC, 2003, INFECT GENET EVOL, V3, P19, DOI 10.1016/S1567-1348(03)00004-2
   Islam MA, 2006, JPN J INFECT DIS, V59, P85
   Jenkins GM, 2002, J MOL EVOL, V54, P156, DOI 10.1007/s00239-001-0064-3
   Klungthong C, 2004, VIROLOGY, V329, P168, DOI 10.1016/j.virol.2004.08.003
   Kobayashi N, 1999, AM J TROP MED HYG, V60, P904, DOI 10.4269/ajtmh.1999.60.904
   LANCIOTTI RS, 1994, J GEN VIROL, V75, P65, DOI 10.1099/0022-1317-75-1-65
   Maddison WP, 2005, MACCLADE 4 ANAL PHYL
   Messer WB, 2003, EMERG INFECT DIS, V9, P800
   Messer WB, 2002, AM J TROP MED HYG, V66, P765, DOI 10.4269/ajtmh.2002.66.765
   Nisalak A, 2003, AM J TROP MED HYG, V68, P191, DOI 10.4269/ajtmh.2003.68.191
   Nogueira RMR, 2001, MEM I OSWALDO CRUZ, V96, P925, DOI 10.1590/S0074-02762001000700007
   Peyrefitte CN, 2005, EMERG INFECT DIS, V11, P757, DOI 10.3201/eid1105.040959
   Peyrefitte CN, 2003, J CLIN MICROBIOL, V41, P5195, DOI 10.1128/JCM.41.11.5195-5198.2003
   Podder G, 2006, AM J TROP MED HYG, V74, P263, DOI 10.4269/ajtmh.2006.74.263
   Raekiansyah Muhareva, 2005, Southeast Asian Journal of Tropical Medicine and Public Health, V36, P1187
   Rambaut A, 2007, TRACER V1 4
   Rico-Hesse R, 2003, ADV VIRUS RES, V59, P315, DOI 10.1016/S0065-3527(03)59009-1
   RicoHesse R, 1997, VIROLOGY, V230, P244, DOI 10.1006/viro.1997.8504
   Rigau-Perez JG, 2002, AM J TROP MED HYG, V67, P355, DOI 10.4269/ajtmh.2002.67.355
   RODRIGUEZ F, 1990, J THEOR BIOL, V142, P485, DOI 10.1016/S0022-5193(05)80104-3
   Rodriguez-Roche R, 2005, EMERG INFECT DIS, V11, P773
   Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180
   Suchard MA, 2001, MOL BIOL EVOL, V18, P1001, DOI 10.1093/oxfordjournals.molbev.a003872
   SUMARMO, 1987, Southeast Asian Journal of Tropical Medicine and Public Health, V18, P269
   SWOFFORD DL, 1987, MATH BIOSCI, V87, P199, DOI 10.1016/0025-5564(87)90074-5
   Swofford DL, 2002, PAUP PHYLOGENETIC AN
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Twiddy SS, 2003, MOL BIOL EVOL, V20, P122, DOI 10.1093/molbev/msg010
   Usuku S, 2001, ARCH VIROL, V146, P1381, DOI 10.1007/s007050170098
   Uzcategui NY, 2003, J GEN VIROL, V84, P1569, DOI 10.1099/vir.0.18807-0
   WALLACE H G, 1980, Southeast Asian Journal of Tropical Medicine and Public Health, V11, P1
   Wittke V, 2002, VIROLOGY, V301, P148, DOI 10.1006/viro.2002.1549
   Worobey M, 1999, P NATL ACAD SCI USA, V96, P7352, DOI 10.1073/pnas.96.13.7352
   Zanotto PMD, 1996, P NATL ACAD SCI USA, V93, P548, DOI 10.1073/pnas.93.2.548
   Zhang CL, 2006, J GEN VIROL, V87, P873, DOI 10.1099/vir.0.81486-0
   Zhang CL, 2005, J VIROL, V79, P15123, DOI 10.1128/JVI.79.24.15123-15130.2005
   Zwickl D. J., 2006, THESIS U TEXAS AUSTI
NR 59
TC 57
Z9 60
U1 0
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567-1348
EI 1567-7257
J9 INFECT GENET EVOL
JI Infect. Genet. Evol.
PD JUL
PY 2009
VL 9
IS 4
BP 716
EP 725
DI 10.1016/j.meegid.2008.10.005
PG 10
WC Infectious Diseases
SC Infectious Diseases
GA 458SW
UT WOS:000267044800041
PM 19010450
DA 2020-12-01
ER

PT J
AU de Araujo, JMG
   Bello, G
   Schatzmayr, HG
   dos Santos, FB
   Nogueira, RMR
AF Galvao de Araujo, Joselio Maria
   Bello, Gonzalo
   Schatzmayr, Hermann Goncalves
   dos Santos, Flavia Barreto
   Ribeiro Nogueira, Rita Maria
TI Dengue virus type 3 in Brazil: a phylogenetic perspective
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE dengue virus type 3; genotypes; Brazil
ID HEMORRHAGIC-FEVER; MOLECULAR EPIDEMIOLOGY; CIRCULATION
AB Circulation of a new dengue virus (DENV)-3 genotype was recently described in Brazil and Colombia, but the precise classification of this genotype has been controversial. Here we perform phylogenetic and nucleotide-distance analyses of the envelope gene, which support the subdivision of DENV-3 strains into five distinct genotypes (GI to GV) and confirm the classification of the new South American genotype as GV. The extremely low genetic distances between Brazilian GV strains and the prototype Philippines/L11423 GV strain isolated in 1956 raise important questions regarding the origin of GV in South America.
C1 [Galvao de Araujo, Joselio Maria; Schatzmayr, Hermann Goncalves; dos Santos, Flavia Barreto; Ribeiro Nogueira, Rita Maria] Fiocruz MS, Inst Oswaldo Cruz, Lab Flavivirus, BR-21045900 Rio De Janeiro, Brazil.
   [Bello, Gonzalo] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, BR-21045900 Rio De Janeiro, Brazil.
RP de Araujo, JMG (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab Flavivirus, Av Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM joselio@ioc.fiocruz.br
RI Bentancor, Gonzalo Jose Bello/N-7377-2019; Araujo, Joselio M
   G/B-5502-2013; Bello, Gonzalo/E-6842-2013
OI Bentancor, Gonzalo Jose Bello/0000-0002-2724-2793; Araujo, Joselio M
   G/0000-0003-3548-2786; 
FU CNPqNational Council for Scientific and Technological Development (CNPq)
   [501564/03-9]; FAPERJCarlos Chagas Filho Foundation for Research Support
   of the State of Rio de Janeiro (FAPERJ) [E-26/152490/2002]
FX CNPq (501564/03-9), FAPERJ (E-26/152490/2002) JMG Ara jo and G Bello
   contributed equally to this article.
CR [Anonymous], 1995, Wkly Epidemiol Rec, V70, P41
   Aquino VH, 2006, AM J TROP MED HYG, V75, P710, DOI 10.4269/ajtmh.2006.75.710
   ARAUJO JM, 2009, INFECT GENE IN PRESS
   Balmaseda A, 1999, AM J TROP MED HYG, V61, P893, DOI 10.4269/ajtmh.1999.61.893
   BrisenoGarcia B, 1996, EMERG INFECT DIS, V2, P133, DOI 10.3201/eid0202.960210
   BUKIN EK, 2006, DENGUE EPIDEMIC PARA
   CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245
   Figueiredo LB, 2008, EMERG INFECT DIS, V14, P314, DOI 10.3201/eid1402.070278
   GUZMAN MG, 1998, ARCH VENEZ MED TROP, V2, P8
   Isturiz RE, 2000, INFECT DIS CLIN N AM, V14, P121, DOI 10.1016/S0891-5520(05)70221-X
   LANCIOTTI RS, 1994, J GEN VIROL, V75, P65, DOI 10.1099/0022-1317-75-1-65
   Linderbach BD, 2001, FIELDS VIROLOGY, P991
   Nogueira MB, 2008, MEM I OSWALDO CRUZ, V103, P483, DOI 10.1590/S0074-02762008000500013
   Nogueira RMR, 2001, MEM I OSWALDO CRUZ, V96, P925, DOI 10.1590/S0074-02762001000700007
   Rosen L, 1999, Med Trop (Mars), V59, P495
   Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092
   Usme-Ciro JA, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-101
   Usuku S, 2001, ARCH VIROL, V146, P1381, DOI 10.1007/s007050170098
   Uzcategui NY, 2003, J GEN VIROL, V84, P1569, DOI 10.1099/vir.0.18807-0
NR 19
TC 11
Z9 11
U1 0
U2 3
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD MAY
PY 2009
VL 104
IS 3
BP 526
EP 529
DI 10.1590/S0074-02762009000300021
PG 4
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 462EX
UT WOS:000267332000021
PM 19547883
OA DOAJ Gold
DA 2020-12-01
ER

PT J
AU Guimaraes, ML
   Vicente, ACP
   Otsuki, K
   da Silva, RFFC
   Francisco, M
   da Silva, FG
   Serrano, D
   Morgado, MG
   Bello, G
AF Guimaraes, Monick L.
   Vicente, Ana Carolina P.
   Otsuki, Koko
   da Silva, Rosa Ferreira F. C.
   Francisco, Moises
   da Silva, Filomena Gomes
   Serrano, Ducelina
   Morgado, Mariza G.
   Bello, Gonzalo
TI Close phylogenetic relationship between Angolan and Romanian HIV-1
   subtype F1 isolates
SO RETROVIROLOGY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; RIO-DE-JANEIRO; INJECTING DRUG-USERS;
   REPUBLIC-OF-CONGO; GENETIC DIVERSITY; SOUTH-AMERICA; MOLECULAR
   EPIDEMIOLOGY; EVOLUTIONARY HISTORY; MAXIMUM-LIKELIHOOD; TYPE-1 SUBTYPES
AB Background: Here, we investigated the phylogenetic relationships of the HIV-1 subtype F1 circulating in Angola with subtype F1 strains sampled worldwide and reconstructed the evolutionary history of this subtype in Central Africa.
   Methods: Forty-six HIV-1-positive samples were collected in Angola in 2006 and subtyped at the env-gp41 region. Partial env-gp120 and pol-RT sequences and near full-length genomes from those env-gp41 subtype F1 samples were further generated. Phylogenetic analyses of partial and full-length subtype F1 strains isolated worldwide were carried out. The onset date of the subtype F1 epidemic in Central Africa was estimated using a Bayesian Markov chain Monte Carlo approach.
   Results: Nine Angolan samples were classified as subtype F1 based on the analysis of the env-gp41 region. All nine Angolan sequences were also classified as subtype F1 in both env-gp120 and pol-RT genomic regions, and near full-length genome analysis of four of these samples confirmed their classification as "pure" subtype F1. Phylogenetic analyses of subtype F1 strains isolated worldwide revealed that isolates from the Democratic Republic of Congo (DRC) were the earliest branching lineages within the subtype F1 phylogeny. Most strains from Angola segregated in a monophyletic group together with Romanian sequences; whereas South American F1 sequences emerged as an independent cluster. The origin of the subtype F1 epidemic in Central African was estimated at 1958 (1934-1971).
   Conclusion: "Pure" subtype F1 strains are common in Angola and seem to be the result of a single founder event. Subtype F1 sequences from Angola are closely related to those described in Romania, and only distantly related to the subtype F1 lineage circulating in South America. Original diversification of subtype F1 probably occurred within the DRC around the late 1950s.
C1 [Guimaraes, Monick L.; Morgado, Mariza G.; Bello, Gonzalo] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Immunol Mol, BR-21045900 Rio De Janeiro, Brazil.
   [Vicente, Ana Carolina P.; Otsuki, Koko; da Silva, Rosa Ferreira F. C.] Fiocruz MS, Inst Oswaldo Cruz, Inst Genet Mol Microorganismos, BR-21045900 Rio De Janeiro, Brazil.
   [da Silva, Rosa Ferreira F. C.; Francisco, Moises; da Silva, Filomena Gomes] Minist Saude, Inst Nacl Saude Publ Angola, Luanda, Angola.
   [Serrano, Ducelina] Minist Saude, Inst Nacl Luta Contra SIDA, Luanda, Angola.
RP Bello, G (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Immunol Mol, BR-21045900 Rio De Janeiro, Brazil.
EM monicklg@ioc.fiocruz.br; anapaulo@ioc.fiocruz.br;
   kotsuki@ioc.fiocruz.br; rosainsp@hotmail.com;
   moisesfrancisco@hotmail.com; inst@ebonet.net;
   ducelinaserrano@yahoo.com.br; mmorgado@ioc.fiocruz.br;
   gbello@ioc.fiocruz.br
RI Bello, Gonzalo/E-6842-2013; Bentancor, Gonzalo Jose Bello/N-7377-2019
OI Bentancor, Gonzalo Jose Bello/0000-0002-2724-2793
FU Oswaldo Cruz Foundation; Eduardo dos Santos Foundation; Brazilian
   "Pesquisador Visitante"/FIOCRUZ Program
FX We wish to thank Dr. Vera Bongertz for critical review of the
   manuscript. Rosa F. C. Ferreira da Silva was supported by the
   "Cooperacao Tecnico Cientifica" program between the Oswaldo Cruz
   Foundation (FIOCRUZ, Brazil) and the Eduardo dos Santos Foundation
   (FESA, Angola). Gonzalo Bello was supported by the Brazilian
   "Pesquisador Visitante"/FIOCRUZ Program.
CR Abecasis A., 2005, Infection Genetics and Evolution, V5, P231, DOI 10.1016/j.meegid.2004.07.007
   Apetrei C, 1998, AIDS, V12, P1079, DOI 10.1097/00002030-199809000-00015
   Apetrei C, 1997, AIDS RES HUM RETROV, V13, P363, DOI 10.1089/aid.1997.13.363
   Aulicino PC, 2007, AIDS RES HUM RETROV, V23, P1176, DOI 10.1089/aid.2007.0038
   Avila MM, 2002, J ACQ IMMUN DEF SYND, V29, P422, DOI 10.1097/00126334-200204010-00015
   BANDEA CI, 1995, EMERG INFECT DIS, V1, P91
   Bartolo I, 2005, AIDS RES HUM RETROV, V21, P306, DOI 10.1089/aid.2005.21.306
   BARTOLO I, 2008, INFECT GENET EVOL
   Bello G, 2006, AIDS, V20, P763, DOI 10.1097/01.aids.0000216377.84313.52
   Bello G, 2008, AIDS, V22, P1993, DOI 10.1097/QAD.0b013e328315e0aa
   Bello G, 2007, INFECT GENET EVOL, V7, P263, DOI 10.1016/j.meegid.2006.11.002
   Bongertz V, 2000, J ACQ IMMUN DEF SYND, V23, P184
   Brindeiro RM, 2003, AIDS, V17, P1063, DOI 10.1097/00002030-200305020-00016
   Chitnis A, 2000, AIDS RES HUM RETROV, V16, P5, DOI 10.1089/088922200309548
   de Coul EO, 2000, VIROLOGY, V270, P267, DOI 10.1006/viro.2000.0247
   de Oliveira T, 2005, BIOINFORMATICS, V21, P3797, DOI 10.1093/bioinformatics/bti607
   Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/msi103
   Drummond AJ, 2002, GENETICS, V161, P1307
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   DUMITRESCU O, 1994, J INFECT DIS, V169, P281, DOI 10.1093/infdis/169.2.281
   Espinosa A, 2004, JAIDS-J ACQ IMM DEF, V36, P630, DOI 10.1097/00126334-200405010-00012
   Gao F, 1998, J VIROL, V72, P5680, DOI 10.1128/JVI.72.7.5680-5698.1998
   Gomez-Carrillo M, 2006, AIDS RES HUM RETROV, V22, P1186, DOI 10.1089/aid.2006.22.1186
   Guimaraes ML, 2001, J CLIN VIROL, V21, P143, DOI 10.1016/S1386-6532(01)00158-5
   Guindon S, 2005, NUCLEIC ACIDS RES, V33, pW557, DOI 10.1093/nar/gki352
   Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520
   Hemelaar J, 2006, AIDS, V20, pW13, DOI 10.1097/01.aids.0000247564.73009.bc
   Heyndrickx L, 1998, AIDS RES HUM RETROV, V14, P1291, DOI 10.1089/aid.1998.14.1291
   Hierholzer J, 2002, AIDS RES HUM RETROV, V18, P1339, DOI 10.1089/088922202320935410
   Kalish ML, 2004, EMERG INFECT DIS, V10, P1227
   Korber B, 2000, SCIENCE, V288, P1789, DOI 10.1126/science.288.5472.1789
   Laukkanen T, 2000, VIROLOGY, V269, P95, DOI 10.1006/viro.2000.0214
   Lukashov VV, 1996, AIDS RES HUM RETROV, V12, P951, DOI 10.1089/aid.1996.12.951
   Marx PA, 2001, PHILOS T R SOC B, V356, P911, DOI 10.1098/rstb.2001.0867
   Masciotra S, 2000, AIDS RES HUM RETROV, V16, P1007, DOI 10.1089/08892220050058425
   Mokili JLK, 1999, AIDS RES HUM RETROV, V15, P655, DOI 10.1089/088922299310953
   Montano SM, 2005, JAIDS-J ACQ IMM DEF, V40, P57, DOI 10.1097/01.qai.0000159667.72584.8b
   Morgado MG, 1998, J ACQ IMMUN DEF SYND, V18, P488, DOI 10.1097/00042560-199808150-00011
   Op De Coul E, 2000, AIDS RES HUM RETROV, V16, P327
   Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817
   Quarleri JF, 2004, AIDS RES HUM RETROV, V20, P1100, DOI 10.1089/aid.2004.20.1100
   Rambaut A, 2007, TRACER V1 4
   Ray S., SIMPLOT V2 5 0
   Rios M, 2007, J MED VIROL, V79, P647, DOI 10.1002/jmv.20881
   Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180
   Rousseau CM, 2007, J VIROL, V81, P4492, DOI 10.1128/JVI.02050-06
   Russell KL, 2000, AIDS, V14, P1785, DOI 10.1097/00002030-200008180-00014
   Sabino EC, 1996, AIDS, V10, P1579, DOI 10.1097/00002030-199611000-00018
   Sanabani S, 2006, INFECT GENET EVOL, V6, P368, DOI 10.1016/j.meegid.2006.01.003
   Teixeira SLM, 2004, J CLIN VIROL, V31, P221, DOI 10.1016/j.jcv.2004.03.016
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Thomson MM, 2000, AIDS, V14, P897, DOI 10.1097/00002030-200005050-00020
   Travers SAA, 2004, J VIROL, V78, P10501, DOI 10.1128/JVI.78.19.10501-10506.2004
   Triques K, 1999, VIROLOGY, V259, P99, DOI 10.1006/viro.1999.9720
   Triques K, 2000, AIDS RES HUM RETROV, V16, P139, DOI 10.1089/088922200309485
   Vidal N, 2000, J VIROL, V74, P10498, DOI 10.1128/JVI.74.22.10498-10507.2000
   Vidal N, 2005, JAIDS-J ACQ IMM DEF, V40, P456, DOI 10.1097/01.qai.0000159670.18326.94
   Walker Polly R., 2005, Infection Genetics and Evolution, V5, P199, DOI 10.1016/j.meegid.2004.06.011
   Worobey M, 2008, NATURE, V455, P661, DOI 10.1038/nature07390
   Yang CF, 2005, AIDS RES HUM RETROV, V21, P661, DOI 10.1089/aid.2005.21.661
   Yang CF, 2001, AIDS RES HUM RETROV, V17, P361, DOI 10.1089/08892220150503726
NR 62
TC 24
Z9 24
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PD APR 22
PY 2009
VL 6
AR 39
DI 10.1186/1742-4690-6-39
PG 11
WC Virology
SC Virology
GA 451TM
UT WOS:000266493100001
PM 19386115
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Bello, G
   Passaes, CPB
   Guimaraes, ML
   Lorete, RS
   Almeida, SEM
   Medeiros, RA
   Alencastro, PR
   Morgado, MG
AF Bello, Gonzalo
   Passaes, Caroline P. B.
   Guimaraes, Monick L.
   Lorete, Roberta S.
   Almeida, Sabrina E. Matos
   Medeiros, Rubia A.
   Alencastro, Paulo R.
   Morgado, Mariza G.
TI Origin and evolutionary history of HIV-1 subtype C in Brazil
SO AIDS
LA English
DT Article
DE Brazil; evolutionary history; HIV-1; origin; subtype C
ID IMMUNODEFICIENCY-VIRUS TYPE-1; RIO-DE-JANEIRO; ANTIRETROVIRAL
   DRUG-RESISTANCE; MOLECULAR EPIDEMIOLOGY; SOUTHERN BRAZIL; BLOOD-DONORS;
   SAO-PAULO; GENETIC DIVERSITY; POPULATION HISTORY; PREVALENCE
AB Objective: To investigate the origin and to reconstruct the onset date of the HIV-1 subtype C epidemic in Brazil.
   Design: Three independent datasets of subtype C sequences isolated from HIV-1-positive patients from southern Brazil over a period of 15 years (1991-2006) were analyzed: 82 env V3 sequences (213nt), 40 env C2-C5 sequences (559nt), and 72 pol sequences (960nt).
   Methods: Brazilian sequences were compared with other subtype C reference strains from the database using basic local alignment search tool, phylogenetic analyses, and searching of specific amino acid signature patterns. Evolutionary parameters were estimated using a Bayesian coalescent-based method under either strict or relaxed molecular clock models.
   Results: HIV-1 subtype C sequences from Brazil and Burundi formed a monophyletic cluster at both env and pol regions and shared specific amino acid signatures in the protease region when compared with other viruses of the same subtype from around the world. All Brazilian strains arose as a monophyletic subcluster within the Burundi-Brazilian lineage, whereas isolates from Burundi appeared at the origin of the clade. Evolutionary analyses of both env and pol genomic regions indicate that the age of the most recent common ancestor of the Brazilian subtype C clade dates back to the early 1980s.
   Conclusion: The subtype C epidemic in the southern Brazilian region was initiated by the introduction of a single founder strain closely related to subtype C strains from Burundi. Our results suggest that this founder event probably took place around the early 1980s, roughly a decade before the previous estimates. (c) 2008 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
C1 [Bello, Gonzalo; Passaes, Caroline P. B.; Guimaraes, Monick L.; Lorete, Roberta S.; Morgado, Mariza G.] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, BR-21045900 Rio De Janeiro, Brazil.
   [Almeida, Sabrina E. Matos; Medeiros, Rubia A.] Fundacao Estadual Prod & Pesquisa Saude, Ctr Desenvolvimento Cient & Tecnol, Porto Alegre, RS, Brazil.
   [Alencastro, Paulo R.] Hosp Sanatorio Partenon, Porto Alegre, RS, Brazil.
RP Bello, G (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, Av Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM gbello@ioc.fiocruz.br
RI de Medeiros, Rubia M/L-2761-2015; Bello, Gonzalo/E-6842-2013; Bentancor,
   Gonzalo Jose Bello/N-7377-2019; Passaes, Caroline/AAH-3392-2020
OI de Medeiros, Rubia M/0000-0001-7403-5650; Bentancor, Gonzalo Jose
   Bello/0000-0002-2724-2793; Passaes, Caroline/0000-0002-0813-2521
FU FAPERJCarlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); CNPqNational Council for Scientific and
   Technological Development (CNPq); Brazilian FAPERJ/FIOCRUZ
   ProgramFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
FX This study was supported by FAPERJ and CNPq grants. G.B. was supportecl
   by the Brazilian FAPERJ/FIOCRUZ Program.
CR Aulicino PC, 2007, AIDS RES HUM RETROV, V23, P1176, DOI 10.1089/aid.2007.0038
   Barreto CC, 2006, JAIDS-J ACQ IMM DEF, V41, P338
   Bello G, 2006, AIDS, V20, P763, DOI 10.1097/01.aids.0000216377.84313.52
   Bello G, 2007, INFECT GENET EVOL, V7, P263, DOI 10.1016/j.meegid.2006.11.002
   Bongertz V, 2000, J ACQ IMMUN DEF SYND, V23, P184
   Brennan CA, 2007, AIDS RES HUM RETROV, V23, P1434, DOI 10.1089/aid.2007.0121
   Brigido LFM, 2005, AIDS RES HUM RETROV, V21, P673, DOI 10.1089/aid.2005.21.673
   Brigido LFM, 2007, AIDS RES HUM RETROV, V23, P1579, DOI 10.1089/aid.2007.0102
   Brindeiro RM, 2003, AIDS, V17, P1063, DOI 10.1097/00002030-200305020-00016
   Cabral VP, 2006, MEM I OSWALDO CRUZ, V101, P881, DOI 10.1590/S0074-02762006000800010
   Caride E, 2000, VIROLOGY, V275, P107, DOI 10.1006/viro.2000.0487
   Couto-Fernandez JC, 2005, MEM I OSWALDO CRUZ, V100, P73, DOI 10.1590/S0074-02762005000100014
   Couto-Fernandez JC, 1999, J ACQ IMMUN DEF SYND, V22, P288
   de Medeiros LB, 2006, MEM I OSWALDO CRUZ, V101, P845, DOI 10.1590/S0074-02762006000800004
   de Oliveira T, 2005, BIOINFORMATICS, V21, P3797, DOI 10.1093/bioinformatics/bti607
   De Sa DJ, 2005, AIDS RES HUM RETROV, V21, P145, DOI 10.1089/aid.2005.21.145
   DELWART EL, 1993, SCIENCE, V262, P1257, DOI 10.1126/science.8235655
   Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/msi103
   Drummond AJ, 2002, GENETICS, V161, P1307
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   Eyer-Silva WA, 2007, AIDS RES HUM RETROV, V23, P303, DOI 10.1089/aid.2006.0199
   Gadelha SR, 2003, MEM I OSWALDO CRUZ, V98, P461, DOI 10.1590/S0074-02762003000400005
   Gilbert MTP, 2007, P NATL ACAD SCI USA, V104, P18566, DOI 10.1073/pnas.0705329104
   Guimaraes ML, 2001, J CLIN VIROL, V21, P143, DOI 10.1016/S1386-6532(01)00158-5
   Guiniaraes ML, 2002, AIDS RES HUM RETROV, V18, P1261, DOI 10.1089/088922202320886307
   Hemelaar J, 2006, AIDS, V20, pW13, DOI 10.1097/01.aids.0000247564.73009.bc
   Hue S, 2005, P NATL ACAD SCI USA, V102, P4425, DOI 10.1073/pnas.0407534102
   Jenkins GM, 2002, J MOL EVOL, V54, P156, DOI 10.1007/s00239-001-0064-3
   Koch N, 2001, AIDS RES HUM RETROV, V17, P269, DOI 10.1089/088922201750063205
   Lacerda HR, 2007, MEM I OSWALDO CRUZ, V102, P693, DOI [10.1590/S0074-02762007005000109, 10.1590/S0074-02762007000600006]
   Leitner T, 1999, P NATL ACAD SCI USA, V96, P10752, DOI 10.1073/pnas.96.19.10752
   Locateli D, 2007, J MED VIROL, V79, P1455, DOI 10.1002/jmv.20955
   Monteiro JP, 2007, AIDS RES HUM RETROV, V23, P135, DOI 10.1089/aid.2006.0064
   MORGADO MG, 1994, AIDS RES HUM RETROV, V10, P569, DOI 10.1089/aid.1994.10.569
   Morgado MG, 1998, J ACQ IMMUN DEF SYND, V18, P488, DOI 10.1097/00042560-199808150-00011
   Paraskevis D, 2007, J INFECT DIS, V196, P1167, DOI 10.1086/521677
   Penny MA, 1996, AIDS RES HUM RETROV, V12, P741, DOI 10.1089/aid.1996.12.741
   Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817
   Rambaut A, 2007, TRACER V1 4
   Ramos A, 1999, EMERG INFECT DIS, V5, P65, DOI 10.3201/eid0501.990108
   Ray S., SIMPLOT V2 5 0
   Robbins KE, 2003, J VIROL, V77, P6359, DOI 10.1128/JVI.77.11.6359-6366.2003
   Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180
   Sa-Ferreira JA, 2007, TRANSFUSION, V47, P97, DOI 10.1111/j.1537-2995.2007.01069.x
   Sabino EC, 1996, AIDS, V10, P1579, DOI 10.1097/00002030-199611000-00018
   Salemi M, 2005, J MOL EVOL, V60, P598, DOI 10.1007/s00239-004-0206-5
   Salemi M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001390
   Sanabani S, 2006, AIDS RES HUM RETROV, V22, P171, DOI 10.1089/aid.2006.22.171
   Santos AF, 2007, JAIDS-J ACQ IMM DEF, V45, P328
   Santos AF, 2006, AIDS, V20, P2011
   Soares EAJM, 2005, AIDS, V19, pS81, DOI 10.1097/01.aids.0000191497.00928.e4
   Soares EAJM, 2003, JAIDS-J ACQ IMM DEF, V34, P520, DOI 10.1097/00126334-200312150-00012
   Soares MA, 2003, AIDS, V17, P11, DOI 10.1097/00002030-200301030-00004
   Stefani MMA, 2007, J CLIN VIROL, V39, P205, DOI 10.1016/j.jcv.2007.04.012
   Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092
   Tanuri A, 1999, J ACQ IMMUN DEF SYND, V20, P60, DOI 10.1097/00042560-199901010-00009
   Teixeira SLM, 2004, J CLIN VIROL, V31, P221, DOI 10.1016/j.jcv.2004.03.016
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Turchi MD, 2002, J ACQ IMMUN DEF SYND, V30, P527, DOI 10.1097/00126334-200208150-00009
   Veras NMC, 2007, AIDS RES HUM RETROV, V23, P1481, DOI 10.1089/aid.2007.0145
   Vicente ACP, 2000, J ACQ IMMUN DEF SYND, V23, P327
   Vidal N, 2007, AIDS RES HUM RETROV, V23, P175, DOI 10.1089/aid.2006.0126
NR 63
TC 69
Z9 70
U1 2
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD OCT 1
PY 2008
VL 22
IS 15
BP 1993
EP 2000
DI 10.1097/QAD.0b013e328315e0aa
PG 8
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 355AD
UT WOS:000259680100011
PM 18753928
DA 2020-12-01
ER

PT J
AU Aulicino, PC
   Bello, G
   Rocco, C
   Romero, H
   Mangano, A
   Morgado, MG
   Sen, L
AF Aulicino, Paula C.
   Bello, Gonzalo
   Rocco, Carlos
   Romero, Hector
   Mangano, Andrea
   Morgado, Mariza G.
   Sen, Luisa
TI Description of the first full-length HIV type 1 subtype F1 strain in
   Argentina: Implications for the origin and dispersion of this subtype in
   South America
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID F/D RECOMBINANT HIV-1; GENETIC-HETEROGENEITY; BF RECOMBINANTS;
   BUENOS-AIRES; V3 REGION; TRANSMISSION; CIRCULATION; POPULATION;
   INFECTIONS; DIVERSITY
AB HIV-1 subtype F1 in South America is mainly found as part of diverse BF1 recombinant forms and only five full-length " pure" F1 strains from Brazil were characterized to date. In the present study we describe the first near full-length sequence of a nonrecombinant F1 HIV-1 strain from Argentina, and explore the epidemiological history of this subtype in South America. Three separate phylogenetic analyses were carried out: with all available F1 full-length sequences, with concatenated F1 sequences contained in F1 and BF1 strains, and with partial F1 env sequences derived from worldwide strains. All analyses were consistent in showing a local origin of the newly reported Argentine subtype F1 strain, and a common ancestry of the South American subtype F1 sequences, present either in pure or recombinant genomes. By coalescent analysis, the onset date of the HIV-1 subtype F1 epidemic in South America was estimated to be around the late 1970s. The results indicate for the first time that nonrecombinant F1 HIV-1 strains are present in Argentina, and suggest that the subtype F1 epidemic in South America was initiated by the introduction of a very small group of genetically related viruses during late 1970s.
C1 Hosp Pediat JP Garrahan, Lab Biol Celular & Retrovirus, CONICET, Buenos Aires, DF, Argentina.
   Inst Oswaldo Cruz Fiocruz, Dept Immunol, Lab AIDS & Mol Immunol, Rio De Janeiro, Brazil.
   Univ Republ, Fac Ciencias, Secc Biomatemat, Lab Organ & Evoluc Genoma, Salto, Uruguay.
RP Aulicino, PC (corresponding author), Hosp Pediat Garrahan, Lab Biol Celular & Retrovirus, Combate Pozos 1881, RA-1245 Buenos Aires, Argentina.
EM paulicino@garrahan.gov.ar
RI Bello, Gonzalo/E-6842-2013; Bentancor, Gonzalo Jose Bello/N-7377-2019
OI Bentancor, Gonzalo Jose Bello/0000-0002-2724-2793
CR Abecasis A., 2005, Infection Genetics and Evolution, V5, P231, DOI 10.1016/j.meegid.2004.07.007
   Apetrei C, 1998, AIDS, V12, P1079, DOI 10.1097/00002030-199809000-00015
   Aulicino PC, 2007, J VIROL, V81, P427, DOI 10.1128/JVI.01403-06
   Aulicino PC, 2005, AIDS RES HUM RETROV, V21, P158, DOI 10.1089/aid.2005.21.158
   BANDEA CI, 1995, EMERG INFECT DIS, V1, P91
   Bello G, 2006, AIDS, V20, P763, DOI 10.1097/01.aids.0000216377.84313.52
   Bello G, 2007, INFECT GENET EVOL, V7, P263, DOI 10.1016/j.meegid.2006.11.002
   Campodonico M, 1996, AIDS RES HUM RETROV, V12, P79, DOI 10.1089/aid.1996.12.79
   Carr JK, 2001, AIDS, V15, pF41, DOI 10.1097/00002030-200110190-00002
   Carrillo MG, 2002, AIDS RES HUM RETROV, V18, P477, DOI 10.1089/088922202317406619
   DAFILHO DJS, 2006, AIDS RES HUM RETROV, V22, P1
   de Coul ELMO, 2001, AIDS, V15, P2277, DOI 10.1097/00002030-200111230-00009
   de Coul EO, 2000, VIROLOGY, V270, P267, DOI 10.1006/viro.2000.0247
   DRUMMOND AJ, 2003, BEAST V1 0
   Espinosa A, 2004, JAIDS-J ACQ IMM DEF, V36, P630, DOI 10.1097/00126334-200405010-00012
   Gao F, 1998, J VIROL, V72, P5680, DOI 10.1128/JVI.72.7.5680-5698.1998
   Guindon S, 2005, NUCLEIC ACIDS RES, V33, pW557, DOI 10.1093/nar/gki352
   HALL TA, 1999, NUCL ACIDS S SER, V41, P95, DOI DOI 10.5598/IMAFUNGUS.2011.02.02.06
   Hierholzer J, 2002, AIDS RES HUM RETROV, V18, P1339, DOI 10.1089/088922202320935410
   Laukkanen T, 2000, VIROLOGY, V269, P95, DOI 10.1006/viro.2000.0214
   LEITNER T, 2005, 060680 LAUR LOS AL N
   LOUWAGIE J, 1994, AIDS RES HUM RETROV, V10, P561, DOI 10.1089/aid.1994.10.561
   Marquina S, 1996, AIDS RES HUM RETROV, V12, P1651, DOI 10.1089/aid.1996.12.1651
   Masciotra S, 2000, AIDS RES HUM RETROV, V16, P1007, DOI 10.1089/08892220050058425
   Mokili JLK, 1999, AIDS RES HUM RETROV, V15, P655, DOI 10.1089/088922299310953
   MORGADO MG, 1994, AIDS RES HUM RETROV, V10, P569, DOI 10.1089/aid.1994.10.569
   Paraskevis D, 2004, J MOL EVOL, V59, P709, DOI 10.1007/s00239-004-2651-6
   Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817
   POTTS KE, 1993, AIDS, V7, P1191, DOI 10.1097/00002030-199309000-00007
   Quarleri JF, 2004, AIDS RES HUM RETROV, V20, P1100, DOI 10.1089/aid.2004.20.1100
   Ray S., SIMPLOT V2 5 0
   Robbins KE, 2003, J VIROL, V77, P6359, DOI 10.1128/JVI.77.11.6359-6366.2003
   Robertson DL, 2000, SCIENCE, V288, P55, DOI 10.1126/science.288.5463.55d
   Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180
   Sanabani S, 2006, INFECT GENET EVOL, V6, P368, DOI 10.1016/j.meegid.2006.01.003
   Sierra Maria, 2005, Infection Genetics and Evolution, V5, P209, DOI 10.1016/j.meegid.2004.07.010
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Thomson MM, 2000, AIDS, V14, P897, DOI 10.1097/00002030-200005050-00020
   Thomson MM, 2004, AIDS RES HUM RETROV, V20, P1126, DOI 10.1089/aid.2004.20.1126
   Thomson MM, 2002, J GEN VIROL, V83, P107, DOI 10.1099/0022-1317-83-1-107
   Yang CF, 2005, AIDS RES HUM RETROV, V21, P661, DOI 10.1089/aid.2005.21.661
NR 41
TC 19
Z9 19
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 2007
VL 23
IS 10
BP 1176
EP 1182
DI 10.1089/aid.2007.0038
PG 7
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 228HO
UT WOS:000250720900003
PM 17961101
DA 2020-12-01
ER

PT J
AU Bello, G
   Casado, C
   Sandonis, V
   Alvaro-Cifuentes, T
   Dos Santos, CAR
   Garcia, S
   Rodriguez, C
   Del Romero, J
   Pilotto, JH
   Grinsztejn, B
   Veloso, VG
   Morgado, MG
   Lopez-Galindez, C
AF Bello, Gonzalo
   Casado, Concepcion
   Sandonis, Virginia
   Alvaro-Cifuentes, Tamara
   Dos Santos, Caio A. Rodrigues
   Garcia, Soledad
   Rodriguez, Carmen
   Del Romero, Jorge
   Pilotto, Jose H.
   Grinsztejn, Beatriz
   Veloso, Valdilea G.
   Morgado, Mariza G.
   Lopez-Galindez, Cecilio
TI Plasma viral load threshold for sustaining intrahost HIV type 1
   evolution
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; ACTIVE ANTIRETROVIRAL THERAPY; LONG-TERM
   NONPROGRESSORS; POTENT ANTIVIRAL THERAPY; CD4(+) T-CELLS; DISEASE
   PROGRESSION; LATENT RESERVOIR; DRUG-RESISTANCE; COMBINATION THERAPY;
   SEQUENCE ALIGNMENT
AB The objective of the present study was to determine if natural suppression of plasma viremia below the detection limit of commercial assays (50-80 copies HIV-1 RNA/ml) can contain the HIV-1 evolution. HIV-1 quasispecies complexity in PBMC DNA was assessed in the env gene at two time points in 14 long-term nonprogressors (LTNPs). Sequence changes consistent with viral evolution was found in all patients with a median plasma RNA viral load >100 copies/ml. Evidence of low-level viral evolution was detected in two of four patients with intermittent viremia and a median plasma HIV-1 RNA load of <80 copies/ml. No significant evolution was observed in the three LTNPs with persistent viral suppression below the detection limit. Overall, a significant positive correlation (p <0.001) was observed between viral evolution and plasma RNA viral load in the LTNPs analyzed. These results suggest that the detection limit of ultrasensitive viremia assays could represent an important threshold below which intrahost HIV-1 evolution does not occur.
C1 Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, BR-21045900 Rio De Janeiro, Brazil.
   Inst Salud Carlos III, Ctr Nacl Microbiol, Serv Microbiol Virol, Madrid 28220, Spain.
   IMSALUD, Ctr Sanitario Sandoval, Comunidad Autonoma Madrid, Madrid, Spain.
   Fiocruz MS, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
RP Lopez-Galindez, C (corresponding author), Inst Salud Carlos III, Ctr Nacl Microbiol, Serv Microbiol Virol, Carretera Majadahonda Pozuelo,Km 2-200, Madrid 28220, Spain.
EM clopez@isciii.es
RI Sandonis, Virginia/K-2884-2014; Pilotto, Jose Henrique/AAD-9773-2019;
   Casado, Concepcion/F-3060-2016; Bello, Gonzalo/E-6842-2013;
   Lopez-Galindez, Cecilio/A-3603-2008; Veloso, Valdilea
   Goncalves/J-6189-2012; Bentancor, Gonzalo Jose Bello/N-7377-2019
OI Sandonis, Virginia/0000-0001-5762-7531; Pilotto, Jose
   Henrique/0000-0003-0521-8597; Casado, Concepcion/0000-0003-3412-2877;
   Lopez-Galindez, Cecilio/0000-0002-2324-9584; Bentancor, Gonzalo Jose
   Bello/0000-0002-2724-2793
CR Bagnarelli P, 1999, J VIROL, V73, P3764, DOI 10.1128/JVI.73.5.3764-3777.1999
   Bello G, 2005, J GEN VIROL, V86, P355, DOI 10.1099/vir.0.80410-0
   Bello G, 2004, ARCH VIROL, V149, P1761, DOI 10.1007/s00705-004-0322-y
   Bello G, 2004, J GEN VIROL, V85, P399, DOI 10.1099/vir.0.19365-0
   Bello G, 2007, VIROLOGY, V362, P294, DOI 10.1016/j.virol.2006.11.039
   Birk M, 2000, HIV Med, V1, P205, DOI 10.1046/j.1468-1293.2000.00030.x
   Casado C, 2001, J GEN VIROL, V82, P2495, DOI 10.1099/0022-1317-82-10-2495
   DELWART EL, 1993, SCIENCE, V262, P1257, DOI 10.1126/science.8235655
   Delwart EL, 1997, J VIROL, V71, P7498, DOI 10.1128/JVI.71.10.7498-7508.1997
   Finzi D, 1999, NAT MED, V5, P512
   Frenkel LM, 2003, J VIROL, V77, P5721, DOI 10.1128/JVI.77.10.5721-5730.2003
   Frost SDW, 2001, VIROLOGY, V284, P250, DOI 10.1006/viro.2000.0887
   Ganeshan S, 1997, J VIROL, V71, P663, DOI 10.1128/JVI.71.1.663-677.1997
   Goudsmit J, 2002, AIDS, V16, P791, DOI 10.1097/00002030-200203290-00016
   Grenfell BT, 2004, SCIENCE, V303, P327, DOI 10.1126/science.1090727
   Greub G, 2002, AIDS, V16, P1967, DOI 10.1097/00002030-200209270-00017
   Gunthard HF, 1999, J VIROL, V73, P9404
   Gunthard HF, 1998, J VIROL, V72, P2422
   Gunthard HF, 2001, J INFECT DIS, V183, P1318, DOI 10.1086/319864
   Hermankova M, 2001, JAMA-J AM MED ASSOC, V286, P196, DOI 10.1001/jama.286.2.196
   Hubert JB, 2000, AIDS, V14, P123, DOI 10.1097/00002030-200001280-00007
   Karlsson AC, 2001, AIDS RES HUM RETROV, V17, P409, DOI 10.1089/088922201750102463
   Kieffer TL, 2004, J INFECT DIS, V189, P1452, DOI 10.1086/382488
   Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150
   Lambotte O, 2005, CLIN INFECT DIS, V41, P1053, DOI 10.1086/433188
   Lefrere JJ, 1999, J INFECT DIS, V180, P526, DOI 10.1086/314906
   Lefrere JJ, 1997, BLOOD, V90, P1133, DOI 10.1182/blood.V90.3.1133.1133_1133_1140
   Liu SL, 1997, J VIROL, V71, P4284, DOI 10.1128/JVI.71.6.4284-4295.1997
   LUKASHOV VV, 1995, J VIROL, V69, P6911, DOI 10.1128/JVI.69.11.6911-6916.1995
   Madec Y, 2005, AIDS, V19, P2001, DOI 10.1097/01.aids.0000194134.28135.cd
   Madec Y, 2005, CLIN INFECT DIS, V40, P1350, DOI 10.1086/429318
   Mani I, 2002, J VIROL, V76, P10745, DOI 10.1128/JVI.76.21.10745-10755.2002
   Markham RB, 1998, P NATL ACAD SCI USA, V95, P12568, DOI 10.1073/pnas.95.21.12568
   Martinez-Picado J, 2000, P NATL ACAD SCI USA, V97, P10948, DOI 10.1073/pnas.97.20.10948
   Menzo S, 1998, AIDS, V12, P985, DOI 10.1097/00002030-199809000-00004
   Mikhail M, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-41
   Nettles RE, 2005, JAMA-J AM MED ASSOC, V293, P817, DOI 10.1001/jama.293.7.817
   Persaud D, 2004, J VIROL, V78, P968, DOI 10.1128/JVI.78.2.968-979.2004
   Persaud D, 2000, J CLIN INVEST, V105, P995, DOI 10.1172/JCI9006
   Riva E, 2001, AIDS RES HUM RETROV, V17, P1599, DOI 10.1089/088922201753342004
   Rodrigo AG, 1997, AIDS RES HUM RETROV, V13, P737, DOI 10.1089/aid.1997.13.737
   Ruff CT, 2002, J VIROL, V76, P9481, DOI 10.1128/JVI.76.18.9481-9492.2002
   Shankarappa R, 1999, J VIROL, V73, P10489, DOI 10.1128/JVI.73.12.10489-10502.1999
   Shioda T, 1997, J VIROL, V71, P4871, DOI 10.1128/JVI.71.7.4871-4881.1997
   Siliciano JD, 2003, NAT MED, V9, P727, DOI 10.1038/nm880
   STRUNNIKOVA N, 1995, J VIROL, V69, P7548, DOI 10.1128/JVI.69.12.7548-7558.1995
   Stuart JWTC, 2001, J ACQ IMMUN DEF SYND, V28, P105, DOI 10.1097/00042560-200110010-00001
   TANURI A, 1999, BRAZIL J ACQUIR IMMU, V20, P60
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Tobin NH, 2005, J VIROL, V79, P9625, DOI 10.1128/JVI.79.15.9625-9634.2005
   Wang B, 2003, VIROLOGY, V312, P135, DOI 10.1016/S0042-6822(03)00159-4
   Wang B, 2000, AIDS, V14, P213, DOI 10.1097/00002030-200002180-00002
   Wolinsky SM, 1996, SCIENCE, V272, P537, DOI 10.1126/science.272.5261.537
   Zhang LQ, 1997, J VIROL, V71, P2555, DOI 10.1128/JVI.71.3.2555-2561.1997
   Zhang LQ, 1999, NEW ENGL J MED, V340, P1605, DOI 10.1056/NEJM199905273402101
NR 55
TC 16
Z9 16
U1 0
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 2007
VL 23
IS 10
BP 1242
EP 1250
DI 10.1089/aid.2007.0074
PG 9
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 228HO
UT WOS:000250720900013
PM 17961111
DA 2020-12-01
ER

PT J
AU Bello, G
   Guimaraes, ML
   Chequer-Fernandez, SL
   Eyer-Silva, WA
   Couto-Fernandez, JC
   Teixeira, SLM
   Morgado, MG
AF Bello, Gonzalo
   Guimaraes, Monick L.
   Chequer-Fernandez, Saada L.
   Eyer-Silva, Walter A.
   Couto-Fernandez, Jose C.
   Teixeira, Sylvia L. M.
   Morgado, Mariza G.
TI Increasing genetic distance to HIV-1 subtype B and F1 consensus
   sequences in the Brazilian epidemic: A challenge for vaccine strategies
   based on central immunogens?
SO INFECTION GENETICS AND EVOLUTION
LA English
DT Article
DE HIV-1; synonymous; non-synonymous; diversity; divergence; subtype B;
   subtype F1; Brazil
ID IMMUNODEFICIENCY-VIRUS TYPE-1; COMMON ANCESTOR; EVOLUTIONARY HISTORY;
   CENTRAL-AFRICA; V3 DOMAIN; DIVERSITY; STRAINS; SUBSTITUTION; PROTEIN;
   ORIGIN
AB It has been postulated that the non-synonymous divergence (distance to the subtype consensus sequence) observed in several HIV-1 subtype populations during 1990s attained the maximum limit that is compatible with viral fitness or survival, at least in the V3 env gene domain. To test this hypothesis, 145 subtype B and 64 subtype F env V3 sequences isolated from Brazilian HIV-1 positive patients between 1989 and 2004 were analyzed. HIV-1 env V3 sequences were grouped by year of collection and the mean intra-subtype diversity and divergence were examined at synonymous, non-synonyinous, and amino acid level. The analyses clearly show that the mean intra-subtype divergence constantly increases in both subtype populations in the last 15 years, and more importantly, this trend was not only driven by a significant increase of the synonymous distance but also by a significant increase of the non-synonyinous and amino acid distances between Brazilian circulating viruses and subtype consensus sequences. These results clearly disagree with the notion that the non-synonyinous distance to the HIV-1 subtype consensus observed at population level had already attained the maximum limit, and suggest that the likelihood for success of vaccines based on "central" immunogens, as those based on any other empirically selected viral sequence, could be continuously diminishing over time. (C) 2007 Elsevier B.V. All rights reserved.
C1 Inst Oswaldo Cruz, Dept Immunol, Lab AIDS & Mol Immunol, BR-21045900 Rio De Janeiro, Brazil.
RP Bello, G (corresponding author), Inst Oswaldo Cruz, Dept Immunol, Lab AIDS & Mol Immunol, Av Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM gbello@ioc.fiocruz.br
RI Bentancor, Gonzalo Jose Bello/N-7377-2019; Bello, Gonzalo/E-6842-2013;
   de Araujo Eyer-Silva, Walter/J-6264-2019
OI Bentancor, Gonzalo Jose Bello/0000-0002-2724-2793; Couto-Fernandez, Jose
   Carlos/0000-0001-7091-9774; Eyer-Silva, Walter de
   Araujo/0000-0001-6386-666X
CR Abascal F, 2005, BIOINFORMATICS, V21, P2104, DOI 10.1093/bioinformatics/bti263
   Abebe A, 2001, AIDS, V15, P1555, DOI 10.1097/00002030-200108170-00013
   Abebe A, 2001, AIDS RES HUM RETROV, V17, P657, DOI 10.1089/088922201300119770
   Bello G, 2006, AIDS, V20, P763, DOI 10.1097/01.aids.0000216377.84313.52
   Bello G, 2007, INFECT GENET EVOL, V7, P263, DOI 10.1016/j.meegid.2006.11.002
   Foley B, 2000, AIDS RES HUM RETROV, V16, P1463, DOI 10.1089/088922200750005985
   Gaschen B, 2002, SCIENCE, V296, P2354, DOI 10.1126/science.1070441
   Grenfell BT, 2004, SCIENCE, V303, P327, DOI 10.1126/science.1090727
   JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275
   Korber B, 2000, SCIENCE, V288, P1789, DOI 10.1126/science.288.5472.1789
   Korber B, 2001, BRIT MED BULL, V58, P19, DOI 10.1093/bmb/58.1.19
   Korber B, 1998, SCIENCE, V280, P1868, DOI 10.1126/science.280.5371.1868
   KUIKEN CL, 1993, P NATL ACAD SCI USA, V90, P9061, DOI 10.1073/pnas.90.19.9061
   Kuiken CL, 1996, AIDS, V10, P31, DOI 10.1097/00002030-199601000-00005
   Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150
   LI WH, 1993, J MOL EVOL, V36, P96, DOI 10.1007/BF02407308
   Lukashov VV, 1997, J VIROL, V71, P6332, DOI 10.1128/JVI.71.9.6332-6338.1997
   Lukashov VV, 2002, J MOL EVOL, V54, P680, DOI 10.1007/s00239-001-0070-5
   Morgado MG, 2002, MEM I OSWALDO CRUZ, V97, P143, DOI 10.1590/S0074-02762002000200001
   MURPHY E, 1993, AIDS RES HUM RETROV, V9, P997, DOI 10.1089/aid.1993.9.997
   Nabel G, 2002, SCIENCE, V296, P2335, DOI 10.1126/science.296.5577.2335
   Nickle DC, 2003, SCIENCE, V299, P1515
   Novitsky V, 2002, J VIROL, V76, P5435, DOI 10.1128/JVI.76.11.5435-5451.2002
   PAMILO P, 1993, MOL BIOL EVOL, V10, P271
   Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817
   Robbins KE, 2003, J VIROL, V77, P6359, DOI 10.1128/JVI.77.11.6359-6366.2003
   Salemi M, 2001, FASEB J, V15, P276, DOI 10.1096/fj.00-0449fje
   Sharp PM, 2001, PHILOS T R SOC B, V356, P867, DOI 10.1098/rstb.2001.0863
   Tamura K, 2013, MOL BIOL EVOL, V30, P2725, DOI [10.1093/molbev/mst197, 10.1093/molbev/msr121]
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Travers SAA, 2004, J VIROL, V78, P10501, DOI 10.1128/JVI.78.19.10501-10506.2004
   Triques K, 1999, VIROLOGY, V259, P99, DOI 10.1006/viro.1999.9720
   VandePeer Y, 1996, AIDS, V10, P1485, DOI 10.1097/00002030-199611000-00005
   Vidal N, 2000, J VIROL, V74, P10498, DOI 10.1128/JVI.74.22.10498-10507.2000
   Yusim K, 2001, PHILOS T R SOC B, V356, P855, DOI 10.1098/rstb.2001.0859
NR 35
TC 3
Z9 4
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567-1348
J9 INFECT GENET EVOL
JI Infect. Genet. Evol.
PD SEP
PY 2007
VL 7
IS 5
BP 594
EP 599
DI 10.1016/j.meegid.2007.05.005
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA 219GH
UT WOS:000250072200006
PM 17574932
DA 2020-12-01
ER

PT J
AU Eyer-Silva, WA
   Bello, G
   Morgado, MG
AF Eyer-Silva, Walter A.
   Bello, Gonzalo
   Morgado, Mariza G.
TI Molecular evidence that human immunodeficiency virus type 1
   dissemination in a small Brazilian city was already taking place in the
   early 1990s
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE Aids; epidemiology; human immunodeficiency virus type 1; Brazil
ID MUNICIPALITY; HISTORY
AB We recently performed a molecular epidemiology survey of human immunodeficiency virus type 1 ( HIV- 1) infection in Miracema, a small city in Southeast Brazil, and found multiple monophyletic clusters, consistent with independent introductions and spread of different viral lineages in the city. Here we apply Bayesian coa-lescent-based methods to the two largest subtype B clusters and estimate that the most recent common ancestors that gave rise to these two transmission chains were in circulation around 1991- 1992. The finding that HIV- 1 spread in this Brazilian small city was already taking place at a time Aids was considered a problem restricted to large urban centers may have important public health implications.
C1 Inst Oswaldo Cruz Fiocruz, Lab Aids & Imunol Mol, BR-21045900 Rio De Janeiro, Brazil.
   Univ Fed Estado Rio De Janeiro, Hosp Univ Gaffree & Guinle, Rio De Janeiro, Brazil.
   Programa Municipal HIV Aids Miracema, Miracema, RJ, Brazil.
RP Eyer-Silva, WA (corresponding author), Inst Oswaldo Cruz Fiocruz, Lab Aids & Imunol Mol, Av Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM walter-eyer@unirio.br
RI Bello, Gonzalo/E-6842-2013; Bentancor, Gonzalo Jose Bello/N-7377-2019;
   de Araujo Eyer-Silva, Walter/J-6264-2019
OI Bentancor, Gonzalo Jose Bello/0000-0002-2724-2793; Eyer-Silva, Walter de
   Araujo/0000-0001-6386-666X
CR Bello G, 2007, INFECT GENET EVOL, V7, P263, DOI 10.1016/j.meegid.2006.11.002
   Brito A M, 2001, Rev Soc Bras Med Trop, V34, P207, DOI 10.1590/S0037-86822001000200010
   DHALIA C, 2000, B EPIDEMIOLOGICO AID, V13
   Drummond AJ, 2002, GENETICS, V161, P1307
   DRUMMOND AJ, 2003, BEAST VERSION 1 0
   Ever-Silva WA, 2006, JAIDS-J ACQ IMM DEF, V41, P664, DOI 10.1097/01.qai.0000194736.66322.02
   Eyer-Silva WA, 2005, REV SAUDE PUBL, V39, P950, DOI [10.1590/S0034-89102005000600013, 10.1590/s0034-89102005000600013]
   Eyer-Silva WA, 2005, MEM I OSWALDO CRUZ, V100, P869, DOI 10.1590/S0074-02762005000800008
   Eyer-Silva WA, 2007, AIDS RES HUM RETROV, V23, P303, DOI 10.1089/aid.2006.0199
   HASEGAWA M, 1985, J MOL EVOL, V22, P160, DOI 10.1007/BF02101694
   Szwarcwald C L, 2000, Cad Saude Publica, V16, P7
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
NR 12
TC 3
Z9 3
U1 0
U2 0
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD AUG
PY 2007
VL 102
IS 5
BP 647
EP 649
DI 10.1590/S0074-02762007000500018
PG 3
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 202QK
UT WOS:000248917900018
PM 17710313
OA DOAJ Gold
DA 2020-12-01
ER

PT J
AU Bello, G
   Casado, C
   Garcia, S
   Rodriguez, C
   del Romero, J
   Carvajal-Rodriguez, A
   Posada, D
   Lopez-Galindez, C
AF Bello, Gonzalo
   Casado, Concepcion
   Garcia, Soledad
   Rodriguez, Carmen
   del Romero, Jorge
   Carvajal-Rodriguez, Antonio
   Posada, David
   Lopez-Galindez, Cecilio
TI Lack of temporal structure in the short term HIV-1 evolution within
   asymptomatic naive patients
SO VIROLOGY
LA English
DT Article
DE intra-host HIV evolution; phylogeny; temporal structure; atemporal
   structure; dN/dS; recombination; in vivo
ID IMMUNODEFICIENCY-VIRUS TYPE-1; ENVELOPE SEQUENCES; IN-VIVO; GENETIC
   DRIFT; DYNAMICS; PROGRESSION; PATTERNS; MODEL; SUBSTITUTION; REPLICATION
AB HIV-1 evolution in the envelope gene (env) was analyzed in four asymptomatic antiretroviral therapy naive patients with typical and slow disease progression rates. In typical progressors, viral populations were monophyletic and two distinct evolutionary patterns were observed. In one patient, HIV-1 evolution displayed a strong temporal structure similar to the consistent pattern previously described. In the other, viral evolution displayed a lack of temporal structure with no increase in genetic heterogeneity and divergence over time. In slow progressors, several clades were observed in viral populations. However, analysis within the major sub-population revealed the same two evolutionary patterns described for typical progressors. Synonymous and non-synonymous substitution rate analyses indicated that positive selection was the major force driving HIV-1 evolution in viral populations with temporal structure, while evolution in viral populations with an atemporal structure was dominated by genetic drift and purifying selection. These results support the existence of distinct patterns of env evolution in untreated HIV-1-infected patients. (C) 2007 Elsevier Inc. All rights reserved.
C1 Inst Salud Carlos III, Ctr Nacl Microbiol, Madrid 28220, Spain.
   Fiocruz MS, Inst Oswaldo Cruz, Dept Immunol, Lab AIDS & Mol Immunol, BR-21045900 Rio De Janeiro, Brazil.
   Ctr Sanitario Sandoval, IMSALUD, Comun Autonoma Madrid, Madrid 28010, Spain.
   Brigham Young Univ, Dept Mol Biol & Microbiol, Provo, UT 84602 USA.
   Univ Vigo, Fac Biol, Vigo 36310, Spain.
RP Lopez-Galindez, C (corresponding author), Inst Salud Carlos III, Ctr Nacl Microbiol, Madrid 28220, Spain.
EM clopez@isciii.es
RI Bello, Gonzalo/E-6842-2013; Carvajal-Rodriguez, Antonio/B-5076-2011;
   Lopez-Galindez, Cecilio/A-3603-2008; Bentancor, Gonzalo Jose
   Bello/N-7377-2019; , ACR/A-7676-2012; Casado, Concepcion/F-3060-2016;
   Posada, David/C-4502-2008
OI Lopez-Galindez, Cecilio/0000-0002-2324-9584; Bentancor, Gonzalo Jose
   Bello/0000-0002-2724-2793; , ACR/0000-0002-6242-3581; Casado,
   Concepcion/0000-0003-3412-2877; Posada, David/0000-0003-1407-3406
FU NIGMS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [R01-GM66276] Funding Source: Medline; NATIONAL
   INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of General Medical Sciences (NIGMS) [R01GM066276, R01GM066276,
   R01GM066276, R01GM066276] Funding Source: NIH RePORTER
CR AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705
   Baccam P, 2001, BIOINFORMATICS, V17, P16, DOI 10.1093/bioinformatics/17.1.16
   Bello G, 2005, J GEN VIROL, V86, P355, DOI 10.1099/vir.0.80410-0
   Bello G, 2004, J GEN VIROL, V85, P399, DOI 10.1099/vir.0.19365-0
   Betts MR, 1999, AIDS RES HUM RETROV, V15, P1219, DOI 10.1089/088922299310313
   Casado C, 2001, J GEN VIROL, V82, P2495, DOI 10.1099/0022-1317-82-10-2495
   FELSENSTEIN J, 1988, ANNU REV GENET, V22, P521, DOI 10.1146/annurev.ge.22.120188.002513
   Frenkel LM, 2003, J VIROL, V77, P5721, DOI 10.1128/JVI.77.10.5721-5730.2003
   Frost SDW, 2001, P NATL ACAD SCI USA, V98, P6975, DOI 10.1073/pnas.131056998
   Ganeshan S, 1997, J VIROL, V71, P663, DOI 10.1128/JVI.71.1.663-677.1997
   Gascuel O, 1997, MOL BIOL EVOL, V14, P685, DOI 10.1093/oxfordjournals.molbev.a025808
   Grenfell BT, 2004, SCIENCE, V303, P327, DOI 10.1126/science.1090727
   Grossman Z, 1999, NAT MED, V5, P1099, DOI 10.1038/13410
   Grossman Z, 1998, P NATL ACAD SCI USA, V95, P6314, DOI 10.1073/pnas.95.11.6314
   Guindon S, 2005, NUCLEIC ACIDS RES, V33, pW557, DOI 10.1093/nar/gki352
   Gunthard HF, 1999, J VIROL, V73, P9404
   Halapi E, 1997, AIDS, V11, P1709, DOI 10.1097/00002030-199714000-00007
   HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0
   HOLMES EC, 1992, P NATL ACAD SCI USA, V89, P4835, DOI 10.1073/pnas.89.11.4835
   Karlsson AC, 1999, J VIROL, V73, P6191, DOI 10.1128/JVI.73.7.6191-6196.1999
   Liu SL, 1997, J VIROL, V71, P4284, DOI 10.1128/JVI.71.6.4284-4295.1997
   Lukashov V V, 1998, AIDS, V12 Suppl A, pS43
   Mani I, 2002, J VIROL, V76, P10745, DOI 10.1128/JVI.76.21.10745-10755.2002
   Markham RB, 1998, P NATL ACAD SCI USA, V95, P12568, DOI 10.1073/pnas.95.21.12568
   McVean G, 2002, GENETICS, V160, P1231
   Muse SV, 1996, MOL BIOL EVOL, V13, P105, DOI 10.1093/oxfordjournals.molbev.a025549
   Nickle DC, 2003, J VIROL, V77, P5540, DOI 10.1128/JVI.77.9.5540-5546.2003
   Nowak P, 2002, HIV Med, V3, P1, DOI 10.1046/j.1464-2662.2001.00097.x
   Ostrowski MA, 1998, J VIROL, V72, P7772, DOI 10.1128/JVI.72.10.7772-7784.1998
   Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582
   Plikat U, 1997, J VIROL, V71, P4233, DOI 10.1128/JVI.71.6.4233-4240.1997
   Pond SK, 2005, MOL BIOL EVOL, V22, P2375, DOI 10.1093/molbev/msi232
   Pond SLK, 2005, BIOINFORMATICS, V21, P2531, DOI 10.1093/bioinformatics/bti320
   Pond SLK, 2005, BIOINFORMATICS, V21, P676, DOI 10.1093/bioinformatics/bti079
   Posada D, 2004, SYST BIOL, V53, P793, DOI 10.1080/10635150490522304
   Posada D, 2001, MOL BIOL EVOL, V18, P897, DOI 10.1093/oxfordjournals.molbev.a003890
   Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817
   Poss M, 1998, J VIROL, V72, P8240, DOI 10.1128/JVI.72.10.8240-8251.1998
   Rodrigo AG, 1997, AIDS RES HUM RETROV, V13, P737, DOI 10.1089/aid.1997.13.737
   Salvatori F, 1997, J VIROL, V71, P4694, DOI 10.1128/JVI.71.6.4694-4706.1997
   Shankarappa R, 1998, VIROLOGY, V241, P251, DOI 10.1006/viro.1997.8996
   Shankarappa R, 1999, J VIROL, V73, P10489, DOI 10.1128/JVI.73.12.10489-10502.1999
   Shioda T, 1997, J VIROL, V71, P4871, DOI 10.1128/JVI.71.7.4871-4881.1997
   SIMMONDS P, 1991, J VIROL, V65, P6266, DOI 10.1128/JVI.65.11.6266-6276.1991
   STRUNNIKOVA N, 1995, J VIROL, V69, P7548, DOI 10.1128/JVI.69.12.7548-7558.1995
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Troyer RM, 2005, J VIROL, V79, P9006, DOI 10.1128/JVI.79.14.9006-9018.2005
   Wang B, 2002, VIROLOGY, V304, P246, DOI 10.1006/viro.2002.1706
   WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0
   Williamson S, 2005, MOL BIOL EVOL, V22, P456, DOI 10.1093/molbev/msi029
   Wolinsky SM, 1996, SCIENCE, V272, P537, DOI 10.1126/science.272.5261.537
   Zhang LQ, 1997, J VIROL, V71, P2555, DOI 10.1128/JVI.71.3.2555-2561.1997
NR 52
TC 14
Z9 14
U1 0
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD JUN 5
PY 2007
VL 362
IS 2
BP 294
EP 303
DI 10.1016/j.virol.2006.11.039
PG 10
WC Virology
SC Virology
GA 172GJ
UT WOS:000246791800005
PM 17275055
DA 2020-12-01
ER

PT J
AU Bello, G
   Eyer-Silva, WA
   Couto-Fernandez, JC
   Guimaraes, ML
   Chequer-Fernandez, SL
   Teixeira, SLM
   Morgado, MG
AF Bello, Gonzalo
   Eyer-Silva, Walter A.
   Couto-Fernandez, Jose C.
   Guimaraes, Monick L.
   Chequer-Fernandez, Saada L.
   Teixeira, Sylvia L. M.
   Morgado, Mariza G.
TI Demographic history of HIV-1 subtypes B and F in Brazil
SO INFECTION GENETICS AND EVOLUTION
LA English
DT Article
DE Brazil; HIV-1; subtype B; subtype F; demographic history; Bayesian;
   coalescent theory
ID RIO-DE-JANEIRO; INJECTING DRUG-USERS; POPULATION HISTORY; MOLECULAR
   EPIDEMIOLOGY; SEROPREVALENCE LEVELS; SAO-PAULO; V3 REGION; STRAINS;
   PREVALENCE; INFERENCE
AB The reconstruction of the epidemic history of several HIV populations, by using methods that infer the population history from sampled gene sequence data, has revealed important subtype-specific and regional-specific differences in patterns of epidemic growth. Here, we employ Bayesian coalescent-based methods to compare the population history of the HIV-1 subtype B and F1 epidemics in Brazil from non-contemporary em, and pol gene sequences. Our results suggest that after the introduction of the subtypes B and F1 into Brazilian population, around mid to late 1960s and late 1970s, respectively, these subtypes experienced an initial period of exponential growth with similar epidemic growth rates (similar to 0.5-0.6 year(-1)). Later, the spreading rate of both subtypes seems to have slowed-down since mid to late 1980s. This demographic pattern is very similar to that reported for the subtype B epidemics in high-income countries where HIV was initially transmitted through homosexual intercourse and injecting drug use, as in Brazil; suggesting that the characteristics of transmission networks may be a key determinant of the HIV epidemic growth pattern. It is important to note that most of the subtype B and F1 sequences used in this study come from the Southeast region that has been the most affected by the AIDS epidemic in Brazil, being responsible for around 63% of all AIDS cases reported since the early eighties; but may not represent the demographic trend of the HIV-1 epidemic in other Brazilian regions. (c) 2006 Elsevier B.V. All rights reserved.
C1 Fiocruz MS, Inst Oswaldo Cruz, Dept Immunol, Lab AIDS & Mol Immunol, BR-21045900 Rio De Janeiro, Brazil.
RP Bello, G (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Dept Immunol, Lab AIDS & Mol Immunol, Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM gbello@ioc.fiocruz.br
RI Bentancor, Gonzalo Jose Bello/N-7377-2019; Bello, Gonzalo/E-6842-2013;
   de Araujo Eyer-Silva, Walter/J-6264-2019
OI Bentancor, Gonzalo Jose Bello/0000-0002-2724-2793; Couto-Fernandez, Jose
   Carlos/0000-0001-7091-9774; Eyer-Silva, Walter de
   Araujo/0000-0001-6386-666X
CR BANDEA CI, 1995, EMERG INFECT DIS, V1, P91
   Bello G, 2006, AIDS, V20, P763, DOI 10.1097/01.aids.0000216377.84313.52
   BLOWER S, 1991, J ACQ IMMUN DEF SYND, V4, P920
   Bongertz V, 2000, J ACQ IMMUN DEF SYND, V23, P184
   *BRAZ MIN HLTH, 2005, AIDS EP B
   Brigido LFM, 2005, AIDS RES HUM RETROV, V21, P673, DOI 10.1089/aid.2005.21.673
   Brito Ana Maria de, 2005, Braz J Infect Dis, V9, P9, DOI 10.1590/S1413-86702005000100004
   Covas DT, 1998, J ACQ IMMUN DEF SYND, V19, P74, DOI 10.1097/00042560-199809010-00012
   Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/msi103
   Drummond AJ, 2002, GENETICS, V161, P1307
   DRUMMOND AJ, 2003, BEAST V1 0
   Ever-Silva WA, 2006, JAIDS-J ACQ IMM DEF, V41, P664, DOI 10.1097/01.qai.0000194736.66322.02
   Friedman SR, 2000, AM J EPIDEMIOL, V152, P913, DOI 10.1093/aje/152.10.913
   Guimaraes ML, 2001, J CLIN VIROL, V21, P143, DOI 10.1016/S1386-6532(01)00158-5
   Guiniaraes ML, 2002, AIDS RES HUM RETROV, V18, P1261, DOI 10.1089/088922202320886307
   HOLMES EC, 1995, PHILOS T R SOC B, V349, P33, DOI 10.1098/rstb.1995.0088
   Hue S, 2005, P NATL ACAD SCI USA, V102, P4425, DOI 10.1073/pnas.0407534102
   Kingman JFC, 2000, GENETICS, V156, P1461
   Leitner T, 1999, P NATL ACAD SCI USA, V96, P10752, DOI 10.1073/pnas.96.19.10752
   Lemey P, 2003, P NATL ACAD SCI USA, V100, P6588, DOI 10.1073/pnas.0936469100
   Levi GC, 2002, AIDS, V16, P2373, DOI 10.1097/00002030-200212060-00001
   MORGADO MG, 1994, AIDS RES HUM RETROV, V10, P569, DOI 10.1089/aid.1994.10.569
   Morgado MG, 1998, J ACQ IMMUN DEF SYND, V18, P488, DOI 10.1097/00042560-199808150-00011
   Morgado MG, 2002, MEM I OSWALDO CRUZ, V97, P143, DOI 10.1590/S0074-02762002000200001
   Morgado MG, 1998, MEM I OSWALDO CRUZ, V93, P383, DOI 10.1590/S0074-02761998000300020
   Okie S, 2006, NEW ENGL J MED, V354, P1977, DOI 10.1056/NEJMp068069
   Opgen-Rhein R, 2005, BMC EVOL BIOL, V5, DOI 10.1186/1471-2148-5-6
   POTTS KE, 1993, AIDS, V7, P1191, DOI 10.1097/00002030-199309000-00007
   Pybus OG, 1999, MOL BIOL EVOL, V16, P953, DOI 10.1093/oxfordjournals.molbev.a026184
   Pybus OG, 2000, GENETICS, V155, P1429
   Ramos A, 1999, EMERG INFECT DIS, V5, P65, DOI 10.3201/eid0501.990108
   Robbins KE, 2003, J VIROL, V77, P6359, DOI 10.1128/JVI.77.11.6359-6366.2003
   RODRIGUEZ F, 1990, J THEOR BIOL, V142, P485, DOI 10.1016/S0022-5193(05)80104-3
   Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180
   Rossini MAA, 2001, BRAZ J MED BIOL RES, V34, P45, DOI 10.1590/S0100-879X2001000100005
   Salemi M, 2005, J MOL EVOL, V60, P598, DOI 10.1007/s00239-004-0206-5
   Strimmer K, 2001, MOL BIOL EVOL, V18, P2298, DOI 10.1093/oxfordjournals.molbev.a003776
   Szwarcwald C L, 2000, Cad Saude Publica, V16, P135
   Szwarcwald C L, 2000, Cad Saude Publica, V16, P7
   SZWARCWALD CL, 2001, AIDS EPIDEMIOL B, V14
   Tanuri A, 1999, J ACQ IMMUN DEF SYND, V20, P60, DOI 10.1097/00042560-199901010-00009
   Teixeira SLM, 2004, J CLIN VIROL, V31, P221, DOI 10.1016/j.jcv.2004.03.016
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   *UNAIDS, 2006, 2006 REP GLOB AIDS E
   Walker Polly R., 2005, Infection Genetics and Evolution, V5, P199, DOI 10.1016/j.meegid.2004.06.011
   Yusim K, 2001, PHILOS T R SOC B, V356, P855, DOI 10.1098/rstb.2001.0859
NR 46
TC 57
Z9 59
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567-1348
EI 1567-7257
J9 INFECT GENET EVOL
JI Infect. Genet. Evol.
PD MAR
PY 2007
VL 7
IS 2
BP 263
EP 270
DI 10.1016/j.meegid.2006.11.002
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA 138GP
UT WOS:000244351400017
PM 17150415
DA 2020-12-01
ER

PT J
AU Bello, G
   Guimares, ML
   Morgado, MG
AF Bello, G
   Guimares, ML
   Morgado, MG
TI Evolutionary history of HIV-1 subtype B and F infections in Brazil
SO AIDS
LA English
DT Article
DE Brazil; subtype B; subtype F; HIV-1 epidemic origin; molecular clock
ID RIO-DE-JANEIRO; GENETIC-ANALYSIS; MOLECULAR CLOCK; DRUG-USERS; V3
   REGION; TYPE-1; EPIDEMIC; ORIGIN; CITY; PREVALENCE
AB Objective: To reconstruct the onset date of the HIV-1 B and F epidemics in Brazil based on virus diversification over time.
   Design: We studied HIV-1 env V3 sequences (210nt) with a known sampling year isolated from HIV-1 positive patients from Brazil between 1989 and 1997: 101 subtype B sequences and 41 subtype F sequences.
   Methods: HIV-1 V3 env sequences were grouped by year of collection and the relationship between the sampling years of HIV-1 sequences and their genetic distance to the reconstructed common ancestor (intra-population divergence) or to other sequences from the same year (intra-population diversity) was examined by using linear regression analysis.
   Results: Regression analysis of nucleotide distances, revealed a highly significant positive correlation between sampling years of subtype B and F V3 sequences and their intra-population divergence (P < 0.001) or diversity (P < 0.0001). In both subtype populations, the divergence and diversity increased at a rate of 0.5 and 0.9% per year, respectively. Considering these evolutionary rates, we estimate the onset of the subtype B and F HIV-1 epidemics in Brazil during early 1970s and early 1980s, respectively.
   Conclusions: The consistent correlation between divergence and diversity of the V3 sequences with their sampling years indicates that the molecular clock is operational in the evolution of the HIV-1 in Brazil's epidemic, and show that Subtypes B and F are evolving at a similar rate over time. The dating results Suggest a discontinuous introduction of these subtypes in the Brazilian population. (C) 2006 Lippincott Williams & Wilkins.
C1 Fiocruz MS, Inst Oswaldo Cruz, Dept Immunol, Lab AIDS & Mol Immunol, BR-21045900 Rio De Janeiro, Brazil.
RP Morgado, MG (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Dept Immunol, Lab AIDS & Mol Immunol, Av Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM mmorgado@ioc.fiocruz.br
RI Bello, Gonzalo/E-6842-2013; Bentancor, Gonzalo Jose Bello/N-7377-2019
OI Bentancor, Gonzalo Jose Bello/0000-0002-2724-2793
CR Abebe A, 2001, AIDS, V15, P1555, DOI 10.1097/00002030-200108170-00013
   Abebe A, 2001, AIDS RES HUM RETROV, V17, P657, DOI 10.1089/088922201300119770
   BANDEA CI, 1995, EMERG INFECT DIS, V1, P91
   Bongertz V, 2000, J ACQ IMMUN DEF SYND, V23, P184
   *BRAZ MIN HLTH, 2005, AIDS EP B JAN JUN 20
   Brindeiro RM, 2003, AIDS, V17, P1063, DOI 10.1097/00002030-200305020-00016
   Carr JK, 2001, AIDS, V15, pF41, DOI 10.1097/00002030-200110190-00002
   Casado C, 2000, J ACQ IMMUN DEF SYND, V23, P68
   CHEVRET S, 1992, J EPIDEMIOL COMMUN H, V46, P582, DOI 10.1136/jech.46.6.582
   Couto-Fernandez JC, 1999, J ACQ IMMUN DEF SYND, V22, P288
   COUTOFERNANDEZ JC, 1994, AIDS RES HUM RETROV, V10, P1157, DOI 10.1089/aid.1994.10.1157
   DELWART EL, 1993, SCIENCE, V262, P1257, DOI 10.1126/science.8235655
   Felsenstein J., 2004, PHYLIP PHYLOGENY INF
   Gao F, 1998, J VIROL, V72, P5680, DOI 10.1128/JVI.72.7.5680-5698.1998
   Guimaraes ML, 2001, J CLIN VIROL, V21, P143, DOI 10.1016/S1386-6532(01)00158-5
   Guiniaraes ML, 2002, AIDS RES HUM RETROV, V18, P1261, DOI 10.1089/088922202320886307
   Korber B, 2000, SCIENCE, V288, P1789, DOI 10.1126/science.288.5472.1789
   Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150
   Leitner T, 1999, P NATL ACAD SCI USA, V96, P10752, DOI 10.1073/pnas.96.19.10752
   Lemey P, 2003, P NATL ACAD SCI USA, V100, P6588, DOI 10.1073/pnas.0936469100
   LI WH, 1988, MOL BIOL EVOL, V5, P313
   Liu Y, 2004, VIROLOGY, V329, P101, DOI 10.1016/j.virol.2004.08.014
   LOUWAGIE J, 1994, AIDS RES HUM RETROV, V10, P561, DOI 10.1089/aid.1994.10.561
   Lukashov VV, 2002, J MOL EVOL, V54, P680, DOI 10.1007/s00239-001-0070-5
   MORGADO MG, 1994, AIDS RES HUM RETROV, V10, P569, DOI 10.1089/aid.1994.10.569
   Morgado MG, 1998, J ACQ IMMUN DEF SYND, V18, P488, DOI 10.1097/00042560-199808150-00011
   Morgado MG, 2002, MEM I OSWALDO CRUZ, V97, P143, DOI 10.1590/S0074-02762002000200001
   OSMANOV S, 1994, AIDS RES HUM RETROV, V10, P1327, DOI 10.1089/aid.1994.10.1327
   Paranjpe S, 2002, AIDS RES HUM RETROV, V18, P1271, DOI 10.1089/088922202320886316
   Pinto ME, 1998, J ACQ IMMUN DEF SYND, V19, P310, DOI 10.1097/00042560-199811010-00017
   POTTS KE, 1993, AIDS, V7, P1191, DOI 10.1097/00002030-199309000-00007
   Ramos A, 1999, EMERG INFECT DIS, V5, P65, DOI 10.3201/eid0501.990108
   Robbins KE, 2003, J VIROL, V77, P6359, DOI 10.1128/JVI.77.11.6359-6366.2003
   Rossini MAA, 2001, BRAZ J MED BIOL RES, V34, P45, DOI 10.1590/S0100-879X2001000100005
   Sabino EC, 1996, AIDS, V10, P1579, DOI 10.1097/00002030-199611000-00018
   Salemi M, 2001, FASEB J, V15, P276, DOI 10.1096/fj.00-0449fje
   Shankarappa R, 1999, J VIROL, V73, P10489, DOI 10.1128/JVI.73.12.10489-10502.1999
   Sharp PM, 2001, PHILOS T R SOC B, V356, P867, DOI 10.1098/rstb.2001.0863
   Soares MA, 2003, AIDS, V17, P11, DOI 10.1097/00002030-200301030-00004
   Tanuri A, 1999, J ACQ IMMUN DEF SYND, V20, P60, DOI 10.1097/00042560-199901010-00009
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Vicente ACP, 2000, J ACQ IMMUN DEF SYND, V23, P327
   Yusim K, 2001, PHILOS T R SOC B, V356, P855, DOI 10.1098/rstb.2001.0859
   Zheng NN, 2004, AIDS RES HUM RETROV, V20, P964, DOI 10.1089/aid.2004.20.964
NR 44
TC 40
Z9 41
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD MAR 21
PY 2006
VL 20
IS 5
BP 763
EP 768
DI 10.1097/01.aids.0000216377.84313.52
PG 6
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 027MZ
UT WOS:000236421000016
PM 16514307
DA 2020-12-01
ER

PT J
AU Bello, G
   Casado, C
   Sandonis, V
   Alonso-Nieto, M
   Vicario, JL
   Garcia, S
   Hernando, V
   Rodriguez, C
   del Romero, J
   Lopez-Galindez, C
AF Bello, G
   Casado, C
   Sandonis, V
   Alonso-Nieto, M
   Vicario, JL
   Garcia, S
   Hernando, V
   Rodriguez, C
   del Romero, J
   Lopez-Galindez, C
TI A subset of human immunodeficiency virus type 1 long-term
   non-progressors is characterized by the unique presence of ancestral
   sequences in the viral population
SO JOURNAL OF GENERAL VIROLOGY
LA English
DT Article
ID NEUTRALIZING ANTIBODY-RESPONSES; HIV-1 INFECTION; T-CELL; DISEASE
   PROGRESSION; LYMPHOCYTE ACTIVITY; INCUBATION PERIOD; HOMOSEXUAL MEN;
   INDIVIDUALS; EPIDEMIC; HISTORY
AB Within human immunodeficiency virus type 1 (HIV-1)-infected patients, there are those who have been infected for more than 10 years with a CD4(+) cell count of >500 cells mul(-1) and Who remain asymptomatic without antiretroviral therapy; these patients are designated lono-term, non-progressors (LTNPs). In a set of 16 LTNPs, viral dating, DNA viral load, quasispecies heterogeneity and antibody (Ab) titres against gp160 and beta(2) microglobulin (beta(2)m) were determined. Plasma viral RNA and CD4(+) and CD8(+) T-cell numbers were estimated in more than three samples per patient. Host genetic characteristics, such as Delta32-CCR5 genotype and human leukocyte antigen (HLA) genotype and supertypes, and clinical-epidemiological factors were evaluated. Dating of global populations and of DNA and RNA viral quasispecies identified two subsets of patients: one displaying only ancestral sequences and the other displaying predominantly modern sequences. The ancestral patients displayed a significant reduction in RNA and DNA viral loads, quasispecies heterogeneity, CD8(+) cell number, anti-gp160 Ab titres and beta(2)m level, and they were also associated with better use of safe-sex practices and higher presence of the HLA sB58 supertype than the modem subset. Viral dating has therefore permitted the segregation of LTNPs into two subsets that show very different virological, immunological, host and clinical-epidemiological characteristics. Moreover, whereas the modern subset displayed low levels of virus replication, the ancestral group displayed not only a very limited virus replication, often to undetectable levels, but also very slow or arrested viral evolution, maintaining the close relationship of the viral population to the transmitted virus.
C1 Inst Salud Carlos III, Ctr Nacl Microbiol, Madrid 28220, Spain.
   Ctr Transfus Comunidad Madrid, Madrid 28032, Spain.
   IMSALUD, Ctr Sanitario Sandoval, Madrid, Spain.
RP Lopez-Galindez, C (corresponding author), Inst Salud Carlos III, Ctr Nacl Microbiol, Madrid 28220, Spain.
EM clopez@isciii.es
RI Sandonis, Virginia/K-2884-2014; Hernando, Victoria/E-1740-2015; Bello,
   Gonzalo/E-6842-2013; Bentancor, Gonzalo Jose Bello/N-7377-2019; Casado,
   Concepcion/F-3060-2016; Lopez-Galindez, Cecilio/A-3603-2008
OI Sandonis, Virginia/0000-0001-5762-7531; Hernando,
   Victoria/0000-0003-2762-4924; Bentancor, Gonzalo Jose
   Bello/0000-0002-2724-2793; Casado, Concepcion/0000-0003-3412-2877;
   Lopez-Galindez, Cecilio/0000-0002-2324-9584
CR BACCHETTI P, 1989, NATURE, V338, P251, DOI 10.1038/338251a0
   Balotta C, 1997, AIDS RES HUM RETROV, V13, P337, DOI 10.1089/aid.1997.13.337
   Barker E, 1998, BLOOD, V92, P3105, DOI 10.1182/blood.V92.9.3105.421k46_3105_3114
   Bello G, 2004, J GEN VIROL, V85, P399, DOI 10.1099/vir.0.19365-0
   BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990
   BUCHBINDER SP, 1994, AIDS, V8, P1123, DOI 10.1097/00002030-199408000-00014
   CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401
   Carotenuto P, 1998, AIDS, V12, P1591, DOI 10.1097/00002030-199813000-00005
   Casado C, 2000, J ACQ IMMUN DEF SYND, V23, P68
   Casado C, 2001, J GEN VIROL, V82, P2495, DOI 10.1099/0022-1317-82-10-2495
   Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856
   Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0
   FERBAS J, 1995, J INFECT DIS, V172, P329, DOI 10.1093/infdis/172.2.329
   Finzi D, 1998, CELL, V93, P665, DOI 10.1016/S0092-8674(00)81427-0
   Harrer T, 1996, AIDS RES HUM RETROV, V12, P585, DOI 10.1089/aid.1996.12.585
   HENDRIKS JCM, 1993, AIDS, V7, P231, DOI 10.1097/00002030-199302000-00012
   Hogan CM, 2001, ANN INTERN MED, V134, P978, DOI 10.7326/0003-4819-134-10-200105150-00012
   HOGERVORST E, 1995, J INFECT DIS, V171, P811, DOI 10.1093/infdis/171.4.811
   KEET IPM, 1994, J INFECT DIS, V169, P1236, DOI 10.1093/infdis/169.6.1236
   KLEIN MR, 1995, J EXP MED, V181, P1365, DOI 10.1084/jem.181.4.1365
   Korber B, 2000, SCIENCE, V288, P1789, DOI 10.1126/science.288.5472.1789
   Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244
   LEARMONT J, 1992, LANCET, V340, P863, DOI 10.1016/0140-6736(92)93281-Q
   Lefrere JJ, 1997, BLOOD, V90, P1133, DOI 10.1182/blood.V90.3.1133.1133_1133_1140
   Leitner T, 1999, P NATL ACAD SCI USA, V96, P10752, DOI 10.1073/pnas.96.19.10752
   Lemey P, 2003, P NATL ACAD SCI USA, V100, P6588, DOI 10.1073/pnas.0936469100
   LEVY JA, 1993, AIDS, V7, P1401, DOI 10.1097/00002030-199311000-00001
   LIFSON AR, 1991, J INFECT DIS, V163, P959, DOI 10.1093/infdis/163.5.959
   Lukashov VV, 2002, J MOL EVOL, V54, P680, DOI 10.1007/s00239-001-0070-5
   Mani I, 2002, J VIROL, V76, P10745, DOI 10.1128/JVI.76.21.10745-10755.2002
   Markham RB, 1998, P NATL ACAD SCI USA, V95, P12568, DOI 10.1073/pnas.95.21.12568
   Menzo S, 1998, AIDS, V12, P985, DOI 10.1097/00002030-199809000-00004
   Michael NL, 1997, NAT MED, V3, P338, DOI 10.1038/nm0397-338
   Montefiori DC, 1996, J INFECT DIS, V173, P60, DOI 10.1093/infdis/173.1.60
   MUNOZ A, 1989, AM J EPIDEMIOL, V130, P530, DOI 10.1093/oxfordjournals.aje.a115367
   PANTALEO G, 1995, NEW ENGL J MED, V332, P209, DOI 10.1056/NEJM199501263320402
   Pilgrim AK, 1997, J INFECT DIS, V176, P924, DOI 10.1086/516508
   RINALDO C, 1995, J VIROL, V69, P5838, DOI 10.1128/JVI.69.9.5838-5842.1995
   Robbins KE, 2003, J VIROL, V77, P6359, DOI 10.1128/JVI.77.11.6359-6366.2003
   Rodrigo AG, 1997, AIDS RES HUM RETROV, V13, P737, DOI 10.1089/aid.1997.13.737
   Sette A, 1999, IMMUNOGENETICS, V50, P201, DOI 10.1007/s002510050594
   SHEPPARD HW, 1993, AIDS, V7, P1159, DOI 10.1097/00002030-199309000-00002
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Trachtenberg E, 2003, NAT MED, V9, P928, DOI 10.1038/nm893
   Visco-Comandini U, 2001, J BIOL REG HOMEOS AG, V15, P299
   Wang B, 2003, VIROLOGY, V312, P135, DOI 10.1016/S0042-6822(03)00159-4
   Zhang YJ, 1997, J INFECT DIS, V176, P1180, DOI 10.1086/514111
   Zhu TF, 1998, NATURE, V391, P594, DOI 10.1038/35400
NR 48
TC 23
Z9 24
U1 0
U2 3
PU MICROBIOLOGY SOC
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER ST, LONDON WC1N 2JU, ERKS, ENGLAND
SN 0022-1317
EI 1465-2099
J9 J GEN VIROL
JI J. Gen. Virol.
PD FEB
PY 2005
VL 86
BP 355
EP 364
DI 10.1099/vir.0.80410-0
PN 2
PG 10
WC Biotechnology & Applied Microbiology; Virology
SC Biotechnology & Applied Microbiology; Virology
GA 893SC
UT WOS:000226738500013
PM 15659755
OA Bronze
DA 2020-12-01
ER

PT J
AU Bello, G
   Casado, C
   Garcia, S
   Rodriguez, C
   del Romero, J
   Borderia, AV
   Lopez-Galindez, C
AF Bello, G
   Casado, C
   Garcia, S
   Rodriguez, C
   del Romero, J
   Borderia, AV
   Lopez-Galindez, C
TI Plasma RNA viral load is not associated with intrapatient quasispecies
   heterogeneity in HIV-1 infection
SO ARCHIVES OF VIROLOGY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; EVOLUTION IN-VIVO; MOLECULAR CLOCK;
   PROGRESSION; PATTERNS; DISEASE; QUANTITATION; INDIVIDUALS; GENETICS;
   INFANTS
AB The human immunodeficiency virus type 1 (HIV-1) viral set point has been associated with the rate of disease progression and with the level of HIV-specific immune response. The analysis of the possible association between viral set point and quasispecies heterogeneity has important consequences in the understanding of HIV-1 in vivo evolution. In this study, we analyzed the association between intrapatient viral diversity and RNA viral load in 16 antiretroviral therapy-naive HIV-1-infected patients at a single time point, during the disease free period. Patients were separated into low and high viral load groups according to plasma RNA values. HIV-1 quasispecies complexity was assessed in the C2-V5 env region. The average intrapatient quasispecies heterogeneity in both groups was not significantly different (t-test, P>0.05). However, while within the low viral load group both synonymous and non-synonymous mutations contribute to the variation observed, in the heterogeneity observed in the high viral load group there was an increase in the contribution of the non-synonymous mutations. Thus, this study show that although intrapatient quasispecies heterogeneity is not associated with viral set point in HIV-1 infection, some differences exist between the two groups in the pattern of mutation accumulation.
C1 Inst Salud Carlos III, Ctr Nacl Microbiol, Madrid 28220, Spain.
   CSS, Madrid, Spain.
RP Lopez-Galindez, C (corresponding author), Inst Salud Carlos III, Ctr Nacl Microbiol, Madrid 28220, Spain.
EM clopez@isciii.es
RI Bello, Gonzalo/E-6842-2013; Bentancor, Gonzalo Jose Bello/N-7377-2019;
   Lopez-Galindez, Cecilio/A-3603-2008; Casado, Concepcion/F-3060-2016
OI Bentancor, Gonzalo Jose Bello/0000-0002-2724-2793; Lopez-Galindez,
   Cecilio/0000-0002-2324-9584; Casado, Concepcion/0000-0003-3412-2877;
   Borderia, Antonio V./0000-0003-0623-1988
CR Alaeus A, 1999, AIDS, V13, P901, DOI 10.1097/00002030-199905280-00005
   [Anonymous], 1992, MMWR Recomm Rep, V41, P1
   Bagnarelli P, 1999, J VIROL, V73, P3764, DOI 10.1128/JVI.73.5.3764-3777.1999
   Casado C, 2001, J GEN VIROL, V82, P2495, DOI 10.1099/0022-1317-82-10-2495
   Delwart EL, 1997, J VIROL, V71, P7498, DOI 10.1128/JVI.71.10.7498-7508.1997
   Ganeshan S, 1997, J VIROL, V71, P663, DOI 10.1128/JVI.71.1.663-677.1997
   GOJOBORI T, 1990, P NATL ACAD SCI USA, V87, P10015, DOI 10.1073/pnas.87.24.10015
   Halapi E, 1997, AIDS, V11, P1709, DOI 10.1097/00002030-199714000-00007
   Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244
   Leitner T, 1999, P NATL ACAD SCI USA, V96, P10752, DOI 10.1073/pnas.96.19.10752
   Liu SL, 1997, J VIROL, V71, P4284, DOI 10.1128/JVI.71.6.4284-4295.1997
   LUKASHOV VV, 1995, J VIROL, V69, P6911, DOI 10.1128/JVI.69.11.6911-6916.1995
   Mani I, 2002, J VIROL, V76, P10745, DOI 10.1128/JVI.76.21.10745-10755.2002
   Markham RB, 1998, P NATL ACAD SCI USA, V95, P12568, DOI 10.1073/pnas.95.21.12568
   Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167
   Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103
   Plikat U, 1997, J VIROL, V71, P4233, DOI 10.1128/JVI.71.6.4233-4240.1997
   Rodrigo AG, 1996, AIDS RES HUM RETROV, V12, P1681, DOI 10.1089/aid.1996.12.1681
   Rodrigo AG, 1999, P NATL ACAD SCI USA, V96, P10559, DOI 10.1073/pnas.96.19.10559
   Rodrigo AG, 1997, AIDS RES HUM RETROV, V13, P737, DOI 10.1089/aid.1997.13.737
   Rouzine IM, 1999, P NATL ACAD SCI USA, V96, P10758, DOI 10.1073/pnas.96.19.10758
   Salvatori F, 1997, J VIROL, V71, P4694, DOI 10.1128/JVI.71.6.4694-4706.1997
   Schwartz DH, 1996, IMMUNOL LETT, V51, P3, DOI 10.1016/0165-2478(96)02547-3
   Shankarappa R, 1999, J VIROL, V73, P10489, DOI 10.1128/JVI.73.12.10489-10502.1999
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Wolinsky SM, 1996, SCIENCE, V272, P537, DOI 10.1126/science.272.5261.537
   Zhang LQ, 1997, J VIROL, V71, P2555, DOI 10.1128/JVI.71.3.2555-2561.1997
NR 27
TC 9
Z9 9
U1 0
U2 4
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
SN 0304-8608
EI 1432-8798
J9 ARCH VIROL
JI Arch. Virol.
PD SEP
PY 2004
VL 149
IS 9
BP 1761
EP 1771
DI 10.1007/s00705-004-0322-y
PG 11
WC Virology
SC Virology
GA 854NH
UT WOS:000223910100007
PM 15593418
DA 2020-12-01
ER

PT J
AU Bello, G
   Casado, C
   Garcia, S
   Rodriguez, C
   del Romero, J
   Lopez-Galindez, C
AF Bello, G
   Casado, C
   Garcia, S
   Rodriguez, C
   del Romero, J
   Lopez-Galindez, C
TI Co-existence of recent and ancestral nucleotide sequences in viral
   quasispecies of human immunodeficiency virus type 1 patients
SO JOURNAL OF GENERAL VIROLOGY
LA English
DT Article
ID IN-VIVO; ENVELOPE SEQUENCES; PERIPHERAL-BLOOD; MOLECULAR CLOCK;
   SUBTYPE-B; EVOLUTION; HIV; REPLICATION; INFECTION; THERAPY
AB In human immunodeficiency virus type 1 (HIV-1) infection, the presence of divergent nucleotide sequences within a quasispecies has been associated with double infections or samples from different times or from different tissue compartments. The authors analysed HIV-1 proviral quasispecies from PBMC of three untreated Spanish patients displaying highly divergent nucleotide sequences without evidence of double infection. The origin of these nucleotide sequences was determined by phylogenetic analysis and by dating of the different groups using a genetic divergence versus sampling year plot from a set of Spanish samples. By their short genetic distance to the node of the patient's HIV-1 phylogenetic tree and by their early date of origin, close to the seroconversion time, some groups of sequences were considered ancestral. The presence within HIV-1 quasispecies of ancestral sequences, dated up to 10 years earlier than present ones, has important consequences for in vivo viral evolution, in the pathogenesis and treatment of HIV-1 infection.
C1 Inst Salud Carlos 3, Ctr Nacl Microbiol CNM, Madrid 28220, Spain.
   Comunidad Autonoma Madrid, CSS, Madrid 28010, Spain.
RP Lopez-Galindez, C (corresponding author), Inst Salud Carlos 3, Ctr Nacl Microbiol CNM, Madrid 28220, Spain.
EM clopez@isciii.es
RI Lopez-Galindez, Cecilio/A-3603-2008; Bello, Gonzalo/E-6842-2013; Casado,
   Concepcion/F-3060-2016; Bentancor, Gonzalo Jose Bello/N-7377-2019
OI Lopez-Galindez, Cecilio/0000-0002-2324-9584; Casado,
   Concepcion/0000-0003-3412-2877; Bentancor, Gonzalo Jose
   Bello/0000-0002-2724-2793
CR Bagnarelli P, 1999, J VIROL, V73, P3764, DOI 10.1128/JVI.73.5.3764-3777.1999
   BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990
   Casado C, 2000, J ACQ IMMUN DEF SYND, V23, P68
   Casado C, 2001, J GEN VIROL, V82, P2495, DOI 10.1099/0022-1317-82-10-2495
   *CDC, 1992, MORBID MORTAL WKLY R, V41
   CHEYNIER R, 1994, CELL, V78, P373, DOI 10.1016/0092-8674(94)90417-0
   Cheynier R, 1998, NAT MED, V4, P421, DOI 10.1038/nm0498-421
   Delwart EL, 1998, J VIROL, V72, P617, DOI 10.1128/JVI.72.1.617-623.1998
   Delwart EL, 1997, J VIROL, V71, P7498, DOI 10.1128/JVI.71.10.7498-7508.1997
   DIAZ RS, 1995, J VIROL, V69, P3273, DOI 10.1128/JVI.69.6.3273-3281.1995
   Domingo E, 1988, RNA GENETICS, P3
   Eigen M, 1988, RNA GENETICS, V3, P211
   Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0
   Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295
   FLESENSTEIN J, 1993, PHYLIP PHYLOGENY INT
   Gunthard HF, 1999, J VIROL, V73, P9404
   Halapi E, 1997, AIDS, V11, P1709, DOI 10.1097/00002030-199714000-00007
   ITESCU S, 1994, P NATL ACAD SCI USA, V91, P11378, DOI 10.1073/pnas.91.24.11378
   Korber B, 1998, SCIENCE, V280, P1868, DOI 10.1126/science.280.5371.1868
   Korber BT, 1999, NATURE, V400, P326
   Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244
   Leitner T, 1999, P NATL ACAD SCI USA, V96, P10752, DOI 10.1073/pnas.96.19.10752
   Lukashov VV, 1997, J VIROL, V71, P6332, DOI 10.1128/JVI.71.9.6332-6338.1997
   Lukashov VV, 2002, J MOL EVOL, V54, P680, DOI 10.1007/s00239-001-0070-5
   LUKASHOV VV, 1995, J VIROL, V69, P6911, DOI 10.1128/JVI.69.11.6911-6916.1995
   MEYERHANS A, 1990, NUCLEIC ACIDS RES, V18, P1687, DOI 10.1093/nar/18.7.1687
   Nijhuis M, 1999, AIDS, V13, P2349, DOI 10.1097/00002030-199912030-00006
   Ostrowski MA, 1998, J VIROL, V72, P7772, DOI 10.1128/JVI.72.10.7772-7784.1998
   Plikat U, 1997, J VIROL, V71, P4233, DOI 10.1128/JVI.71.6.4233-4240.1997
   Poss M, 1998, J VIROL, V72, P8240, DOI 10.1128/JVI.72.10.8240-8251.1998
   Rodrigo AG, 1997, AIDS RES HUM RETROV, V13, P737, DOI 10.1089/aid.1997.13.737
   Ryzhova EV, 2002, VIROLOGY, V297, P57, DOI 10.1006/viro.2002.1395
   SALA M, 1994, J VIROL, V68, P217
   Shankarappa R, 1999, J VIROL, V73, P10489, DOI 10.1128/JVI.73.12.10489-10502.1999
   SIMMONDS P, 1991, J VIROL, V65, P6266, DOI 10.1128/JVI.65.11.6266-6276.1991
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Wolinsky SM, 1996, SCIENCE, V272, P537, DOI 10.1126/science.272.5261.537
   Wong JK, 1997, J VIROL, V71, P2059, DOI 10.1128/JVI.71.3.2059-2071.1997
   Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291
   ZHU TF, 1995, J VIROL, V69, P1324, DOI 10.1128/JVI.69.2.1324-1327.1995
NR 40
TC 16
Z9 18
U1 0
U2 2
PU MICROBIOLOGY SOC
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER ST, LONDON WC1N 2JU, ERKS, ENGLAND
SN 0022-1317
EI 1465-2099
J9 J GEN VIROL
JI J. Gen. Virol.
PD FEB
PY 2004
VL 85
BP 399
EP 407
DI 10.1099/vir.0.19365-0
PN 2
PG 9
WC Biotechnology & Applied Microbiology; Virology
SC Biotechnology & Applied Microbiology; Virology
GA 777AU
UT WOS:000189152500013
PM 14769897
OA Bronze
DA 2020-12-01
ER

PT J
AU Casado, C
   Garcia, S
   Rodriguez, C
   del Romero, J
   Bello, G
   Lopez-Galindez, C
AF Casado, C
   Garcia, S
   Rodriguez, C
   del Romero, J
   Bello, G
   Lopez-Galindez, C
TI Different evolutionary patterns are found within human immunodeficiency
   virus type 1-infected patients
SO JOURNAL OF GENERAL VIROLOGY
LA English
DT Article
ID LONG-TERM SURVIVOR; IN-VIVO; DISEASE PROGRESSION; POPULATION-DYNAMICS;
   G->A HYPERMUTATION; GENETIC-VARIATION; HIV-1 INFECTION; SUBTYPE-B;
   SEQUENCES; RECOMBINATION
AB In order to study the evolution in vivo of human immunodeficiency virus type 1 (HIV-1) inpatients with normal clinical evolution, six individuals were selected from a group of 46 patients followed for 1 to 4 years. Patients were selected not by clinical progression characteristics but on the basis of virus genetic variability, as analysed by heteroduplex mobility assay and RNase A mismatch cleavage method. Two patients displayed a homogeneous virus population, two showed very heterogeneous quasispecies and two presented two distinct variants within the virus population. Virus quasispecies were studied by nucleotide sequencing of the C2-fusion domain of the env gene. Virus evolution was approached by analysing the distribution of genetic distances, calculation of divergence and heterogeneity as well as the K-a/K-s ratio and by the construction of the phylogenetic trees. Three patients displayed the same tree topology, characterized by the presence of independent clades supported by high bootstrap values, whereas this pattern was not present in the other three patients. In the three patients displaying independent clades, a recombination analysis was carried out between distinct subpopulations and recombinant variants were identified. In one patient of this group, different selective pressures were detected in distinct virus clades, measured by their corresponding Ka/Ks ratios, revealing that different evolutionary forces are occurring at the same time within the same patient. These results show that multiple evolutionary patterns can be found in typical HIV-1-infected patients.
C1 Inst Salud Carlos III, Ctr Nacl Biol Fundamental, Madrid 28220, Spain.
   Comunidad Autonoma Madrid, Ctr Salud Sadoval, Madrid 28010, Spain.
RP Lopez-Galindez, C (corresponding author), Inst Salud Carlos III, Ctr Nacl Biol Fundamental, Madrid 28220, Spain.
RI Casado, Concepcion/F-3060-2016; Lopez-Galindez, Cecilio/A-3603-2008;
   Bello, Gonzalo/E-6842-2013; Bentancor, Gonzalo Jose Bello/N-7377-2019
OI Casado, Concepcion/0000-0003-3412-2877; Lopez-Galindez,
   Cecilio/0000-0002-2324-9584; Bentancor, Gonzalo Jose
   Bello/0000-0002-2724-2793
CR Bagnarelli P, 1999, J VIROL, V73, P3764, DOI 10.1128/JVI.73.5.3764-3777.1999
   BALL JK, 1994, J GEN VIROL, V75, P867, DOI 10.1099/0022-1317-75-4-867
   BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990
   Casado C, 2000, AIDS RES HUM RETROV, V16, P299, DOI 10.1089/088922200309403
   Casado C, 2000, J ACQ IMMUN DEF SYND, V23, P68
   Chao Lin, 1994, P233
   CHEYNIER R, 1994, CELL, V78, P373, DOI 10.1016/0092-8674(94)90417-0
   Cheynier R, 1998, NAT MED, V4, P421, DOI 10.1038/nm0498-421
   COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947
   DELASSUS S, 1992, J VIROL, V66, P5642, DOI 10.1128/JVI.66.9.5642-5645.1992
   Delwart EL, 1998, J VIROL, V72, P617, DOI 10.1128/JVI.72.1.617-623.1998
   DELWART EL, 1993, SCIENCE, V262, P1257, DOI 10.1126/science.8235655
   Delwart EL, 1997, J VIROL, V71, P7498, DOI 10.1128/JVI.71.10.7498-7508.1997
   DOMINGO D, 1994, EVOLUTIONARY BIOL VI, P161
   Eigen M, 1988, RNA GENETICS, V3, P211
   FELSENSTEIN J, 1993, PHYLIP PHYLOGENY INT
   Ganeshan S, 1997, J VIROL, V71, P663, DOI 10.1128/JVI.71.1.663-677.1997
   HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0
   Jetzt AE, 2000, J VIROL, V74, P1234, DOI 10.1128/JVI.74.3.1234-1240.2000
   KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I
   KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405
   KORBER BTM, 1994, J VIROL, V68, P6730, DOI 10.1128/JVI.68.10.6730-6744.1994
   KUMAR S, 1993, MEGA MOL EVOLUTIONAR
   LAI MMC, 1992, CURR TOP MICROBIOL, V176, P21
   LARDER BA, 1990, ANTIMICROB AGENTS CH, V34, P436, DOI 10.1128/AAC.34.3.436
   LIU SL, 1997, J VIROL, V71, P4184
   LOPEZGALINDEZ C, 1991, P NATL ACAD SCI USA, V88, P4280, DOI 10.1073/pnas.88.10.4280
   Lukashov VV, 1997, J VIROL, V71, P6332, DOI 10.1128/JVI.71.9.6332-6338.1997
   Mariani R, 1996, J VIROL, V70, P7752, DOI 10.1128/JVI.70.11.7752-7764.1996
   McDonald RA, 1997, J VIROL, V71, P1871, DOI 10.1128/JVI.71.3.1871-1879.1997
   MEYERHANS A, 1994, J VIROL, V68, P535, DOI 10.1128/JVI.68.1.535-540.1994
   MEYERHANS A, 1989, CELL, V58, P901, DOI 10.1016/0092-8674(89)90942-2
   MULDER J, 1994, J CLIN MICROBIOL, V32, P292, DOI 10.1128/JCM.32.2.292-300.1994
   MYERS G, 1995, HUMAN RETROVIRUSES A
   NEI M, 1986, MOL BIOL EVOL, V3, P418
   NIXON DF, 1988, NATURE, V336, P484, DOI 10.1038/336484a0
   Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357
   PANTALEO G, 1995, NEW ENGL J MED, V332, P209, DOI 10.1056/NEJM199501263320402
   PANTALEO G, 1994, IMMUNOL REV, V140, P105, DOI 10.1111/j.1600-065X.1994.tb00867.x
   PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0
   PELLETIER E, 1995, VIROLOGY, V208, P644, DOI 10.1006/viro.1995.1195
   PERUCHO M, 1981, CELL, V27, P467, DOI 10.1016/0092-8674(81)90388-3
   Plikat U, 1997, J VIROL, V71, P4233, DOI 10.1128/JVI.71.6.4233-4240.1997
   RAY SC, 1999, SIMPLOT WINDOWS 95 N
   SABINO EC, 1994, J VIROL, V68, P6340, DOI 10.1128/JVI.68.10.6340-6346.1994
   SALA M, 1995, AIDS RES HUM RETROV, V11, P653, DOI 10.1089/aid.1995.11.653
   Salvatori F, 1997, J VIROL, V71, P4694, DOI 10.1128/JVI.71.6.4694-4706.1997
   SANCHEZPALOMINO S, 1993, J VIROL, V67, P2938
   Shankarappa R, 1998, VIROLOGY, V241, P251, DOI 10.1006/viro.1997.8996
   Shankarappa R, 1999, J VIROL, V73, P10489, DOI 10.1128/JVI.73.12.10489-10502.1999
   Shioda T, 1997, J VIROL, V71, P4871, DOI 10.1128/JVI.71.7.4871-4881.1997
   SIMMONDS P, 1991, J VIROL, V65, P6266, DOI 10.1128/JVI.65.11.6266-6276.1991
   Takehisa J, 1999, J VIROL, V73, P6810, DOI 10.1128/JVI.73.8.6810-6820.1999
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   VARTANIAN JP, 1994, P NATL ACAD SCI USA, V91, P3092, DOI 10.1073/pnas.91.8.3092
   VARTANIAN JP, 1991, J VIROL, V65, P1779, DOI 10.1128/JVI.65.4.1779-1788.1991
   Wang B, 2000, VIROLOGY, V274, P105, DOI 10.1006/viro.2000.0402
   WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0
   Wolinsky SM, 1996, SCIENCE, V272, P537, DOI 10.1126/science.272.5261.537
   Wong JK, 1997, J VIROL, V71, P2059, DOI 10.1128/JVI.71.3.2059-2071.1997
   Yamaguchi Y, 1997, P NATL ACAD SCI USA, V94, P1264, DOI 10.1073/pnas.94.4.1264
   Yuste E, 1999, J VIROL, V73, P2745, DOI 10.1128/JVI.73.4.2745-2751.1999
   ZHANG LQ, 1993, J VIROL, V67, P3345, DOI 10.1128/JVI.67.6.3345-3356.1993
   ZHU TF, 1995, J VIROL, V69, P1324, DOI 10.1128/JVI.69.2.1324-1327.1995
   Zhu TF, 1996, J VIROL, V70, P3098, DOI 10.1128/JVI.70.5.3098-3107.1996
   1992, MORBIDITY MORBALITY, V41, P1
NR 66
TC 17
Z9 17
U1 1
U2 3
PU SOC GENERAL MICROBIOLOGY
PI READING
PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AE,
   BERKS, ENGLAND
SN 0022-1317
J9 J GEN VIROL
JI J. Gen. Virol.
PD OCT
PY 2001
VL 82
BP 2495
EP 2508
DI 10.1099/0022-1317-82-10-2495
PN 10
PG 14
WC Biotechnology & Applied Microbiology; Virology
SC Biotechnology & Applied Microbiology; Virology
GA 476ME
UT WOS:000171230200019
PM 11562542
OA Bronze
DA 2020-12-01
ER

EF